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Abstract
Hypoxia has been shown to promote pluripotency in human embryonic stem 
cells (hESCs), but the mechanism by which this occurs in poorly understood. To gain 
insight into this mechanism, we used mass spectrometry to investigate changes in 
protein expression in hESCs cultured in hypoxia. hESCs in feeder free culture were 
incubated in 1% oxygen or 20% oxygen for 48 and 72 hours. The medium was not 
changed during this time to accelerate differentiation. Immunofluroescence localization 
of Oct-4 revealed that cultures incubated in hypoxia were less differentiated than 
cultures incubated in normoxia. Electrospray tandem mass spectrometry was 
performed to compare global protein expression of hESCs from each oxygen condition. 
Changes were observed in the expression of proteins involved in metabolism, chromatin 
modification, post-transcriptional modification, and regulation of the transcription 
factor, c-Myc. The results of this study will improve our understanding of the 
mechanism by which hypoxia maintains pluripotency of hESCs in vitro.
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1.1 Human embryonic stem cells
The successful derivation of human embryonic stem cells (hESCs) was a 
tremendous advancement in medical science, as these cells have exciting potential in a 
remarkable variety of research and clinical applications [1]. hESCs offer promise in 
regenerative medicine for the treatment of many diseases including cancer, Alzheimer's 
and Parkinson's disease [2-5]. They have invaluable potential for use in tissue 
replacement therapies and provide unique insight into early human development [6-8]. 
Controlled differentiation of hESCs that possess the genotypic abnormalities of a 
particular genetic disease could create a powerful system to study that disease [9]. In 
addition, hESCs can be used in drug efficacy and toxicity testing to facilitate the 
selection of candidate molecules and to reduce the risk of side-effects in later stages of 
drug development [10]. hESCs are promising for medical use because they have two 
special properties. The first is that they are pluripotent, which means they have the 
ability to differentiate into an impressive diversity of cells from the three primary germ 
layers: endoderm, mesoderm, and ectoderm [11], The second is that they have the 
ability to self-renew continuously in culture while remaining undifferentiated [12].
Thomson et al. derived the first hESC lines in 1998 from the inner cell mass of 
donated blastocysts that were produced by in vitro fertilization clinics [13]. A blastocyst 
is a pre-implantation embryo that consists of an outer layer of cells called the 
trophoblast, which could become a placenta if the blastocyst implants, and the inner cell 
mass (ICM), which has the potential to develop into an embryo (Figure 1). In order to 
derive a hESC line, the inner cell mass (ICM) of the blastocyst was removed, placed on 
inactivated mouse embryonic fibroblasts (MEFs), and passaged serially. The 
pluripotency of these cell lines was demonstrated in vitro by their ability to form 
embryoid bodies (EB). It was also demonstrated in vivo after injection of the cells into
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Figure 1. Derivation of hESCs. The inner cell mass of a blastocyst is removed and 
cultured on a layer of feeder cells, such as MEFs, or on a layer of extracellular matrix, 
such as Matrigel®. After serial passaging, ICM cells become hESCs.
3
severe combined immunodeficient (SCID) beige mice produced teratomas, which are 
tumors with tissue components resembling normal derivatives of all three germ layers 
[13]. ICM cells differ from hESCs in that they are transient, while hESCs are stable in 
vitro artifacts of the derivation process. However, hESCs are believed to posses the 
same developmental potential as ICM cells.
Further studies of hESCs revealed that these cells express high levels of the pluripotency 
associated transcription factor, Oct4 and the telomere extending polymerase, 
telomerase [14]. Oct4, Nanog, and Sox2 function as core transcription factors in 
maintaining pluripotency of ESCs and act as a complex to repress genes involved in 
lineage specification [15].
1.2 Maintenance of hESCs in vitro
Whether hESCs remain pluripotent or begin to differentiate down a particular 
lineage is determined largely by extracellular signals from the surrounding dynamic 
microenvironment. These signals include growth factors, nutrients and morphogens in 
the culture medium, extracellular matrix proteins, and even oxygen gradients.
Many research experiments and proposed clinical applications of hESCs require 
the cells to be pluripotent and free of non-human contamination. However, a major 
limitation to the use of hESCs in medical research is that they can undergo spontaneous 
differentiation in culture if proper conditions for pluripotency are not maintained. Either 
passage must always be performed early, before differentiated cells are observable, or 
pluripotent cells must be separated from differentiated cells during passage.
Currently, the in vitro microenvironment that sustains hESC pluripotency is not 
well understood. One reason for this is that many breakthrough discoveries in culture 
conditions for mouse embryonic stem cells (mESCs) are not applicable to hESCs [16]. 
For example, LIF is sufficient to maintain mESC pluripotency on gelatin as an attachment 
layer, but LIF does not maintain hESC pluripotency in the absence of feeders [17]. More 
surprisingly, BMP-4 increases the proliferative capacity of mESCs, but promotes 
differentiation of hESCs [18].
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Since the optimal mixture of factors that maintain hESC pluripotency is 
unknown, hESCs are often derived on a feeder layer of mitotically inactivated mouse or 
human fibroblast cells. This layer provides a growth substrate and secretes various 
growth factors, cytokines, and adhesion related proteins that promote pluripotency [19, 
20]. A significant leap forward in hESC culture methods was the discovery by Xu et al. 
that hESCs can be maintained on a layer of basement membrane matrix, called 
M atrigef, in media that has been conditioned by y-irradiated MEFs (MEF-CM) [21]. 
Matrigel , which is extracted from Englebreth-Holm-Swarm tumors in mice, is a complex 
mixture of extracellular matrix (ECM) proteins that is composed primarily of laminin, 
collagen-IV, and enactin [22-24]. This type of culture is called feeder-free, and it 
increases the efficiency and consistency of the culture environment compared to 
feeder-dependant culture. However, both MEFs and Matrigel* provide a source of 
experimental variability and a risk of xeno-transmission from non-human sources [25, 
26]. Moreover, different stem cell lines are cultured on different strains of MEFs, adding 
an additional layer of complexity. Therefore, it is necessary to determine which of the 
fibroblast-secreted proteins promote pluripotency so that these alone can be used to 
maintain hESC cultures.
If the replacement of necessary culture components with defined human factors 
is incomplete, hESCs may be forced to alter their gene expression in order to adapt. This 
was demonstrated when Ludwig etal., derived the first hESC lines in defined feeder-free 
conditions with all proteins derived from human material [27]. High concentrations of 
bFGF were used instead of MEF conditioning of the media to support hESC self-renewal. 
Disappointingly, the cultures became unstable in these defined conditions and could not 
maintain a normal karyotype for more than six months [27].
Future studies that aim to increase our understanding of the regulatory 
mechanisms involved in hESC pluripotency and differentiation may allow for the 
development of effective, xeno-free, defined culture conditions. Furthermore, this 
knowledge will increase our ability to produce homogeneous populations of cells that 
could be used safely in clinical applications. For this reason, hESC research has focused
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as much on revealing mechanisms to maintain hESCs in the pluripotent state as on 
methods to direct differentiation along specific cell lineages.
1.3 Hypoxia and human embryonic stem cells
Oxygen is not only an essential substrate for metabolism in aerobic organisms, it 
is also a signaling molecule that influences cellular activity. It is therefore an important 
component of the cellular microenvironment [28]. In the early days of hESC culture, 
little attention was paid to the importance of oxygen tensions in the microenvironment, 
and the cells were thus maintained in atmospheric oxygen [29]. However, atmospheric 
oxygen tensions are significantly higher than oxygen tensions in the reproductive tract, 
which is the natural environment of hESCs [30]. During implantation, the embryo has 
not yet accessed maternal circulation and as a result, it resides in a hypoxic environment 
of about 2% oxygen at the uterine surface [31]. Not only does the early embryo develop 
in a hypoxic environment, but studies have shown that oxygen gradients actually have a 
large influence on embryogenesis [32], In most mammalian species that have been 
studied, low oxygen has been shown to improve in vitro embryo development and 
increase cell number of the inner cell mass [33, 34]. This provided the first clue that 
oxygen concentration may play an important role in hESC fate.
The second clue was from studies of adult human stem cells, which revealed that 
hypoxia has an important regulatory role in these cells. After air enters the lungs, the 
partial pressure of oxygen progressively decreases as it travels to organs and tissues 
[35]. Adult stem cells reside in anatomical compartments that are relatively hypoxic 
compared to other tissues of the body. For example, hematopoietic stem cells (HSCs), 
which reside in bone marrow and replenish blood and immune cells, are physically 
separated from blood vessels by several stromal cells and progenitor cells. Studies have 
consistently shown that bone marrow aspirates are hypoxic, with some levels as low as 
1-2% [36]. It has been demonstrated that HSCs that reside in the hypoxic regions of the 
bone marrow express higher levels of Notch-1, telomerase, and p21 than cells that 
reside in regions that are closer to blood vessels [37].
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Mesenchymal stem cells (MSCs) are multipotent cells that are capable of 
differentiating into bone, cartilage, fat, tendon, and other progenitor cells. These cells 
are located in close proximity to blood vessels, but their niche is still relatively hypoxic 
because it is within tissues that have low oxygen tensions [38]. Hypoxic culture of MSCs 
in vitro has been shown to increase their proliferative lifespan, to diminish their 
differentiation capacity [39], and to increase Oct4 expression and telomerase activity 
[40, 41].
Neural stem cells (NSCs), which are multipotent, self-renewing cells that 
differentiate into cells of the nervous system, reside in the subventricular zone and the 
hippocampus. Oxygen tensions in the brain range from 3-4%, and NSCs are believed to 
reside in especially hypoxic regions because of the distance between their niche and 
blood vessels [29]. In vitro studies have shown that hypoxia increases proliferation and 
promotes multipotency in NSCs, while atmospheric oxygen tensions lead to mitotic 
arrest and promote glial differentiation [42].
Since oxygen concentration plays such an important role in the biological niche 
of adult stem cells, the importance of controlling oxygen concentrations in in vitro cell 
culturing is becoming increasingly appreciated. It is hypothesized that stem cells reside 
in hypoxic niches because it is important for them to avoid DNA damage since their 
biological role is to replenish cells [43]. Aerobic metabolism causes some degree of DNA 
damage through the generation of reactive oxygen species and stem cells may escape 
this damage by residing in hypoxic niches [37].
1.3.1 Hypoxia Inducible Factors
Hypoxia-inducible factors (HIFs) play a fundamental role in the cellular response 
to oxygen concentration [44]. Active HIF complexes consist of an oxygen-labile a 
subunit, which exists in three isoforms, and a stable P subunit [45]. H IF la  is expressed 
in almost all mammalian cell types, whereas HIF2a and HIF3a are only expressed in 
specific tissues [45]. In hypoxia, HIFa subunits are stabilized and form heterodimers 
with the constitutively expressed protein, HIFip (ARNT). HIF heterodimers regulate
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transcriptional responses by binding to hypoxia-response elements (HREs) on their 
target genes (Figure 2; [46]). In the presence of increased oxygen tensions, HIFa 
subunits are hydroxylated by prolyl-hydroxylase domain enzymes (PHD), which require 
oxygen for their activation [47]. Hydroxylated HIFa is subsequently marked for 
proteosomal degradation by the E3 ubiquitin ligase, von Hippel-Lindau factor (VHL).
Numerous studies have revealed that H IFla  and HIF2a have a role in the 
maintenance of hESC pluripotency. For example, HIF2a has been shown to regulate 
Oct-4 expression, which suggests one mechanism by which hypoxia could affect hESC 
pluripotency [48]. In another study, H IFla  was shown to interact with the Notch 
intracellular domain to induce expression of Notch target genes, which are important 
for the maintenance of undifferentiated stem cells [49].
While HIFs are known to play a significant role in the cellular response to 
hypoxia, it is believed that there are multiple oxygen sensing pathways involved in the 
response. For example, PHDs hydroxylate proteins other than HIFa in the presence of 
oxygen, and these other substrates may play an important role in the cell's response to 
oxygen [50]. In addition, PHDs belong to a family of 2-oxogluterate-dependant 
dioxygenases, all of which require oxygen for their enzymatic activity [51].
1.3.2 Hypoxia prom otes pluripotency o f stem cells
A striking study by Ezashi et at. in 2005 showed that hESCs not only grow as well 
in hypoxic conditions as they do in normoxic conditions, but that hypoxic culture 
actually reduces the amount of spontaneous differentiation that occurs in hESC colonies 
[52]. In this study, hESCs were cultured on MEFs or Matrigel® in hypoxic (1, 3, 5% 
oxygen) and normoxic (21% oxygen) conditions for twelve days. After nine days, areas 
of enlarged, flattened cells that did not express Oct-4 or SSEA-4 appeared in normoxic 
cultures. In hypoxic conditions, patches of differentiating cells were smaller in size and 
less numerous, and expression of Oct-4 and SSEA-4 was maintained throughout the 
colony. Production of human chorionic gonadotropin (hCG), which reflects spontaneous
8
Figure 2. HIFs translate changes in oxygen concentration to changes in protein 
expression. Hypoxia prevents the hydroxylation of HIFa by PHD, which would result in 
proteosomal degradation of HIFa. Stabilized HIFa subunits travel to the nucleus and 
form heterodimers with the stable subunit, HIFip. HIF heterodimers regulate 
transcriptional responses by binding to hypoxia-response elements (HREs) on their 
target genes.
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differentiation of hESCs, began to increase after five days in normoxic culture; however, 
only low concentrations of hCG were detected in hypoxic culture beginning at day 
seven. Hypoxia did not appear to limit the growth of hESCs, as the number of colonies 
and average colony surface area did not differ between oxygen conditions, although it 
was noted that less DNA was recovered from the cells grown at 1% oxygen. After 
thirteen days, the cells were passaged and cultures that had been grown in normoxic 
conditions were transferred to hypoxic conditions and vice versa. The cells were 
cultured in the alternate oxygen condition for an additional 14 days. Cultures that had 
been exposed to hypoxia for half of the experiment had a much lower degree of overall 
differentiation compared to control cultures that had been exposed to normoxia for the 
entire time course. The authors concluded that hypoxia promotes pluripotency of hESCs 
and does not inhibit proliferation. This suggests that hESCs do not need to be passaged 
as frequently when maintained in hypoxia, and that hypoxia may decrease the risk of 
transferring hESCs already marked for differentiation but not easily distinguished from 
pluripotent cells.
Zachar et al. expanded on this by studying the long term effects of hypoxia on 
hESC culture [53]. In this study, hESCs were cultured in 21% or 5% oxygen for eighteen 
months. At the end of the time course, colonies that had been maintained in 21% 
oxygen had central zones of spontaneously differentiated cells that did not express Oct-
4. Colonies that had been maintained in 5% oxygen consisted largely of homogeneous 
cells that expressed Oct-4. Only 56% of the colony area was undifferentiated in cultures 
maintained in 21% oxygen, while 98% of the colony area was undifferentiated in 
cultures maintained in 5% oxygen. Contrary to Ezashi et al.'s findings, measurements of 
colony size and incorporation of [H3]-labeled thymidine revealed that the colonies 
maintained at atmospheric oxygen grew significantly faster than the colonies 
maintained in hypoxic conditions. After four weeks, colonies cultured in 21% oxygen 
had a 2.6-fold greater area than those cultured in 5% oxygen. The authors concluded 
that hypoxia enhances the long-term self-renewal and pluripotency of hESCs but 
decreases the rate of proliferation.
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A study by Prasad et al. compared short- and long-term effects of hypoxia on 
hESCs [54]. To study the effect of short-term hypoxic culture, hESCs were cultured in 
1%, 5%, 10%, 15% or 20% oxygen for four weeks. After two weeks, pericentral thick 
zones, which indicate spontaneous differentiation, became evident around colonies 
cultured in 10%, 15% or 20% oxygen. The cells cultured in 1% and 5% oxygen were 
homogeneous and did not have pericentral thickening; however, most of the colonies in 
1% oxygen did not survive beyond 2 weeks. Immunofluorescence assays revealed that 
only 60% of the cells cultured in 10% and 15% were Oct-4 positive, undifferentiated cells 
after 4 weeks, while cells cultured in 1% and 5% were 100% undifferentiated at 4 weeks. 
In order to compare short- and long-term effects of hypoxia, some hESC cultures were 
maintained in 5% oxygen for 18 months prior to the 4-week experiment. Colonies that 
had been maintained in hypoxia for the long-term displayed similar structural 
development to the colonies maintained in 21% oxygen prior to the experiment. 
However, real time RT-PCR analysis revealed that the colonies that had been maintained 
in 5% oxygen for 18 months expressed lower levels of Nanog and Notchl mNA than cells 
maintained in 5% oxygen for only 4 weeks. After the four week experiment, all cultures 
were transferred back to normoxic conditions, and after only one week, differentiation 
zones appeared in all cultures, except for the cultures originally maintained in 1% 
oxygen. By the end of four weeks, all cultures contained 60% undifferentiated cells. 
The authors additionally noted that the rate of proliferation was lower in 5% oxygen and 
especially lower 1% oxygen compared to cells cultured in higher oxygen tensions, as 
determined by incorporation of [H3]-labeled thymidine.
Prompted by the finding that hypoxia promotes pluripotency in hESCs, Westfall 
et al. investigated the molecular basis of the phenomenon by studying differences in 
RNA transcript levels between hESCs maintained in low and high oxygen tensions [55]. 
RNA was collected after hESCs had been maintained in 4% or 20% oxygen for one week, 
at which point the colonies were indistinguishable in morphology and size, and neither 
culture had visible signs of differentiation. When three samples from each condition 
were compared, the samples from hESCs cultured in 20% oxygen exhibited greater
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variance in their gene expression profile that those cultured in 4% oxygen. A total of 
149 transcripts demonstrated consistent differences in expression level between the 
two oxygen conditions; however, the changes observed were quite small. Of these, 42 
transcripts had increased expression in 20% oxygen and 107 transcripts had decreased 
expression in 20% oxygen compared to 4% oxygen. Several genes considered to be 
under the transcriptional control of the Oct4/Nanog/Sox2 complex, including LEFTY2 
and endothelin receptor type B (EndRB), were expressed at much lower levels in cells 
cultured in 20% oxygen than cells cultured in 4% oxygen. hESCs cultured in 20% oxygen 
also had decreased expression of genes that are known to be regulated by Oct4, such as 
SALL1, Trim2, Zic2, and FGFR2. However, several genes that have been found to be 
associated with pluripotency in hESCs, including Oct4, Nanog, Lin28, Sox2, ZFP42/Rexl, 
Tert, and PodXL did not show a significant difference in transcript levels between the 
two oxygen conditions. In addition, there was no difference in the expression of the 
TDGF1 (CRIPTO) gene, which has been shown to be down-regulated during the initial 
steps of hESC differentiation. The authors suggest that although transcriptional profiles 
of the core pluripotency genes may not be greatly affected by oxygen conditions, the 
expression of their downstream targets might be. As one would expect, several genes 
associated with oxidative stress responses, such as NRF2, NQOl, AKR1C3, VCAN and 
CTNS, showed increased expression in 20% oxygen conditions. The biochemical pathway 
that had the greatest number of downregulated genes in 20% oxygen was glycolysis, 
which agrees with the fact that most genes encoding enzymes of the glycolytic pathway 
are known to be regulated by H IFla. H IFla  mRNA was highly expressed, but the 
transcript concentration did not differ between the oxygen conditions. Flowever, 
several genes thought to be under the control of H IF la  and that contribute to 
apoptosis, cellular redox regulation, and proliferation were down-regulated under 20% 
oxygen; for example, BNIP3, TXNIP (thioredoxin interacting protein), DDIT4 (DNA 
damage inducible transcript 4), IGFBP2, LGALS1 and VEGF. HIF2a was expressed at a 
much lower level than HIFla, but its transcript concentration was increased at 20% 
oxygen, and transcripts for HIF0 were unaffected by oxygen concentration. It was not
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surprising that there was no change in H IFla  mRNA expression because H IFla  is 
primarily regulated at the level of protein turnover. Studying the proteome by mass 
spectrometry may provide more insight into differences in gene expression because 
changes in many other proteins may exist through alterations in the rate of translation 
or protein degradation.
The observation that hypoxia prevents differentiation of hESCs led Yoshida et al. 
to hypothesize that hypoxia could enhance the generation of induced pluripotent stem 
cells (iPSCs) [56]. iPSCs are pluripotent stem cells that are artificially derived from 
differentiated cells by the forced expression of four transcription factors (Oct3/4; Sox2, 
Klf4, and c-Myc) [57]. They are nearly indistinguishable from ESCs, but the full extent of 
their similarity to natural pluripotent stem cells is currently being assessed. Yoshida et 
al. used retroviral vectors to introduce four or three transcription factors (Oct3/4, Sox2, 
Klf4, +/- c-Myc) into MEFs, and then cultured the cells in 5% or 21% oxygen from day 5 
to day 14 after transduction. The percentage of pluripotent cells was greater in cultures 
reprogrammed in hypoxia than cells reprogrammed in atmospheric oxygen. The four 
transcription factors were also introduced into human dermal fibroblasts (HDFs) and the 
cells were maintained in 5% oxygen for 7, 14, 21, or 33 days. The efficiency of iPSC 
generation was increased by 4.2 fold after 14 and 21 days in hypoxia, and by 3.6 fold 
after 24 days in hypoxia. Interestingly, iPSCs could be generated in the presence of 
hypoxia when only 2 transcription factors (Oct3/4 and Klf4) were used. The authors 
concluded that conducting reprogramming in hypoxic conditions results in improved 
efficiency for both mouse and human cells and they suggested that hypoxia may 
contribute to the reprogramming process itself.
Recently, Lengner et al. derived a new hESC line in 5% oxygen [58]. Interestingly, 
these cells contained two active X chromosomes (XaXa). The presence of two active X 
chromosomes is observed in pluripotenct mESCs, whereas all previous hESC lines have 
undergone X chromosome inactivation (XCI) and are considered developmentally more 
advanced than mESCs. Using the XaXa hESC line that had been derived in hypoxia, the 
authors demonstrated that random XCI is induced during differentiation and that
13
continuous exposure to 20% oxygen induces irreversible XCI. These findings indicate 
that human ICM cells have two active X chromosomes, and that culturing hESCs in 
hypoxia preserves this state.
Collectively, these studies have demonstrated that hypoxia plays a significant 
role in hESC self-renewal and pluripotency and that hypoxia must therefore be carefully 
controlled when culturing hESCs in vitro. This phenomenon is not well understood, and 
future studies are needed to determine exactly how hypoxia exerts this effect on 
protein expression and activity.
1.3.3 Hypoxia can improve differentiation of stem cells
While many studies have shown that culturing hESCs in hypoxia promotes 
pluripotency and self renewal, other studies have shown that hypoxia is able to improve 
the efficiency of hESC differentiation, especially to chondrocytes and cardiomyocytes 
[28]. In a study by Koay et al., hESCs that were differentiated to chondrocytes in 2% 
oxygen had significantly greater biomechanical functionality and production of cartilage 
matrix proteins, especially collagen, than hESCs differentiated in 20% oxygen [59]. 
Niegruegge et al. differentiated hESCs to cardiomyocytes in 4% oxygen and found that 
the total cell number increased by 30-47% and some cardiac markers increased 
compared to cardiomyocytes that had been differentiated in 20% oxygen [60].
It is not surprising that hypoxia has been shown to promote pluripotency in 
hESCs and also to improve the efficiency of differentiation. At the beginning of its 
development, the pre-implantation embryo consists largely of pluripotent cells. These 
cells soon begin to differentiate down particular lineages as directed by external signals. 
Until the embryo accesses maternal circulation, it resides in a hypoxic environment. 
Therefore, pluripotency and differentiation both naturally occur in hypoxia.
1.4 Fundamentals of mass spectrometry
Proteomics is a rapidly evolving field that provides unparalleled insight into a 
cell's biochemistry. Mass spectrometry (MS) has become a central technology for
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proteomic studies because it is highly sensitive and can generate spectral information 
about a peptide's amino acid sequence in milliseconds [61].
In order to measure the mass-to-charge ratio (m/z) of peptides, a mass 
spectrometer must convert these large biomolecules to ions in the gas phase, which was 
a long-standing barrier to the efficacy of MS. The development of two soft ionization 
techniques, Matrix Assisted Laser Desorption Ionization (MALDI) and Electrospray 
Ionization (ESI), revolutionized this technology [61]. In the MALDI technique, a peptide 
is mixed with a low-molecular weight aromatic acid that forms a light-absorbing matrix. 
A focused laser beam irradiates the sample, causing the matrix molecules to sublime 
and transfer the embedded peptides into the gas phase. Generally, the peptide ions are 
singly charged. In the ESI technique, a peptide solution is dispersed into airborne 
droplets as it exits a charged needle or the tapered end of an LC column that is held at a 
high electrical potential with respect to the MS. This generates a high positive charge 
on the droplets, which undergo desorption of analyte ions and/or droplet fission as the 
solvent evaporates. Eventually, each droplet contains an average of one multiply- 
charged analyte ion [61]. ESI ionization was used in this thesis because it allows liquid 
separation techniques to be coupled directly to MS analysis, and because multiply- 
charged ions are more easily characterized by MS.
Numerous types of mass analyzers are available to measure the mass-to-charge 
ratio of peptide ions. These include the quadrupole (Q), time-of-f light (ToF), ion trap 
(IT), and the newer Orbitrap and Fourier transform ion-cyclotron-resonance (FT-ICR) 
analyzers. Most mass spectrometers are hybrids that contain different types of mass 
analyzers in a single instrument; for example, QqQ, Q-ToF, QqlT, ITqOrbitrap, and qFT- 
ICR. Each of these platforms has advantages and limitations, but they share the ability 
to generate spectra containing sequence data for thousands of species in a short period 
of time. Currently, FT ICR and Orbitrap instruments have the highest resolution and 
mass accuracy, but they are expensive and difficult to operate. Ion traps are robust and 
usually less expensive than other models, but their mass accuracy and effective mass 
range are not as great. A Q-ToF is the only type of MS used in this thesis. In this
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instrument, the quadrupole is used as a mass filter because it has high efficiency in 
transmitting a small m/z window. The ToF is used for measuring the m/z of the 
selected ion because it has a higher mass accuracy.
1.4.1 Peptide sequencing by tandem mass spectrometry
The ability to interface electrospray ionization with these advanced tandem mass 
analyzers meant that thousands of peptides in a single sample could be analyzed in a 
high-throughput manner. In a tandem MS experiment, the mass spectrometer first 
determines the mass of peptide ions as they elute from the LC column. One at a time, 
abundant ions are selected and allowed to pass to the collision cell, where they are 
fragmented by Collision Induced Dissociation (CID) with an inert gas or Electron Transfer 
Dissociation (ETD). CID causes cleavage at the peptide bond, and the resulting ions are 
called b-ions if the charge is at the amino-terminal and y-ions if the charge is at the 
carboxy-terminal [61]. ETD causes cleavage between the amino group and the alpha 
carbon, and the resulting ions are called c-ions if the charge is at the amino-terminal and 
z-ions if the charge is at the carboxy-terminal. The fragmentation techniques are mild 
so that the peptide only fragments in one place along the backbone. The peptide 
fragments move to another mass analyzer, which generates a spectrum of all m/z values 
in the pool of fragments. The difference in mass between the fragment ions corresponds 
to the mass of an amino acid, and the sequence can be determined from this spectrum 
(Figure 3, reviewed in [62]).
1.4.2 Sample preparation for MS analysis
Even with advancements in instrument scan speed, mass spectrometers can only 
detect a limited number of ions in a given period of time. Proteomes are difficult to 
study because they are extremely complex and the dynamic range of protein 
concentrations can span ten orders of magnitude. To alleviate this complexity, the 
proteome can be fractionated by one- or two-dimensional SDS PAGE or any type of 







Figure 3. Liquid-chromatography tandem mass spectrometry. In an LC-MS/MS 
experiment, peptides ions are separated by LC, which is directly coupled to MS. At a 
given point in time, the m/z of peptides eluting from the LC column is determined by 
MS1. An abundant peptide ion is selected and fragmented such that it breaks in one 
place along the backbone. The m/z of the fragments is measured in MS/MS. The 
sequence of the peptide can be determined because the difference in mass between the 
fragments is equal to the mass of the corresponding amino acid.
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MS experiments are typically done in a 'bottom-up' approach, in which proteins 
are enzymatically digested to peptides prior to fractionation and analysis (Figure 4). An 
important reason for this is that it is difficult to generate sequence information from 
polypeptides that contain more than 20 amino acids. In addition, many proteins are 
difficult to solubilize and/or have multiple modification sites, which complicates the 
identification of the protein. Trypsin, which cleaves peptides on the C-terminal side of 
arginine and lysine, is a popular choice for enzymatic digestion of proteins. This is 
because it is stable and highly specific, and it creates appropriately sized peptides that 
have a charged amino acid at the C-terminus. These properties allow for generation of 
fragmentation spectra that are easy to interpret. Other enzymes may be used to 
generate peptides that are complementary to the tryptic peptides or when proteins 
must be solubilized in conditions that affect trypsin's activity.
It is very common to perform a second fractionation to separate the resulting 
peptides for MS analysis. The most popular method to identify more ions in a given 
sample is to interface the MS with a RP, SCX, or SAX LC device (Figure 4). Each of these 
column types has a different ability to separate a mixture, so the column choice 
depends on the sample type and proteomics application. Complementary types of 
fractionation can be used to increase proteome coverage; however, many peptides will 
not be characterized, making experiments difficult to reproduce.
1.4.3 Quantitative proteomics
Mass spectrometers are not strictly quantitative; therefore, in order to obtain 
accurate quantitative information in proteomic experiments, stable isotopic labeling is 
typically used. In techniques involving isotopic labels, such as stable isotope labeling of 
amino acids in culture (SILAC), one sample is labeled with a stable isotope through 
metabolic incorporation, and then mixed with an unlabeled sample at a 1:1 ratio of 
protein concentration [64]. The resolution of current mass spectrometers is high enough 
to resolve heavy (labeled) from light (unlabeled) peptides, and the intensities of the 
spectral peaks they produce can be directly compared to determine their relative
18
Extract protein from 
cells
Fractionate proteome 
with SDS PAGE or liquid 
chromatography
Alkylate cysteines and digest 
proteins with a restriction 
enzyme
Analyze MS specta with 
bioinformatics software to 
identify proteins
Analyze peptides by 
tandem MS
.
Fractionate peptides by 
any type of liquid 
chromatography
Figure 4. Overview of a general proteomics workflow. Proteins are extracted from cells 
and fractionated by ID  or 2D electrophoresis or some type of liquid chromatography 
(RP, SCX, SEC, etc.). Cysteines are often reduced and alkylated, and proteins are digested 
to peptides with a site specific enzyme. The resultant peptides are then fractionated by 
liquid chromatography, which can be coupled directly to MS. The peptides are analyzed 
by MS/MS, and bioinformatics software is used to identify the peptide sequences.
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abundance (Figure 5; [65]). Alternatively, samples can be labeled following digestion by 
way of isobaric labeling techniques, such as iTRAQ. After the samples are mixed at a 1:1 
ratio, the peptide abundance levels can be compared quantitatively based on the 
amount of tag present in the MS/MS spectrum. These methods allow minute changes 
between cellular states to be monitored over time.
There are limitations to most label-based quantification approaches. 
Specifically, sample preparation techniques can be very complicated, there is often a 
need for high sample concentration, and labeling is frequently incomplete. For these 
reasons, label-free techniques are becoming increasingly popular. A recent study by 
Patel et al. compared a label-free quantitative proteomics approach with an iTRAQ 
approach [66]. There was good agreement between the results generated by each 
technique; however, more peptides were detected using the label-free approach.
1.4.4 Bioinformatic analysis of MS spectra
In order to identify the peptides present in a given sample, fragmentation 
spectra generated by the MS must be accurately interpreted. There are many software 
platforms available for analyzing MS/MS spectra with sophisticated algorithms and 
scoring schemes [67]. The primary method by which software interprets MS/MS spectra 
is through comparison of observed spectra to in silico spectral databases [68]. These in 
silico databases are generated using theoretical digests of protein sequences that have 
been observed or predicted from genome sequencing projects [69]. By statistically 
matching MS/MS spectra to in silico databases, the actual sequence of the peptide does 
not need to be measured, and the peptides can be more rapidly identified. Three 
search engines were used to analyze data in this thesis: Mascot, XITandem and OMSSA. 
All of these tools compare observed spectra to in silico databases, but they use different 
scoring schemes to establish the best peptide match [70-72]. Although spectral 
interpretation software offer rapid analysis of a large number of spectra, the majority of 
spectra generated in a typical MS experiment will remain unidentified [73]. Background 
peaks can be mistaken as peptide peaks, resulting in false positive identifications and
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Figure 5. Stable isotope labeling of amino acids in culture. A) The amino acids, 
arginine and lysine are labeled with heavy isotopes, N15 and C13, and added to culture 
medium that does not contain arginine and lysine. B) Labeled medium is added to a cell 
culture so that cells in that culture incorporate heavy isotopes into their proteins. C) 
Proteins from labeled and unlabeled cultures can be mixed at a 1:1 ratio and differences 
in abundance between particular proteins can be observed by mass spectrometry.
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unpredicted posttranslational modifications (PTMs) or sequence polymorphisms can 
result in missed identifications. Combining results of multiple search engines can 
increase the percentage of peptides that are identified in a sample and increase 
confidence that the identified peptides are not false positives [74].
1.5 Mass spectrometry analysis of the hESC proteomet
In an effort to better characterize hESCs, many studies have employed large 
scale genetic screens to identify genes that regulate the pluripotent state. Large-scale 
analyses of the hESC transcriptome have revealed valuable information about gene 
expression in pluripotent hESCs, as well as changes in transcription that occur during 
differentiation [75-82]. These studies were important for the identification of some key 
genes involved in pluripotency, such as Oct 3/4, Nanog, and Sox 2 [78, 80, 83, 84], 
However, changes in RNA levels do not always correspond to changes in the respective 
protein levels because of post-transcriptional factors, such as stability of mRNA, rate of 
translation, and rate of protein degradation. Since proteins are the effectors of cellular 
processes, it is important to investigate hESC expression at the protein level as well as 
the transcript level [85]. In addition, posttranslational modifications, such as 
phosphorylation, may influence the activity of pivotal proteins in hESCs, and this 
information can only be determined by studying the proteome. For this reason, there 
has been a surge of proteomic studies of hESCs in the past few years [86-88].
Baharvand et al. performed one of the first proteomic analyses of hESCs, using 
2D-SDS-PAGE followed by spot identification with MALDI-TOF-TOF MS [89]. This study 
compared protein expression of three hESC lines: Royan H2, H3, and H5 and identified a 
total of 685 proteins. A significant portion of these were localized to the nucleus, which 
agrees with the fact that hESCs have a high nucleus to cytoplasm ratio. Of the proteins 
identified, many are involved in protein synthesis and regulation, which the authors 
suggest reflects the ability of hESCs to change phenotype rapidly. The authors also 
acknowledged that 2D-SDS-PAGE has limited ability to detect low abundance proteins.
t  Parts of this section are excerpts from Hughes CS*, Nuhn AA*, Postovit LM, and Lajoie GA. Proteomics 
of human embryonic stem cells. Proteomics. 2011.11(4): 675-90. (*co-first authors).
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In the same year, Van Hoof et al., reported a more extensive analysis of the hESC 
proteome, and compared the proteomes of undifferentiated mouse and human ESCs to 
their differentiated counterparts [90]. Using tandem MS analysis on an FT-ICR-MS, the 
authors identified 1871 and 1775 unique proteins from undifferentiated mESCs and 
hESCs respectively, 639 and 743 of which were found only in pluripotent ESCs. The 
proteins that were uniquely identified or enriched in mouse and human ESCs include 
important transcription factors such as Oct4 and UTF-1, and the ESC marker, alkaline 
phosphatase. The relative expression of selected proteins was determined by western 
blotting, and this data correlated well with the proteomics data. This validates the 
ability of an MS-based screen to fish out cell specific markers.
In an attempt to elucidate which proteins secreted by MEFs support pluripotency 
of hESCs, Lim et al. used MS to identify 136 unique proteins in MEF-CM [91]. The MEF- 
CM was concentrated, separated by 2D-SDS-PAGE, and compared to gels from media 
that was not conditioned. Differential spots were excised and identified by MS using a 
MALDI-TOF. An interesting candidate for a hESC pluripotency regulator was pigment 
epithelium-derived factor (PEDF), a protein with a diverse array of functions. A similar 
study by Chin et al. used 2D-SDS-PAGE and MALDI-TOF analysis of CM from MEFs 
(supportive of hESC growth) and AE-MEF (not supportive of hESC growth) [92], Of the 
proteins identified as differentially abundant, they chose six growth factors including 
PEDF, MCP-1, PAI, IGFBP-2 and 7, and IL-6 as supplements for defined hESC media. 
Using this cocktail, they were able to maintain the hESCs in an undifferentiated state 
based on Oct4 and Tra-1-60 detection, although for only 5 passages. Gonzalez et al. 
later demonstrated that PEDF can maintain undifferentiated hESCs without the addition 
of other exogenous supplements [93].
Two studies by Prowse et al. revealed some proteins that are secreted into 
conditioned medium (CM) by other types of fibroblasts. The first study surveyed media 
conditioned by human neonatal fibroblasts [94]. A 2D-SDS PAGE gel of CM was 
compared to that of unconditioned media, and differential spots were analyzed by 
MALDI-TOF/TOF-MS. The CM was also analyzed by Q-Star tandem MS after SCX-RP-LC
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fractionation. A total of 102 proteins were identified. Some of these proteins are 
known to function in pathways related to development, including the BMP inhibitor 
Gremlin, members of the insulin-like growth factor family, and ECM proteins such as 
SPARC and follistatin. Some of the identified proteins were also detected in the studies 
by Chin et al. and Lim et al., including IGF binding proteins. The second study by Prowse 
et al. used the same fractionation and analysis techniques to identify proteins in the 
conditioned media of three fibroblast lines (human neonatal, human foreskin, and 
mouse embryonic) that are commonly used to maintain hESC pluripotency [95]. They 
identified a total of 175 proteins, 34 of which were common between all three cell lines. 
Based on previous literature and ontology classification, proteins most likely to be 
involved in growth, differentiation, and maintenance of hESC pluripotency were found. 
Many of these proteins were extracellular matrix core, binding, and remodeling 
proteins. Some interesting proteins that were not identified in the first study were 
Activin A, IGF-1, and proteins involved in TGF-pi signaling. Activin A has been shown 
through supplementation in culture medium to promote the feeder-independent 
growth of hESCs in the absence of MEF pre-conditioning [96, 97]. TGF-pi is known to 
promote hESC pluripotency, and has also been shown to promote the feeder 
independent growth of hESCs [27], IGF-1 has also been shown to function with bFGF in 
the maintenance of hESCs [98]. These studies offered valuable insight into potential 
regulators of hESC pluripotency in vitro; however, they demonstrated the limitations of 
reproducibility and the inability to sample low abundance proteins.
Bendall et al. hypothesized that growth factors secreted by both feeder cells and 
hESCs themselves are involved in the microenvironment that maintains hESC 
pluripotency in culture [99]. A variety of fractionation and analysis methods were used 
in combination with an iterative exclusion technique to provide the most in-depth 
analysis of CM from MEFs and hESCs at the time of publication. In iterative exclusion, 
the first round of MS analysis identifies the most abundant proteins in the fraction. In 
subsequent rounds, ions that were selected in all previous rounds are ignored based on 
m/z and retention time to allow for the identification of previously uncharacterized,
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lower abundance ions. This resulted in the identification of 550 and 2493 proteins in 
the MEF media and hESC media, respectively. Some of these proteins were also 
identified by Prowse et a!., including IGF binding protein 3, 6, and 7, follistatin, DKK3, 
TGF-P-binding protein, PEDF, and inhibin P A. In addition, IGF-II, TGF-pi, and over 40 
new potential growth factors were identified. From this dataset, a model was proposed 
for in vitro hESC signaling with human dermal fibroblasts (hDfs), wherein bFGF in the 
medium signaled the production and release of IGF-II from hDfs to maintain hESCs in an 
undifferentiated state [98]. This model indicated that hESCs may communicate with 
fibroblast-like cells in vitro to sustain pluripotency, and highlighted the utility of 
proteomics analysis for this research.
Many studies have compared the protein expression of hESCs with the protein 
expression of differentiated derivatives of hESCs, different hESC cell lines, or other 
pluripotent cells. These studies have revealed hESC specific markers, proteins 
associated with the pluripotent state, and changes in gene expression that occur during 
differentiation.
To characterize the differences between hESCs and their differentiated 
equivalents after 3, 6, 12, and 20 days toward EB formation, Fathi et al. utilized a 2D- 
SDS-PAGE tandem-MS approach [100]. Of 979 reliably detected protein spots, 58 spots 
were up-regulated and 38 were down-regulated as hESCs differentiated into EBs. 
Functional analysis revealed that many of the down-regulated proteins are involved in 
cell cycle, developmental, and protein degradation processes. Some of the proteins that 
were more abundant in hESCs than EBs, such as NPM1, Ebpl, and Sutgl, have been 
shown to be down-regulated as mESCs differentiate. The researchers also acquired 
genomic expression data using RT-PCR to obtain mRNA levels for comparison to the 
proteomic data. A total of 6187 transcripts were found to be modulated upon 
differentiation. When the proteomic and genomic data were compared, there was 
minimal correlation between the two sets. While some transcripts and proteins shared 
the same change in expression, others displayed opposite patterns. The authors
25
mention limitations in the sensitivity of the proteomic assay, as well as discordance 
between protein and mRNA abundance levels as possible reasons for this.
1.6 Objectives of this thesis
It is known that hypoxia promotes pluripotency in hESCs, but the mechanism by 
which this occurs is poorly understood. A few proteins have been linked to oxygen 
signaling and pluripotency in hESCs, but it is believed that there are several oxygen 
signaling networks involved, and that many proteins are differentially expressed in 
hypoxia. Microarray analysis of hESCs cultured in hypoxia shed some light on global 
changes in protein expression in hypoxia; however, since there is little correlation 
between changes in RNA expression and changes in protein levels, it is important to 
study this problem at the proteome level for a complete picture. In this thesis, mass 
spectrometry is used to identify proteins that are expressed differently under low 
oxygen conditions. We hypothesized that hESCs alter their protein expression in 
response to decreased oxygen levels, and that these changes in protein expression are 
associated with the pluripotent state. The results of this study will improve our 
understanding of the mechanism by which hypoxia maintains pluripotency in hESCs in 
vitro and in ICM cells during development of embryos in the hypoxic reproductive tract. 
In addition, the identification of proteins associated with pluripotency of hESCs could 
aid the development of defined, xeno-free culture conditions for hESCs.
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Chapter 2: Experimental Procedures
2.1 Maintenance of hESC cultures
H9 and CA1 hESCs were maintained on a feeder layer of MEFs because MEFs 
provide a growth substrate and secrete various proteins that are needed to maintain 
hESC pluripotency [19]. The MEFs (strain CF-1; American Type Culture Collection, 
Manassas, VA, http://www.atcc.org) were y-irradiated so they could no longer 
proliferate, and were plated in gelatin-coated six-well polystyrene dishes at 200 000 
cells per well in 2 mL of MEF medium (MM; 90% Dulbecco's modified Eagle's medium, 
8% fetal bovine serum, 1% nonessential amino acids, and 1% L-Glutamine). After a 
minimum of 24 hours, when the MEFs had attached to the bottom of the dish, the MM 
was aspirated and hESCs were transferred to each well in 2.5 mL of stem cell medium 
(SM; 80% Dulbecco's modified Eagle's medium-F12, 20%, 1% nonessential amino acids, 
1 mM L-Glutamine, and 4 ng/ml basic fibroblast growth factor (Invitrogen) and 0.1 mM 
mercaptoethanol). The cultures were incubated at 37°C in 5% CO2 and the SM was 
changed daily. If differentiating colonies became visible, they were removed manually 
by scraping with a glass pick.
Cultures were passaged approximately every five days to prevent differentiation 
and were passaged less than 50 times to limit the risk of karyotypic abnormalities. H9 
hESCs were passaged manually and CA1 hESCs were passaged enzymatically or 
manually. For manual passaging, small clusters of hESCs were mechanically detached 
from the MEF layer with a glass pick and transferred to a new six-well dish of MEFs. For 
enzymatic passaging, hESCs were rinsed with phosphate buffered saline (PBS) and 
incubated with 500 pL of 0.05% trypsin until the cells detached from the plate in small 
clumps. MM was added to each well to deactivate the trypsin and the suspension was 
centrifuged to collect the hESCs in a pellet. The supernatant was aspirated and replaced 
with SM, and the hESCs were transferred to a fresh six-well dish of irradiated MEFs. For 
both cell lines, one well of a six-well dish was split into six wells and cells were
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transferred in compact colonies of at least 3 cells, as single-celled hESCs are prone to 
differentiation [101].
2.2 Culture of hESCs in different oxygen conditions
A feeder-free system was used for all hypoxia experiments to limit the 
transmission of MEF proteins into the experimental samples [21]. To create a 3D 
extracellular matrix for hESC attachment, each well of a six-well dish was coated in 800 
pL of growth factor-reduced Matrigel® (1 mg/ml dissolved in DMEM-F12; BD 
Biosciences, San Diego, http://www.bdbiosciences.com) for 30 minutes. Excess 
Matrigel® solution was aspirated and hESCs were transferred in compact colonies from 
a MEF layer onto the Matrigel® coated wells. Since MEFs secrete proteins that are 
necessary for hESC pluripotency, special medium is needed when hESCs are maintained 
in the absence of a MEF feeder layer [102]. For proteomics, western blotting, and real 
time reverse transcription polymerase chain reaction (RT-PCR) experiments, the hESCs 
were cultured in mTeSR®l medium, which is a defined, serum-free medium that 
contains all growth factors needed to maintain hESCs in feeder free conditions [103]. 
For immunofluorescence experiments, the hESCs were maintained in SM that had been 
preconditioned for 24 hours on irradiated MEFs seeded at a density of 2.12 x 10s MEFs 
per mL of medium.
Twenty-four hours after the hESCs were seeded onto Matrigel®, the medium was 
changed, and the cultures were placed in 1% oxygen (hypoxia) or 20% oxygen 
(normoxia). To establish hypoxic conditions, cells were placed in airtight chambers 
(BioSpherix) that were flushed with a gas mixture of 5% C02 and 95% N2. Oxygen 
concentrations within these chambers were maintained at 1% using Pro-Ox Model 
110 0 2 regulators (BioSpherix, Redfield, NY). In each oxygen condition, one plate of 
hESCs was incubated for 48 hours, and another was incubated for 72 hours. The 
medium was not changed during this time in order to accelerate differentiation and to 
accumulate hESC derived signals within the culture milieu. At the appropriate time 
points, the medium was removed and cells were washed with PBS. Phase contrast
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images were taken of the hESC colonies in order to assess cell growth and morphology. 
The medium was then removed and culture dishes were wrapped in parafilm and frozen 
at -80°C until protein and RNA could be extracted.
2.3 Protein extraction and quantification
Immediately after frozen six-well dishes of hESCs were transferred from -80°C to 
room temperature, each well was covered with 150 pL of the nondenaturing detergent, 
Mammalian Protein Extraction Reagent (mPER; Thermo Scientific) mixed with 1.5 pL 
100X EDTA-Free Protease Inhibitor Cocktail (Thermo Scientific) and 1.5 pL 100X Halt™ 
Phosphatase Inhibitor Cocktail (Thermo Scientific) for five minutes. The wells were then 
scraped with a disposable cell scraper (Fischer Scientific) to aid the removal of cells. The 
cell lysates were transferred to microcentrifuge tubes and kept on ice. Each sample was 
then sonicated to ensure all membranes had been lysed. The samples were centrifuged 
at 14 000 g for 20 minutes at 4°C to remove large cytoskeleton proteins and other cell 
debris. The supernatant was then aliquoted and stored at -80°C for future mass 
spectrometry and Western blot analysis.
A modified Bradford assay was used to quantify the protein [104]. A protein 
standard was prepared by diluting a solution of bovine serum albumin (BSA; Pierce) to 1 
mg/mL. The protein standard and protein samples of unknown concentration were 
diluted with ddH20 to a final volume of 10 pL in a 96-well flat bottom plate as shown in 
Figure 6. 200 pL of Coomassie Protein Assay Reagent (Thermo Scientific) was dispensed 
into each well. The absorbance at 595 nm was measured with a Victor3V 1420 
Multilabel Counter (Perkin Elmer). A standard curve was created by plotting absorbance 
at 595 nm versus concentration of BSA. The concentrations of the protein samples were 
calculated by inserting their absorbance values into the equation of the standard curve.
2.4 RNA extraction and quantification
RNA was extracted from hESCs using a Purification Column and proprietary 
solutions from a Perfect Pure RNA Purification Kit (5Prime). Immediately after frozen
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Figure 6. Modified Bradford assay setup. Various volumes of protein standard (BSA) 
and samples (SI, S2, S3 and S4) were brought up to 10 pL with ddH20. Two hundred 
microlitres of Coomassie Protein Assay Reagent was then added to each well.
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six-well dishes of hESCs were transferred from -80°C to room temperature, each well 
designated to be used for RNA experiments was covered with 400 pL of Lysis Buffer. 
After five minutes of gentle rocking at room temperature, the solution was pipetted up 
and down vigorously to homogenize and lyse the cells. The solution was then 
transferred to a Purification Column. Four hundred microlitres of Wash 1 Solution was 
added to the column to wash away residual lysate, to eliminate RNase activity, and to 
support full DNase activity. To degrade DNA, 50 pL of DNase Solution was added to the 
column and incubated at room temperature for 15 minutes. Two 200 pL aliquots of 
DNase Wash Solution were then added to inactivate DNase and keep RNA bound to the 
column. Next, Wash 2 Solution was added in two separate applications of 200 pL to 
remove salts. Finally, 50 pL of Elution Solution was added to elute RNA into a clean 
tube. After each solution was added to the column, the collection tube was centrifuged 
at 13 000 g for 1 minute to pass the solution through the column. The collection tube 
was changed every time 400 pL of solution collected in the bottom. The eluted RNA was 
stored on ice or in the freezer at -80°C until it was quantified.
RNA was quantified using a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific). The instrument was rinsed with ddH20  and the sample type was set to "RNA- 
40". Two microlitres of Elution Solution was loaded to blank the instrument, and then 2 
pL of each sample was loaded and measured. Each sample was measured twice and an 
average concentration was calculated. The instrument was washed with ddH20  between 
measurements.
2.5 Immunofluorescence
H9 and CA1 compact hESC colonies were seeded onto Matrigel® in twelve-well 
dishes and cultured in 1% or 20% oxygen as described in section 2.2. After 48 or 72 
hours, the wells were rinsed twice in PBS and incubated in 0.5 mL of fixing solution (4% 
paraformaldehyde, 4% sucrose, 300 pM CaCI2 in PBS) for 20 minutes at room 
temperature. After the cells had been fixed, they were rinsed three times in PBS and 
stored at 4°C until staining was performed. Before staining for Oct-4, which is an
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intracellular protein, the cells were permeabilized with 0.1% Triton X-100 in PBS for 10 
minutes. After two five-minute washes in IX  Rinse Buffer (5% Tris-CI buffer, 150 mM 
NaCI, 0.05% Tween 20 in ddH20), the cells were treated with Serum-Free Protein Block 
(0.25% casein in PBS, containing stabilizing protein and 0.015 M sodium azide; Dako) for 
30 minutes at room temperature to inhibit non-specific staining. The cells were then 
incubated with 0.5 m Lof a primary antibody against human Oct-4 (Oct-3/4 probe mouse 
monoclonal IgG; Santa Cruz Biotechnology) diluted 1:50 in Antibody Diluent (Tris-HCI 
buffer containing stabilizing protein and 0.015 M sodium azide; Dako) for one hour. 
After three five-minute washes in IX  Rinse Buffer, the cells were incubated with a 
secondary antibody against mouse IgG (AlexaFluor 488 goat anti-mouse IgG (H+L); 
Invitrogen). After another three five-minute washes in IX  Rinse Buffer, fluorescence 
micrographs were taken of random colonies. The total number of colonies in three wells 
for each time point and oxygen condition was counted. The number of colonies 
containing at least one region that was not expressing Oct-4 was also counted and 
divided by the total number of colonies to determine the percentage of colonies that 
contained differentiated cells. A Two Way Analysis of Variance (ANOVA) with a Student- 
IMewman-Keuls post hoc test was performed for each cell line to determine whether 
there was a significant difference between time points and between oxygen availiability 
in the datasets. A P value < 0.05 was considered significant.
2.6 Western blotting
Twenty-five micrograms of each protein sample was mixed in a 5:1 ratio with 5X 
loading buffer (28% glycerol, 17% Tris-HCI buffer, pH 6.8, 0.2 M SDS, 4 mM 
bromophenol blue in ddH20) and 1 M dithiothreitol (DTT) for a final concentration of 
100 mM DTT. The mixtures were heated at 100°C for five minutes to denature the 
proteins and reduce disulfide bonds. The samples were then loaded onto a 1.5 mm, 8% 
polyacrylamide mini-gel and run at 200 V. When 20 kDa proteins had run off the gel, 
the voltage was turned off and the gel was placed in Transfer Buffer (1.4% glycine, 0.3% 
Tris Base, 20% methanol in ddH20) for five minutes. Polyvinlyidene difluoride (PVDF)
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paper was activated in methanol for five minutes and then soaked in Transfer Buffer for 
ten minutes. The gel and PVDF paper were clamped together and transferring was 
performed in Transfer Buffer on ice at 100V for 2 hours. The PVDF paper was then 
stained with Amido Black Staining Solution (0.1% Amido black, 50% methanol, 10% 
acetic acid in ddH20) to visualize total protein present. The paper was cut in half 
horizontally at 75 kDa so that H IF-la  (~120 kDa) and P-actin (~42 kDa) could be imaged 
at the same time.
Each half of the PVDF blot was incubated in 5% milk in Tris-Buffered Saline with 
Tween (TBS-T; 0.15 M NaCl, 0.05M Tris buffer (pH 7.6), 0.2% Tween in ddH20) for one 
hour. The milk was drained and the top half of the PDVF paper was incubated for one 
hour with 0.5 pg/mL mouse anti-human H IF-la antibody (BD BioSciences, Lot: 06820) in 
1% BSA in TBS-T. The bottom half of the PDVF paper was incubated for one hour with 
20 ng/mL monoclonal mouse anti-human p-actin antibody (Santa Cruz Biotechnology, 
Lot: D1610) in 1% BSA in TBS-T. Excess primary antibody was rinsed away with four five- 
minute washes of TBS-T. The PDVF paper was then incubated for one hour with goat 
anti-mouse IgG antibody containing a horseradish peroxidase (HRP) conjugate (BioRad). 
Excess secondary antibody was rinsed away with five five-minute washes of TBS-T. The 
membrane was coated with a 1:1 mixture of Peroxidase Solution and Luminol/Enhancer 
Solution from an Immuno-Star™ Western C™ Kit (BioRad) and wrapped with Saran wrap. 
CL-X Posure™ Film (Thermo Scientific) was pressed against the PDVF paper in a dark 
room for 1 second to 5 minutes and was developed with a M35A X-OMAT Processor 
(Kodak).
2.7 Real-time RT-PCR
In order to make cDNA from RNA, 1 pg of RNA from each sample was mixed with 
10 pL Master Medium (20% 10 RT PCR buffer, 32% RNase free ddH20, 8% dNTPs, 20% 
random primers, 10% reverse transcriptase, 10% RNase inhibitor) from a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). ddH20  was added to bring the 
final volume up to 20 pL. The samples were placed in a BioRad C1000 Thermal Cycler at
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25°C for 10 minutes, 37°C for 2 hours, 85°C for five minutes, and 4°C until the samples 
were retrieved.
For real time RT-PCR, a Master Mix solution containing specific primer probes 
was prepared for each gene that would be analyzed. The Master Mix contained 56% 
TaqMan Universal PCR Master Mix (Applied Biosystems), 4% MgCI2, and 6% primer 
probes in RNase free ddH20. Primer probes were selected for the housekeeping gene, 
HPRT1, which served as comparison for the other genes that were analyzed: Oct 4, 
Nanog, Nodal and HIF-la. In a 96-well PCR plate, 2 pL of cDNA from each sample was 
mixed with 18 pL of Master Mix for each primer probe, in duplicate. Two microlitres of 
water was mixed with 18 pL of Master Mix for each primer probe as a no template 
control (NTC). The plate was placed in a C1000™ Thermal Cycler (BioRad) and run at 
50°C for 2 minutes, 95°C for 10 minutes, and then repeating cycles of 95°C for 15 
minutes and 58°C for one minute. The following equation was used to calculate fold 
difference based on CT values:
¡r lACPtarget (control - sample)Ittarget/
ratio - ¿̂CPref(control-sample)
Man-Whitney Rank sum tests were performed to determine whether the 
differences in RNA levels were significant. A P value < 0.05 was considered significant.
2.8 Fractionation and tryptic digestion of proteins for MS analysis
To reduce the complexity of samples for MS analysis, the proteomes were 
fractionated by ID  gel electrophoresis [104], Eighty micrograms of each protein sample 
was mixed in a 5:1 ratio with 5X loading buffer (28% glycerol, 17% Tris-HCI buffer, pH 
6.8, 0.2 M SDS, 4 mM bromophenol blue in ddH20) and 1 M DTT for a final 
concentration of 100 mM DTT. The mixtures were heated at 90°C for 5 minutes to 
denature the proteins and reduce disulfide bonds. The samples were then loaded onto 
a 1.5 mm, 12% SDS-PAGE mini-gel and run at 100 V. When the run was complete, the 
gel was fixed for one hour in Fixing Solution (50% methanol, 10% acetic acid in ddH20), 
stained for one hour with Coomassie Stain Solution (1 mM Brilliant Blue R-250 (BBR),
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50% methanol, 10% acetic acid in ddH20), and destained overnight in Destaining 
Solution 1 (45% methanol, 10% acetic acid in ddH20).
Each lane representing the concentrated sample was then cut into fifteen 
fractions. Gel fractions were cut into small cubes (~1 mm2) and placed into separate 
microcentrifuge tubes. The gel pieces were destained by alternating between washes in 
Destaining Solution 1 and Destaining Solution 2 (20% acetonitrile [ACN] in 100 mM 
ammonium bicarbonate [NH4HC03]).
The cysteines were reduced and alkylated to eliminate disulfide linkages. First, 
the gel pieces were dehydrated with 100% ACN and completely dried by spinning in a 
SpeedVac centrifuge. Then the gel pieces were rehydrated with 10 mM (DTT) in 100 
mM NH4HC03 for 30 min. The DTT solution was removed and 100 mM iodoacetamide 
(IDA) in 100 mM NH4HCO3 was added for 30 min to alkylate the cysteines. The gel 
pieces were washed and dehydrated with 100% ACN, and then rehydrated with 50 mM 
NH4HCO3 twice.
For tryptic digestion, the gel pieces were first dehydrated with 100% ACN, and 
then rehydrated with modified procine trypsin (Promega, Madison, Wl) (20 pg/mL in 50 
mM NH4FICO3) on ice for 15 min. Fifty millimolar NFI4FICO3 was added to cover the gel 
pieces and the samples were maintained at 37°C for 18 h. To extract the tryptic 
peptides, the supernatant was collected and the gel pieces were washed three times 
with 10% formic acid (FA). The samples were then placed in a Speedvac centrifuge until 
the volume was approximately 50 pL. The tubes were centrifuged at 10 000 g for three 
minutes to remove insoluble matter and the supernatant was transferred to MS tubes.
2.9 Iterative exclusion tandem mass spectrometry analysis
LC separation (5-50% ACN, 0.1% FA gradient) was performed on a NanoAcquity 
UPLC (Waters, Milford, MA) with a 15 cm x 75 pm Ci8 reverse phase column. Peptide 
ions were detected in data-dependent acquisition (DDA) mode by tandem MS (Q-ToF 
Ultima; Waters). To identify lower abundance proteins, each sample was injected 
multiple times using iterative exclusion to ignore previously selected ions [99]. Ions that
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Figure 7. Proteomic analysis of hESCs cultured in hypoxia. A) hESCs were cultured in 
1% or 20% oxygen for 48 or 72 hours. B) The proteome was fractionated by ID  gel 
electrophoresis and proteins were alkylated, digested with trypsin, and separated with 
reversed-phase LC. C) The peptides were analyzed by ESI tandem mass spectrometry 
and identified with bioinformatics software.
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had previously been selected were excluded (MassLynx DDA exclude functionality; 
Waters) in subsequent injections of a given fraction using a m/z tolerance window of 
±0.8, based on average mass and a retention time window of ±60 s. Five rounds of 
iterative exclusion were performed on each fraction. To generate the highest quality 
MS/MS spectra, the following DDA parameters were used: survey scan (MS only) range 
m/z 400-1800, 1 s scan time, 1-4 precursor ions selected based on intensity (30 cps) and 
charge state (+2, +3, and +4). For each MS/MS scan, the m/z range was extended to m/z 
50 -1800, a scan time of 1 s used in early exclusions, with an increase to a scan time of 1- 
4 s in later exclusions (signal dependent -  TIC 6000 cps). The MassLynx charge state- 
dependent collision energy profile was used. Selected precursors were then excluded 
for 45 s.
2.10 Bioinformatic analysis
MS/MS raw data files were processed using Mascot Distiller (Matrix Science, 
London, UK) and summarized to Mascot Generic Files (MGF). All MGF files were 
analyzed using Mascot (Matrix Science, London, UK), OMSSA (NCBI, Bethesda, MD, USA) 
and XITandem (The GPM, thepgm.org; version TORNADO (2009.04.01.4)). OMSSA, 
Mascot and XITandem were all set up to search ipi.HUMAN.v3.78_REVERSE.fasta 
(selected for All Entries, 173404 entries) assuming the digestion enzyme trypsin and 
allowing for 2 missed cleavages. Mascot, OMSSA and XITandem were searched with a 
fragment ion mass tolerance of 0.15 Da and a parent ion tolerance of 0.15 Da. For all 
search engines, iodoacetamide derivative of cysteine was specified as a fixed 
modification and oxidation of methionine was specified as a variable modification. 
Acetylation of the N-terminus was specified in XITandem as a variable modification.
Scaffold (version Scaffold_3_00_08, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications from Mascot, OMSSA 
and XITandem. Peptide identifications were accepted if they could be established at 
greater than 95.0% probability as specified by the Peptide Prophet algorithm in [105]. 
Protein identifications were accepted if they could be established at greater than 99.0%
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probability and contained at least 2 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm in [106]. Proteins that contained similar 
peptides and could not be differentiated based on MS/MS analysis alone were grouped 
to satisfy the principles of parsimony.
The results of all six replicates (three for each cell line) were combined and 
compared manually in Excel. Proteins were said to be up-regulated in hypoxia if they 
were identified in two out of three replicates in both cell lines in hypoxia but not 
identified in any replicates in normoxia. Some additional proteins were categorized as 
up-regulated in hypoxia if the number of peptide identifications for a particular protein 
was much higher (>3) in hypoxia than in normoxia for four replicates. Proteins were 
said to be down-regulated in hypoxia if the opposite trend was observed.
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Figure 8. Iterative exclusion tandem mass spectrometry. In this technique, the first 
round of MS analysis identifies the most abundant proteins in the fraction. In 
subsequent rounds, ions that were selected in all previous rounds are ignored based on 
m/z and retention time to allow for the identification of previously uncharacterized, 
lower abundance ions. Image from [99].
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Chapter 3: Results
3.1 Hypoxia promotes pluripotency in our experimental system
H9 and CA1 hESCs in feeder-free cultures were incubated in 1% or 20% oxygen 
for up to 96 hours. The medium was not changed during this time in order to promote 
differentiation. After 48, 72 and 96 hours, a phase contrast microscope was used to 
take micrographs of random colonies. After 48 hours, almost all hESC colonies that had 
been cultured in either oxygen condition had sharp edges and uniformly consisted of 
small, compact cells (Figure 9). This is consistent with the appearance of pluripotent 
hESC colonies [13]. After 72 hours, a small number of colonies that had been cultured in 
1% oxygen contained regions of cells that had a flat and elongated morphology and a 
decreased index of refraction. This indicates that the cells had begun to differentiate or 
were differentiated. Cultures that had been maintained in 20% oxygen for 72 hours 
contained notably more colonies with differentiating areas than cultures that had been 
maintained in 1% oxygen (Figure 9). Cultures that had been incubated in either oxygen 
tension for 96 hours without a change of media had a large amount of differentiation 
(Figure 9).
Cultures that contain large numbers of differentiated cells no longer represent a 
hESC population. Therefore, hESCs that are beginning to differentiate in 20% oxygen 
but are still mostly pluripotent would provide the most insight into how hypoxia 
promotes pluripotency in hESCs. This is most consistent with the level of differentiation 
observed after 48 hours and 72 hours; therefore, these time points were chosen for all 
subsequent experiments. Since there was excessive differentiation after 96 hours of 
culture in unchanged media, no further experiments were carried out at this time point.
3.1.1 Im m unofluorescence localization o f Oct-4
To confirm the observation from phase contrast images that hypoxia promotes 
pluripotency in our system, immunofluorescence analysis was performed to detect the
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Figure 9. hESC morphology after 48 or 72 hours of culture in 1% or 20% oxygen. H9
and CA1 hESC compact colonies were seeded onto a 3D matrix comprised of growth 
factor-reduced Matrigel® and were cultured in the presence of conditioned stem cell 
medium for 48, 72 or 96 hours in 1% or 20% oxygen. The medium was not changed 
during this time in order to accelerate differentiation. Phase-contrast micrographs were 
taken of randomly selected colonies at each time point. Biological replicates were 
performed with (A) the H9 hESC line and (B) the CA1 hESC line. Arrows point to areas of 
differentiation.
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presence of Oct-4, which is a transcription factor that is only present in the nucleus of 
pluripotent hESCs. hESC colonies in feeder-free culture were incubated in 1% or 20% 
oxygen for 48 or 72 hours. At the appropriate time point, the cells were fixed and 
permeabilized, and immunofluorescence analysis was performed for Oct-4. After 48 
hours, almost all colonies that had been cultured in 1% oxygen emitted bright 
fluorescence throughout the colony, indicating that Oct-4 was expressed in all cells of 
these colonies (Figure 10). Some colonies that had been cultured in 20% oxygen for 48 
hours had regions of darkness that did not fluoresce, indicating that these cells were not 
expressing detectable levels of Oct-4. Phase contrast micrographs were taken of the 
same colonies to show that cells were present in these dark regions. After 72 hours, 
more areas that did not stain for Oct-4 appeared in cultures maintained at both oxygen 
tensions, with appreciably more dark regions in the 20% cultures than the 1% cultures 
(Figure 10).
For each oxygen condition, the number of colonies that contained at least one 
dark area not expressing Oct-4 was counted. This was divided by the total number of 
colonies to give the percentage of colonies with areas of differentiation. Three 
replicates were performed with each cell line. In hypoxia, 3.0 ± 3.1% of H9 hESCs and
2.0 ± 1.7% of CA1 hESCs contained areas of differentiation after 48 hours and 11.7 ± 
2.5% of H9 hESCs and 15.5 ± 5.6% of CA1 hESCs contained areas of differentiation after 
72 hours. In normoxia, 20.3 ± 7.1% of H9 hESCs and 18.4 ± 5.2% of CA1 hESCs contained 
areas of differentiation after 48 hours and 38.7 ± 8.0% of H9 hESCs and 34.3 ± 7.4% of 
CA1 hESCs contained areas of differentiation after 72 hours (Figure 11). For both cell 
lines, there was a significant difference in the percentage of colonies with areas of 
differentiation between hypoxic and normoxic culture for both time points (P<0.01, 
n=3). For the CA1 cell line, there was a significantly higher percentage of colonies with 
differentiation at 72 hours than at 48 hours for cultures maintained in hypoxia. For both 
cell lines, there was a significantly higher percentage of colonies with differentiation at 
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Figure 10. Immunofluorescent detection of Oct-4 in hESCs cultured in 1% or 20% 
oxygen for 48 or 72 hours. hESCs cultured on growth factor-reduced Matrigel® in 
conditioned stem cell medium were incubated in 1% or 20% oxygen for 48 or 72 hours. 
The medium was not changed during this time in order to accelerate differentiation. 
The cultures were fixed with paraformaldehyde and immunostained for Oct-4, a protein 
known to be expressed only in pluripotent cells. Biological replicates were performed 
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Figure 11. Percentage of colonies with areas of differentiation for hESCs cultured in 
1% or 20% oxygen, as determined by Immunofluorescent detection of Oct-4. hESCs in 
feeder-free culture were maintained for 48 or 72 hours in 1% or 20% oxygen. The 
cultures were immunostained for Oct-4, a marker of pluripotency. The number of 
colonies containing regions that did not express Oct-4 was counted. This was divided by 
the total number of colonies to give the percentage of colonies with areas of 
differentiation. Biological replicates were performed with (A) the H9 hESC line and (B) 
the CA1 hESC line (mean ± SD, n=3). Values that differ significantly between oxygen 
tensions within a time point are shown with asterisks (*, P < 0.01; **, P < 0.001) and 
values that differ significantly between time points within an oxygen tension are shown 
with daggers (+, P < 0.05; T P  < 0.01).
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3.2 Real-time RT-PCR Analysis of Pluripotency Associated Genes in Hypoxia
Oct-4, Nanog and Nodal are proteins that are known to be expressed in 
pluripotent hESCs but not in differentiated cells. Nodal and H IF-la  protein have been 
shown to be up-regulated in hypoxia compared to normoxia in cancer cells. To 
investigate how these genes are expressed in our experimental system, real-time RT- 
PCR anaylsis was performed. H9 and CA1 hESC colonies were seeded onto Martrigel® in 
the presence of mTESR®l media and incubated in 1% or 20% oxygen for 48 or 72 hours. 
RNA was extracted from the cells and cDNA was made from the extracts. Real-time RT- 
PCR analysis was performed for each oxygen tension and time point with primers for 
Oct-4, Nanog, Nodal, and HIF-la. The analysis was repeated three times for each cell 
line. There was no significant difference (P> 0.05, n=3) in mRNA levels between hypoxia 
and normoxia for any of the genes analyzed (Figures 12-15).
3.3 H IF-la  Protein Expression in hESCs Cultured in Hypoxia and Normoxia
Although real-time RT-PCR analysis revealed that there is no change in H IF-la 
mRNA levels when hESCs are cultured in hypoxia, Western blot analysis of H IF-la  was 
performed because it is known that there is limited correlation between mRNA levels 
and protein levels in hESCs, and HIFa proteins are regulated predominantly via 
alterations in protein degradation. CA1 and H9 hESCs in feeder-free culture were 
maintained in 1% or 20% oxygen for 48 or 72 hours. Western blot analysis was 
performed with anti-HIF-la and anti-P-actin antibodies. Distinct double bands, 
representing phosphorylated and unphosphorylated H IF-la , were present around 120 
kDa in all lanes containing protein from hESCs cultured in hypoxia. The same double 
band was much fainter or not visible in lanes containing protein from hESCs cultured in 
normoxia. Densitometry analysis of the plots was performed for three replicates with 
each cell line and results were analysed with t-tests. There was significantly greater 
expression of H IF-la  in hypoxic samples than in normoxic samples (P< 0.01, n=3) for 
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Figure 12. Real-time RT-PCR analysis of Oct-4 mRNA in hESCs cultured in hypoxia and 
normoxia. H9 and CA1 hESCs were cultured in 1% or 20% oxygen for 48 or 72 hours. At 
each time point, RNA was extracted and quantified, and real-time RT PCR was 
performed with a primer for the Oct-4 transcript. CT values were normalized to the 
housekeeping gene, HPRT1. Graphs depict relative levels of Oct-4 mRNA in hypoxia 
compared to normoxia for (A) H9 hESCs after 48 hours, (B) CA1 hESCs after 48 hours, (C) 
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Figure 13. Real-time RT-PCR analysis of Nanog mRNA in hESCs cultured in hypoxia and 
normoxia. H9 and CA1 hESCs were cultured in 1% or 20% oxygen for 48 or 72 hours. At 
each time point, RNA was extracted and quantified, and real-time RT-PCR was 
performed with a primer for the Nanog transcript. CT values were normalized to the 
housekeeping gene, HPRT1. Graphs depict relative expression of Nanog in hypoxia 
compared to normoxia for (A) H9 hESCs after 48 hours, (B) CA1 hESCs after 48 hours, (C) 
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Figure 14. Real-time RT-PCR analysis of Nodal mRNA in hESCs cultured in hypoxia and 
normoxia. H9 and CA1 hESCs were cultured in 1% or 20% oxygen for 48 or 72 hours. At 
each time point, RNA was extracted and quantified, and real-time RT-PCR was 
performed with a primer for the Nodal transcript. CT values were normalized to the 
housekeeping gene, HPRT1. Graphs depict relative expression of the transcript in 
hypoxia compared to normoxia for (A) H9 hESCs after 48 hours, (B) CA1 hESCs after 48 
hours, (C) H9 hESCs after 72 hours and (D) CA1 hESCs after 72 hours. Values are means 
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Figure 15. Real-time RT-PCR analysis of H IF-la  mRNA in hESCs cultured in hypoxia and 
normoxia. H9 and CA1 hESCs were cultured in 1% or 20% oxygen for 48 or 72 hours. At 
each time point, RNA was extracted and quantified, and real-time RT-PCR was 
performed with a primer for the H IF-la  transcript. CT values were normalized to the 
housekeeping gene, HPRT1. Graphs depict relative expression of the transcript in 
hypoxia compared to normoxia for (A) H9 hESCs after 48 hours, (B) CA1 hESCs after 48 
hours, (C) H9 hESCs after 72 hours and (D) CA1 hESCs after 72 hours. Values are means ± 









Figure 16. Expression of HIF-la in hESCs cultured in hypoxia and normoxia. hESCs 
were cultured in 1% or 20% oxygen for 48 or 72 hours. Western blot analysis was 
performed for H IF-la, normalized to P-actin for A) H9 hESCs and B) CA1 hESCs. 
Densitometry analysis was performed to compare H IF-la  expression at C) 48 hours in 
H9 hESCs, D) 48 hours in CA1 hESCs, E) 72 hours in H9 hESCs, and F) 72 hours in CA1 
hESCs. Values (mean ± SD, n=3) that differ significantly between oxygen tensions are 
shown with asterisks (*, P < 0.01; **, P < 0.001).
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3.4 Numerous proteins were up- or down-regulated in hypoxia
Shotgun proteomics was used to compare global protein expression of hESCs 
cultured in hypoxia with that of hESCs cultured in normoxia. After H9 and CA1 hESCs 
had been cultured in 1% or 20% oxygen for 48 or 72 hours, the proteome was extracted 
and purified. To increase the number of proteins that could be identified by MS 
analysis, the proteome was separated by ID  gel electrophoresis and each lane was 
divided into 15 fractions (Figure 17). Equal quantities of each protein sample were 
loaded onto the gel so that results could be compared semi-quantitatively. The proteins 
were digested with trypsin and the tryptic peptides of each fraction were separated by 
nano reverse phase liquid chromatography to further simplify the fractions for MS 
analysis. The peptides were then analyzed by electrospray tandem MS on a Q-Tof, 
which generated spectra containing sequence information about the peptides. To 
increase the number of peptides identified in the samples, each sample was injected 5 
times and the MS was instructed to ignore previously identified peptides from that 
sample.
The bioinformatics search engines, Mascot, OMSSA, and XlTandem were used to 
identify peptides from the MS/MS spectra and Scaffold was used to validate MS/MS 
based peptide and protein identifications. Peptide identifications were accepted if they 
could be established at greater than 95.0% probability and protein identifications were 
accepted if they could be established at greater than 99.0% probability and contained at 
least 2 identified peptides. The results of all six replicates (three for each cell line) were 
combined and compared manually in Microsoft Office Excel. Proteins were said to be 
up-regulated in hypoxia if they were identified in two out of three replicates in both cell 
lines in hypoxia but not identified in any replicates in normoxia. Some additional 
proteins were categorized as up-regulated in hypoxia if the number of peptide 
identifications for a particular protein was much higher (>3) in hypoxia than in normoxia 
for four replicates. Proteins were said to be down-regulated in hypoxia if the opposite 
trend was observed. (See appendices A-D for lists of the number of peptide 
identifications in each replicate for proteins up- and down-regulated in hypoxia).
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A total of 1358 distinct proteins were identified in at least two replicates in both 
H9 and CA1 hESCs at 48 hours from cells cultured under both oxygen conditions (see 
Appendix E for a complete list of proteins identified in hypoxia). A total of 1649 distinct 
proteins were identified in at least two replicates in both H9 and CA1 hESCs at 72 hours 
from cells cultured under both oxygen conditions (see Appendix F for a complete list of 
proteins identified in hypoxia). Of the proteins identified at 48 hours, 17 were up- 
regulated in hypoxia and 48 were down-regulated in hypoxia (Figure 18). Of the 
proteins identified at 72 hours, 27 were up-regulated in hypoxia and 32 were down- 
regulated in hypoxia (Figure 18). Only four of the proteins that were up- or down- 
regulated at 48 hours were also up- or down-regulated at 72 hours, respectively.
3.4.1 Hypoxia influenced the expression of some metabolic proteins
Several proteins involved in metabolism were either up- or down-regulated in 
hESCs that had been cultured in hypoxia (Figure 19). Flexol<inase-2, which catalyses the 
first committed step of glucose metabolism [107], was up-regulated in hypoxia at both 
48 and 72 hours (Table 1 and 3). Solute carrier family 2, facilitated glucose transporter 
member 1 (GLUT1), which transports glucose across the plasma membrane [108], was 
also up-regulated at both 48 hours and 72 hours in hypoxia (Table 1 and 3).
Pyruvate dehydrogenase E la  1 (PDFIA1) precursor was down-regulated at 48 
hours in hypoxia (Table 2). PDHA1 is a mitochondrial enzyme that catalyzes the 
conversion of pyruvate to acetyl-CoA and C02 [109]. a-ketoglutarate-dependent 
dioxygenase FTO was also down-regulated at 48 hours in hypoxia (Table 2). This protein 
is a dioxygenase that uses molecular oxygen, a-ketoglutarate and iron to repair 
alkylated ssDNA and RNA by oxidative déméthylation [110] and contributes to the 
regulation of the global metabolic rate and energy expenditure [111]. Aldose-1 
epimerase, which converts D-glucose, L-arabinose, D-xylose, D-galactose, maltose and 
lactose to the P-anomer [112], was down-regulated at 48 hours in hypoxia (Table 2). At 
48 hours, there was also down-regulation of Arginase-2, which is an inducible protein
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Figure 17. Fractionation of the hESC proteome by ID  gel electrophoresis. To simplify 
hESC proteomes for MS analysis, ID  gel electrophoresis was performed as a pre­
fractionation step. Each lane was divided into 15 fractions. Regions of each lane that 
contained more protein as revealed by Coomassie blue staining were cut into narrower 
fractions so that each fraction contained approximately the same amount of protein. 
Proteomes were extracted from hESCs that had been cultured for (A) 48 hours in 1% 
oxygen, (B) 48 hours in 20% oxygen, (C) 72 hours in 1% oxygen and (D) 72 hours in 20% 
oxygen. Molecular weight standards are shown in Lane M.
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48 hours 72 hours
17 1293 48 27 1590 32
1 % oxygen 20% oxygen
Figure 18. Number of proteins consistently identified by MS in hypoxic and normoxic 
hESC samples. Venn diagrams display the number of distinct proteins identified in at 
least two replicates in both H9 and CA1 hESCs after 48 and 72 hours of culture in either 
oxygen tension. O The number of proteins detected only in hypoxia, O the number of 
proteins detected only in normoxia, and O the number of proteins detected in both 
oxygen conditions.
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that catalyzes the hydrolysis of arginine to ornithine and urea and inhibits the 
production of nitric oxide ([113]; Table 2).
Two components of Complex I of the electron transport chain: NADH 
dehydrogenase 75 kDa subunit and NADH dehydrogenase a subcomplex 5, were up- 
regulated at 72 hours in hypoxia (Table 3). Bifunctional coenzyme A synthase, which is a 
bifunctional enzyme that catalyzes two sequential steps of the CoA biosynthetic 
pathway [114], was down-regulated at 72 hours in hypoxia (Table 4).
3.4.2 Proteins involved in cell signaling were expressed differently in hypoxia
Proteins involved in various signaling pathways were either up- or down- 
regulated in hESCs cultured under hypoxia. At 48 hours in hypoxia, there was up- 
regulation of mitogen-activated protein kinase 14 (MAPK14; Table 1). This kinase has a 
role in stress related transcription and cell cycle regulation and mediates 
developmental, differentiation and proliferation processes [115]. Mitogen activated 
protein kinase kinase 4 (MAP2K4), which is a dual specificity kinase that activates the 
JUN kinases MAPK8 (JNK1) and MAPK9 (JNK2) as well as MAPK14 (p38) [116], was 
down-regulated at 48 hours in hypoxia (Table 2).
Insulin-like growth factor binding protein 2 (IGFBP-2), which modulates the 
action of insulin-like growth factors (IGFs) and also acts independently to affect 
proliferation, apoptosis, and mobility [117], was up-regulated at 72 hours in hypoxia 
(Table 3). PERQ amino acid-rich with GYF domain-containing protein 2 (GIGYF2), which 
may regulate tyrosine kinase receptor signaling at endosomes and regulate IGF-1 
receptor trafficking [118], was also up-regulated at 72 hours in hypoxia.
Oxysterol-binding protein (OSBP) was down-regulated at 48 hours in hypoxia 
(Table 2). OSBP is a scaffold protein that binds cholesterol and other oxysterols and 
coordinates the activity of PP2A and a tyrosine phosphatase on the ERK signaling 
pathway [119]. Tetratricopeptide repeat protein 1 (TPR1), which competes with the 
Ras-binding domain of Raf-1 [120], was also down-regulated at 48 hours in hypoxia 
(Table 2).
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Table 1: Proteins Up-regulated in Hypoxia at 48 Hours
Symbol Protein Name IPI Number
AARS Alanyl-tRNA synthetase IPI00910701
CSE1L Exportin-2 (Isoform 1) IPI00022744
DCTN1 Dynactin, subunit 1 (Isoform pl50) IPI00029485
DHX38 Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 IPI00294211
EXOSC7 Exosome complex exonuclease RRP42 IPI00014198
FAM96B Protein FAM96B IPI00007024
FDPS Farnesyl pyrophosphate synthase (Isoform B) IPI00914971
GLUT1 Solute carrier family 2, facilitated glucose transporter, member 1 IPI00220194
HIST1H2A Histone H2A type 1-H IPI00081836
HK2 Hexokinase-2 IPI00102864
KIAA1524 Protein CIP2A (Isoform 1) IPI00154283
LRBA Lipopolysaccharide-responsive and beige-like anchor protein 
(Isoform 1)
IPI00002255
MAPK14 Mitogen-activated protein kinase 14 (Isoform CSBP2) IPI00002857
PPP1CA Serine/threonine-protein phosphatase PPl-a, catalytic subunit 
(Isoform 3)
IPI00027423
SMC4 Structural maintenance of chromosomes protein 4 (Isoform 2) IPI00328298
SQLE Squalene monooxygenase IPI00291544
TOMM22 Mitochondrial import receptor subunit, TOM22 homolog IPI00024976
- Actin-like protein (Fragment) IPI00556391
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Table 2: Proteins Down-regulated in Hypoxia at 48 Hours
Symbol Protein Name IPI Number
ARG2 Arginase-2, mitochondrial IPI00020332
ATG3 Ubiquitin-like-conjugating enzyme ATG3 (Isoform 1) IPI00022254
C10orfll9 UPF0557 protein C10orfll9 (Isoform 2) IPI00552546
C5orf51 UPF0600 protein C5orf51 1P100374272
DCTD Deoxycytidylate deaminase (Isoform 1) IPI00296863
DCTN3 Dynactin subunit 3 (Isoform 2) IPI00013654
DCUN1D1 DCNl-like protein 1 IPI00291893
DERA Putative deoxyribose-phosphate aldolase IPI00219677
DYNLRB1 Dynein, light chain, roadblock-type 1 IPI00412497
EIF2B1 Translation initiation factor elF-2B, subunit a IPI00221300
EML4 Echinoderm microtubule-associated protein-like 4 IPI00001466
FAM129B Niban-like protein 1 IPI00456750
FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 IPI00002535
FTO a-ketoglutarate-dependent dioxygenase FTO (Isoform 1) IPI00028277
G3BP2 Ras GTPase-activating protein-binding protein 2 (Isoform A) IPI00009057
MAP2K4 Mitogen-activated protein kinase kinase 4 (Isoform 2) IPI00024674
MARCKS Myristoylated alanine-rich C-kinase substrate IPI00219301
MNAT1 CDK-activating kinase assembly factor MAT1 IPI00294701
MRPL19 39S ribosomal protein L19, mitochondrial IPI00027096
MRPS28 28S ribosomal protein S28, mitochondrial IPI00022276
NAA25 N-alpha-acetyltransferase 25, NatB auxiliary subunit (Isoform 1) IPI00025890
NAA38 N-alpha-acetyltransferase 38, NatC auxiliary subunit IPI00219871
NLN Neurolysin, mitochondrial IPI00010346
NSFL1C NSFLl cofactor p47 (Isoform 1) IPI00100197
NUP48 Nucleoporin 43 kDa IPI00742943
NUP98 Nucleoporin 98 kDa IPI00006038
OSBP Oxysterol-binding protein 1 (Isoform 1) IPI00024971
PCYT2 Ethanolamine-phosphate cytidylyltransferase IPI00015285
PDCT3 Pentatricopeptide repeat domain 3 (Isoform 2) IPI00783302
PDHA1 Pyruvate dehydrogenase E l alpha 1 (Isoform 2) precursor IPI00306301
P1R Pirin IPI00012575
PP2AC Serine/threonine-protein phosphatase PPl-a, catalytic subunit IPI00550451
PSMF1 Proteasome inhibitor, PI31 subunit IPI00009949
PTCD1 Pentatricopeptide repeat domain 1 IPI00926491
RAB4A RAB4A, member RAS oncogene family variant IPI00480056
REEP5 Receptor expression-enhancing protein 5 IPI00024670
SLC16A1 Monocarboxylate transporter 1 IPI00024650
SMC4 Structural maintenance of chromosomes protein 4 (Isoform 1) IPI00411559
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SQSTM1 Sequestosome-1 (Isoform 1) IPI00179473
ST0ML2 Stomatin-like protein 2 IPI00334190
SUGT1 Suppressor of G2 allele of SKP1 homolog (Isoform 2) IPI00791573
TBRG4 Transforming growth factor beta regulator 4 IPI00329625
TOMM34 Mitochondrial import receptor, subunit TOM34 IPI00009946
TSFM Elongation factor Ts, mitochondrial (Isoform 1) IPI00021016
TTC1 Tetratricopeptide repeat protein 1 IPI00016912
XPNPEP1 xaa-Pro aminopeptidase 1 (Isoform 1) IPI00645898
_ Protein of unknown function, DUF410 family protein IPI00419575
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Table 3: Proteins Up-regulated in Hypoxia at 72 Hours
Symbol Protein Nome IPI Number
ACOl Cytoplasmic aconitate hydratase IPI00008485
AP1B1 AP-1 complex subunit beta-1 (Isoform A) IPI00328257
ENAH Protein enabled homolog (Isoform 2) IPI00374054
FAM162A Protein FAM162A IPI00023001
FANCI Fanconi anemia group 1 protein (Isoform 1) IPI00019447
FUBP1 Far upstream element-binding protein 1 (Isoform 1) IPI00375441
GIGYF2 PERQ amino acid-rich with GYF domain-containing protein 2 
(Isoform 2)
IPI00647635
GLUT1 Solute carrier family 2, facilitated glucose transporter, member 1 IPI00220194
HK2 Hexokinase-2 IPI00102864
IDI1 Isopentenyl-diphosphate Delta-isomerase 1 (Isoform 1) IPI00645307
IGFBP2 Insulin-like growth factor-binding protein 2 precursor IPI00297284
LEPREL1 Prolyl 3-hydroxylase 2 1PI00217055
LUZPl Leucine zipper protein 1 (Isoform 1) IPI00296830
MAP4 Microtubule-associated protein 4 (Isoform 1) IPI00396171
MLLT4 Afadin (Isoform 4) IPI00023461
MOBKL3 Mps one binder kinase activator-like 3 (Isoform 1) IPI00386122
MOGS Mannosyl-oligosaccharide glucosidase IPI00328170
NDUFAS NADH dehydrogenase (ubiquinone) la , subcomplex 5 IPI00412545
NDUFS1 NADH-ubiquinone oxidoreductase, 75 kDa subunit IPI00604664
P4HA1 Prolyl 4-hydroxylase subunit a-1 (Isoform 1) IPI00009923
PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (Isoform 2) IPI00337495
RPL35A 60S ribosomal protein L35a IPI00029731
RPRD1A Regulation of nuclear pre-mRNA domain-containing protein 1A 
(Isoform 2)
IPI00062336
SAP18 Histone deacetylase complex subunit SAP18 IPI00011698
SNX3 Sorting nexin-3 (Isoform 4} IPI00552276
TPD52 Tumor protein D52 (Isoform 1) IPI00619958
YRDC YrdC domain-containing protein, mitochondrial IPI00384180
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Table 4: Proteins Down-regulated in Hypoxia at 72 Hours
Symbol Protein Name IPI Number
ARPC1B Actin-related protein 2/3 complex, subunit IB IPI00005160
BOLA2 BolA-like protein 2 IPI00301434
CDC73 Parafibromin IPI00300659
CLASP1 CLIP-associating protein 1 (Isoform 1) IPI00396279
COASY Bifunctional coenzyme A synthase (Isoform 1) IPI00184821
CTSA Lysosomal protective protein IPI00021794
DCTN1 Dynactin, subunit 1 (Isoform 4) IPI00914026
DDX19A ATP-dependent RNA helicase DDX19A IPI00019918
DNAJA3 DnaJ homolog subfamily A member 3, mitochondrial (Isoform 2) IPI00179187
FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 IPI00002535
GLS Glutaminase kidney isoform, mitochondrial (Isoform 3) IPI00215687
H1FX Histone Hlx IPI00021924
H3F3A Histone H3.3 IPI00219038
IDIl Isopentenyl-diphosphate Delta-isomerase 1 (Isoform 2) IPI00220014
MINPP1 Multiple inositol polyphosphate phosphatase 1 (Isoform 1) IPI00293748
MLLT4 Afadin (Isoform 3) IPI00216505
MRPL15 39S ribosomal protein L15, mitochondrial IPI00023086
MRPL19 39S ribosomal protein L19, mitochondrial IPI00027096
MRPS9 28S ribosomal protein S9, mitochondrial IPI00641924
MYOIC Myosin-lc (Isoform 2) IPI00010418
PFDN4 Prefoldin, subunit 4 IPI00015891
POLR2G DNA-directed RNA polymerase II, subunit RPB7 IPI00218895
PTK2 Focal adhesion kinase 1 (Isoform 1) IPI00012885
SEC11A Signal peptidase complex, catalytic subunit SEC11A IPI00104128
SNX3 Sorting nexin-3 (isoform 1) IPI00815770
SPCS3 Signal peptidase complex, subunit 3 IPI00300299
TBPL1 TATA box-binding protein-like protein 1 1PI00032911
TMEM109 Transmembrane protein 109 1PI00031697
VPS26A Vacuolar protein sorting-associated protein 26A IPI00411426
YLPM1 YLP motif-containing protein 1 IPI00165434
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3.4.3 Enzymes involved in steroid biosynthesis were up-regulated in hypoxia
Three proteins involved in biosynthesis of isoprenoids and steroid molecules
were up-regulated in hypoxia (Figure 18). At 72 hours in hypoxia, there was up- 
regulation of Isoform 1 and down-regulation of Isoform 2 of Isopentenyl-diphosphate 
Delta-isomerase 1 (IPPI1), which catalyses the interconversion of isopentenyl 
pyrophosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are both substrates 
for Farnesyl pyrophosphate synthase (FDPS) [121]. FDPS, which is a key branch point 
the isoprenoid biosynthesis pathway, was also up-regulated at 48 hours in hypoxia 
(Table 1). FDPS creates lipids that are incorporated into sterols, dolichols, ubiquinones 
and carotenoids or used as substrates for farnesylation and geranylgeranylation of 
proteins [122]. At 48 hours, there was up-regulation of squalene monooxygenase 
(SQLE), which catalyzes the first oxygenation step in sterol biosynthesis ([123]; Table 1).
3.4.4 Transcriptional regulatory proteins were expressed differently in hypoxia
Proteins involved in the regulation of transcription were up- or down-regulated
in hypoxia. Far upstream element-binding protein 1, which stimulates the expression of 
c-Myc in undifferentiated cells by activating the far upstream element of c-Myc [124], 
was up-regulated at 72 hours in hypoxia (Table 3). Protein CIP2A, which prevents 
proteolytic degradation of c-Myc by inhibiting PP2A tumor suppressor activity towards it 
[125], was up-regulated at 48 hours in hypoxia (Table 1). DNA-directed RNA polymerase 
II, subunit RPB7, which is a subunit of RNA polymerase II that is dispensable under 
optimal growth conditions, but essential for transcription of specific genes when cells 
are in stressful environments [126], was down-regulated at 72 hours in hypoxia (Table 
4).
Several transcription factors were down-regulated in hypoxia. CDK-activating 
kinase assembly factor MAT1 (MNAT1) was down-regulated at 48 hours (Table 2). 
MNAT1 forms a trimeric complex with CDK7 and cyclin FI called the CAK complex [127], 
which associates with additional proteins to form the TFIIFI basal transcription factor 
[128]. The transcription regulator, Pirin, which has been shown to be necessary for
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terminal myeloid differentiation [129], was down-regulated at 48 hours in hypoxia. 
TATA box-binding protein-like protein 1 (TBPL1) was down-regulated at 72 hours (Table 
4). TBPL1 is a promoter-specific recognition factor that can replace TATA binding 
protein in transcription regulation of specific genes [130].
3.4.5 Proteins involved in RNA processing were expressed differently in hypoxia
Some proteins involved in RNA splicing, processing, and export from the nucleus
were differentially expressed in hypoxia. Pre-mRNA-splicing factor ATP-dependent RNA 
helicase PRP16, which is essential for catalytic step II in the pre-mRNA splicing process 
[131], was up-regulated at 48 hours in hypoxia (Table 1). Exosome complex exonuclease 
RRP42 (EXOSC7) was also up-regulated at 48 hours in hypoxia (Table 1). EXOSC7 is a 
component of the exosome 3'-5' exoribonuclease complex, which degrades unstable 
mRNAs that have AU-rich elements (AREs) in their 3'-untranslated region and it is also 
required for processing of 7S pre-RNA to the mature 5.8S rRNA [132], N-a- 
acetyltransferase 38, NatC auxiliary subunit (NAA38), which binds to the 3'-terminal U- 
tract of U6 snRNA and is involved in mRNA processing and splicing [133], was down- 
regulated at 48 hours in hypoxia (Table 2). ATP-dependent RNA helicase DDX19A, which 
is an ATP-dependent RNA helicase involved in mRNA export from the nucleus [134], was 
down-regulated at 72 hours in hypoxia (Table 4).
3.4.6 Protein-processing enzymes were differentially expressed in hypoxia
Some enzymes involved in posttranslational processing of proteins were up- or
down-regulated in hypoxia. Mannosyl-oligosaccharide glucosidase, which is the first 
enzyme in the N-linked oligosaccharide processing pathway, was up-regulated at 72 
hours in hypoxia. This enzyme is found in the endoplasmic reticulum and it cleaves the 
distal glucose from Glc(3)-Man(9)-GlcNAc(2) glycosylated proteins [135].
Peptidyl-prolyl cis-trans isomerase FKBP2, which accelerates protein folding in 
the endoplasmic reticulum [136], was down-regulated at both 48 and 72 hours in 
hypoxia (Table 2 and 4). Signal peptidase complex catalytic subunit SEC11A and Signal
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peptidase complex subunit 3, which are components of the signal peptidase complex 
that removes signal peptides from nascent proteins as they are translated into the 
endoplasmic reticulum [137, 138], were down-regulated at 72 hours in hypoxia (Table 
4).
3.4.7 Proteins involved in cell trafficking were expressed differently in hypoxia
Proteins involved in trafficking and sorting of proteins through the Golgi and 
endosomes were up- or down- regulated in hypoxia. Lipopolysaccharide-responsive and 
beige-like anchor protein (LBRA) was up-regulated at 48 hours in hypoxia (Table 1). 
LRBA may be involved in coupling signal transduction and vesicle trafficking for polarized 
secretion and/or membrane deposition of immune effector molecules [139]. Isoform 
p l50  of dynactin subunit 1 was up-regulated at 48 hours in hypoxia, isoform 2 of 
dynactin subunit 3 was down-regulated at 48 hours and isoform 4 of dynactin subunit 1 
was down-regulated at 72 hours. Dynactin is involved in many cell functions, 
including ER-to-Golgi transport, centripetal movement of lysosomes and endosomes, 
spindle formation, and chromosome movement [140,141],
Adaptor protein complex 1, subunit beta, which is involved in protein sorting in 
the Golgi and endosomes, was up-regulated at 72 hours in hypoxia. The AP complexes 
mediate the recruitment of clathrin to membranes and the recognition of sorting signals 
[142]. Isoform 4 of sorting nextin-3 (SNX3) was up-regulated at 72 hours in hypoxia 
(Table 3) and isoform 1 was down-regulated (Table 4). SNX3 is required for 
multivesicular body formation and plays a role in protein transport between cellular 
compartments [143]. Tumor protein D52, which is an adaptor protein that is involved in 
lysosomal membrane trafficking to and from the plasma membrane and regulation of 
vesicle trafficking [144], was also up-regulated at 72 hours in hypoxia.
Rab4A was down-regulated at 48 hours in hypoxia (Table 2). Rab4A is a member 
of the Rab family of small GTPases that regulates intracellular transport, and has been 
localized to early endosomes and dynein light intermediate chain 1 [145]. Dynein, light 
chain, roadblock-type 1, which links dynein to cargos and to adapter proteins that
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regulate dynein function, was also down-regulated at 48 hours in hypoxia. Dynein 1 acts 
as a motor for the retrograde movement of vesicles and organelles along microtubules 
[146]. Vacuolar protein sorting-associated protein 26A (VPS26A) was down-regulated at 
72 hours in hypoxia (Table 4). VPS26A is a necessary component of the retromer 
complex, which retrieves lysosomal enzyme receptors (IGF2R and M6PR) from 
endosomes to the trans-Golgi network [147].
Some proteins involved in the transport of proteins between mitochondria, the 
cytoplasm, and the nucleus, were differentially expressed in hypoxia. Nucleoporin 43 
kDa (NUP43) and Nucleoporin 98 kDa (NUP98) were down-regulated at 48 hours in 
hypoxia (Table 2). NUP43 is responsible for assembly of a functional nuclear pore 
complex for transport of molecules between the nucleus and cytoplasm, and it is also 
required for normal kinetochore microtubule attachment, mitotic progression and 
chromosome segregation [148], NUP98 is a component of the nuclear pore complex 
that contributes to nuclear-cytoplasmic trafficking, including mRNA export. In addition, 
it may play a role in gene expression, mitotic checkpoints, and pathogenesis [149]. At 
48 hours, mitochondrial import receptor subunit TOM34, was down-regulated (Table 2) 
and Mitochondrial import receptor subunit TOM22 homolog was up-regulated (Table 1). 
TOM34 and TOM22 play roles in the import of pre-proteins that were synthesized in the 
cytosol into mitochondria [150].
3.4.8 Proteins involved in epigenetics were expressed differently in hypoxia
Several proteins associated with chromatin structure and epigenetic regulation 
were up- or down-regulated in hypoxic conditions. Histone H2A type 1-H was up- 
regulated at 48 hours in hypoxia (Table 1) and Histone H1X and H3.3 were 
downregulated in hypoxia at 72 hours (Table 4). Histones are core components of the 
nucleosome, which wraps DNA into chromatin, limiting the ability of transcription 
factors to access DNA [151]. Histone deacetylase complex subunit SAP18, which is a 
component of the SIN3-repressing complex that enhances transcriptional repression 
[152], was up-regulated in hypoxia at 72 hours (Table 3). Parafibromin (CDC73), which
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was down-regulated at 72 hours in hypoxia (Table 4), is a component of the PAF1 
complex, which activates transcription of specific genes by ubiquitinating and 
methylating histones [153, 154]. The PAF1 complex regulates transcription of genes 
involved in cell growth and survival and it is essential for normal embryonic 
development [155].
3.4.9 Some procollagen hydroxylases were up-regulated in hypoxia
Three enzymes that hydroxylate components of collagen were up-regulated at 
72 hours in hypoxia: Prolyl 4-hydroxylase, subunit a-1 (P4HA1), Prolyl 3-hydroxylase 2 
(LEPREL1), and Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) (Table 3). 
P4HA1 and LEPREL1 hydroxylate prolyl residues and PLOD2 hydroxylates lysyl residues 
in collagen-like peptides [156]. P4HA1 and PLOD2 have been shown to be up-regulated 
in rat vascular smooth muscle cells cultured in hypoxia [156].
3.4.10 Proteins involved in proliferation or mitosis were differentially expressed
Some proteins that inhibit proliferation were up-regulated in hypoxia, and some
proteins that are associated with increased proliferation or mitotic progression were 
down-regulated. Transforming growth factor beta regulator 4 (TBRG4), which may play 
a role in cell cycle progression [157], was down-regulated at 48 hours. NSFL1C cofactor 
p47, which is necessary for the fragmentation of Golgi stacks during mitosis and for 
reassembly of Golgi stacks after mitosis [158], was also down-regulated at 48 hours in 
hypoxia (Table 2). Deoxycytidylate deaminase, which creates the substrate for 
thymidylate synthetase to make dTMP for use in DNA synthesis and repair [159], was 
down-regulated at 48 hours in hypoxia (Table 2). Echinoderm microtubule-associated 
protein-like 4 (EML4) was down-regulated at 48 hours in hypoxia. EML4, which is highly 
expressed during mitosis and is associated with the mitotic spindle, is needed for correct 
microtubule formation [160]. Isoform 2 of structural maintenance of chromosomes 
protein 4 (SMC4) was up-regulated at 48 hours in hypoxia (Table 1) and isoform 1 was 
down-regulated at 48 hours (Table 2). SMC4 is a core component of the condensin
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complex, which converts interphase chromatin into condensed chromosomes for 
mitosis [161]. Focal adhesion kinase 1, which is a tyrosine kinase that has been linked to 
increased proliferation and cell motility and decreased apoptosis [162, 163], was down- 
regulated at 72 hours in hypoxia (Table 4). Regulation of nuclear pre-mRNA domain- 
containing protein 1A, which may act as a negative regulator in G (l) phase by repressing 
translation of cyclin D1 and cyclin E, was up-regulated at 72 hours in hypoxia (Table 3).
Some proteins that are associated with mitotic progression were up-regulated in 
hypoxia. Microtubule associated protein 4 (MAP4), which contributes to the formation 
of a radial array of microtubules during mitosis [164], and Mps one binder kinase 
activator-like 3 (MOBKL3), which coordinates mitotic exit and cytokinesis [165], were 
up-regulated at 72 hours (Table 3).
3.4.11 Proteins involved in apoptosis were expressed differently in hypoxia
Some proteins that induce apoptosis were up-regulated in hypoxia and some 
proteins that suppress apoptosis were down-regulated. Exportin-2 was up-regulated at 
48 hours in hypoxia (Table 1). This protein functions as a nuclear transport factor, but 
has also been shown to bind preferentially to p53 target promoters, which increases 
transcription of p53 target genes and causes increased apoptosis [166]. The negative 
regulator of p53, Ras GTPase-activating protein-binding protein 2 (G3BP2) was down- 
regulated at 48 hours in hypoxia. G3BP2 binds to p53, leading to the redistribution of 
p53 from the nucleus to the cytoplasm and a reduction in p53 induced apoptosis [167]. 
FAM162A (HGTD-P), which is a HIF-la-responsive pro-apoptotic molecule [168], was up- 
regulated at 72 hours in hypoxia (Table 3). DnaJ homolog subfamily A member 3 
(Isoform 2), which suppresses apoptosis by preventing cytochrome c release from the 
mitochondria and caspase 3 activation [169], was down-regulated at 72 hours in hypoxia 
(Table 4). DNAJA3 had also been shown to enhance the interaction between H IF-la and 
pVHL, which destabilizes H IF-la  [170].
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3.4.12 Proteins involved in autophagy were expressed differently
Sequestosome-1 (SQSTM1) was down-regulated at 48 hours in hypoxia (Table 2).
SQ.STM1 has multiple functions and participates in signal transduction, protein 
degradation and cell differentiation [171]. It has been shown to be degraded in hypoxia, 
not through HIF signaling or the proteasome, but through autophagy [171]. Ubiquitin- 
like-conjugating enzyme ATG3, which is involved in autophagy and mitochondrial 
homeostasis, was down-regulated at 48 hours in hypoxia (Table 2). Knockdown of ATG3 
produces an expansion in mitochondrial mass [172], and rat APG3 mRNA is up-regulated 
by hypoxic preconditioning but down-regulated by prolonged hypoxia [173].
3.4.13 Proteins involved in translation were down-regulated in hypoxia
Proteins involved in translation in the cytoplasm were differentially expressed in
hypoxia. Translation initiation factor elF-2B subunit alpha was down-regulated at 48 
hours (Table 2) and 60S ribosomal protein L35a was up-regulated at 72 hours (Table 3).
Some proteins involved in translation of mitochondrial proteins were down- 
regulated in hypoxia. At 48 hours, there was down-regulation of the mitochondrial 
ribosomal proteins: ribosomal protein S28 and ribosomal protein L19 (Table 2) and at 72 
hours there was down-regulation of ribosomal protein S9, ribosomal protein L15, and 
ribosomal protein L19 (Table 4). Elongation factor Ts, which is a mitochondrial 
elongation factor [174], was down-regulated at 48 hours in hypoxia (Table 2). 
Pentatricopeptide repeat domain 1 (PTCD1) and Pentatricopeptide repeat domain 3, 
mitochondrial (PTCD3), were down-regulated at 48 hours in hypoxia (Table 2). PTCD1 
and PTCD3 are predicted to be involved in the assembly of respiratory chain complexes 
[175], and PTCD3 has been shown to associate with the mitochondrial small ribosomal 
subunit and to activate mitochondrial translation [176,177].
Cytoplasmic aconitrate hydratase (ACOl) was up-regulated at 72 hours in 
hypoxia (Table 3). ACO l is an mRNA binding protein that regulates uptake, 
sequestration and utilization of iron when iron levels in the cell are low [178].
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3.4.14 Proteins associated with cytoskeleton were up-regulated in hypoxia
Isoform 4 of Afadin was up-regulated in hypoxia at 72 hours (Table 3) and
isoform 3 was down-regulated at 72 hours (Table 4). Afadin connects the adhesion 
molecule, nectin, to the actin cytoskeleton and is activated by Rapl to regulate VEGF- 
and SIP-induced angiogenesis [179], Protein enabled homolog, which induces the 
formation of F-actin rich outgrowths and links signal transduction pathways to localized 
actin cytoskeleton remodeling [180], was up-regulated at 72 hours in hypoxia (Table 3).
Myristoylated alanine-rich C-kinase substrate (MARCKS), which is an F-actin 
cross-linking protein [181], was down-regulated at 48 hours in hypoxia (Table 2). Actin- 
related protein 2/3 complex subunit IB, which is a regulator of actin dynamics, was 
down-regulated in hypoxia at 72 hours (Table 4; [182]). CLASP1, which facilitates the 
recognition of actin filaments by the plus ends of growing microtubules, was also down- 
regulated at 72 hours in hypoxia (Table 4). Dynamic communication between actin 
filaments and microtubules is required for cell morphogenesis [183].
3.4.15 Proteasomal proteins were down-regulated in hypoxia
Several proteins involved in proteasomal degradation were down-regulated in 
hypoxia. For example, Suppressor of G2 allele of SKP1 homolog (SUGT1), which 
interacts with E3 ubiquitin ligase complexes and plays a role in ubiquitination and 
subsequent proteosomal degradation of target proteins [184], was down-regulated at 
48 hours (Table 2). SUGT1 also activates the kinetochore core complex and is important 
for both the GJS  and G2/M transitions in the cell cycle [184]. Proteasome inhibitor PI31 
subunit (PSMF1) was also down-regulated at 48 hours (Table 2). PSMF1 plays an 
important role in controlling proteasome function by inhibiting the 20S proteasome, and 
also by inhibiting activation of the proteasome by two regulatory proteins, PA700 and 
PA28 [185]. DCNl-like protein 1 (DCUN1D1) was down-regulated at 48 hours in 
hypoxia (Table 2). DCUN1D1 is part of an E3 ubiquitin ligase complex for neddylation, 
and is involved in nuclear localization of neddylation components [186].
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Chapter 4: Discussion
Hypoxia has been shown to promote pluripotency in hESCs, but the mechanism 
by which this occurs in unknown [52]. To gain insight into this mechanism, we 
investigated differences in protein expression between hESCs cultured in 1% oxygen and 
hESCs cultured in 20% oxygen for 48 and 72 hours. Interesting changes were observed 
in the expression of proteins involved in metabolism, post-transcriptional modification, 
chromatin modification and regulation of the transcription factor, c-Myc.
4.1 Establishment of a model to study the effects of oxygen in the regulation 
of pluripotency
The experimental model used in this study was developed to investigate the 
effect of hypoxia versus normoxia on hESCs that were cultured in unchanged media for 
up to three days. The objective of leaving the media unchanged was to promote 
differentiation so that differences in pluripotency between hESCs cultured in hypoxia 
and normoxia could be observed. hESCs were studied after 48 and 72 hours in the 
experimental system in order to observe changes in protein expression just as the cells 
in normoxia were beginning to differentiate. In order to validate the experimental 
model, immunofluoresence localization of Oct-4 was performed to assess the 
pluripotency of hESCs after 48 and 72 hours in the experiment. Western blot analysis 
was performed for H IF-la  to confirm that a difference in protein expression between 
the experimental oxygen conditions could be observed for a protein known to be 
regulated by hypoxia.
At 48 hours, almost all hESC colonies that had been cultured in either oxygen 
condition were morphologically pluripotent. However, immunofluorescent detection of 
Oct-4 revealed that there was significantly more differentiation in cultures that had 
been incubated at 20% oxygen than in cultures that had been incubated in 1% oxygen. 
At 72 hours, cultures that had been maintained in 20% oxygen contained notably more 
morphologically differentiated colonies than cultures that had been maintained in 1%
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oxygen. Moreover, immunofluorescent detection of Oct-4 revealed that this difference 
was significant. These results demonstrate that hESCs in our system survive in both 
oxygen concentrations, but cultures incubated in 1% oxygen contain more pluripotent 
cells than cultures incubated in 20% at both 48 and 72 hours. By observation with a 
phase-contrast microscope, there was not a qualitative difference in proliferation 
between hESCs cultured in 1% oxygen and hESCs cultured in 20% oxygen. This agrees 
with the findings of Ezashi et al. that hESCs cultured for 12 days in 1-5% oxygen are 
more pluripotent than hESCs cultured in atmospheric oxygen and that there is no 
difference in average colony size between the conditions [52]. However, it differs from 
the observations of Zachar et al. and Prasad et al., which are that 1% oxygen inhibits 
hESC growth [53, 54],
Real-time RT-PCR analysis showed that there was no significant difference in 
mRNA levels of Oct-4, Nanog, Nodal or H IF-la  in hESCs cultured in 1% oxygen versus 
hESCs cultured in 20% oxygen at both 48 and 72 hours. This agrees with the findings of 
Westfall et al., who used microarray analysis to compare mRNA expression of hESCs 
cultured at 4% oxygen to mRNA expression of hESCs cultured at 20% oxygen for seven 
days. Their results revealed that there is no change in the transcript level of Oct4, 
Nanog, or H IF-la  and there is no change or a mild increase in Nodal transcript levels 
[55]. It has been shown for many genes that there is not a direct correlation between 
changes in mRNA expression and changes in the corresponding protein levels during 
stem cell differentiation [187]. This is because protein levels are influenced by post- 
transcriptional factors, such as stability of mRNA, rate of translation, and rate of protein 
degradation. Since proteins are the effectors of cellular processes, it is important to 
investigate hESC expression at the protein level as well as the transcript level [85].
Although real-time RT-PCR analysis revealed that there is no change in H IF-la 
mRNA levels when hESCs are cultured in hypoxia, Western blot analysis revealed that 
H IF-la  protein expression was up-regulated in hypoxia at both 48 and 72 hours. It is not 
surprising that a difference in H IF-la expression is observed in the proteome, but not in 
the transcriptome, because H IF-la  is largely regulated at the protein level. In hypoxia,
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H IF-la  is stabilized and forms a heterodimer with the constitutively expressed protein, 
HIF-ip. In the presence of increased oxygen concentration, HIF-lot is hydroxylated by 
prolyl-hydroxylase domain enzymes, which are only active in the presence of oxygen 
[47]. Flydroxylated H IF-la  is subsequently marked for proteosomal degradation.
4.2 Hypoxia influenced the expression of some metabolic proteins
When oxygen is available, most human cells rely on mitochondrial oxidative 
phosphorylation to produce ATP; however, in hypoxia, cells have the ability to use 
glycolysis as a primary source of ATP because oxygen is not available to be a terminal 
electron acceptor in the electron transport chain (ETC) [188], Thus, it is not surprising 
that H IF-la  acts as a transcription factor for many rate-limiting glycolytic enzymes and 
transporters [189]. Interestingly, it only up-regulates specific isoforms of each of the 
glycolytic proteins that it modulates [189].
Hexokinase-2, which catalyses the first committed step of glycolysis [107], was 
up-regulated in hypoxia at both 48 and 72 hours. Flexokinase-1 and -2 are special 
isoforms of hexokinase that have the ability to bind to the external mitochondrial 
membrane in order to inhibit apoptosis by blocking cytochrome c release [190] and to 
ensure that mitochondrial ATP is used for glucose phosphorylation [191]. It is known 
that the Flexokinase-2 promoter contains an FIRE and that its gene expression is 
activated by H IF-la  [192], It is also known that Flexokinase-2 is increased at the 
transcript level in hESCs cultured in hypoxia [55]. Other transcription factors and 
growth factors that modulate hexokinase-2 expression and activity include: insulin 
growth factor, c-Myc, glucagon, and cAMP [193]. Flexokinase-2 is the principal 
regulated isoform of hexokinase in many cell types and it is up-regulated in many 
cancers [189], Its depletion in cancer cells results in decreased proliferation and 
angiogenesis as well as diminished expression of H IF-la  and VEGF, and its over­
expression leads to increased proliferation and therapeutic resistance [194],
GLUT1, which transports glucose across the plasma membrane [108], was up- 
regulated at both 48 hours and 72 hours in hypoxia. It is known that GLUT1 is up-
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regulated at the transcript level in hESCs cultured in hypoxia [55] and its expression is 
directly regulated by H IF-la  [195], GLUT1 is a rate-limiting transporter for glucose 
uptake [196] and it is the most widely over-expressed glucose transporter in 
proliferative cancer cells [197]. It has been suggested that GLUT1 is over-expressed in 
cancer cells because it has a higher affinity for glucose than other glucose transporters 
[198],
Pyruvate dehydrogenase E la  1 (PDHA1) precursor was down-regulated at 48 
hours in hypoxia. Down-regulation of PDHA1, which catalyzes the conversion of 
pyruvate to acetyl-CoA and C 02, reduces the delivery of acetyl-CoA to the tricarboxylic 
acid cycle, thus reducing transfer of electrons to the ETC [109]. It is known that 
pyruvate dehydrogenase kinase 1 (PDK1) is up-regulated by HIF-la, which results in 
decreased activity of PDHA1 [109]; however, it has not been shown previously that 
PDHA1 protein expression is decreased in hypoxia. Together, these data suggest that 
hypoxia triggers up-regulation of isoforms of key glycolytic enzymes that increase flux 
through the glycolytic pathway and it promotes down-regulation of PDHA1 to limit entry 
into aerobic metabolism.
Low oxygen levels cause an increase in the generation of reactive oxygen 
species (ROS) in mitochondria by respiratory complexes I and III [188, 199]. It has been 
hypothesized that the increased concentration of ROS induces oxidation of Fe2+ to Fe3+, 
which cannot be used as a cofactor for PHD to hydroxylate H IF-la  for degradation [200]. 
In agreement with this hypothesis, H IF-la  is hydroxylated and degraded in hypoxia in 
cells that have been treated with anti-oxidants [201]. Two components of Complex I of 
the electron transport chain were up-regulated at 72 hours in hypoxia. Up-regulation of 
Complex I subunits may be necessary for continuous ROS production and subsequent 
stabilization of HIF during hypoxia.
The presence of ROS in hypoxic conditions induces phosphorylation of the 
protein kinase, MAPK14 [202], which was up-regulated at 48 hours in hypoxia in this 
proteomic analysis. A common feature of cancer cells, which tend to reside in poorly 
vascularized hypoxic tumors, is the increased use of glycolysis to produce ATP, even in
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Figure 19. Metabolic proteins that were differentially expressed in hypoxia. Several 
proteins that play key roles in glycolysis or entry into the tricarboxylic acid cycle (TCA) 
showed increased (green arrows) or decreased (red arrows) expression in hypoxia. 
GLUT1: Solute carrier family 2, facilitated glucose transporter, member 1, PDK1: 
pyruvate dehydrogense kinase isozyme 1, HIF: hypoxia inducible factor, PDH: pyruvate 
dehydrogenase, MAPK14: mitogen activated protein kinase 14, ROS: reactive oxygen 
species.
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the presence of oxygen [203]. This is called aerobic glycolysis, and it is largely sustained 
through the stabilization and activation of H IF-la  in normoxia [204], MAPK14 is 
necessary for HIF-la-dependent aerobic glycolysis, as inhibition of MAPK14 results in 
decreased levels of H IF-la  and H IF-la target genes, such as GLUT1 and hexokinase 2 
[205]. MAPK14 has also been shown to stabilize H IF-la  in hypoxic conditions [206, 207]. 
The MAPK14 pathway plays a role in proliferation, differentiation, metabolism and cell 
death [115, 208] by regulating the activity of several transcription factors and 
interacting with other signaling pathways [209, 210]. Given that it is activated in 
hypoxia and it is necessary for HIF-la-dependent aerobic glycolysis, MAPK14 is likely a 
key modulator for the increase of glycolysis in hESCs in response to hypoxia.
Three metabolic proteins involved in the biosynthesis of isoprenoids and steroid 
molecules were up-regulated in hypoxia: Isopentenyl-diphosphate Delta-isomerase 1 
(IPPI1), Farnesyl pyrophosphate synthase (FDPS), and squalene monooxygenase.
FDPS creates lipids that are either incorporated into sterols, dolichols, 
ubiquinones and carotenoids or used as substrates for farnésylation and 
geranylgeranylation of proteins [122]. Covalent attachment of isoprenyl chains 
produced by FDPS is essential for intracellular localization and function of small GTPase 
binding proteins (for example, Ras, Rac, Rho, and CDC42), which play a fundamental role 
in signaling pathways that modulate cell proliferation and survival [211]. The important 
role of FDPS is demonstrated by the fact that its inhibition in cancer cells causes 
modulation of proliferation, apoptosis, cell migration and invasion, angiogenesis, and 
tumor-mediated immunosuppression. Inhibition of FDPS is known to cause a reduction 
is several signaling pathways, including TGF-|3 signaling [212]. FDPS inhibition has also 
been shown to suppress the accumulation of H IF-la  in response to IGF-1 stimulation in 
part by increasing degradation of H IF-la  [213]. This suggests a potential role for the 
isoprenoid biosynthesis pathway, particularly FDPS, in modulating the cell's response to 
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Figure 20. Hypoxic up-regulation of proteins involved in steroid biosynthesis. Several 
proteins involved in isoprenoid and steroid biosynthesis showed increased expression 
(green arrows) or differential expression of isoforms (yellow arrows) in hypoxia. IPPI1: 
isopentenyl diphosphate isomerase, GPPS: geranyl diphosphate synthase, FDPS: farnesyl 
pyrophosphate synthase, SQLE: squaline monooxygenase.
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4.3 Hypoxia influenced the expression of some proteins involved in chromatin 
modification
Pluripotent hESCs maintain a wide open chromatin structure, which is selectively 
condensed as differentiation down a particular lineage progresses [214], This process is 
directed by epigenetic modifications, which control gene expression without changing 
DNA sequence. The histone family of proteins, which can be modified through 
acetylation, methylation, phosphorylation, and ubiquitination, plays an important role in 
epigenetic regulation. It has been shown in mESCs that there are epigenetic markers of 
open and active chromatin on genes such as Oct-4 and Sox-2 in early replication, 
whereas genes for lineage specification have both active and repressive markers, 
suggesting that the expression of these genes could be rapidly controlled [215].
Some histone variants were differentially expressed in hypoxia. Histone H2A 
type 1-H was up-regulated at 48 hours and Histone H1X and H3.3 were down-regulated 
at 72 hours. Histone H3.3 replaces conventional Histone H3 in a wide range of 
nucleosomes in actively transcribed genes and it seems to be required for development, 
although its role in development is poorly understood [216]. Histone variants alter the 
functional properties of chromatin and play crucial roles in embryonic stem cell 
maintenance and differentiation [217]. Up- or down-regulation of specific histone 
variants may be one mechanism by which hypoxia modulates gene expression and thus 
pluripotency in hESCs.
Two proteins that modify epigenetic labels of histones were differentially 
expressed in hypoxia. Histone deacetylase complex subunit SAP18, which is a 
component of the SIN3-repressing complex that enhances transcriptional repression 
[152], was up-regulated at 72 hours. Parafibromin was down-regulated at 72 hours in 
hypoxia. Parafibromin is a component of the PAF1 complex, which activates 
transcription of specific genes by ubiquitinating and methylating histones [153, 154], 
The PAF1 complex regulates transcription of genes involved in cell growth and survival 
and it is essential for normal embryonic development [155]. The differential expression 
of these proteins may promote pluripotency in hypoxia by adjusting epigenetic marks in 
such a way as to reduce transcription of genes associated with differentiation.
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The actin cytoskeleton has an essential role In cell migration, determination of 
cell shape and polarity, and protein and organelle trafficking [218]. It is now generally 
accepted that actin also has a role in transcription and transcriptional regulation 
through several mechanisms [219], Actin is a member of several chromatin remodeling 
and HAT complexes and is essential for the function of these complexes in 
transcriptional activation [218, 220], It also physically interacts with all three RNA 
polymerases and this interaction is necessary for transcription in vitro and in vivo [218, 
220]. Monomeric actin regulates gene transcription by binding to specific transcription 
factors and targeting them for the cytoplasm. It is suggested that actin polymerization 
may regulate gene transcription by affecting the concentration of monomeric actin that 
is available to interact with nuclear components.
The highly dynamic organization of actin is controlled by environmental signals 
that activate signaling pathways and actin-regulatory proteins [221]. In hypoxia, there 
was up-regulation of protein enabled homolog, which induces the formation of F-actin 
rich outgrowths and links signal transduction pathways to localized actin cytoskeleton 
remodeling [180], There was also down-regulation of MARCKS, which is an F-actin 
cross-linking protein [181], and Actin-related protein 2/3, which is a regulator of actin 
dynamics [182], This suggests that hypoxia may promote pluripotency in hESCs in part 
by up-regulating actin regulatory proteins, which in turn affect chromatin remodeling 
and transcription in the nucleus. Very little is known about actin function in nuclear 
processes and more research must be done to confirm this idea.
4.4 Some proteins that regulate c-Myc expression or activity were up- 
regulated in hypoxia
As cells progress through the multistage process of differentiation, they 
selectively activate and silence sets of genes in order to acquire specific functions and 
lose self-renewal capacity. These changes in gene expression are coordinated by the 
action of many transcription factors that have temporal and cell-type specific expression 
[222]. The transcription factor, c-Myc has been implicated in the modulation of many
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cell functions, including cell cycle regulation, proliferation, growth, differentiation, and 
metabolism [223]. It acts as a transcription factor for an extremely large number of 
genes -  perhaps 15% of genes in the genome [224], Two proteins that are associated 
with increased levels of c-Myc were up-regulated in hypoxia. Protein CIP2A, which 
prevents proteolytic degradation of c-Myc by inhibiting PP2A tumor suppressor activity 
towards it [125], was up-regulated at 48 hours. Over-expression of CIP2A promotes Ras- 
elicited cell growth and knock-down of CIP2A correlates with differentiation of neural 
progenitor cells [225]. FUBP1, which stimulates the expression of c-Myc in 
undifferentiated cells by activating the far upstream element of c-Myc [124], was up- 
regulated at 72 hours. c-Myc is one of only four proteins needed to reprogram 
differentiated cells to iPSCs, indicating its important role in promoting the pluripotent 
state of human cells. Therefore, the up-regulation of Protein CIP2A and FUBP1 in 
hypoxia may result in the maintenance of pluripotency through up-regulation of c-Myc.
4.5 Proteins involved in post-transcriptional modification were differentially 
expressed in hypoxia
Protein expression and activity are regulated at many levels beyond 
transcription, including RNA splicing, translation, protein trafficking, and proteasomal 
degradation. Alternative splicing, a process in which the exons of an RNA transcript are 
connected in different combinations during RNA splicing, provides a flexible mechanism 
through which cells can generate proteins with different properties [226]. The resulting 
mRNAs may be translated into different isoforms of a protein. For example, a change in 
splice isoforms from the adult pyruvate kinase muscle 1 (PKM1) to the fetal PKM2, is 
observed in lung cancer cell lines and this change is believed to promote aerobic 
glycolysis and tumor growth [227], Many human genes are known to be alternatively 
spliced in response to hypoxia, and in some cases this has been shown to be regulated 
by H IF-la  [228-231]. In this study, some proteins involved in RNA splicing were 
differentially expressed in hypoxia. PRP16, which is essential for catalytic step 11 in the 
pre-mRNA splicing process [131], and EXOSC7, which is a component of the exosome 3’-
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5' exoribonuclease complex that degrades unstable mRNAs [132], were up-regulated at 
48 hours. NAA38, which binds to the 3'-terminal U-tract of U6 snRNA and is involved in 
mRNA processing and splicing [133], was down-regulated at 48 hours. NAA38 has been 
shown to be regulated by hypoxia in human retina cells [232], In response to 
environmental stress, cells use alternative splicing to rapidly and specifically alter gene 
expression [233]. It is possible that these RNA splicing proteins were up- or down- 
regulated in response to hypoxia in order to facilitate splicing of genes that mediate the 
cell's response to hypoxia.
Several proteins that were differentially expressed in hypoxia in this study 
displayed up-regulation of one isoform alongside down-regulation of another isoform 
(see Tables 1-4). One example is serine/threonine-protein phosphatase PPl-a, catalytic 
subunit, which has three different isoforms that are generated through alternative 
splicing. For most of the proteins that had differential expression of isoforms, little 
information is available on differences in function between the isoforms. It would be 
interesting to investigate whether these proteins are spliced differently in response to 
hypoxia, and whether these changes promote pluripotency.
In order to survive in hypoxia, cells must suppress their metabolic rate to a level 
that can be sustained with the ATP produced through glycolysis alone [234]. The most 
energy consuming process in cells is translation of mRNA into protein; therefore, it is 
not surprising that protein synthesis is globally reduced in hypoxia [235]. In addition, 
cells can respond to environmental stimuli more rapidly when changes in gene 
expression are targeted at translation rather than transcription, as protein synthesis is 
thought to be the rate limiting step in gene expression [236, 237], Severe hypoxia has 
been shown to cause a rapid decline in protein synthesis from about 30% of the cell's 
energy expenditure to about 7% [238], Global regulation of protein synthesis is largely 
accomplished through the modification of translation initiation factors [239]. In 
hypoxia, short term inhibition of translation occurs through phosphorylation elF-2a, 
which inhibits GDP-GTP exchange catalyzed by elF-2B, thus halting initiation of 
translation [240, 241] In this proteomic analysis, translation initiation factor elF-2B
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subunit a was down-regulated at 48 hours in hypoxia. This result suggests that hypoxia 
may also decrease global protein expression through down-regulation of elF-2B.
Some proteins involved in translation of mitochondrial proteins were down- 
regulated in hypoxia. At 48 hours, there was down-regulation of the mitochondrial 
ribosomal proteins: S28 and L19 and at 72 hours there was down-regulation of S9, L15, 
and L19. Elongation factor Ts, which is a mitochondrial elongation factor [174], and 
PTCD1 and PTCD3, which are predicted to be involved in the assembly of respiratory 
chain complexes [175], were down-regulated at 48 hours. PTCD3 can additionally 
associate with the mitochondrial small ribosomal subunit to activate mitochondrial 
translation [176, 177]. These results complement the theory that protein expression is 
globally decreased in hypoxia and also suggest that there may be a particularly large 
decrease in expression of proteins associated with mitochondria, which are mostly 
inactive in hypoxia. Anaerobic energy production in a human cell causes the production 
of lactic acid, which is secreted from the cell and causes extracellular acidosis. Increased 
production of H+ ions during hypoxia promotes interactions between the von Hippel- 
Lindau tumor suppressor protein and rRNA genes, resulting in a reduction of rRNA 
synthesis [242].
Numerous proteins involved in cell trafficking through endosomes, vesicles, and 
the Golgi aparatus were differentially expressed in hypoxia. Little is known about the 
role of these proteins in the response to hypoxia or differentiation of stem cells. They 
may have a role in the response to hypoxia by processing, degrading, secreting, 
localizing, and endocytosing proteins that have a role in pluripotency or differentiation. 
For example, Rab4A, which is a member of the Rab family of small GTPases that 
regulates intracellular transport [145], was down-regulated at 48 hours. Rab4A has an 
interesting role in the activity of plasma membrane receptors. After activation, many 
receptors are endocytosed and sorted through endosomes to the lysosome for 
proteolytic degradation. However, some receptors in Rab4a-positive endosomes are 
recycled back to the plasma membrane, rather than sent to the lysosome [243-245]. 
Additionally, VEGF receptor 2 has been shown to stimulate MAPK signaling from the
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endosome during this recycling process [243], Therefore, down-regulation of Rab4A in 
hypoxia may result in decreased signaling from the receptors that are recycled in a 
Rab4A dependent manner.
Several proteins involved in proteasomal degradation were down-regulated at 
48 hours in hypoxia. These include: SUGT1, which plays a role in ubiquitination and 
subsequent proteosomal degradation of target proteins [184], PSMF1, which controls 
proteasome function by inhibiting the 20S proteasome, and also by inhibiting activation 
of the proteasome by two regulatory proteins, PA700 and PA28 [185], and DCUN1D1, 
which is part of an E3 ubiquitin ligase complex for neddylation of target proteins [186]. 
The proteasome ultimately degrades most intracellular proteins in a highly regulated 
fashion; therefore, it has a crucial role in the regulation of cellular processes such as cell 
cycle progression, proliferation, differentiation, angiogenesis and apoptosis [246],
The fact that proteins that regulate translation, protein trafficking, and protein 
degradation were expressed differently in hypoxia strengthens the notion that changes 
in protein expression in hypoxia do not directly correlate with changes in transcript 
levels. This highlights the necessity of looking for changes in gene expression at the 
level of the proteome in addition to the transcriptome.
4.6 Some proteins that require oxygen as a substrate were differentially 
expressed in hypoxia
The synthesis of collagen deposits involves many steps, including procollagen 
protein synthesis, prolyl hydroxylation, lysyl hydroxylation, and covalent cross-bridging 
between collagen fibres [247]. Two enzymes that hydroxylate prolyl residues in 
collagen, P4HA1 and LEPREL1, were up-regulated at 72 hours in hypoxia. Although 
prolyl hydroxylation is required for both collagen synthesis and for the stability of H IF-la 
protein, different prolyl hydroxylases perform these functions [248], and P4HA1 and 
LEPREL1 do not accept H IFl-a as a substrate [249]. P4HA1 is essential for triple helix 
formation and has been shown to be up-regulated in hypoxia in fetal lung fibroblasts in 
a HIF-la-dependent manner [250]. The prolyl hydroxylase, LEPREL1, has not previously 
been shown to be up-regulated in hypoxia.
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During the maturation of procollagen, lysine residues must also be hydroxylated, 
and this is performed by procollagen lysyl-hydroxylases [251], The procollagen lysyl- 
hydroxylase, PROD2 was up-regulated at 72 hours in hypoxia. Hypoxia has been shown 
to stimulate the expression of several hydroxylases, including P4HA1 and PROD2, in a 
H IF-la  dependent mechanism in rat vascular smooth muscle cells [156].
All of the collagen hydroxylases use oxygen directly as a substrate [252]. These 
enzymes may be up-regulated in hypoxia because (a) collagen formation must be 
increased in hypoxic tissues, or (b) because the concentration of enzyme must increase 
in order to maintain a normal rate of procollagen hydroxylation in the presence of 
decreased oxygen substrate. The latter hypothesis is supported by the observation that 
only components of collagen synthesis that depend on oxygen as a substrate are up- 
regulated in hypoxia, whereas other components, such as procollagen (la) are not up- 
regulated by hypoxia [156], Together, these results suggest that hypoxia stimulates the 
expression of a group of hydroxylases that are essential for collagen fiber formation in 
order to compensate for the lack of oxygen molecules available for use as substrates.
In hypoxia, the high affinity of cytochrome oxidase for oxygen means that the 
majority of available oxygen is sequestered by the ETC, leaving little in the cytosol for 
dioxygenases, such as prolyl hydroxylases, which require oxygen as a substrate [253], 
The consumption of oxygen by the ETC may be regulated by the endogenous gas, nitric 
oxide (NO). NO competitively inhibits cytochrome oxidase by competing for binding 
with molecular oxygen [254]. Arginase-2, which is an inducible mitochondrial protein 
that inhibits the production of NO [113], was down-regulated at 48 hours in hypoxia. 
Reduction of Arginase 2 may allow for the production of NO, which can limit binding of 
oxygen to the ETC in hypoxic conditions.
4.7 Proteins associated with proliferation and apoptosis were differentially 
expressed in hypoxia
Some proteins that inhibit proliferation were up-regulated in hypoxia, and some 
proteins that are associated with increased proliferation or mitotic progression were
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down-regulated. Regulation of nuclear pre-mRNA domain-containing protein 1A, which 
may act as a negative regulator in G (l) phase by repressing translation of cyclin D1 and 
cyclin E, was up-regulated at 72 hours in hypoxia. EML4, which is highly expressed 
during mitosis and is needed for proper microtubule formation [160], was down- 
regulated at 48 hours. TBRG4, which may play a role in cell cycle progression [157], 
was also down-regulated at 48 hours in hypoxia. Other proteins that were down- 
regulated at 48 hours include: NSFL1C cofactor p47, which is necessary for the 
fragmentation of Golgi stacks during mitosis and for reassembly of Golgi stacks after 
mitosis [158], and neoxycytidylate deaminase, which creates the substrate for 
thymidylate synthetase to make dTMP for use in DNA synthesis and repair [159]. At 48 
hours, isoform 2 of SMC4 was up-regulated and isoform 1 was down-regulated. SMC4 is 
a core component of the condensin complex, which converts interphase chromatin into 
condensed chromosomes for mitosis [161]. Focal adhesion kinase 1, which is a tyrosine 
kinase that has been linked to increased proliferation and cell motility and decreased 
apoptosis [162, 163], was down-regulated at 72 hours.
These results correspond with the findings of two studies of the long term 
culture of hESCs in hypoxia, which showed that the rate of proliferation of hESCs is 
significantly higher in normoxia than in hypoxia [53, 54]. Since hESCs must switch from 
aerobic metabolism to glycolysis in hypoxia, which results in significantly less ATP 
production per glucose molecule, they must also suppress their metabolic rate and 
growth to a level that can be sustained with the ATP produced through glycolysis alone 
[234],
Most genes that are up-regulated by H IF-la  promote cell survival in hypoxic 
conditions, such as genes that increase oxygen availability or ATP production through 
glycolysis. Paradoxically, H IF-la  also participates in hypoxic cell death through 
interaction with the pro-apoptotic transcription factor, p53 and by up-regulating other 
pro-apoptotic factors [255, 256]. In tolerable hypoxia, anti-apoptotic Bcl-2 family 
proteins prevent cell death by stabilizing mitochondria or inhibiting caspase activation;
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however, in the case of severe cell damage caused by hypoxia beyond the cell's adaptive 
capacity, apoptosis-promoting genes are expressed [257].
Some proteins that promote apoptosis were up-regulated in hypoxia, and some 
proteins that inhibit apoptosis were down-regulated. The pro-apoptotic molecule, 
FAM162A, was up-regulated at 72 hours in hypoxia. FAM162A facilitates cell death by 
induction of the mitochondrial permeability transition (PT), and its transcription is 
known to be up-regulated by the binding of H IF-la  to its promoter [168], Exportin-2, 
which binds to p53 target promoters to increase transcription of p53 target genes and 
increase apoptosis [166], was up-regulated at 48 hours in hypoxia. The negative 
regulator of p53, Ras GTPase-activating protein-binding protein 2 (G3BP2) [167], was 
down-regulated at 48 hours and DNAJA3, which suppresses apoptosis by preventing 
cytochrome c release and caspase 3 activation [169], was down-regulated at 72 hours. 
DNAJA3 had also been shown to enhance the interaction between HIF-lcx and VHL, 
leading to HIF-lcx degradation [170].
These results suggest that there may have been increased apoptosis in the hESCs 
cultured at 1% oxygen, although no cell death was observed by phase contrast 
microscopy. In a study that compared the effects of hypoxia on hESCs cultured in 1%, 
5%, 10%, 15% or 20% oxygen for four weeks, most of the colonies in 1% oxygen did not 
survive beyond 2 weeks [54], Since hypoxia up to 5% oxygen has been shown to 
promote pluripotency in hESCs [52] , and the natural environment of hESCs is closer to 
2% [28], culture of hESCs above 1% oxygen but below 5% oxygen may be ideal to 
promote pluripotency, but prevent apoptosis.
4.8 Suggestions for future experiments
In this study, immunofluoresence localization of Oct-4 was used to determine 
the percentage of colonies that were differentiating in each oxygen condition. This 
technique gave an approximate estimation of the percentage of cells that had 
differentiated, but since some colonies may have had larger patches of differentiation 
than others, it would be more accurate to determine the percentage of differentiated
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cells by measuring the cells individually. This could be achieved by incubating the cells 
with an antibody against SSEA-4, which is a cell surface marker of pluripotency, and then 
performing flow cytometry.
Some studies have shown that hypoxia does not affect the rate of proliferation 
of stem cells, while others have shown that it does (discussed in section 1.3). 
Proliferation is likely affected by the degree of hypoxia, duration of incubation, and 
whether the cells are occasionally exposed to oxygen when the incubator door is 
opened. In order to determine the best culture conditions for hESCs, a study should be 
performed to determine whether hypoxia does in fact slow proliferation, and under 
what circumstances this happens.
Dramatic changes were observed in the number of peptides identified for some 
proteins. For example, Far upstream element-binding protein 1 was not detected in any 
replicates of hESCs that had been cultured in normoxia, but 8, 3, 9, 8, 10, and 6 peptides 
were identified in the six replicates of hESCs cultured in hypoxia for 72 hours. For other 
proteins, the changes in number of peptides were more subtle. For example, RRP4S was 
not detected in any replicates of hESCs that had been cultured in normoxia, but 2, 1, 2, 
1, 1, and 2 peptides were identified in the six replicates of hESCs cultured in hypoxia for 
48 hours. Further experiments that utilize Western blotting, selected reaction 
monitoring, or shotgun MS/MS with isotopic labeling should be performed to confirm 
that some of the proteins identified in this study are in fact differentially expressed.
Selected reaction monitoring (SRM) is a highly selective and sensitive MS 
technique that can be used for precise and accurate quantification of low-abundance 
proteins in complex proteomics samples [258]. In this technique, specific precursor ions 
are selected and fragmented and a few specific fragments are monitored for detection 
and quantification purposes [259]. SRM is emerging in proteomics as an excellent 
method to complement shotgun qualitative studies [259].
As discussed in section 1.5.3, accurate quantitative information can be obtained 
in shotgun proteomics experiments through stable isotopic labeling using SILAC or 
iTRAQ. These methods allow minute changes between cellular states to be monitored
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over time. Since label free MS was used in this study, changes in protein expression 
were only detected if the difference was large. In future experiments, SILAC or iTRAQ 
should be used to quantitatively compare protein expression so that more subtle 
changes in protein expression can be identified.
The importance of candidate proteins such as FUBP1, CIP2A, and MAPK14 in the 
maintenance of pluripotency can be determined through genetic knock-down of each 
protein of interest, followed by culture in hypoxia and normoxia.
A major challenge in shotgun proteomics is to identify as many peptides as 
possible in an LC-MS/MS run. Many proteins known to be present in the hESC 
proteome, such as Oct-4, Nanog, Nodal and H IF-la  were not identified by MS/MS in this 
study. Primary reasons for missed peptide identifications are limitations in sequencing 
speed and sensitivity of mass spectrometers and the very high complexity of proteomics 
samples [73], Another major factor is that the resolution of quadrupoles and ion traps is 
not high enough to separate all precursor ions, which leads to cofragmentation of 
precursor ions that are present in the same window [260]. Because of these limitations, 
even state-of-the-art mass spectrometers do not identify a large percentage of peptides 
in complex proteomics samples [73]. It is likely that proteins in addition to the ones 
identified in this study are differentially expressed in hypoxia, but were not identified 
due to limitations of the experimental technology.
There was little overlap between the proteins expressed differently at 48 hours 
and the proteins expressed differently at 72 hours, which may be in part due to dynamic 
regulation of gene expression in the first 72 hours of exposure to hypoxia. Another 
possibility is that the protein was differentially expressed at both time points, but this 
change was only detected at one time point due to aforementioned limitations of 
shotgun proteomics. Since the regulation of gene expression in hESCs after exposure to 
hypoxia is dynamic, it would be useful to measure protein expression at more frequent 
time points in future studies, for example every 12 hours for 72 hours over the course of 
the experiment.
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Another important extension of this experiment would be to measure 
differences in posttranslational modifications, such as phosphorylation of proteins 
expressed in hESCs cultured under hypoxia versus normoxia. This would provide more 
insight into the mechanism by which hypoxia promotes pluripotency in hESCs as 
posttranslational modifications play an important role in the activity or localization of 
proteins. It would also be interesting to investigate which proteins are up-regulated in 
hypoxia from specific protein fractions, such as extracellular proteins or nuclear 
proteins.
4.9 Conclusion
In this study, shotgun proteomics was used for the first time to investigate 
changes in protein expression that occur when hESCs are cultured in hypoxia. In 
addition, a new experimental system was developed to compare the pluripotency of 
hESCs cultured in hypoxia to that of hESCs cultured in normoxia. Many changes in 
protein expression were observed in hypoxia, particularly in proteins involved in 
metabolism, chromatin remodeling, post-transcriptional modification, and regulation of 
c-Myc.
Many experiments and therapeutic applications of hESCs require the cells to be 
pluripotent [261]. Knowing which proteins are expressed differently in hypoxia and 
therefore, which proteins may promote pluripotency is important for the development 
of methods to maintain hESC pluripotency and prevent differentiation in culture [262]. 
In addition, cancer cells are often exposed to a hypoxic microenvironment due to poor 
vascularisation of tumors, which is associated with increased invasion and metastatic 
potential of the cells. The identification of proteins that are expressed differently under 
hypoxic conditions may be useful for the development of therapeutic strategies to 
target invasive cells in tumors. This knowledge will also improve our understanding of 
the ability of hESCs to remain pluripotent during their pre-implantation development in 
the hypoxic reproductive tract.
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Actin-like protein (Fragment) 2 2 1 2 1 0 0 0 0 0 0 0
Alanyl-tRNA synthetase 0 2 1 5 3 2 0 0 0 0 0 0
Dynactin, subunit 1 (Isoform pl50) 7 2 4 2 7 4 3 0 1 0 0 0
Exosome complex exonuclease RRP42 2 1 2 1 1 2 0 0 0 0 0 0
Exportin-2 (Isoform 1) 2 1 0 4 2 0 0 0 0 0 0 0
Farnesyl pyrophosphate synthase 7 4 10 6 7 2 0 0 0 4 4 5
Hexokinase-2 10 12 5 5 3 1 3 3 1 1 1 2
Histone H2A type 1-H 1 4 12 i i 5 2 0 0 0 0 0 0
Lipopolysaccharide-responsive and beige­
like anchor protein (Isoform 1)
2 2 2 i 4 0 0 0 0 0 0 0
Mitochondrial import receptor subunit, 
TOM22 homolog
2 0 1 2 5 2 0 0 0 0 0 0
Mitogen-activated protein kinase 14 
(Isoform CSBP2)
3 2 0 5 0 1 0 0 0 0 0 0
Pre-mRNA-splicing factor ATP-dependent 
RNA helicase PRP16
2 1 0 2 0 i 0 0 0 0 0 0
Protein CIP2A (Isoform 1) 3 1 0 2 2 0 0 0 0 0 0 0
Protein FAM96B 3 0 1 2 1 0 0 0 0 0 0 0
Serine/threonine-protein phosphatase PP1- 
a, catalytic subunit (Isoform 3)
12 8 9 10 10 7 0 0 0 0 0 0
Solute carrier family 2, facilitated glucose 
transporter, member 1
6 4 3 4 3 1 2 0 0 2 2 0
Squalene monooxygenase 2 1 2 1 4 0 0 0 0 0 0 0
Structural maintenance of chromosomes 
protein 4 (Isoform 2)
1 2 4 2 4 0 0 0 0 0 0 0
Note: "Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line and each 
oxygen concentration.
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28S ribosomal protein S28, mitochondrial 0 0 0 0 0 0 2 0 5 1 0 2
39S ribosomal protein L19, mitochondrial 0 0 0 0 0 0 2 0 1 2 1 0
Arginase-2, mitochondrial 0 0 0 0 0 0 2 2 2 0 2 1
CDK-activating kinase assembly factor MAT1 0 0 0 0 0 0 1 0 2 2 0 1
DCNl-like protein 1 0 0 0 0 0 0 2 0 1 1 2 0
Deoxycytidylate deaminase (Isoform 1) 0 0 0 0 0 0 1 0 2 3 0 1
Dynactin subunit 3 (Isoform 2) 0 0 0 0 0 0 1 2 0 2 2 2
Dynein, light chain, roadblock-type 1 0 0 0 0 0 0 0 2 2 5 1 2
Echinoderm microtubule-associated protein­
like 4
0 0 0 0 0 0 1 0 3 1 3 0




0 0 0 0 0 0 2 0 1 1 3 0
0 0 0 0 0 0 1 0 2 1 2 0
Mitochondrial import receptor, subunit 
TOM34
0 0 0 0 0 0 1 0 2 2 1 0
Mitogen-activated protein kinase kinase 4 
(Isoform 2)
0 0 0 0 0 0 2 1 2 1 2 1
Monocarboxylate transporter 1 0 0 0 0 0 0 3 3 1 1 2 0
Myristoylated alanine-rich C-kinase 
substrate
0 0 0 0 0 0 0 1 4 1 0 2
N-alpha-acetyltransferase 25, NatB auxiliary 
subunit (Isoform 1)
0 0 0 0 0 0 1 0 2 2 1 0
N-alpha-acetyltransferase 38, NatC auxiliary 
subunit
0 0 0 0 0 0 2 1 2 3 0 1
Neurolysin, mitochondrial 0 0 0 2 2 0 5 5 9 5 5 2
Niban-like protein 1 0 0 0 0 0 0 2 0 1 4 4 1
NSFL1 cofactor p47 (Isoform 1) 0 0 0 0 0 0 3 1 2 5 5 0
Nucleoporin 43 kDa 0 0 0 0 0 0 1 4 2 1 2 1
Nucleoporin 98 kDa 0 0 0 0 0 0 2 2 2 2 1 1
Oxysterol-binding protein 1 (Isoform 1) 0 0 0 0 0 0 1 0 2 2 2 0
Pentatricopeptide repeat domain 1 0 0 0 0 0 0 2 2 2 3 1 2
Pentatricopeptide repeat domain 3 (Isoform 
2)
Peptidyl-prolyl cis-trans isomerase FKBP2
0 0 0 0 0 0 0 1 2 1 2 0
0 0 0 0 0 0 2 1 1 2 1 1
Pirin 0 0 0 0 0 0 3 2 2 1 3 1
Proteasome inhibitor, PI31 subunit 0 0 0 0 0 0 1 0 2 2 1 0
Protein of unknown function, DUF410 family 
protein |
0 0 0 0 0 0 3 1 2 2 3 1
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Putative deoxyribose-phosphate aldolase 
Pyruvate dehydrogenase El alpha 1 (Isoform 
2) precursor
RAB4A, member RAS oncogene family 
variant
Ras GTPase-activating protein-binding 
protein 2 (Isoform A)
Receptor expression-enhancing protein 5 
Sequestosome-1 (Isoform 1) 
Serine/threonine-protein phosphatase PP1- 
a, catalytic subunit 
Stomatin-like protein 2 
Structural maintenance of chromosomes 
protein 4 (Isoform 1)
Suppressor of G2 allele of SKP1 homolog 
(Isoform 2)
Tetratricopeptide repeat protein 1 
Transforming growth factor beta regulator 4 
Translation initiation factor elF-2B, subunit a 
Ubiquitin-like-conjugating enzyme ATG3 
(Isoform 1)
UPF0557 protein C10orfll9 (Isoform 2) 
UPF0600 protein C5orf51 
xaa-Pro aminopeptidase 1 (Isoform 1) 
a-ketoglutarate-dependent dioxygenase FTO 
(Isoform 1) ____________
0 0 0 0 0 0 3 1 1 1 4 0
0 0 0 0 0 0 1 0 3 1 4 1
0 0 0 0 0 0 2 0 1 2 2 0
0 0 0 0 0 0 4 1 3 4 6 0
0 0 0 0 0 0 2 0 2 2 2 1
0 0 0 0 0 0 1 0 3 1 2 0
0 0 0 0 0 0 9 7 1 12 7 9
2
0 0 0 2 4 3 5 2 5 3 7 2
0 0 0 0 0 0 1 1 3 4 3 0
6 2 5 4 9 5 11 5 9 9 1 7
0
0 0 0 0 0 0 4 0 4 1 6 0
0 0 0 0 0 0 1 0 2 4 1 0
2 0 2 3 2 0 6 1 5 7 3 0
0 0 0 0 0 0 2 1 1 1 3 1
0 0 0 0 0 0 2 1 3 2 1 0
0 0 0 0 0 0 0 1 2 3 1 0
0 0 0 0 0 0 4 0 2 3 2 1
0 0 0 0 0 0 2 0 1 2 1 0
Note: '"Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line and each 
oxygen concentration.
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60S ribosomal protein L35a 1 3 3 2 1 2 0 0 0 0 0 0
Afadin (Isoform 4) 4 1 1 3 1 0 0 0 0 0 0 0
AP-1 complex subunit beta-1 (Isoform A) 12 4 8 5 7 4 0 0 0 0 3 5
Cytoplasmic aconitate hydratase 11 8 6 7 9 7 4 0 5 3 2 1
Fanconi anemia group 1 protein (Isoform 1) 4 0 1 3 3 1 0 0 0 0 0 0
Far upstream element-binding protein 1 8 3 9 8 10 6 0 0 0 0 0 0
(Isoform 1) 
Hexokinase-2 7 6 12 6 8 4 4 1 5 1 0 4
Histone deacetylase complex subunit SAP18 2 1 0 5 1 1 0 0 0 0 0 0
Insulin-like growth factor-binding protein 2 4 2 7 1 2 2 0 0 2 0 0 0
precursor
Isopentenyl-diphosphate Delta-isomerase 1 6 5 9 4 5 4 0 0 0 0 0 0
(Isoform 1)
Leucine zipper protein 1 (Isoform 1) 2 0 1 3 2 1 0 0 0 0 0 0
Mannosyl-oligosaccharide glucosidase 1 2 1 6 3 3 0 0 0 0 0 0
Microtubule-associated protein 4 (Isoform 
1)
Mps one binder kinase activator-like 3
6 6 4 11 9 12 3 4 3 0 0 0
2 0 1 0 3 2 0 0 0 0 0 0
NADH dehydrogenase (ubiquinone) la , 1 0 2 1 1 2 0 0 0 0 0 0
subcomplex 5
NADH-ubiquinone oxidoreductase, 75 kDa 4 4 2 1 1 3 0 0 0 0 0 0
PERQ amino acid-rich with GYF domain- 2 0 1 0 3 1 0 0 0 0 0 0
containing protein 2 (Isoform 2) 
Procollagen-lysine, 2-oxoglutarate 5- 7 1 1 2 6 1 0 0 0 0 0 0
dioxygenase 2 (Isoform 2) 
Prolyl 3-hydroxylase 2 2 1 1 2 1 0 0 0 0 0 0 0
Prolyl 4-hydroxylase subunit a-1 (Isoform 1) 4 1 3 11 14 3 0 0 0 6 3 1
Protein enabled homolog (Isoform 2) 1 0 5 2 2 0 0 0 0 0 0 0
Protein FAM162A 1 3 0 3 1 1 0 0 0 0 0 0
Regulation of nuclear pre-mRNA domain- 2 0 6 1 2 0 0 0 0 0 0 0
containing protein 1A (Isoform 2)
Solute carrier family 2, facilitated glucose 5 5 4 7 9 5 3 1 3 1 3 0
transporter, member 1 
Sorting nexin-3 (Isoform 4) 3 0 3 2 2 1 0 0 0 0 0 0
Tumor protein D52 (Isoform 1) 3 3 3 5 5 4 0 0 0 0 0 0
YrdC domain-containing protein 2 0 2 2 i 0 0 0 0 0 0 0
Note: “Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line and each 
oxygen concentration.
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28S ribosomal protein S9, mitochondrial 0 0 0 0 0 0 1 0 4 3 1 1
39S ribosomal protein L15, mitochondrial 0 0 0 0 0 0 1 1 3 2 3 0
39S ribosomal protein L19, mitochondrial 0 0 0 0 0 0 1 1 3 1 3 0
Actin-related protein 2/3 complex, sub IB 0 0 0 0 0 0 1 1 2 2 0 1
Afadin (Isoform 3) 0 0 0 0 0 0 6 0 3 2 4 1
ATP-dependent RNA helicase DDX19A 0 0 0 0 0 0 0 1 4 4 1 3
Bifunctional coenzyme A synthase 0 0 0 0 0 0 2 0 1 2 2 2
BolA-like protein 2 0 0 0 0 0 0 0 1 2 0 1 2
CLIP-associating protein 1 (Isoform 1) 0 0 0 0 0 0 5 0 3 1 4 0
DNA-directed RNA polymerase II, subunit 
RPB7 0 0 0 0 0 0 2 1 4 3 2 2
DnaJ homolog subfamily A member 3, 
mitochondrial (Isoform 2) 0 0 0 0 0 0 2 0 i 2 i 0
Dynactin, subunit 1 (Isoform 4) 4 1 1 0 0 0 8 0 4 9 2 3
Focal adhesion kinase 1 (Isoform 1) 0 0 0 0 0 0 1 1 3 1 2 0
Glutaminase kidney isoform, mitochondrial 0 0 0 0 0 0 3 2 3 1 0 3
Histone Hlx 0 0 0 0 0 0 0 1 4 1 2 1
Histone H3.3 0 0 0 0 0 0 3 1 3 0 2 3
Isopentenyl-diphosphate Delta-isomerase 1 0 0 0 0 0 0 4 2 7 4 5 4
Lysosomal protective protein 0 0 0 0 0 0 1 0 2 2 2 1
Multiple inositol polyphosphate 
phosphatase 1 (Isoform 1) 0 0 0 0 0 0 2 1 3 1 2 0
Myosin-lc (Isoform 2) 0 0 0 0 0 0 3 1 1 6 0 3
Parafibromin 0 0 0 0 0 0 1 0 2 1 2 0
Peptidyl-prolyl cis-trans Isomerase FKBP2 0 0 0 0 0 0 2 1 0 1 2 1
Prefoldin, subunit 4 0 0 0 0 0 0 1 0 3 1 2 1
Signal peptidase complex, subunit SEC11A 0 0 0 0 0 0 0 1 2 1 2 1
Signal peptidase complex, subunit 3 0 0 0 0 0 0 2 1 0 1 1 2
Sorting nexin-3 (Isoform 1) 0 0 0 0 0 0 2 0 3 3 3 2
TATA box-binding protein-like protein 1 0 0 0 0 0 0 1 1 4 2 1 1
Transmembrane protein 109 0 0 0 0 0 0 2 1 1 1 2 1
Vacuolar protein sorting-associated 26A 0 0 0 0 0 0 1 0 5 2 0 2
YLP motif-containing protein 1 0 0 0 0 0 0 1 0 2 2 1 0
Note: "Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line and each 
oxygen concentration.
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Appendix E All proteins identified ot 48 hours in hypoxia





10 kDa h e at sh o c k  p ro te in , m ito ch o n d ria l IP I0 0 2 2 0 3 6 2 8 8 13 9 1 2
116 kDa U 5 sm a ll n u c le a r  r ib o n u c le o p ro te in  c o m p o n e n t 1P I0 0 0 0 3 5 19 14 7 7 11 16 10
14-3-3  p ro te in  e p silo n IP I0 0 0 0 0 8 1 6 28 22 19 23 25 17
14 -3 -3  p ro te in  eta 1P I0 0 2 16319 14 8 13 11 7 8
14 -3 -3  p ro te in  ga m m a IP I0 0 2 2 0 6 4 2 8 9 6 5 6 5
14 -3 -3  p ro te in  th e ta IP I0 0 0 1 8 1 4 6 16 10 14 12 11 8
14 -3 -3  p ro te in  ze ta /d e lta 1P I0 0 0 2 1263 19 14 21 25 13 12
15 kDa se le n o p ro te in  iso fo rm  1 p recu rsor IP I0 0 0 3 0 8 7 7 2 2 3 2 0 2
l-p h o s p h a t id y lin o s ito l-4 ,5 -b is p h o s p h a te  p h o sp h o d ie ste ra se  b e ta -3 IP I0 0 0 1 0 4 0 0 2 1 1 2 3 4
2 4 -d e h y d ro c h o le s te ro l re d u cta se IP I0 0 0 1 6 7 0 3 3 2 2 0 2 1
2 6S  p ro te a se  re g u la to ry  su b u n it  10B 1P I0 0 0 2 1926 10 5 11 11 6 9
2 6S  p ro te a se  re g u la to ry  su b u n it  4 1P I0 0 0 1 1126 4 6 4 5 4 5
2 6 S  p ro te a se  re g u la to ry  su b u n it 6A IP I0 0 0 1 8 3 9 8 14 10 12 10 8 10
2 6 S  p ro te a se  re g u la to ry  su b u n it  7 IP I0 0 0 2 1 4 3 5 15 8 8 14 10 7
2 6S  p ro te a se  re g u la to ry  su b u n it  8 1P I0 0 0 2 3 9 19 13 9 7 3 1 1
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 14 IP I0 0 0 2 4 8 2 1 6 6 5 9 7 4
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 2 IP I0 0 0 1 2 2 6 8 15 16 4 22 20 9
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 3 IP I0 0 0 1 1 6 0 3 8 7 5 2 1 0
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 5 IP I0 0 0 0 2 1 3 4 6 3 5 9 3 3
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 6 IP I0 0 0 1 4 1 5 1 14 15 14 13 8 6
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 7 IP I0 0 0 1 9 9 2 7 5 6 5 10 4 4
2 6S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 8 IP I0 0 9 3 7 2 7 8 3 3 2 5 1 1
28  kDa h e a t- a n d  a c id -s ta b le  p h o sp h o p ro te in IP I0 0 0 1 3 2 9 7 2 2 2 2 1 4
29 kD a p ro te in IP I0 0 4 5 3 4 7 6 31 22 25 25 22 14
2 -o x o g lu ta ra te  d e h y d ro g e n a s e , m ito ch o n d ria l IP I0 0 0 9 8 9 0 2 1 2 2 6 2 2
33 kDa p ro te in IP I0 0 4 1 3 1 0 8 15 8 14 15 14 12
39 S  r ib o so m a l p ro te in  L I ,  m ito ch o n d ria l IP I0 0 5 4 9 3 8 1 2 0 3 2 1 3
39 S  r ib o so m a l p ro te in  L l l ,  m ito ch o n d ria l IP I0 0 0 0 7 0 0 1 3 1 3 4 0 1
39 S  r ib o so m a l p ro te in  L13, m ito ch o n d ria l IP I0 0 0 2 2 4 0 3 1 2 1 2 1 0
39S r ib o so m a l p ro te in  L44, m ito ch o n d ria l IP I0 0 0 0 9 6 8 0 2 1 3 1 1 2
3 9S  r ib o so m a l p ro te in  L49, m ito ch o n d ria l 1P I0 0 0 1 3 195 2 1 1 1 0 2
3 -h y d ro x y iso b u ty ra te  d e h y d ro g e n a se , m ito ch o n d ria l IP I0 0 0 1 3 8 6 0 2 0 2 3 1 0
3 -k e to a c y l-C o A  th io la se , m ito ch o n d ria l IP I0 0 0 0 1 5 3 9 4 4 5 7 5 9
4 0 S  r ib o so m a l p ro te in  S10 IP I0 0 0 0 8 4 3 8 3 4 5 5 2 3
4 0 S  r ib o so m a l p ro te in  S l l IP I0 0 0 2 5 0 9 1 5 6 6 5 5 3
4 0 S  r ib o so m a l p ro te in  S12 1P I0 0 0 1 3 9 17 11 10 13 15 4 4
4 0 S  r ib o so m a l p ro te in  S13 1P I0 0 2 2 1089 12 15 12 13 6 5
4 0 S  r ib o so m a l p ro te in  S14 IP I0 0 0 2 6 2 7 1 7 5 10 9 5 5
4 0 S  r ib o so m a l p ro te in  S15 IP I0 0 4 7 9 0 5 8 6 7 4 8 3 2
4 0 S  r ib o so m a l p ro te in  S16 1P I0 0 2 2 1092 6 6 10 6 7 3
4 0 S  r ib o so m a l p ro te in  S17 IP I0 0 2 2 1 0 9 3 11 7 8 8 7 4
4 0 S  r ib o so m a l p ro te in  S18 IP I0 0 0 1 3 2 9 6 16 11 11 10 10 6
4 0 S  r ib o so m a l p ro te in  $19 IP I0 0 2 1 5 7 8 0 8 10 8 7 5 5
4 0 S  r ib o so m a l p ro te in  S2 IP I0 0 0 1 3 4 8 5 8 7 7 9 6 7
4 0 S  r ib o so m a l p ro te in  S20 IP I0 0 0 1 2 4 9 3 6 6 7 5 3 4
4 0 S  r ib o so m a l p ro te in  S21 IP I0 0 0 1 7 4 4 8 7 4 4 5 2 2
4 0 S  r ib o so m a l p ro te in  S23 1P I0 0 2 18606 3 3 1 1 1 2
4 0 S  r ib o so m a l p ro te in  S25 IP I0 0 0 1 2 7 5 0 3 5 5 4 5 3
4 0 S  r ib o so m a l p ro te in  S26 IP I0 0 6 5 5 6 5 0 2 3 2 3 2 1
4 0 S  r ib o so m a l p ro te in  S3 1P I0 0 0 1 1253 15 15 19 17 10 13
4 0 S  r ib o so m a l p ro te in  S3a IP I0 0 4 1 9 8 8 0 18 15 17 16 10 12
4 0 S  r ib o so m a l p ro te in  S4, X iso fo rm 1P I0 0 2 17030 16 12 8 10 7 6
40$  r ib o so m a l p ro te in  S5 IP I0 0 0 0 8 4 3 3 7 8 10 6 5 7
1 0 6
4 0 S  r ib o so m a l p ro te in  S6 1P I0 0 0 2 1840 10 9 11 6 7
4 0 S  r ib o so m a l p ro te in  S7 IP I0 0 0 1 3 4 1 5 11 13 13 11 7
4 0 S  r ib o so m a l p ro te in  S8 IP I0 0 2 1 6 5 8 7 8 9 10 12 8
4 0 S  r ib o so m a l p ro te in  S9 IP I0 0 2 2 1 0 8 8 9 11 7 6 5
482  kDa p ro te in IP I0 0 1 7 9 2 9 8 11 10 12 9 16
4 -tr im e th y la m in o b u ty ra ld e h y d e  d e h yd ro g e n a se IP I0 0 4 7 9 8 7 7 2 2 3 3 3
51 kD a p ro te in IP I0 0 0 3 3 0 2 5 4 2 0 3 4
59 kD a p ro te in IP I0 0 3 0 2 9 2 5 18 21 14 14 15
5 '-n u c le o tid a se  d o m a in -c o n ta in in g  prote in  1 IP I0 0 1 7 7 9 6 5 3 2 4 4 4
60  kD a h e a t s h o c k  p ro te in , m ito ch o n d ria l IP I0 0 7 8 4 1 5 4 47 46 26 49 37
60 S  a c id ic  r ib o so m a l p ro te in  P0 IP I0 0 0 0 8 5 3 0 16 13 6 15 10
60 S  a c id ic  r ib o so m a l p ro te in  P I IP I0 0 0 0 8 5 2 7 2 6 3 1 4
60 S  a c id ic  r ib o so m a l p ro te in  P2 IP I0 0 0 0 8 5 2 9 7 9 4 10 6
60 S  r ib o so m a l p ro te in  L10 IP I0 0 5 5 4 7 2 3 7 8 6 9 9
6 0 S  r ib o so m a l p ro te in  L lO a IP I0 0 4 1 2 5 7 9 10 12 8 10 7
6 0 S  r ib o so m a l p ro te in  L13 IP I0 0 4 6 5 3 6 1 5 3 5 7 2
6 0 S  r ib o so m a l p ro te in  L13a IP I0 0 3 0 4 6 1 2 4 5 3 4 3
6 0 S  r ib o so m a l p ro te in  L15 IP I0 0 4 7 0 5 2 8 3 6 6 4 6
6 0 S  r ib o so m a l p ro te in  L17 IP I0 0 4 1 3 3 2 4 10 7 7 10 5
60 S  r ib o so m a l p ro te in  L18 IP I0 0 2 1 5 7 1 9 9 9 8 5 4
6 0 S  r ib o so m a l p ro te in  L18a IP I0 0 0 2 6 2 0 2 4 4 2 2 4
6 0 S  r ib o so m a l p ro te in  L19 IP I0 0 0 2 5 3 2 9 3 4 2 7 4
6 0 S  r ib o so m a l p ro te in  L21 IP I0 0 2 4 7 5 8 3 6 6 4 9 7
60 S  r ib o so m a l p ro te in  L22 IP I0 0 2 1 9 1 5 3 5 3 4 9 3
60 S  r ib o so m a l p ro te in  L2 2 -like  1 IP I0 0 8 5 6 0 4 9 3 2 0 1 2
60 S  r ib o so m a l p ro te in  L23 IP I0 0 0 1 0 1 5 3 5 4 4 4 4
60 S  r ib o so m a l p ro te in  L23a IP I0 0 0 2 1 2 6 6 11 13 9 12 3
6 0S  r ib o so m a l p ro te in  L24 IP I0 0 3 0 6 3 3 2 4 1 3 4 4
6 0S  r ib o so m a l p ro te in  L26 IP I0 0 0 2 7 2 7 0 9 14 8 7 5
6 0 S  r ib o so m a l p ro te in  L27 1P I0 0 2 19155 8 6 5 5 5
6 0 S  r ib o so m a l p ro te in  L27a IP I0 0 4 5 6 7 5 8 4 4 4 5 5
6 0S  r ib o so m a l p ro te in  L28 IP I0 0 1 8 2 5 3 3 7 7 6 6 2
6 0S  r ib o so m a l p ro te in  L3 IP I0 0 5 5 0 0 2 1 7 8 7 12 9
6 0 S  r ib o so m a l p ro te in  L30 1PI00219156 6 4 3 5 4
6 0 S  r ib o so m a l p ro te in  L31 IP I0 0 0 2 6 3 0 2 4 5 3 5 3
6 0S  r ib o so m a l p ro te in  L32 IP I0 0 3 9 5 9 9 8 5 3 4 5 3
6 0 S  r ib o so m a l p ro te in  L35 IP I0 0 4 1 2 6 0 7 3 2 5 5 2
6 0 S  r ib o so m a l p ro te in  L35a IP100029731 1 3 0 1 3
6 0 S  r ib o so m a l p ro te in  L36 1P I0 0 2 16237 2 3 4 5 1
6 0 S  r ib o so m a l p ro te in  L3 6 a -like IP I0 0 0 5 6 4 9 4 3 0 2 2 2
6 0 S  r ib o so m a l p ro te in  L38 IP I0 0 2 1 5 7 9 0 2 1 3 3 2
6 0S  r ib o so m a l p ro te in  L4 IP I0 0 0 0 3 9 1 8 15 12 12 20 16
6 0 S  r ib o so m a l p ro te in  L5 IP I0 0 0 0 0 4 9 4 11 12 5 11 9
6 0 S  r ib o so m a l p ro te in  L6 IP I0 0 3 2 9 3 8 9 12 18 8 14 6
6 0S  r ib o so m a l p ro te in  L7 IP I0 0 0 3 0 1 7 9 13 9 13 10 9
6 0S  r ib o so m a l p ro te in  L7a IP100299573 13 9 10 8 9
6 0S  r ib o so m a l p ro te in  L8 IP I0 0 0 1 2 7 7 2 8 2 8 8 5
60 S  r ib o so m a l p ro te in  L9 IP I0 0 0 3 1 6 9 1 6 9 5 8 2
6 -p h o sp h o fru c to k in a s e  typ e  C IP I0 0 0 0 9 7 9 0 4 2 3 7 9
6 -p h o sp h o g lu c o n a te  d e h y d ro g e n a se , d e ca rb o x y la t in g IP I0 0 2 1 9 5 2 5 22 17 17 12 11
6 -p h o sp h o g lu c o n o la c to n a se IP I0 0 0 2 9 9 9 7 8 4 10 5 7
A A R S  c D N A  F U 6 1 3 3 9 , h igh ly  s im ila r  to  A la n y l-tR N A  sy n th e ta se IP I0 0 9 1 0 7 0 1 0 2 1 5 3
A cid ic  le u c in e -r ic h  n u c le a r  p h o sp h o p ro te in  32 fa m ily  m e m b e r A IP I0 0 0 2 5 8 4 9 6 6 5 11 2
A cid ic  le u c in e -r ic h  n u c le a r  p h o sp h o p ro te in  32 fa m ily  m e m b e r E IP I0 0 1 6 5 3 9 3 6 6 2 4 1
A co n ita te  h y d ra ta se , m ito ch o n d ria l IP I0 0 0 1 7 8 5 5 5 2 3 5 3
A ctin , a lp h a  c a rd ia c  m u sc le  1 1P I00023006 11 7 9 9 7
A ctin , c y to p la s m ic  2 IP I0 0 0 2 1 4 4 0 52 70 58 55 48



























































A ctin -re la te d  p ro te in  2 
A ct in -re la te d  p ro te in  2/3  c o m p le x  su b u n it 2 
A ct in -re la te d  p ro te in  2/3  c o m p le x  su b u n it 3 
A ctin -re la te d  p ro te in  2/3  c o m p le x  su b u n it 4 
A ctin -re la te d  p ro te in  3
A ctiv a te d  R N A  p o ly m e ra se  II tra n scrip tio n a l c o a c t iv a to r  p l5
A c t iv a to r  o f 9 0  kD a h e a t sh o ck  p rote in  A T P a se  h o m o lo g  1
A cy l-p ro te in  th io e s te ra se  2
A d e n in e  p h o sp h o rib o sy ltra n sfe ra se
A d e n o sy lh o m o c y s te in a s e
A d e n y la te  k in a se  iso e n z y m e  4, m ito ch o n d ria l
A d e n y lo su c c in a te  s y n th e ta se  iso zym e  2
A D P /A T P  tra n s lo c a s e  2
A D P -rib o sy la t io n  fa c to r  1
A D P -rib o sy la t io n  fa c to r  4
A D P -rib o sy la t io n  fa c to r  5
A D P -r ib o sy la t io n  fa c to r  6
A D P -r ib o sy la t io n  fa c to r-lik e  p ro te in  2
A D P -rib o sy la t io n  fa c to r-lik e  prote in  3
A fla to x in  B l  a ld e h y d e  re d u cta se  m e m b e r 2
A -k in a se  a n c h o r  p ro te in  12 iso fo rm  2
A la n y l-tR N A  sy n th e ta se , cy to p la sm ic
A lc o h o l d e h y d ro g e n a se  [N A D P + ]
A lc o h o l d e h y d ro g e n a se  c la ss-3  
A ld e h y d e  d e h y d ro g e n a se  X, m ito ch o n d ria l 
A ld e h y d e  d e h y d ro g e n a se , m ito ch o n d ria l 
A ld o se  re d u cta se
A lk a lin e  p h o sp h a ta se , t is su e -n o n sp e c if ic  iso zym e
A lp h a -a ct in in -1
A lp h a -a ct in in -4
A lp h a -a m in o a d ip ic  s e m ia ld e h y d e  sy n th a se , m ito ch o n d ria l 
A lp h a -c e n tra c t in
A lp h a -s o lu b le  N SF  a tta c h m e n t p ro te in  
A m id o p h o s p h o rib o s y ltra n sfe ra s e
A m in o a c y l tR N A  sy n th a se  c o m p le x -in te ra c t in g  m u ltifu n ctio n a l 
p ro te in  1
A m in o a c y l tR N A  sy n th a se  c o m p le x -in te ra c t in g  m u ltifu n ctio n a l
p ro te in  2
A n n e x in  A 1
A n n e x in  A 3
a n n e x in  A 4
A n n e x in  A 5
A n n e x in  A 6
A p o lip o p ro te in  E
A rg in in o su c c in a te  syn th a se
A sp a ra g in e  sy n th e ta se  [g lu ta m in e -h yd ro lyz in g ]
A sp a ra g in y l-tR N A  sy n th e ta se , c y to p la sm ic
A sp a rta te  a m in o tra n sfe ra se , cy to p la sm ic
A sp a rta te  a m in o tra n sfe ra se , m ito ch o n d ria l
A sp a rty l-tR N A  sy n th e ta se , cy to p la sm ic
A stro c y t ic  p h o sp h o p ro te in  PEA -15
A ta x in -1 0
A T P  sy n th a se  s u b u n it  a lp h a , m ito ch o n d ria l 
A T P  sy n th a se  s u b u n it  b, m ito ch o n d ria l 
A T P  sy n th a se  s u b u n it  b e ta , m ito ch o n d ria l 
A T P  sy n th a se  s u b u n it  O , m ito ch o n d ria l 
A T P a se  A S N A 1
A T P -b in d in g  c a s se tte  su b -fa m ily  E m e m b e r 1
1 0 7
1P I0 0 0 0 5 159 8 5 4 5 8 6
IP I0 0 0 0 5 1 6 1 10 4 6 7 4 5
IP I0 0 0 0 5 1 6 2 7 4 4 5 5 2
IP I0 0 5 5 4 8 1 1 3 6 4 3 2 2
IP100028091 6 3 6 8 8 6
1P I0 0 2 2 1222 2 1 4 7 1 2
IP I0 0 0 3 0 7 0 6 3 3 5 3 2 2
IP I0 0 0 2 7 0 3 2 4 2 7 4 3 3
IP I0 0 2 1 8 6 9 3 8 12 10 9 4 4
IP I0 0 0 1 2 0 0 7 15 11 16 11 13 5
IP I0 0 0 1 6 5 6 8 4 5 6 6 5 3
IP I0 0 0 2 6 8 3 3 11 7 7 6 5 3
IP I0 0 0 0 7 1 8 8 5 4 4 4 5 4
IP I0 0 2 1 5 9 1 4 8 12 8 11 10 5
1P I0 0 2 15918 4 3 1 5 1 4
1P I0 0 2 15919 4 4 3 3 3 0
IP I0 0 2 1 5 9 2 0 2 1 2 3 3 2
IP 100003326 4 4 3 4 5 0
IP I0 0 0 0 3 3 2 7 4 3 6 6 3 3
IP I0 0 3 0 5 9 7 8 2 1 1 3 2 2
1P I0 0 2 17683 8 3 7 5 6 0
IP I0 0 0 2 7 4 4 2 18 12 14 16 22 14
IP I0 0 2 2 0 2 7 1 7 7 7 8 8 3
IP I0 0 7 4 6 7 7 7 4 3 5 6 8 5
IP I0 0 1 0 3 4 6 7 5 5 5 4 3 1
IP I0 0 0 0 6 6 6 3 3 3 2 7 5 4
IP I0 0 4 1 3 6 4 1 3 3 2 7 3 4
IP I0 0 4 1 9 9 1 6 1 3 2 4 3 3
IP I0 0 0 1 3 5 0 8 38 23 19 43 37 25
IP I0 0 0 1 3 8 0 8 16 11 6 21 22 13
IP I0 0 0 3 3 2 1 7 17 14 15 10 10 11
IP I0 0 0 2 9 4 6 8 6 2 2 4 2 1
IP I0 0 0 0 9 2 5 3 5 5 7 1 2 1
IP I0 0 0 2 9 5 3 4 1 3 1 6 2 1
IP I0 0 0 0 6 2 5 2 3 2 4 4 5 3
1P I0 0 0 1 1916 2 2 3 2 2 2
IP I0 0 2 1 8 9 1 8 4 3 4 16 9 7
IP I0 0 0 2 4 0 9 5 10 9 6 14 8 6
IP I0 0 7 9 3 1 9 9 3 2 1 7 3 2
IP I0 0 3 2 9 8 0 1 26 19 18 20 17 16
1P I0 0 2 2 1226 15 5 1 20 8 3
IP I0 0 0 2 1 8 4 2 11 2 14 8 7 3
IP I0 0 0 2 0 6 3 2 6 2 2 2 1 1
IP I0 0 5 5 4 7 7 7 8 4 7 7 7 0
IP I0 0 3 0 6 9 6 0 5 2 0 7 10 1
IP I0 0 2 1 9 0 2 9 9 6 8 9 9 8
IP I0 0 0 1 8 2 0 6 10 9 9 10 7 5
1P I0 0 2 16951 8 6 6 8 9 4
IP I0 0 0 1 4 8 5 0 3 3 2 3 1 2
1PI00001636 8 2 2 2 6 0
IP I0 0 4 4 0 4 9 3 16 16 14 17 12 7
1P I0 0 0 2 9 133 8 5 8 7 6 5
IP I0 0 3 0 3 4 7 6 26 24 22 32 27 23
IP I0 0 0 0 7 6 1 1 7 8 7 8 4 2
IP I0 0 0 1 3 4 6 6 4 4 3 4 2 3
IP I0 0 3 0 3 2 0 7 5 1 3 3 10 0
108
A T P -c itra te  sy n th a se 1P I0 0 0 2 1290 32 23 30 14 19 15
A T P -d e p e n d e n t  R N A  h e lica se  A IP I0 0 8 4 4 5 7 8 25 27 20 22 24 16
A T P -d e p e n d e n t  R N A  h e lica se  D D X1 IP I0 0 2 9 3 6 5 5 10 11 4 3 1 7
A T P -d e p e n d e n t  R N A  h e lica se  D D X 18 IP100301323 2 4 1 2 1 1
A T P -d e p e n d e n t  R N A  h e licase  D D X 1 9 A IP I0 0 0 1 9 9 1 8 2 0 3 3 4 2
A T P -d e p e n d e n t  R N A  h e licase  D D X3X IP I0 0 2 1 5 6 3 7 11 7 6 13 1 4
B and 4 .1 -lik e  p ro te in  2 IP I0 0 0 1 5 9 7 3 3 1 1 5 7 0
B a rr ie r-to -a u to in te g ra tio n  fa cto r IP I0 0 0 2 6 0 8 7 2 2 2 4 1 2
B a sic  le u c in e  z ip p e r  and  W 2 d o m a in -co n ta in in g  p ro te in  2 IP I0 0 0 2 2 3 0 5 4 3 1 4 2 2
B -ce ll re c e p to r-a s so c ia te d  prote in  31 IP I0 0 2 1 8 2 0 0 2 1 0 2 4 0
B e ta -a ct in -lik e  p ro te in  2 IP I0 0 0 0 3 2 6 9 2 1 2 1 1 2
B ifu n ctio n a l 3 ’-p h o sp h o a d e n o s in e  5 '-p h o sp h o su lfa te  syn th a se  1 1P I0 0 0 1 1619 5 2 0 3 3 0
B ifu n ct io n a l a m in o a c y l-tR N A  syn th e ta se IP I0 0 0 1 3 4 5 2 10 3 13 14 22 10
B ifu n ct io n a l m e th y le n e te tra h y d ro fo la te 1P I0 0 0 1 1307 4 4 0 1 2 1
d e h y d ro g e n a s e / c y c lo h y d ro la se , m ito ch o n d ria l 
B ifu n ctio n a l p ro te in  N C O A T IP I0 0 4 7 7 2 3 1 3 3 2 3 1 0
B ifu n ct io n a l p u rin e  b io sy n th e s is  prote in  PURH IP I0 0 2 8 9 4 9 9 25 16 14 24 19 7
B ra n ch e d -c h a in -a m in o -a c id  a m in o tra n sfe ra se IP I0 0 3 8 2 4 1 2 5 5 5 3 1 2
B re fe ld in  A -in h ib ite d  g u a n in e  n u c le o tid e -e xch a n g e  p ro te in  1 1P I0 0 0 0 2 188 2 1 3 1 5 0
C - l- te t r a h y d r o fo la te  sy n th a se , cyto p la sm ic 1P I0 0 2 18342 19 19 18 18 15 14
C A D  p ro te in IP I0 0 3 0 1 2 6 3 21 17 19 7 13 5
C a d h e rin -1 IP I0 0 0 2 5 8 6 1 5 1 3 0 3 1
C a lc iu m -re g u la te d  h e at sta b le  p ro te in  1 IP I0 0 3 0 4 4 0 9 4 3 2 5 4 2
C a lm o d u lin IP I0 0 0 7 5 2 4 8 14 8 2 10 0 5
C a lp a in  sm a ll su b u n it  1 IP I0 0 0 2 5 0 8 4 3 1 2 3 3 5
C a lp a in -1  c a ta ly tic  su b u n it IP I0 0 0 1 1 2 8 5 2 3 0 7 3 1
C a lp o n in -2 IP I0 0 0 1 5 2 6 2 8 4 3 4 4 4
C a lp o n in -3 IP I0 0 2 1 6 6 8 2 6 1 5 7 6 6
C a lre t ic u lin IP I0 0 0 2 0 5 9 9 12 9 8 12 19 8
C a rb o n ic  a n h y d ra se  2 IP I0 0 2 1 8 4 1 4 2 1 1 3 2 2
C a rb o n y l re d u cta se  [N A D P H ] 1 IP I0 0 2 9 5 3 8 6 6 1 7 5 3 6
C a se in  k in ase  II s u b u n it  a lp h a 1 IP I0 0 0 2 0 6 0 2 3 1 4 2 1 0
C a se in  k in a se  II su b u n it  beta IP I0 0 0 1 0 8 6 5 2 2 1 2 1 2
C a sp a se -3 IP I0 0 2 9 2 1 4 0 2 1 4 5 2 2
C a t io n -in d e p e n d e n t  m a n n o se -6 -p h o sp h a te  re ce p to r IP I0 0 2 8 9 8 1 9 3 1 5 1 4 0
C C R 4 -N O T  tra n scr ip tio n  c o m p le x  su b u n it  7 IP I0 0 0 0 6 5 5 2 4 1 3 3 1 1
c D N A  F U 2 5 6 7 8  fis, c lo n e  T S T 0 4 0 6 7 , h igh ly  s im ila r  to  P U R IN E IP100017672 14 11 9 11 7 9
N U C L E O S ID E  P H O S P H O R Y LA S E
c D N A  F U 3 5 8 0 9  fis, c lo n e  T E S T I2 0 0 6 0 1 6 , h igh ly  s im ila r  to  E u ka ry o tic IP I0 0 6 4 7 6 5 0 4 4 4 3 4 1
tra n s la t io n  in itia tio n  fa c to r  3 su b u n it 3
c D N A  F U 3 6 1 9 2  fis, c lo n e  T E S T I2 0 2 7 4 5 0 , h igh ly  s im ila r  to  E u ka ry o tic IP I0 0 6 5 4 7 7 7 7 8 6 6 2 4
tra n s la t io n  in itia tio n  fa c to r  3 su b u n it 5
c D N A  F U 4 4 4 3 6  fis, c lo n e  U T E R U 2 0 1 9 7 0 6 , h igh ly  s im ila r  to  T -c o m p le x IP I0 0 2 9 0 7 7 0 18 10 9 18 14 10
p ro te in  1 s u b u n it  ga m m a
c D N A  F U 5 1 9 0 9 , h igh ly  s im ila r  to  S e rin e -th re o n in e  k in a se  re ce p to r- IP I0 0 2 9 4 5 3 6 8 9 4 8 12 5
a ss o c ia te d p ro te in
c D N A  F U 5 2 7 1 2 , h ig h ly  s im ila r  to  T u b u lin  b e ta -6  ch a in IP I0 0 9 0 8 4 6 9 3 0 2 1 1 2
c D N A  F U 5 3 1 9 3 , h ig h ly  s im ila r  to  H o m o  sap ie n s ca ld e sm o n  1 (C A LD 1 ), IP I0 0 2 1 8 6 9 6 4 4 6 10 6 3
tra n s c r ip t  v a r ia n t  5, m R N A
c D N A  F U 5 3 9 7 5 , h ig h ly  s im ila r  to  A ce ty l-C o A  a ce ty ltra n sfe ra se , IP I0 0 2 9 1 4 1 9 10 14 18 6 6 1
c y to so lic
cD N A  F U 5 4 3 6 5 , h ig h ly  s im ila r  to  D N A  re p lica tio n  lic e n s in g  fa c to r IP I0 0 7 9 5 3 1 8 23 12 8 17 12 8
M C M 4
c D N A  F U 5 4 5 3 6 , h ig h ly  s im ila r  to  M ito ch o n d ria l 28 S  rib o so m a l p ro te in IP I0 0 0 2 2 0 0 2 4 2 1 1 1 2
S27
c D N A  F U 5 4 9 5 7 , h ig h ly  s im ila r  to  Tra n sk e to la se IP I0 0 6 4 3 9 2 0 28 28 17 32 22 7
c D N A  F U 5 5 3 8 2 , h ig h ly  s im ila r  to  H sp 7 0 -b in d in g  p ro te in  1 IP I0 0 1 0 0 7 4 8 4 3 3 4 1 2
c D N A  F U 5 5 4 8 2 , h ig h ly  s im ila r  to  A n n e x in  A l l IP I0 0 4 1 4 3 2 0 2 1 0 2 2 0
109
c D N A  F U 5 5 5 7 4 , h igh ly  s im ila r  to  Calnexin IP I0 0 0 2 0 9 8 4 10 8 4 10 9 9
c D N A  F U 5 5 5 8 6 , h ig h ly  s im ila r  to M M S19-like  p rote in IP I0 0 1 5 4 4 5 1 5 3 2 8 3 2
c D N A  F U 5 5 5 9 9 , h ig h ly  s im ila r  to  DN A  rep lication  lice n sin g  fa cto r 
M C M 3
IP I0 0 0 1 3 2 1 4 18 13 12 8 10 15
cD N A  F U 5 6 3 0 7 , h ig h ly  s im ila r  to U biq u itin  th io e ste ra se  protein  
O T U B 1
IP I0 0 0 0 0 5 8 1 4 7 4 5 4 3
cD N A  F U 5 9 2 1 1 , h ig h ly  s im ila r  to  G lu co sid a se  2 su b u n it  beta IP I0 0 0 2 6 1 5 4 4 5 8 4 8 7
c D N A  F U 5 9 3 6 7 , h ig h ly  s im ila r  to  A d en y lo su cc in ate  lyase IP I0 0 0 2 6 9 0 4 10 6 7 10 7 5
c D N A  F U 5 9 7 5 8 , h ig h ly  s im ila r  to S -m e th y l-5 -th io a d e n o sin e  
p h o sp h o ry la se
IP I0 0 0 1 1 8 7 6 7 6 8 2 0 1
cD N A  F U 6 0 0 7 6 , h igh ly  s im ila r  to  ELA V -like  protein  1 IP I0 0 3 0 1 9 3 6 10 5 5 8 6 3
c D N A  F U 6 0 0 9 7 , h igh ly  s im ila r  to  Tu b u lin  a lp h a -u b iq u ito u s  chain IP I0 0 7 9 2 6 7 7 30 33 30 32 36 19
cD N A  F U 6 0 4 2 4 , h igh ly  s im ila r  to  Ju n ctio n  p lako glob in IP I0 0 7 8 9 3 2 4 9 4 6 3 4 3
c D N A  F U 6 0 6 0 7 , h igh ly  s im ila r  to  A cy l-p ro te in  th io e ste ra se  1 IP I0 0 0 0 7 3 2 1 5 3 4 3 3 3
c D N A  F U 6 1 1 6 2 , h igh ly  s im ila r  to R as-re lated  protein  R-Ras2 IP I0 0 0 1 2 5 1 2 4 1 2 4 2 3
c D N A  F U 7 5 0 8 5 , h igh ly  s im ila r  to  H om o sap iens g lu ta m in y l-tR N A  
sy n th e ta se  (Q A R S), m R N A
IP I0 0 0 2 6 6 6 5 8 7 3 3 1 3
c D N A  F U 7 7 1 7 7 , h igh ly  s im ila r to  H om o sap iens arg in in e -rich , 
m u ta te d  in e a rly  stage  tu m o rs  (A R M ET), m RN A
IP I0 0 3 2 8 7 4 8 1 2 0 1 2 1
c D N A  F U 7 7 4 2 2 , h igh ly  s im ila r  to  H om o sap iens RN A  b in d in g p rote in , 
a u to a n tig e n ic  (h n R N P -a sso c ia te d  w ith  lethal ye llo w  h om o lo g 
(m o u se )), t ra n scrip t  v a r ia n t 1, m R N A  (Fragm ent)
IP I0 0 0 1 1 2 6 8 2 1 2 2 2 1
cD N A , F U 7 9 1 8 4 , h igh ly  s im ila r  to  P ro co lla ge n -lys in e , 2 -oxoglu tarate  
5 -d io x y g e n a se  1
IP I0 0 0 2 7 1 9 2 2 1 0 1 2 0
cD N A , F U 9 6 5 0 8 , H o m o  sa p ie n s S H 3 -d o m ain  G RB2-!ike  1 (SH 3G L1), 
m R N A
IP I0 0 0 1 9 1 6 9 3 1 3 2 1 0
Cell d iv is io n  p ro te in  k in ase  2 1P I0 0 0 3 1681 2 2 1 1 2 1
C e llu la r  re tin o ic  a c id -b in d in g  p rote in  1 IP I0 0 2 1 9 9 3 0 6 7 6 10 8 5
C e llu la r  re tin o ic  a c id -b in d in g  p rote in  2 IP I0 0 2 1 6 0 8 8 5 1 1 5 3 2
C h lo rid e  in tra ce llu la r  ch a n n e l p rote in  1 IP I0 0 0 1 0 8 9 6 9 5 10 11 10 8
C h lo rid e  in tra ce llu la r  ch a n n e l p rote in  4 IP I0 0 0 0 1 9 6 0 15 11 9 9 8 8
C h ro m o b o x  p rote in  h o m o lo g  3 IP I0 0 2 9 7 5 7 9 6 4 4 5 3 6
C itra te  sy n th a se , m ito ch o n d ria l IP I0 0 0 2 5 3 6 6 5 5 3 7 4 1
C la u d in -6 IP I0 0 0 1 1 0 8 4 4 3 3 2 2 2
C le a v a g e  an d  p o ly a d e n y la tio n  sp e c ific ity  fa c to r  su b u n it 5 IP I0 0 6 4 6 9 1 7 6 4 6 2 0 1
C le a v a g e  s tim u la tio n  fa c to r  su b u n it  3 IP I0 0 0 1 5 1 9 5 2 2 1 5 1 0
C o a c to s in -like  p rote in IP I0 0 0 1 7 7 0 4 1 2 1 3 1 2
C o a to m e r su b u n it beta IP100295851 8 4 4 13 13 7
C o a to m e r su b u n it beta' IP I0 0 2 2 0 2 1 9 7 1 6 2 10 5
C o a to m e r su b u n it delta v a ria n t 2 IP I0 0 2 9 8 5 2 0 9 4 7 9 8 3
C o a to m e r su b u n it ep silo n 1P I0 0 4 6 5 132 6 2 2 4 4 4
C o a to m e r su b u n it gam m a IP I0 0 7 8 3 9 8 2 11 7 3 11 12 10
C o a to m e r su b u n it ga m m a-2 IP I0 0 0 0 2 5 5 7 3 4 2 8 2 2
C o a to m e r su b u n it ze ta-1 IP I0 0 0 3 2 8 5 1 3 5 6 3 3 4
C o filin -1 1P I0 0 0 1 2 0 11 12 19 17 18 12 7
C o ile d -co il d o m a in -co n ta in in g  p rote in  58 IP I0 0 0 4 6 8 2 8 2 0 2 2 1 0
C o ld -in d u c ib le  R N A -b in d in g  protein IP I0 0 1 8 0 9 5 4 2 0 2 3 2 2
C o lla p sin  re sp o n se  m e d ia to r p rote in  4  lon g va ria n t 1P I0 0 0 2 9 1 11 20 9 8 15 10 7
C o m p le m e n t c o m p o n e n t 1 Q  su b co m p o n e n t-b in d in g  p rote in , 
m ito ch o n d ria l
IP I0 0 0 1 4 2 3 0 11 12 5 7 6 7
C o n d e n s in  c o m p le x  su b u n it 1 IP I0 0 2 9 9 5 2 4 5 3 3 3 5 1
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 4 IP I0 0 1 7 1 8 4 4 6 4 6 5 3 4
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 5 IP I0 0 0 0 9 9 5 8 0 1 2 2 2 3
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 6 IP100163230 3 2 1 4 0 1
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 7a IP I0 0 3 0 1 4 1 9 3 3 2 3 4 3
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 8 IP I0 0 0 0 9 4 8 0 3 1 4 4 1 1
C re a tin e  k in a se  B -typ e IP I0 0 0 2 2 9 7 7 11 14 10 16 15 11
C S E 1 L  Iso fo rm  1 o f Exp o rtin -2 IP100022744 2 1 0 4 2 0
1 1 0
C S N K 2 A 1  p rote in IP I0 0 0 1 6 6 1 3 10 7 10 1 2 2
C T P syn th ase  1 IP I0 0 2 9 0 1 4 2 6 2 3 8 4 2
C u llin -1 IP I0 0 0 1 4 3 1 0 4 1 1 3 0 2
C y sta tin -B 1P I0 0 0 2 1828 3 2 3 3 2 2
C y ste in e  an d  g ly c in e -r ich  p rote in  2 IP I0 0 0 0 2 8 2 4 3 3 2 5 6 2
c y ste in y l-tR N A  sy n th e ta se , cyto p lasm ic  iso form  c IP I0 0 0 2 7 4 4 3 4 6 7 3 4 0
cy to c h ro m e  b5 typ e  B p recu rso r IP I0 0 3 0 3 9 5 4 4 2 2 2 4 2
C y to ch ro m e  c IP I0 0 4 6 5 3 1 5 5 4 6 6 1 3
C y to ch ro m e  c o x id a se  su b u n it 2 IP I0 0 0 1 7 5 1 0 3 3 1 4 1 1
C y to ch ro m e  c o x id a se  su b u n it 4 iso form  1, m ito ch o n d ria l IP I0 0 0 0 6 5 7 9 2 1 0 1 2 0
C y to ch ro m e  c o x id a se  su b u n it 5A, m ito ch o n d ria l IP I0 0 0 2 5 0 8 6 3 1 0 2 0 2
C y to p la sm ic  a co n ita te  hyd ratase IP I0 0 0 0 8 4 8 5 7 6 1 1 2 1
C y to p la sm ic  d yn e in  1 h e avy chain  1 IP I0 0 4 5 6 9 6 9 64 37 36 14 33 0
C y to so lic  Fe-S  c lu ste r a sse m b ly  fa cto r N U BP2 IP I0 0 6 4 4 6 7 4 3 1 3 0 2 2
D -3 -p h o sp h o g ly ce ra te  d eh yd ro g en a se IP I0 0 0 1 1 2 0 0 16 11 15 14 13 9
d C T P  p y ro p h o sp h a ta se  1 IP I0 0 0 1 2 1 9 7 0 4 2 3 0 1
D -d o p a ch ro m e  d e ca rb o xy lase IP I0 0 2 9 3 8 6 7 4 3 6 6 2 2
D e strin IP I0 0 4 7 3 0 1 4 1 4 3 3 3 1
D e v e lo p m e n ta l p lu rip o te n cy-a sso c ia te d  protein  4 IP I0 0 0 1 8 8 7 8 2 0 1 2 1 0
D ia b lo  h o m o lo g , m ito ch o n d ria l precursor IP I0 0 0 0 8 4 1 8 3 3 1 2 3 0
D ih y d ro lip o y l d e h yd ro g e n a se , m ito ch o n d ria l IP I0 0 0 1 5 9 1 1 3 1 3 5 5 2
D ih y d ro lip o y lly s in e -re s id u e  a ce ty ltra n sfe rase  co m p o n e n t o f p yru vate  
d e h y d ro g e n a se  co m p le x , m ito ch o n d ria l
1P I0 0 0 2 1338 6 1 3 3 4 0
D ih y d ro p te rid in e  re d u cta se IP I0 0 0 1 4 4 3 9 3 2 0 2 2 1
D ih y d ro p y r im id in a se -re la te d  p rote in  2 IP I0 0 2 5 7 5 0 8 17 5 8 13 10 7
D ip h o sp h o m e v a lo n a te  d e ca rb o xy la se IP I0 0 0 2 2 7 4 5 1 2 7 1 2 1
D N A  d a m a g e -b in d in g  p ro te in  1 IP I0 0 2 9 3 4 6 4 6 2 2 6 10 1
D N A  ligase  1 IP I0 0 2 1 9 8 4 1 5 3 0 2 1 1
D N A  m ism a tch  re p a ir  p ro te in  M sh2 IP I0 0 0 1 7 3 0 3 9 7 6 8 5 3
D N A  re p lica tio n  lice n sin g  fa c to r  M CM 2 IP I0 0 1 8 4 3 3 0 19 14 13 12 16 14
D N A  re p lica tio n  lice n sin g  fa c to r  M C M 5 IP I0 0 0 1 8 3 5 0 10 16 9 7 8 10
D N A  re p lica tio n  lice n sin g  fa c to r  M C M 6 1P I0 0 0 3 1517 15 12 8 13 9 6
D N A -(a p u rin ic  o r a p y rim id in ic  site ) lyase 1P100215911 5 4 5 9 11 10
D N A -d ire cte d  R N A  p o ly m e ra se  II su b u n it RPB1 1P I0 0 0 3 1627 2 2 2 4 2 0
D N A -d ire cte d  RN A  p o ly m e ra se  II su b u n it RPB3 IP I0 0 0 1 8 2 8 8 4 3 2 6 2 1
D N A -d ire cte d  RN A  p o ly m e ra se s  1, II, an d  III su b u n it R P A B C 1 IP I0 0 2 9 1 0 9 3 2 1 2 1 2 3
D n aJ h o m o lo g  su b fa m ily  A  m e m b e r 1 IP100012535 10 10 4 5 8 4
D n aJ h o m o lo g  su b fa m ily  A  m e m b e r 2 IP I0 0 0 3 2 4 0 6 7 2 4 5 4 5
D n aJ h o m o lo g  su b fa m ily  B m e m b e r 11 IP I0 0 0 0 8 4 5 4 1 1 2 0 1 2
D n aJ h o m o lo g  su b fa m ily  C m e m b e r 7 IP I0 0 3 2 9 6 2 9 3 0 2 2 5 0
DnaJ h o m o lo g  su b fa m ily  C m e m b e r 8 IP I0 0 0 0 3 4 3 8 6 1 2 4 4 4
D o lich o l-p h o sp h a te  m a n n o sy ltra n sfe ra se IP I0 0 0 2 2 0 1 8 2 1 3 3 2 0
D o lic h y l-d ip h o s p h o o lig o s a c c h a r id e -p ro te in  g ly co sy ltra n sfe ra se  
su b u n it  1 p re cu rso r
IP100025874 3 1 3 10 11 1
D o lic h y l-d ip h o s p h o o lig o s a c c h a r id e -p ro te in  g ly co sy ltra n sfe ra se  
su b u n it  2
IP I0 0 0 2 8 6 3 5 5 1 1 2 8 3
D u al s p e c ific ity  m ito ge n -a ctiva te d  p rote in  k in ase  k in ase  1 IP100219604 2 0 3 2 2 1
D u al s p e c ific ity  p rote in  p h o sp h a ta se  3 IP I0 0 0 1 8 6 7 1 2 3 1 4 1 1
d yn a ctin  su b u n it  2 IP I0 0 2 2 0 5 0 3 4 1 5 1 2 0
D y n e in  lig h t ch a in  T cte x-typ e  1 IP I0 0 0 1 9 4 9 5 3 0 2 2 0 1
E3 S U M O -p ro te in  ligase  RanBP2 IP I0 0 2 2 1 3 2 5 5 2 5 2 1 0
E3 u b iq u itin -p ro te in  ligase  KCM F1 IP I0 0 3 0 6 6 6 1 2 2 1 2 1 1
E le ctro n  tra n s fe r  fla v o p ro te in  su b u n it a lp h a, m ito ch o n d ria l IP I0 0 0 1 0 8 1 0 5 3 6 7 3 8
E lo n g a tio n  fa c to r  1-a lp ha 1 IP I0 0 3 9 6 4 8 5 24 31 28 19 23 16
E lo n g a tio n  fa c to r  1-beta IP I0 0 1 7 8 4 4 0 4 4 4 2 5 5
E lo n g a tio n  fa c to r  1-gam m a IP I0 0 9 3 7 6 1 5 17 12 8 13 14 14
E lo n g a tio n  fa c to r  2 IP I0 0 1 8 6 2 9 0 53 50 29 50 40 33
Em erin IP I0 0 0 3 2 0 0 3 1 1 j 2 1 3 1
I l l
E n d o p la sm ic  re ticu lu m  resid en t p rote in  29 1P I0 0 0 2 4 9 11 8 5 9 8 7 5
E n d o p la sm ic  re ticu lu m  resid en t p rote in  44 IP I0 0 4 0 1 2 6 4 3 0 2 5 2 0
En d o p la sm in IP I0 0 0 2 7 2 3 0 34 22 21 32 29 23
E n h a n ce r o f  ru d im e n ta ry  h om o lo g IP I0 0 0 2 9 6 3 1 4 3 0 4 2 2
E n o y l-C o A  h yd ra ta se , m ito ch o n d ria l IP I0 0 0 2 4 9 9 3 9 4 4 10 8 6
Ep ip lak in IP I0 0 0 1 0 9 5 1 3 4 2 2 3 1
Ep ith e lia l ce ll a d h e s io n  m olecu le 1P I0 0 2 9 6 2 15 1 2 5 3 5 3
E R O l- lik e  p ro te in  a lpha IP I0 0 3 8 6 7 5 5 1 0 3 1 2 0
E stra d io l 1 7 -b e ta -d e h y d ro g e n a se  12 IP I0 0 0 0 7 6 7 6 10 9 11 10 7 5
E u k a ry o tic  in itia tio n  fa c to r  4A-I IP I0 0 0 2 5 4 9 1 27 24 26 20 23 15
E u k a ry o tic  in itia tio n  fa cto r 4A-III IP I0 0 0 0 9 3 2 8 13 4 6 3 8 6
e u ka ry o tic  p e p tid e  chain  release  fa cto r G T P -b in d in g  su b u n it ER F3A  
iso fo rm  2
IP I0 0 9 0 9 0 8 3 4 4 0 4 2 1
E u k a ry o tic  p e p tid e  ch ain  release  fa cto r su b u n it 1 IP I0 0 4 2 9 1 9 1 5 3 4 7 7 4
E u k a ry o tic  tra n s la tio n  e lo n ga tio n  fa cto r 1 ep silo n -1 IP I0 0 0 0 3 5 8 8 5 4 4 4 3 2
E u k a ry o tic  tra n s la tio n  in itiation  fa cto r 2 su b u n it 1 IP I0 0 2 1 9 6 7 8 6 3 4 5 7 7
E u k a ry o tic  tra n s la tio n  in itiatio n  fa cto r 2 su b u n it 2 IP I0 0 0 2 1 7 2 8 3 0 2 4 3 1
E u k a ry o tic  tra n s la tio n  in itiatio n  fa cto r 2 su b u n it 3 IP I0 0 2 9 7 9 8 2 10 6 2 8 7 5
E u k a ry o tic  tra n s la tio n  in itiatio n  fa cto r 3 su b u n it A IP I0 0 0 2 9 0 1 2 24 22 16 23 19 15
E u k a ry o tic  tra n s la t io n  in itiatio n  fa c to r  3 su b u n it C IP I0 0 0 1 6 9 1 0 10 10 5 9 10 7
E u k a ry o tic  tra n s la t io n  in itiatio n  fa cto r 3 su b u n it D IP I0 0 0 0 6 1 8 1 3 1 1 4 10 1
E u k a ry o tic  tra n s la tio n  in itiatio n  fa cto r 3 su b u n it E IP I0 0 0 1 3 0 6 8 13 5 6 7 9 6
E u k a ry o tic  tra n s la t io n  in itiatio n  fa cto r 3 su b u n it G IP I0 0 2 9 0 4 6 0 5 3 7 4 4 3
E u k a ry o tic  tra n s la t io n  in itia tio n  fa cto r 3 su b u n it 1 IP I0 0 0 1 2 7 9 5 7 3 3 0 3 1
E u ka ry o tic  tra n s la t io n  in itia tio n  fa c to r  3 su b u n it K IP I0 0 0 3 3 1 4 3 4 3 6 6 1 3
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it M IP I0 0 1 0 2 0 6 9 8 11 7 4 7 7
E u ka ry o tic  tra n s la t io n  in itia tio n  fa c to r  3, su b u n it E in te ractin g  protein IP I0 0 4 6 5 2 3 3 7 5 5 6 12 0
e u ka ry o tic  tra n s la t io n  in itia tio n  fa c to r  4  gam m a 1 iso form  1 IP I0 0 4 7 9 2 6 2 11 6 8 10 10 7
E u k a ry o tic  tra n s la t io n  in itia tio n  fa c to r  5 IP I0 0 0 2 2 6 4 8 3 2 5 5 4 2
E u ka ry o tic  tra n s la t io n  in itia tio n  fa c to r  5B IP I0 0 2 9 9 2 5 4 4 4 2 5 0 2
E u k a ry o tic  tra n s la t io n  in itia tio n  fa c to r  6 IP I0 0 0 1 0 1 0 5 5 5 4 3 6 6
E xo so m e  c o m p le x  e xo n u c le a se  M TR 3 IP I0 0 0 7 3 6 0 2 2 2 2 1 2 2
E xo so m e  c o m p le x  e xo n u c le a se  R R P 4 IP I0 0 0 1 5 9 0 5 3 2 2 3 3 4
Exo so m e  c o m p le x  e xo n u c le a se  R R P41 IP I0 0 7 4 5 6 1 3 2 2 2 2 1 2
Exo so m e  c o m p le x  e xo n u c le a se  R R P4 2 IP I0 0 0 1 4 1 9 8 2 1 2 1 1 2
Exo so m e  c o m p le x  e xo n u c le a se  R R P4 3 IP I0 0 5 5 2 9 2 0 2 0 1 1 2 1
Exp o rtin -1 IP I0 0 2 9 8 9 6 1 26 16 13 18 16 20
Exp o rtin -4 IP I0 0 0 2 8 3 5 7 5 0 1 1 2 3
Exp o rtin -5 IP I0 0 6 4 0 7 0 3 17 7 7 6 14 5
Exp o rtin -7 IP I0 0 3 0 2 4 5 8 5 6 7 6 3 2
E xp o rtin -T IP I0 0 3 0 6 2 9 0 5 3 4 1 4 1
Ezrin IP I0 0 8 4 3 9 7 5 9 15 6 19 13 10
F A C T  c o m p le x  su b u n it S PT16 IP I0 0 0 2 6 9 7 0 5 1 1 11 10 5
F A C T  c o m p le x  su b u n it SSR P1 IP I0 0 0 0 5 1 5 4 3 3 1 5 3 5
F -a ctin -ca p p in g  p rote in  su b u n it a lp h a-1 IP I0 0 0 0 5 9 6 9 8 3 5 5 8 5
F -a ctin -ca p p in g  p rote in  su b u n it a lp h a-2 IP I0 0 0 2 6 1 8 2 5 3 3 3 5 3
fa rn e sy l p yro p h o sp h a te  syn th ase  iso form  b IP I0 0 9 1 4 9 7 1 7 4 10 6 7 2
Fascin IP I0 0 1 6 3 1 8 7 12 11 5 16 14 10
F atty  a cid  syn th a se IP I0 0 0 2 6 7 8 1 89 93 99 47 45 37
F atty  a c id -b in d in g  p rote in , e p id e rm al IP I0 0 0 0 7 7 9 7 9 3 8 13 9 8
Ferritin  h e a v y  chain IP I0 0 5 5 4 5 2 1 1 0 2 2 1 0
Flap e n d o n u c le a se  1 IP I0 0 0 2 6 2 1 5 2 2 2 2 4 2
F ru cto se -b isp h o sp h a te  a ld o lase IP I0 0 4 1 8 2 6 2 9 6 11 7 4 3
F ru cto se -b isp h o sp h a te  a ld o lase  A IP I0 0 4 6 5 4 3 9 30 26 31 29 26 17
G 2 /m ito tic -sp e c ific  c y c lin -B l IP I0 0 7 4 5 7 9 3 3 0 1 2 2 0
G a m m a -e n o la se IP I0 0 2 1 6 1 7 1 7 4 4 4 7 3
G lia m a tu ra tio n  fa c to r, beta IP I0 0 4 1 2 9 8 7 4 3 3 6 2 0
G lu co sa m in e  6 -p h o sp h a te  N -a cety ltra n sfe rase IP I0 0 0 6 1 5 2 5 4 1 3 5 4 3
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G lu co sa m in e -6 -p h o sp h a te  iso m e ra se  1 
G lu co se -6 -p h o sp h a te  iso m e ra se  
G lu ta m a te  d e h y d ro g e n a se  1, m ito ch o n d ria l 
G lu ta re d o x in -3
G lu ta th io n e  S -tra n sfe ra se  o m e ga-1  
G lu ta th io n e  S -tra n sfe ra se  P 
G lyce ra ld e h y d e -3 -p h o sp h a te  d e h yd ro g e n a se  
G ly co g e n  p h o sp h o ry la se , brain  form  
G ly p ica n -4
G M P  syn th a se  [g lu tam in e -h yd ro lyz in g ]
G -rich  se q u e n ce  fa cto r 1
G T P :A M P  p h o sp h o tra n sfe ra se , m ito ch o n d ria l
G T P a se  N Ras
G T P -b in d in g  n u clear p ro te in  Ran 
G T P -b in d in g  p rote in  R heb
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (I)/G (S)/G (T ) su b u n it beta-1
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (I)/G ($)/G (T ) su b u n it beta-2
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (k) su b u n it a lpha
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (q) su b u n it a lpha
G u a n in e  n u c le o tid e -b in d in g  p rote in  su b u n it a lp h a -1 3
G u a n in e  n u c le o tid e -b in d in g  p rote in  su b u n it b e ta -2 -like  1
H eat sh o ck  70  kDa p ro te in  1A /1B
H eat sh o ck  70 kDa p rote in  4
H eat sh o c k  p rote in  75 kDa, m ito ch o n d ria l
H eat sh o c k  p rote in  beta-1
H e a t sh o ck  p ro te in  H SP  90 -b e ta
H eat sh o c k-re la te d  70 kDa p rote in  2
H e m e  o x y g e n a se  1
H e m e -b in d in g  p ro te in  1
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  AO
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  F
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  G
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  H
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  K
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  L
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  U -like  p rote in  2
H e x o k in a se -2
H igh  m o b ility  g ro u p  p rote in  B1
H ist id y l-tR N A  syn th e ta se , c yto p la sm ic
H isto n e  H I . 5
H isto n e  H 2A  typ e  1-H
H isto n e  H 2A .V
H isto n e  H4
H sc 7 0 -in te ra ct in g  protein  
H sp 9 0  c o -ch a p e ro n e  Cdc37 
H SP A 5  p rote in
H y d ro x y m e th y lg lu ta ry l-C o A  syn th ase , cyto p lasm ic
H y p o x a n th in e -g u a n in e  p h o sp h o rib o sy ltran sfe ra se
H yp o xia  u p -re g u la te d  p rote in  1
Im p o rtin  su b u n it  a lp h a -2
Im p o rtin  su b u n it  a lp h a -3
Im p o rtin  s u b u n it  a lp h a -4
Im p o rtin  s u b u n it  beta-1
lm p o rtin -1 1
lm p o rtin -7
lm p o rtin -9
In o rgan ic  p y ro p h o sp h a ta se  
In o sin e  trip h o sp h a te  p yro p h o sp h a ta se
IP I0 0 0 0 9 3 0 5 5 2 5 1 2 1
1PI00027497 21 14 9 17 15 6
IP I0 0 0 1 6 8 0 1 2 2 1 6 5 3
IP I000 08552 13 7 9 15 6 6
IP I000 19755 3 1 1 2 1 0
IP I0 0 2 1 9 7 5 7 18 15 17 22 14 9
1P I0 0 2 19018 52 60 50 57 37 25
IP I0 0 0 0 4 3 5 8 3 5 3 8 5 2
IP I0 0 2 3 2 5 7 1 11 5 9 7 5 8
IP I0 0 0 2 9 0 7 9 25 9 6 16 12 3
IP I0 0 4 7 8 6 5 7 2 1 1 2 2 2
IP I0 0 4 6 5 2 5 6 3 1 2 1 2 1
IP I0 0 0 0 0 0 0 5 1 1 2 5 2 2
IP I0 0 6 4 3 0 4 1 11 10 10 11 5 5
IP I0 0 0 1 6 6 6 9 4 2 3 1 2 0
IP I0 0 0 2 6 2 6 8 7 2 6 8 7 6
IP I0 0 0 0 3 3 4 8 2 1 3 3 4 3
IP I0 0 2 2 0 5 7 8 3 1 0 3 6 4
IP I0 0 2 8 8 9 4 7 1 0 2 2 2 1
IP I0 0 2 9 0 9 2 8 1 0 2 2 1 0
IP I0 0 8 4 8 2 2 6 17 14 11 15 15 16
IP I0 0 3 0 4 9 2 5 15 3 10 6 6 0
IP I0 0 0 0 2 9 6 6 25 21 18 16 28 21
IP I0 0 0 3 0 2 7 5 10 3 4 7 3 2
IP I0 0 0 2 5 5 1 2 7 5 3 4 2 3
IP I0 0 4 1 4 6 7 6 70 73 42 62 60 34
IP I0 0 0 0 7 7 0 2 2 1 2 2 1 2
IP I0 0 2 1 5 8 9 3 1 0 3 3 2 1
IP I0 0 1 4 8 0 6 3 5 3 2 3 3 0
1P I0 0 0 1 1913 4 2 4 7 5 3
IP I0 0 0 0 3 8 8 1 7 5 5 5 1 3
(P I0 0304692 7 5 6 8 6 5
IP I0 0 0 1 3 8 8 1 6 4 4 9 12 10
IP I0 0 5 1 4 5 6 1 21 16 12 19 16 11
IP I0 0 0 2 7 8 3 4 9 4 3 6 12 4
IP I0 0 4 5 6 8 8 7 3 2 4 3 6 2
IP I0 0 1 0 2 8 6 4 10 12 5 5 3 1
IP I0 0 4 1 9 2 5 8 9 10 4 11 7 5
1P I0 0 0 2 1808 2 0 3 6 3 0
IP I0 0 2 1 7 4 6 8 5 4 7 7 4 4
IP I0 0 0 8 1 8 3 6 1 4 12 11 5 2
IP I0 0 0 1 8 2 7 8 2 2 1 3 2 3
IP I0 0 4 5 3 4 7 3 6 7 17 17 10 7
IP I0 0 0 3 2 8 2 6 5 6 4 4 4 4
1P I0 0 0 1 3 122 7 2 5 0 2 1
IP I0 0 0 0 3 3 6 2 35 30 23 31 19 14
IP I0 0 0 0 8 4 7 5 23 18 17 7 12 7
IP I0 0 2 1 8 4 9 3 7 10 6 7 6 5
IP I0 0 0 0 0 8 7 7 22 16 16 15 24 15
IP I0 0 0 0 2 2 1 4 16 14 10 10 11 9
IP I0 0 2 9 9 0 3 3 5 2 1 2 0 1
IP I0 0 0 1 2 5 7 8 4 1 0 4 4 1
IP I0 0 0 0 1 6 3 9 22 22 9 22 17 17
1P I0 0 3 0 1 107 4 0 3 2 1 4
IP I0 0 0 0 7 4 0 2 12 7 9 10 11 9
IP I0 0 1 8 5 1 4 6 7 7 7 3 11 6
IP I0 0 0 1 5 0 1 8 9 3 3 8 4 3
IP I0 0 0 1 8 7 8 3 2 0 2 3 2 1
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ln o s in e -5 '-m o n o p h o sp h a te  d e h y d ro g e n a se  2 
in o s ito l-3 -p h o sp h a te  syn th a se  1 iso fo rm  2 
In su lin -d e g ra d in g  e n zym e
In su lin -like  gro w th  fa c to r  2 m R N A -b in d in g  p rote in  1
In te rle u k in  e n h a n ce r-b in d in g  fa c to r  2
Iso ch o rism a ta se  d o m a in -co n ta in in g  p rote in  1
Iso c itra te  d e h yd ro g e n a se  [N A D P] cyto p la sm ic
Iso c itra te  d e h yd ro g e n a se  [N A D P ], m ito ch o n d ria l
Iso fo rm  1 o f 26S p ro tea se  re g u la to ry  su b u n it 6B
Iso fo rm  1 o f 26S p ro te a so m e  n o n -A TP ase  re g u la to ry  su b u n it 1
Iso fo rm  1 o f 3 ,2 -tra n s-e n o y l-C o A  iso m e ra se , m ito ch o n d ria l
Iso form  1 o f  39S rib o so m al p rote in  L22, m ito ch o n d ria l
Iso form  1 o f  3 -h y d ro x y a cy l-C o A  d e h yd ro g e n a se  typ e -2
Isoform  1 o f 3 -h y d ro x y iso b u ty ry l-C o A  h yd ro lase , m ito ch o n d ria l
Iso fo rm  1 o f 40 S  rib o so m al p rote in  S24
Iso fo rm  1 o f 5 '(3 ')-d e o xy rib o n u cle o tid a se , c y to so lic  type
Isoform  1 o f 5'-3 ' e xo rib o n u c le a se  2
Iso form  1 o f  5 '-n u c le o tid a se  d o m a in -co n ta in in g  p ro te in  2
Iso fo rm  1 o f  60S rib o so m al p rote in  L l l
Iso fo rm  1 o f  60S rib o so m al p rote in  L12
Isoform  1 o f  6 -p h o sp h o fru cto k in a se , liver type
Iso fo rm  1 o f A ce ty l-C o A  ca rb o xy la se  1
Iso fo rm  1 o f A cid ic  leu c in e-rich  n u c le a r p h o sp h o p ro te in  32 fa m ily  
m e m b e r B
Iso fo rm  1 o f A ctin -re la te d  p rote in  2/3 co m p le x  su b u n it 5
Iso fo rm  1 o f A d e n y la te  k in ase  2, m ito ch o n d ria l
Iso fo rm  1 o f A d e n y ly l cy c la se -a sso c ia te d  protein  1
Iso fo rm  1 o f  A d ip o cy te  p lasm a m e m b ra n e -a sso cia te d  protein
Iso form  1 o f A n n e x in  A 7
Iso fo rm  1 o f A P -2  co m p le x  su b u n it  beta
Iso fo rm  1 o f A p o p to s is -a sso c ia te d  sp e ck-like  p ro te in  co n ta in in g  a 
C A R D
Iso fo rm  1 o f A TP  syn th ase  su b u n it  d, m ito ch o n d ria l
Iso fo rm  1 o f  B asic  leucine  z ip p e r and W 2 d o m a in -co n ta in in g  p rotei
Iso fo rm  1 o f B R C A 2  and C D K N IA -in te ra c t in g  p rote in
Iso fo rm  1 o f C a lcy c lin -b in d in g  p rote in
Iso form  1 o f C ap rin -1
Iso fo rm  1 o f C aten in  a lp h a-1
Iso fo rm  1 o f C aten in  beta-1
Iso fo rm  1 o f C C R 4 -N O T  tra n scrip tio n  co m p le x  su b u n it 1
Iso fo rm  1 o f  C e llu la r nucle ic  a c id -b in d in g  protein
Iso fo rm  1 o f C h ro m o d o m a in -h e lica se -D N A -b in d in g  p rote in  4
Iso fo rm  1 o f  C la th rin  h e avy chain  1
Iso fo rm  1 o f C o a to m e r su b u n it a lpha
Iso fo rm  1 o f  C o ile d -co il d o m a in -co n ta in in g  p rote in  47
Iso fo rm  1 o f  C O P 9  s ig n a lo so m e  co m p le x su b u n it 2
Iso fo rm  1 o f  C O P 9  s ig n a lo so m e  co m p le x su b u n it 7b
Iso fo rm  1 o f C -te rm in a l-b in d in g  p rote in  2
Iso fo rm  1 o f  C u llin -4 A
Iso fo rm  1 o f  C u llin -a sso c ia te d  N ED D 8 -d isso cia te d  p rote in  1 
Iso fo rm  1 o f  C y sta th io n in e  b e ta-syn th ase
Iso fo rm  1 o f C y ste in e  an d  h istid in e-rich  d o m a in -co n ta in in g  protein
Iso form  1 o f C y to so l a m in o p e p tid a se
Iso fo rm  1 o f C y to so lic  acy l co e n zym e  A  th io e ste r h yd ro lase
Iso fo rm  1 o f C y to so lic  n o n -sp e cific  d ip ep tid ase
Iso fo rm  1 o f D ip e p tid y l p e p tid a se  1
Iso fo rm  1 o f D ip e p tid y l p e p tid a se  3
Iso fo rm  1 o f D N A  re p lica tio n  lice n sin g  fa cto r M C M 7
IP I0 0 2 9 1 5 1 0 11 10 8 8 10 3
IP I0 0 4 7 8 8 6 1 3 1 1 6 3 1
IP I0 0 2 2 0 3 7 3 2 4 3 4 2 0
IP I0 0 0 0 8 5 5 7 10 5 7 11 9 1
1P I0 0 0 0 5 198 11 11 11 14 9 9
IP I003 04082 5 3 4 4 1 2
IP I000 27223 20 17 27 20 14 7
IP I0 0 0 1 1 1 0 7 2 1 0 4 2 0
IP I000 20042 11 8 6 7 6 3
IP I0 0 2 9 9 6 0 8 10 6 9 13 12 10
IP I0 0 3 0 0 5 6 7 2 3 2 5 2 1
IP I0 0 4 1 4 4 1 0 3 3 1 3 0 1
IP I0 0 0 1 7 7 2 6 12 7 7 9 6 4
IP I0 0 4 1 9 8 0 2 3 3 0 3 1 0
IP I0 0 0 2 9 7 5 0 5 5 4 5 4 3
IP I0 0 0 0 5 5 7 3 2 2 2 2 1 1
IP I0 0 1 0 0 1 5 1 8 6 3 3 5 2
IP I0 0 0 0 9 6 6 2 3 1 1 3 2 1
IP I0 0 3 7 6 7 9 8 4 8 3 4 2 2
IP I0 0 0 2 4 9 3 3 6 5 6 4 4 4
IP I0 0 3 3 2 3 7 1 4 2 1 4 6 3
IP I0 0 0 1 1 5 6 9 11 9 15 0 3 3
IP I0 0 0 0 7 4 2 3 2 2 0 3 1 2
IP I0 0 5 5 0 2 3 4 3 1 1 4 2 2
IP I0 0 2 1 5 9 0 1 5 5 7 7 3 4
IP I0 0 0 0 8 2 7 4 12 12 5 14 8 7
IP I0 0 0 3 1 1 3 1 3 0 1 1 4 3
IP I0 0 0 0 2 4 6 0 3 1 1 2 2 1
IP I0 0 7 8 4 1 5 6 11 5 6 8 14 9
IP I0 0 0 0 1 6 9 9 4 5 3 4 2 0
IP I0 0 2 2 0 4 8 7 4 3 3 11 3 2
IP I0 0 7 8 5 0 9 6 7 6 4 8 4 2
IP I0 0 0 0 2 2 0 3 3 3 1 2 1 1
IP I0 0 3 9 5 6 2 7 10 9 5 10 12 7
IP I0 0 7 8 3 8 7 2 7 1 3 4 2 1
IP I0 0 2 1 5 9 4 8 15 7 9 20 16 16
IP I0 0 0 1 7 2 9 2 5 5 4 10 9 4
IP I0 0 1 6 6 0 1 0 5 3 6 3 6 0
IP I0 0 4 3 0 8 1 2 2 2 0 2 1 2
IP I0 0 0 0 0 8 4 6 2 0 1 7 3 1
IP I0 0 0 2 4 0 6 7 46 44 31 30 40 36
IP I0 0 2 9 5 8 5 7 8 8 8 5 14 7
IP I0 0 0 2 4 6 4 2 3 2 0 4 4 1
IP I0 0 7 4 3 8 2 5 5 4 2 2 3 3
IP I0 0 0 0 9 3 0 1 3 1 3 4 0 2
IP I0 0 0 1 0 1 2 0 2 1 4 4 2 2
IP I0 0 4 1 9 2 7 3 4 3 3 2 0 1
IP I0 0 1 0 0 1 6 0 21 19 17 12 18 18
1P I0 0 2 19352 10 8 3 4 6 2
IP I0 0 0 1 5 8 9 7 3 1 1 0 5 1
IP I0 0 4 1 9 2 3 7 3 2 2 7 3 0
IP I0 0 0 1 0 4 1 5 8 6 4 5 4 3
IP I0 0 1 7 7 7 2 8 11 14 11 16 10 9
IP I0 0 0 2 2 8 1 0 2 2 1 1 3 0
IP I0 0 0 2 0 6 7 2 11 9 2 11 5 2
IP I0 0 2 9 9 9 0 4 17 14 9 11 14 14
1 1 4
Iso fo rm  1 o f D N A -d e p e n d e n t protein  k in ase ca ta ly tic  su b u n it IP I0 0 2 9 6 3 3 7 35 28 27 30 39 0
Iso fo rm  1 o f D reb rin IP I0 0 0 0 3 4 0 6 8 3 7 6 10 6
Isoform  1 o f E n o la se -p h o sp h a ta se  E l IP I0 0 0 3 8 3 7 8 3 3 2 2 2 1
Iso fo rm  1 o f  E n o y l-C o A  h yd ratase  d o m a in -co n ta in in g  p rote in  1 IP I0 0 3 0 2 6 8 8 6 0 2 1 1 2
Iso fo rm  1 o f E u k a ry o tic  in itiation  fa cto r 4A-II IP I0 0 3 2 8 3 2 8 7 1 1 1 3 1
Iso fo rm  1 o f E u k a ry o tic  tra n sla tio n  in itiation  fa c to r  3 su b u n it B IP I0 0 3 9 6 3 7 0 13 9 6 9 16 13
Iso fo rm  1 o f E xo so m e  co m p le x exo n u clea se  R R P44 IP I0 0 7 4 6 3 5 1 2 0 1 1 3 1
Iso fo rm  1 o f  Exp o rtin -2 IP I0 0 0 2 2 7 4 4 27 21 21 20 18 26
Iso fo rm  1 o f  Exte n d e d  syn a p to ta gm in -1 IP I0 0 0 2 2 1 4 3 11 4 5 3 3 0
Iso fo rm  1 o f  Far u p stre am  e le m e n t-b in d in g  p rote in  2 IP I0 0 4 7 9 7 8 6 8 9 7 10 12 6
Iso fo rm  1 o f F ilam in -B IP I0 0 2 8 9 3 3 4 32 22 24 55 59 23
Iso fo rm  1 o f F ilam in -C IP I0 0 1 7 8 3 5 2 2 2 0 29 40 10
Iso fo rm  1 o f Fragile  X m ental reta rd a tio n  syn d ro m e -re la te d  p rote in  1 IP100016249 3 2 2 2 1 0
Iso fo rm  1 o f Friend  o f PR M T1 protein IP I0 0 3 0 0 9 9 0 1 0 2 2 2 1
Iso fo rm  1 o f G a m m a -g lu ta m ylcyc lo tra n sfe ra se IP100031564 4 4 7 8 2 1
Iso fo rm  1 o f G e n era l tra n scrip tio n  fa cto r ll-l IP I0 0 0 5 4 0 4 2 5 4 2 2 5 3
Iso fo rm  1 o f G e n era l ve sicu la r  tra n sp o rt  fa cto r p l ! 5 IP I0 0 9 4 1 1 6 1 11 6 8 10 15 8
Iso fo rm  1 o f G lu co sa m in e -fru cto se -6 -p h o sp h a te  a m in o tra n sfe ra se  
[iso m e riz in g] 1
IP I0 0 2 1 7 9 5 2 9 4 3 7 10 4
Iso fo rm  1 o f G ro w th  fa cto r rece p to r-b o u n d  p rote in  2 1P I0 0 0 2 1327 4 3 2 2 3 4
Iso fo rm  1 o f  G u a n in e  n u c le o tid e -b in d in g  protein  G (i) su b u n it a lp h a -2 IP I0 0 7 4 8 1 4 5 6 3 3 4 0 3
Iso fo rm  1 o f  Fleat sh o ck  co gn a te  71 kDa protein IP I0 0 0 0 3 8 6 5 48 35 32 38 33 26
Iso fo rm  1 o f F le m ato lo g ica l and n e u ro logica l e xp ressed  1-like p rote in IP I0 0 0 2 7 3 9 7 2 2 3 3 1 0
Iso fo rm  1 o f  F le te ro g en e o u s n u clear r ib o n u cle o p ro te in  DO IP I0 0 0 2 8 8 8 8 15 8 14 12 16 9
Iso fo rm  1 o f F le te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  M IP I0 0 1 7 1 9 0 3 18 13 14 15 21 3
Isoform  1 o f F le te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  Q IP I0 0 0 1 8 1 4 0 9 9 6 2 2 1
Iso fo rm  1 o f  F le te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  R IP I0 0 0 1 2 0 7 4 6 4 4 5 4 3
Iso fo rm  1 o f  F le xo kin a se -1 1PI00018246 2 3 3 8 7 6
Iso fo rm  1 o f  F lis to n e -b in d in g  p rote in  R BBP4 IP I0 0 3 2 8 3 1 9 5 3 3 3 6 0
Iso fo rm  1 o f  lm p o rtin -4 IP I0 0 1 5 6 3 7 4 11 4 11 9 8 6
Iso fo rm  1 o f lm p o rtin -5 IP I0 0 7 9 3 4 4 3 30 22 23 23 29 26
Iso fo rm  1 o f  In su lin -like  gro w th  fa c to r  2 m R N A -b in d in g  p rote in  3 IP I0 0 6 5 8 0 0 0 8 1 2 5 8 1
Iso fo rm  1 o f  Iso c itra te  d e h y d ro g e n a se  [N A D ] su b u n it  a lpha, 
m ito ch o n d ria l
IP I0 0 0 3 0 7 0 2 2 2 2 2 4 3
Iso fo rm  1 o f  KH d o m a in -co n ta in in g , R N A -b in d in g , s ig n a l tra n sd u ctio n - 
a sso c ia te d  p rote in  1
IP I0 0 0 0 8 5 7 5 4 3 2 6 6 1
Iso fo rm  1 o f K inesin  h e av y  ch a in  iso fo rm  5C IP I0 0 0 2 8 5 6 1 3 2 3 0 2 1
Iso fo rm  1 o f Large p ro lin e-rich  p rote in  BA T3 IP I0 0 4 6 5 1 2 8 3 1 1 2 1 0
Iso fo rm  1 o f Le u ko trie n e  A -4  h yd ro lase IP I0 0 2 1 9 0 7 7 8 6 3 0 3 1
Iso fo rm  1 o f LIM  and SFI3 d o m a in  p rote in  1 IP I0 0 0 0 0 8 6 1 3 1 4 5 3 1
Iso fo rm  1 o f L ip o p o ly sa cch a rid e -re sp o n siv e  and b e ig e -like  a n ch o r 
p ro te in
IP I0 0 0 0 2 2 5 5 2 2 2 1 4 0
Iso fo rm  1 o f L -lactate  d e h yd ro g e n a se  A  chain 1P I0 0 2 17966 46 37 26 45 30 22
Iso fo rm  1 o f Low  m o le cu la r w e ig h t p h o sp h o ty ro sin e  p rote in  
p h o sp h a ta se
IP I0 0 2 1 9 8 6 1 5 2 4 3 5 2
Iso fo rm  1 o f  M align a n t T  ce ll-am p lifie d  se q u e n ce  1 IP I0 0 1 7 9 0 2 6 1 3 2 5 2 1
Iso fo rm  1 o f M ed iu m -ch a in  sp e c ific  a cy l-C o A  d e h yd ro g e n a se , 
m ito ch o n d ria l
IP I0 0 0 0 5 0 4 0 3 0 2 1 2 2
Iso fo rm  1 o f  M e ta sta s is-a sso c ia te d  p rote in  M TA3 IP I0 0 1 6 5 3 5 7 5 2 1 5 4 0
Iso fo rm  1 o f  M e th y l-C p G -b in d in g  dom ain  p rote in  3 IP I0 0 4 3 9 1 9 4 2 3 1 4 2 1
Iso fo rm  1 o f M icro tu b u le -a sso cia te d  p rote in  4 IP I0 0 3 9 6 1 7 1 3 2 2 6 9 4
Iso fo rm  1 o f  M ito tic  c h e ckp o in t p rote in  BU B3 IP I0 0 0 1 3 4 6 8 4 3 5 1 3 1
Iso fo rm  1 o f  M y b -b in d in g  p rote in  1A IP I0 0 0 0 5 0 2 4 7 8 5 1 4 2
Iso fo rm  1 o f  M yo sin -1 0 IP I0 0 3 9 7 5 2 6 34 20 38 46 36 25
Iso fo rm  1 o f M yo sin -9 IP I0 0 0 1 9 5 0 2 64 53 61 63 49 45
Iso fo rm  1 o f N A C H T, LRR and PYD d o m a in s-co n ta in in g  p rote in  2 IP I0 0 0 1 6 4 8 0 3 2 3 1 1 3
Iso fo rm  1 o f N A D F I-cyto ch ro m e  b5 red u ctase  3 IP I0 0 3 2 8 4 1 5 3 4 4 7 5 2
Iso fo rm  1 o f N -a lp h a -a ce ty ltra n sfe ra se  50, N atE ca ta ly tic  su b u n it IP I0 0 0 1 8 6 2 7 6 3 3 6 4 3
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Iso fo rm  1 o f N u c le a r a u to a n tig e n ic  sp erm  protein IP I001 79953 26 17 15 23 23 15
Iso fo rm  1 o f  N u c le a r pore  c o m p le x  p rote in  N u p l5 5 IP I000 26625 11 3 3 1 5 2
Iso fo rm  1 o f  N u c le a r pore c o m p le x  p rote in  N u p l6 0 IP I0 0 7 4 8 8 0 7 5 2 3 2 2 3
Iso fo rm  1 o f  N u c le o la r R N A  h e licase  2 IP I000 15953 12 10 9 2 4 4
Iso fo rm  1 o f N u cleo re d o xin IP I0 0 3 0 4 2 6 7 2 2 1 5 4 1
Iso fo rm  1 o f N u cleo sid e  d ip h o sp h a te  k in ase  A IP I0 0 0 1 2 0 4 8 2 2 1 1 3 1
Iso fo rm  1 o f O b g-like  A T P a se  1 IP I002 90416 9 7 5 7 5 2
Iso fo rm  1 o f O lig o rib o n u c le a se , m ito ch o n d ria l (Frag m e n t) IP I0 0 0 3 2 8 3 0 3 4 3 5 0 1
Iso fo rm  1 o f P ara sp e ckle  c o m p o n e n t 1 IP I001 03525 3 2 1 3 4 1
Iso fo rm  1 o f P artn e r o f Y 1 4  and m ago IP100305092 2 1 1 2 1 1
Iso fo rm  1 o f P e p tid y l-p ro ly l c is-tra n s iso m e ra se -like  3 IP I003 00952 2 1 2 0 3 3
Iso fo rm  1 o f P e ro x id asin  h o m o lo g IP I000 16112 3 2 1 1 5 0
Iso fo rm  1 o f  P h o sp h a tid y lin o s ito l tra n sfe r p rote in  beta iso form IP I0 0 3 3 4 9 0 7 7 3 1 3 3 1
Iso fo rm  1 o f  P h o sp h o g lu co m u ta se -1 IP I0 0 2 1 9 5 2 6 7 4 6 14 11 0
Iso fo rm  1 o f P la te le t-a ct iv a tin g  fa c to r  a ce ty lh yd ro la se  IB su b u n it a IP I0 0 2 1 8 7 2 8 2 1 2 1 6 0
Iso fo rm  1 o f P lectin IP I0 0 0 1 4 8 9 8 2 0 3 43 32 2
Iso fo rm  1 o f P o ly a d e n y la te -b in d in g  p rote in  1 IP I0 0 0 0 8 5 2 4 19 13 8 15 14 6
Iso fo rm  1 o f P o ly a d e n y la te -b in d in g  p rote in  2 IP I0 0 0 0 5 7 9 2 2 2 1 2 1 1
Iso fo rm  1 o f P o ly a d e n y la te -b in d in g  p rote in  4 IP I0 0 0 1 2 7 2 6 3 2 0 4 1 1
Iso fo rm  1 o f P o ly p y rim id in e  tra c t-b in d in g  p rote in  1 IP I0 0 1 7 9 9 6 4 14 11 10 16 12 7
Iso fo rm  1 o f P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  D H X36 IP I0 0 0 2 7 4 1 5 3 2 1 1 3 1
Iso fo rm  1 o f Pro ly l 4 -h y d ro xy la se  su b u n it a lp h a-1 IP100009923 3 0 1 2 3 1
iso fo rm  1 o f P ro te a so m e  a ct iv a to r co m p le x  su b u n it 3 IP I0 0 0 3 0 2 4 3 9 5 6 7 6 7
Iso fo rm  1 o f P ro te a so m e  a ct iv a to r co m p le x  su b u n it 4 IP I0 0 0 0 5 2 6 0 5 2 1 1 2 0
Iso fo rm  1 o f P ro te a so m e  su b u n it a lpha typ e -7 IP I0 0 0 2 4 1 7 5 15 9 7 8 10 6
Iso fo rm  1 o f P ro te in  ca n o p y  h o m o lo g  2 IP I0 0 4 4 3 9 0 9 4 4 5 5 3 2
Iso fo rm  1 o f P ro te in  C IP 2 A IP I0 0 1 5 4 2 8 3 3 1 0 2 2 0
Iso fo rm  1 o f P ro te in  d ia p h a n o u s h o m o lo g  1 IP I0 0 8 5 2 6 8 5 4 1 3 1 3 0
Iso fo rm  1 o f P ro te in  K IA A 1967 IP I0 0 1 8 2 7 5 7 7 2 5 6 10 2
Iso fo rm  1 o f P ro te in  LSM 12 h o m o lo g IP I0 0 4 1 0 3 2 4 3 2 1 1 2 1
Iso fo rm  1 o f  P ro te in  p h o sp h a ta se  1 re g u la to ry  su b u n it 12A IP I0 0 1 8 3 0 0 2 2 0 2 3 3 0
Iso fo rm  1 o f P ro te in  p h o sp h a ta se  1 re g u la to ry  su b u n it  7 IP I0 0 0 3 3 6 0 0 3 1 2 2 1 1
Iso fo rm  1 o f P ro te in  SET IP I0 0 0 7 2 3 7 7 12 11 11 4 1 1
Iso fo rm  1 o f P ro te in  syn d e sm o s IP I0 0 0 3 1 6 5 0 2 3 4 5 3 1
Iso fo rm  1 o f Pu tative  h e licase  M O V -IO IP I0 0 4 4 4 4 5 2 3 1 1 1 2 1
Iso fo rm  1 o f Q u in on e  o x id o re d u cta se  P IG 3 IP I0 0 3 8 4 6 4 3 2 0 1 2 2 0
Iso fo rm  1 o f  Rab3 G T P a se -a ctiv a tin g  p rote in  n o n -ca ta lytic  su b u n it IP I0 0 5 5 4 5 9 0 2 1 1 2 2 0
Iso fo rm  1 o f R a s-re la te d  p rote in  R ab -1A IP I0 0 0 0 5 7 1 9 4 3 4 5 1 2
Iso fo rm  1 o f R a s-re la te d  p rote in  Rab -34 IP I0 0 3 2 8 1 8 0 5 1 0 2 2 1
Iso fo rm  1 o f R e g u lato r o f n o n se n se  tra n scrip ts  1 IP I0 0 0 3 4 0 4 9 6 3 3 3 4 1
Iso fo rm  1 o f R ep licatio n  fa c to r  C su b u n it 2 IP I0 0 0 1 7 4 1 2 3 1 4 3 1 2
Iso fo rm  1 o f R ep licatio n  p rote in  A  32 kDa su b u n it IP I0 0 0 1 3 9 3 9 5 1 1 3 3 2
Iso fo rm  1 o f R etin o l d e h yd ro g e n a se  11 IP I0 0 3 3 9 3 8 4 5 0 2 2 2 2
Iso fo rm  1 o f R N A  3 ’-te rm in a l p h o sp h a te  cyclase IP I0 0 0 1 1 7 2 6 2 1 2 2 1 0
Iso fo rm  1 o f R N A -b in d in g  p rote in  25 IP I0 0 0 0 4 2 7 3 3 0 1 3 3 0
Iso fo rm  1 o f  R u vB -like  1 IP I0 0 0 2 1 1 8 7 7 8 7 11 8 8
Iso fo rm  1 o f  S E C 2 3 -in te ra ct in g  protein IP100026969 0 3 1 1 2 0
Iso fo rm  1 o f  S e p tin -2 IP I0 0 0 1 4 1 7 7 8 5 4 4 3 5
Iso fo rm  1 o f  S e rin e /a rg in in e -r ich  sp lic in g  fa cto r 7 IP I0 0 0 0 3 3 7 7 4 3 5 7 3 0
Iso fo rm  1 o f S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  6 cata ly tic  
su b u n it
IP I0 0 0 1 2 9 7 0 1 2 1 4 5 1
Iso fo rm  1 o f  S p e rm in e  syn th ase IP I0 0 0 0 5 1 0 2 9 4 5 5 3 3
Iso fo rm  1 o f  S -p h a se  k in a se -a sso cia te d  protein  1 IP I0 0 3 0 1 3 6 4 6 6 4 7 3 3
Iso fo rm  1 o f S p lic in g  fa c to r  3B su b u n it 3 IP I0 0 3 0 0 3 7 1 17 6 9 8 11 5
Iso fo rm  1 o f S q u a m o u s cell ca rc in o m a  a ntigen  reco g n ized  by T -ce lls  3 IP I0 0 0 0 6 0 2 5 1 0 2 2 2 0
Iso fo rm  1 o f S tru ctu ra l m a in te n a n ce  o f ch ro m o so m e s p rote in  2 IP I0 0 0 0 7 9 2 7 3 0 1 4 3 1
Iso fo rm  1 o f Su rfe it  locu s p rote in  4 IP I0 0 0 0 5 7 3 7 2 2 1 3 3 2
Iso fo rm  1 o f  S yn ta x in -7 IP I0 0 2 8 9 8 7 6 3 1 0 4 3 2
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Iso fo rm  1 o f T P 5 3 R K -b in d in g  p rote in
Iso fo rm  1 o f T ra n sc rip t io n  e lo n g a tio n  fa cto r A  p rote in  1
Iso fo rm  1 o f T ra n sc rip t io n  fa c to r  BTF3
Iso fo rm  1 o f T ra n scrip t io n  in te rm e d ia ry  fa c to r  1-beta
Iso fo rm  1 o f T ra n sfo rm e r-2  p rote in  h o m o lo g  beta
Iso fo rm  1 o f  T ra n sp o rtin -1
Iso fo rm  1 o f T ro p o m y o sin  a lp h a -4  chain
Iso fo rm  1 o f T ry p to p h a n y l-tR N A  syn th e ta se , cyto p la sm ic
Iso fo rm  1 o f U 2 -asso c ia te d  p rote in  SR 1 4 0
Iso fo rm  1 o f U5 sm all n u c le a r rib o n u cle o p ro te in  200  kDa h e licase  
Iso fo rm  1 o f U b iq u itin  co n ju g a tio n  fa c to r  E4 B 
Iso fo rm  1 o f U b iq u itin -co n ju g a tin g  e n zym e  E2 K 
Iso fo rm  1 o f U b iq u itin -like  m o d ifie r-a ctiva tin g  e n zym e  6 
Iso fo rm  1 o f U D P -g lu co se :g lyco p ro te in  g lu co sy ltra n sfe ra se  1 
Iso fo rm  1 o f U rid in e  5 '-m o n o p h o sp h a te  syn th ase  
Iso fo rm  1 o f U T P --g lu c o s e -l-p h o sp h a te  u rid y ly ltra n sfe ra se  
Iso fo rm  1 o f  V in cu lin
Iso fo rm  1 o f W D  re p e a t-co n ta in in g  p rote in  1
Iso fo rm  1AB o f C a ten in  d e lta -1
Iso fo rm  2 o f A p o p to s is  in h ib ito r 5
Iso fo rm  2 o f A T P -d e p e n d e n t R N A  h e licase  D D X 54
Iso fo rm  2 o f Basigin
Iso fo rm  2 o f C a t eye  syn d ro m e  critica l reg ion  p rote in  5
Iso fo rm  2 o f Cell d iv isio n  co n tro l p rote in  42  h o m o lo g
Iso fo rm  2 o f C y to ch ro m e  P 450  2S1
Iso fo rm  2 o f E u ka ry o tic  tra n sla tio n  in itiatio n  fa cto r 5A -1
Iso fo rm  2 o f  F -a ctin -ca p p in g  p rote in  su b u n it beta
Iso fo rm  2 o f F ila m in -A
Iso fo rm  2 o f G o lg i a p p a ra tu s  p rote in  1
Iso fo rm  2 o f G o lg in  su b fa m ily  A  m e m b e r 2
Iso fo rm  2 o f H eat sh o ck  p rote in  H SP 90-a lp h a
Iso fo rm  2 o f H e te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  A /B
Iso fo rm  2 o f Iso ch o rism a ta se  d o m a in -co n ta in in g  p ro te in  2
Iso fo rm  2 o f Ly s in e -sp e c ific  h isto n e  d e m e th y la se  1A
Iso fo rm  2 o f N -a lp h a -a ce ty ltra n sfe ra se  15, N atA  a u x ilia ry  su b u n it
Iso fo rm  2 o f  N eu tra l a lp h a -g lu co s id a se  A B
Iso fo rm  2 o f N u c lea r m ito tic  a p p ara tu s p rote in  1
Iso fo rm  2 o f N u cleo p o rin  N U P 188  h o m o lo g
Iso fo rm  2 o f P ro te a so m e  su b u n it a lpha typ e -3
Iso fo rm  2 o f Pro te in  d isu lfid e -iso m e ra se  A6
Iso fo rm  2 o f P ro th y m o sin  alpha
Iso fo rm  2 o f R a s-re la te d  p rote in  R a b -6A
Iso fo rm  2 o f  S a rco p la sm ic/e n d o p la sm ic  reticu lu m  ca lc iu m  A TPa se  
Iso fo rm  2 o f Serrate  R N A  e ffe cto r m ole cu le  h o m o lo g  
Iso fo rm  2 o f  S p lice o so m e  RN A h e licase  BA T1 
Iso fo rm  2 o f  S p lic in g  fa cto r 1
Iso fo rm  2 o f  S tru ctu ra l m ain ten an ce  o f c h ro m o so m e s  p rote in  4
Iso fo rm  2 o f  S u cc in y l-C o A  ligase [A D P -fo rm in g] su b u n it beta
Iso fo rm  2 o f S u p p re sso r o f G 2 a lle le  o f SKP1 h o m o lo g
Iso fo rm  2 o f T A R  D N A -b in d in g  protein  43
Iso fo rm  2 o f T ro p o m y o s in  a lp h a -3  chain
Iso fo rm  2 o f  T u m o r  p rote in  D54
Iso fo rm  3 o f A n a m o rs in
Iso fo rm  3 o f E p ith e lia l sp lic in g  regu la to ry  p rote in  1 
Iso fo rm  3 o f N u c le o la r an d  co ile d -b o d y  p h o sp h o p ro te in  1 
Iso fo rm  3 o f P ro te in  P R R C 1  
Iso fo rm  3 o f P ro te in  tra n sp o rt  p rote in  Sec31A  
Iso fo rm  3 o f R ib o so m e -b in d in g  p rote in  1
IP I003 01432 1 3 2 2 0 1
IP I003 33215 5 2 4 4 8 3
IP I002 21035 8 3 6 7 3 2
1PI00438229 12 8 12 8 16 14
IP I003 01503 4 1 3 2 2 2
IP I0 0 0 2 4 3 6 4 10 8 8 12 10 10
IP I000 10779 6 7 8 6 2 5
IP I0 0 2 9 5 4 0 0 13 9 4 9 8 1
IP I0 0 1 4 3 7 5 3 3 1 0 4 3 1
IP I0 0 4 2 0 0 1 4 23 20 14 6 13 5
IP I0 0 0 0 5 7 1 5 1 1 2 2 1 0
1P I0 0 0 2 1370 6 4 7 3 4 3
IP I0 0 0 2 3 6 4 7 3 2 2 2 1 3
IP I0 0 0 2 4 4 6 6 10 6 3 2 4 1
IP I0 0 0 0 3 9 2 3 3 3 2 3 3 1
IP I0 0 3 2 9 3 3 1 23 20 14 19 17 8
IP I0 0 2 9 1 1 7 5 56 32 43 56 36 40
IP I0 0 7 4 6 1 6 5 5 3 2 9 6 3
IP I0 0 1 8 2 4 6 9 1 3 2 7 3 5
IP I0 0 5 5 4 7 4 2 9 6 3 2 1 1
IP I0 0 1 5 2 5 1 0 2 0 1 2 1 0
IP I0 0 0 1 9 9 0 6 6 3 7 3 4 4
1P I0 0 0 1 1511 3 1 3 2 4 1
IP I0 0 0 1 6 7 8 6 6 2 8 7 3 4
IP I0 0 1 6 4 0 1 8 5 2 4 0 3 1
IP I0 0 3 7 6 0 0 5 13 12 12 7 12 8
IP I0 0 6 4 2 2 5 6 11 7 6 9 7 8
IP I0 0 3 0 2 5 9 2 98 76 69 80 94 55
IP I0 0 4 1 4 7 1 7 4 2 5 4 11 3
IP I0 0 4 1 3 8 9 5 1 0 2 2 2 0
IP I0 0 3 8 2 4 7 0 33 30 13 39 27 15
IP I0 0 3 3 4 5 8 7 7 6 5 7 7 5
IP I0 0 0 0 3 0 3 1 1 1 2 3 1 0
IP I0 0 2 1 7 5 4 0 2 1 1 3 5 2
IP I0 0 0 3 2 1 5 8 4 3 3 2 3 1
IP I0 0 0 1 1 4 5 4 13 12 9 26 15 7
IP I0 0 0 0 6 1 9 6 8 2 6 5 6 3
IP I0 0 3 8 5 0 0 1 2 2 1 2 2 1
IP I0 0 1 7 1 1 9 9 9 10 6 5 6 1
IP I0 0 2 9 9 5 7 1 21 15 19 16 10 7
IP I0 0 4 5 5 5 1 0 3 4 3 3 0 6
IP I0 0 2 1 7 9 4 3 6 3 5 6 4 1
IP I0 0 1 7 7 8 1 7 10 1 4 5 7 7
IP I0 0 2 2 0 0 3 8 1 2 4 1 7 0
IP I0 0 6 4 1 8 2 9 10 7 9 15 9 11
IP I0 0 2 9 4 6 2 7 2 2 1 5 5 1
IP I0 0 3 2 8 2 9 8 1 2 4 2 4 0
1P I0 0 2 17232 2 1 1 2 1 1
IP I0 0 7 9 1 5 7 3 6 2 5 4 9 5
IP I0 0 0 2 5 8 1 5 3 2 3 2 3 1
IP I0 0 2 1 8 3 1 9 27 24 24 26 19 9
IP I0 0 2 2 1 1 7 8 3 4 5 1 3 4
IP I0 0 0 2 5 3 3 3 4 0 1 3 6 1
IP I0 0 1 8 4 2 6 2 3 1 2 2 1 2
IP I0 0 9 0 8 8 7 3 2 2 1 2 0 1
IP I0 0 2 1 7 0 5 3 2 1 2 3 2 1
IP I0 0 3 0 5 1 5 2 5 2 2 5 3 2
1P100215743 5 0 1 4 6 0
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Iso fo rm  3 o f S e rin e /a rg in in e -r ich  sp lic in g  fa c to r  10 IP I0 0 0 0 9 0 7 1 1 1 2 3 2 0
Iso fo rm  3 o f  U b iq u it in -co n ju g a tin g  en zym e E2 va ria n t 1 IP I0 0 4 7 2 4 9 8 2 2 3 4 3 0
Iso fo rm  4 o f T ro p o m y o s in  a lp h a -1  chain IP I0 0 2 9 6 0 3 9 8 9 9 9 0 3
Iso fo rm  4 o f T u b u lin -sp e c ific  ch ap e ron e  D IP I0 0 0 3 0 7 7 4 2 1 1 1 5 1
Iso fo rm  5 o f D y n a m in - l- l ik e  protein IP I0 0 0 3 7 2 8 3 7 7 2 2 1 3
Iso fo rm  5 o f  In te rle u k in  e n h a n ce r-b in d in g  fa cto r 3 IP I0 0 2 1 9 3 3 0 12 13 7 17 9 8
Iso fo rm  5 o f  T h io re d o x in  red u ctase  1, cyto p lasm ic IP I0 0 5 5 4 7 8 6 6 4 0 3 6 1
Iso fo rm  A  o f  R a s-re la te d  C3 b otu linum  toxin  su b stra te  1 IP I0 0 0 1 0 2 7 1 3 1 1 3 3 4
Iso fo rm  A  o f R N A -b in d in g  protein  w ith m ultip le  sp lic in g IP I0 0 0 0 4 0 4 5 2 2 3 1 1 2
Iso fo rm  A  o f  T ry p s in -3 IP I0 0 0 1 5 6 1 4 2 0 1 1 3 2
Iso fo rm  A 1 o f T ig h t  ju n ctio n  protein  ZO -2 IP I0 0 0 0 3 8 4 3 3 2 3 1 7 0
Iso fo rm  A l - B  o f H e te ro ge n e o u s nu clear rib o n u cle o p ro te in  A1 IP I0 0 2 1 5 9 6 5 32 33 15 36 30 13
Iso fo rm  A lp h a  o f A p o p to s is  reg u la to r BAX IP I0 0 4 4 3 7 7 3 8 4 4 7 3 4
Iso fo rm  A lp h a -6 X 1 X 2 B  o f  Integrin  a lpha-6 IP I0 0 0 1 0 6 9 7 3 1 2 6 6 0
Iso fo rm  a lp h a -e n o la se  o f A lp h a -e n o lase IP I0 0 4 6 5 2 4 8 48 48 54 46 34 21
Iso fo rm  A SF -1  o f S e rin e /a rg in in e -rich  sp lic in g  fa cto r 1 IP I0 0 2 1 5 8 8 4 7 7 9 9 7 9
Iso fo rm  B o f P e rilip in -3 IP I0 0 3 0 3 8 8 2 8 2 4 11 10 6
Iso fo rm  B1 o f H e te ro g e n e o u s nu clear rib o n u cle o p ro te in s  A 2/B 1 IP I0 0 3 9 6 3 7 8 22 23 15 21 15 14
Iso fo rm  Beta  o f H eat sh o ck  protein  105 kDa IP I0 0 2 1 8 9 9 3 18 9 13 16 18 19
Iso fo rm  B e ta -1  o f P ro te in  p h o sp h a ta se  IB IP I0 0 0 2 6 6 1 2 1 0 3 3 4 1
Iso fo rm  C l  o f  H e te ro g e n e o u s n u c le a r rib o n u cle o p ro te in s  C1/C2 IP I0 0 2 1 6 5 9 2 10 12 11 16 9 9
Iso fo rm  C o m p le xe d  o f A rg in y l-tR N A  syn th etase , cyto p lasm ic IP I0 0 0 0 4 8 6 0 10 3 4 12 8 2
Iso fo rm  C S B P 2  o f M ito g e n -a ctiva te d  protein  k inase 14 IP I0 0 0 0 2 8 5 7 3 2 0 5 0 1
Iso fo rm  C y to p la sm ic  o f Ly sy l-tR N A  syn th eta se IP I0 0 0 1 4 2 3 8 11 4 4 6 5 0
Iso fo rm  D e lta -1  o f  S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  2A 56 kDa 
re g u la to ry  su b u n it de lta  iso form
IP100000030 1 2 2 3 1 0
Iso fo rm  D FF4 5  o f D N A  fra g m e n ta tio n  fa cto r su b u n it a lpha (Fragm en t) IP I0 0 0 1 0 8 8 2 2 1 0 2 0 2
Iso fo rm  G a m m a -1  o f S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  PP1- 
g a m m a  ca ta ly tic  su b u n it
IP I0 0 0 0 5 7 0 5 1 2 2 1 2 2
Iso fo rm  G T B P -N  o f D N A  m ism a tch  re p a ir p rote in  M sh6 IP100384456 7 6 8 6 9 10
Iso fo rm  II o f U b iq u it in -p ro te in  lig ase  E3A IP I0 0 0 1 1 6 0 9 4 0 1 4 1 0
Iso fo rm  Lo n g  o f 1 4 -3 -3  p rote in  b eta /alp h a IP I0 0 2 1 6 3 1 8 14 8 11 13 11 9
Iso fo rm  Lo n g  o f Co ld  sh o c k  d o m a in -co n ta in in g  p ro te in  E l IP I0 0 4 7 0 8 9 1 4 0 3 4 4 1
Iso fo rm  Lo n g o f D e lta -l-p y rro lin e -5 -c a rb o x y la te  syn th ase IP I0 0 0 0 8 9 8 2 10 8 9 7 5 4
Iso fo rm  Lo n g o f D o u b le -stra n d e d  R N A -b in d in g  p ro te in  Staufen  
h o m o lo g  1
IP I0 0 0 0 0 0 0 1 4 1 1 3 2 0
Iso fo rm  Lo n g o f E u ka ry o tic  tra n s la tio n  in itia tio n  fa c to r  4H IP I0 0 0 1 4 2 6 3 2 3 4 3 3 2
Iso fo rm  Lo n g  o f G lu co se -6 -p h o sp h a te  1 -d e h yd ro g e n a se IP I0 0 2 1 6 0 0 8 6 4 1 2 2 0
Iso fo rm  Lo n g o f H e te ro ge n e o u s n u c le a r r ib o n u c le o p ro te in  U IP I0 0 8 8 3 8 5 7 21 17 12 22 21 14
Iso fo rm  Lo n g o f S o d iu m /p o ta ss iu m -tra n sp o rtin g  A T P a se  su b u n it a -1 IP I0 0 0 0 6 4 8 2 15 11 10 13 13 8
Iso fo rm  Lo n g o f S p ectrin  beta ch ain , brain  1 IP I0 0 0 0 5 6 1 4 34 18 19 33 46 16
Iso fo rm  Lo n g o f Sp lic in g  facto r, p ro lin e- an d  g lu ta m in e -rich IP100010740 9 11 11 13 15 7
Iso fo rm  Lo n g o f T r ifu n ctio n a l purine  b io syn th e tic  p rote in  ad e n o sin e -3 IP I0 0 0 2 5 2 7 3 11 11 9 8 15 10
Iso fo rm  Lo n g o f U biq u itin  ca rb o xy l-te rm in a l h yd ro la se  5 IP I0 0 0 2 4 6 6 4 12 6 6 4 4 4
Iso fo rm  M 2 o f P yru vate  k in ase iso zym e s M 1/M 2 1P I0 0 4 7 9 186 42 40 27 51 38 26
Iso fo rm  M ito ch o n d ria l o f P e ro x ire d o x in -5 , m ito ch o n d ria l IP100024915 7 4 9 10 4 6
Iso fo rm  M ito ch o n d ria l o f P h osp h o lip id  h y d ro p e ro x id e  g lu tath io n e  
p e ro x id a se , m ito ch o n d ria l
IP I0 0 3 0 4 8 1 4 6 4 1 4 1 0
Iso fo rm  p l5 0  o f D yn actin  su b u n it 1 IP I0 0 0 2 9 4 8 5 7 2 4 2 7 4
Iso fo rm  p26 o f  7 ,8 -d ih yd ro -8 -o xo gu a n in e  trip h o sp h a ta se IP I0 0 0 0 4 3 9 2 2 2 3 4 2 1
Iso fo rm  p 2 7 -L  o f 26S p ro tea so m e  n o n -A TP ase  re g u la to ry  su b u n it 9 IP I0 0 0 1 0 8 6 0 2 0 3 1 3 0
Iso fo rm  R p n lO A  o f 26S p ro tea so m e  n o n -A TP ase  re g u la to ry  su b u n it 4 IP I0 0 0 2 2 6 9 4 3 1 3 6 7 0
Iso fo rm  S a p -m u -0  o f P ro a ctiv a to r p o lyp ep tid e IP100012503 3 1 2 1 1 2
Iso fo rm  S h o rt o f P ro te a so m e  su b u n it a lpha typ e -1 IP I0 0 0 1 6 8 3 2 15 4 7 5 5 4
Iso fo rm  S h o rt  o f R N A -b in d in g  protein  FUS IP I0 0 2 2 1 3 5 4 5 0 3 8 6 0
Iso fo rm  S h o rt  o f U b iq u itin  fu sio n  d e grad a tio n  p ro te in  1 h o m o lo g 1P I0 0 2 18292 2 0 2 1 3 2
Iso fo rm  S M -B ' o f  S m a ll n u c le a r r ib o n u c le o p ro te in -a sso c ia te d  p rote in s 
B and B'
IP I0 0 0 2 7 2 8 5 2 4 2 4 2 2
1 1 8
Iso fo rm  S N A P -2 3 a  o f  S yn a p to so m a l-a sso c ia te d  p rote in  23
Iso fo rm  S R P 5 5 -1  o f S e rin e /a rg in in e -rich  sp lic in g  fa c to r  6
Iso le u cy l-tR N A  sy n th e ta se , cyto p lasm ic
Ju n c tio n  p la k o g lo b in
Ju n c tio n a l a d h e s io n  m o le cu le  A
K e ratin , typ e  I cy to ske le ta l 10
K e ratin , ty p e  I c y to ske le ta l 18
K e ratin , ty p e  I c y to ske le ta l 9
K e ratin , ty p e  II cy to ske le ta l 1
K e ra tin , ty p e  II c y to ske le ta l 2 e p iderm al
K e ratin , ty p e  II cy to ske le ta l 8
K in e sin -1  h e a v y  chain
K in e sin -lik e  p ro te in  KIF11
L a c to y lg lu ta th io n e  lyase
L a m in -B l
La m in in  su b u n it  a lp h a -1  
La m in in  su b u n it  beta-1  
La m in in  su b u n it  ga m m a -1  
La n o ste ro l syn th ase
Le u c in e -r ich  PPR  m o tif-co n ta in in g  protein, m ito ch o n d ria l
Le u c in e -r ich  re p e a t-co n ta in in g  p rote in  47
Le u c in e -r ich  re p e a t-co n ta in in g  p rote in  59
Le u c y l-tR N A  syn th e ta se , c yto p la sm ic
LIN E -1  typ e  tra n sp o sa se  d o m a in -co n ta in in g  protein  1
L-la cta te  d e h y d ro g e n a se  B chain
Lo n  p ro te a se  h o m o lo g , m ito ch o n d ria l
L o n g -c h a in -fa tty -a c id --C o A  ligase  3
Lu p u s La p rote in
M a cro p h a g e  m ig ra tio n  in h ib ito ry  fa cto r 
M ala te  d e h yd ro g e n a se  
M ala te  d e h y d ro g e n a se , m ito ch o n d ria l 
M atrin -3
M e m b ra n e -a sso c ia te d  p ro g e ste ro n e  re ce p to r co m p o n e n t 1 
M e th io n y l-tR N A  syn th e ta se , c yto p la sm ic
M e th y le n e te tra h y d ro fo la te  d e h y d ro g e n a se  (N A D P +  d e p en d e n t) 1 
M e th y lo so m e  su b u n it pICIn 
M icro so m a l g lu tath io n e  S -tra n sfe ra se  1 
M icro tu b u le -a sso c ia te d  p rote in  I B  
M icro tu b u le -a sso c ia te d  p rote in  R P /EB  fa m ily  m e m b e r 1 
M id asin
M ito ch o n d ria l fiss io n  1 protein
M ito ch o n d ria l im p o rt rece p to r su b u n it T O M 2 2  h o m o lo g  
M o e sin
m R N A  tu rn o v e r  p rote in  4  h o m o lo g 
M u ltifu n ctio n a l p rote in  A D E2
N (G ),N (G )-d im e th y la rg in in e  d im e th y la m in o h y d ro la se  1 
N a (+ )/H (+ ) e xch a n g e  re g u la to ry  co fa cto r N H E-R F1 
N -a c e ty ltra n sfe ra se  10
N A D H  d e h y d ro g e n a se  [u b iq u in on e ] flavo p ro te in  2, m ito ch o n d ria l 
N A D H  d e h y d ro g e n a se  [u b iq u in on e ] iro n -su lfu r p ro te in  3 
N A D P H -c y to c h ro m e  P 450  red u ctase  
N -a lp h a -a c e ty ltra n sfe ra se  10, N atA  cata ly tic  su b u n it 
N a sce n t p o ly p e p tid e -a sso c ia te d  co m p le x su b u n it a lp h a  
N E D D 8 -a c tiv a tin g  e n zy m e  E l  cata ly tic  su b u n it 
N E D D 8 -c o n ju g a tin g  e n zym e  U b c l2  
N estin
N H P 2 -like  p ro te in  1
N ico tin a m id e  p h o sp h o rib o sy ltra n sfe ra se
IP I0 0 0 1 0 4 3 8 2 2 2 2 1 1
IP I0 0 0 1 2 3 4 5 2 2 4 2 1 1
IP I0 0 6 4 4 1 2 7 20 9 6 13 25 5
IP I0 0 5 5 4 7 1 1 2 2 0 4 5 3
IP I0 0 0 0 1 7 5 4 3 1 3 3 4 1
IP I0 0 0 0 9 8 6 5 13 11 6 21 20 15
IP I0 0 5 5 4 7 8 8 8 6 6 20 19 8
IP I0 0 0 1 9 3 5 9 8 3 5 5 15 13
IP I0 0 2 2 0 3 2 7 10 9 6 25 18 17
IP I0 0 0 2 1 3 0 4 4 4 4 17 16 9
IP I0 0 5 5 4 6 4 8 21 7 17 42 33 16
IP I0 0 0 1 2 8 3 7 13 5 8 8 11 11
IP I0 0 3 0 5 2 8 9 4 5 3 4 5 0
IP I0 0 2 2 0 7 6 6 5 5 5 5 3 4
IP I0 0 2 1 7 9 7 5 4 1 4 5 7 3
IP I0 0 3 7 5 2 9 4 3 4 4 1 3 0
IP I0 0 0 1 3 9 7 6 5 2 4 1 5 6
IP I0 0 2 9 8 2 8 1 9 2 2 3 11 4
IP I0 0 0 0 9 7 4 7 5 5 7 6 4 0
IP I0 0 7 8 3 2 7 1 43 36 19 18 22 16
IP I0 0 1 7 0 9 3 5 5 2 4 5 3 0
IP I0 0 3 9 6 3 2 1 4 2 5 9 4 2
IP I0 0 1 0 3 9 9 4 18 13 12 7 14 8
IP I0 0 2 5 3 0 5 0 18 9 12 17 10 14
IP I0 0 2 1 9 2 1 7 20 27 19 23 15 15
1P I0 0 0 0 5 158 5 2 3 5 1 0
IP I0 0 0 3 1 3 9 7 2 1 1 1 4 1
IP I0 0 0 0 9 0 3 2 17 13 14 15 8 8
IP I0 0 2 9 3 2 7 6 3 2 2 3 3 2
IP I0 0 9 1 6 1 1 1 11 11 8 10 8 8
IP I0 0 2 9 1 0 0 6 22 13 16 17 13 13
IP I0 0 0 1 7 2 9 7 19 11 14 9 10 11
IP I0 0 2 2 0 7 3 9 4 4 3 3 3 3
IP I0 0 0 0 8 2 4 0 13 7 6 11 11 10
IP I0 0 2 9 1 6 4 6 3 1 4 2 3 0
IP I0 0 0 0 4 7 9 5 2 3 2 3 3 2
IP I0 0 0 2 1 8 0 5 4 1 2 1 3 2
IP I0 0 0 0 8 8 6 8 1 0 4 4 6 0
IP I0 0 0 1 7 5 9 6 8 1 8 5 5 7
IP I0 0 1 6 7 9 4 1 17 9 11 3 8 0
IP I0 0 0 0 7 0 5 2 2 2 3 3 2 3
IP I0 0 0 2 4 9 7 6 2 0 1 2 5 2
IP I0 0 2 1 9 3 6 5 18 11 5 14 8 7
IP I0 0 1 0 6 4 9 1 6 2 1 2 2 1
IP I0 0 2 1 7 2 2 3 21 16 14 21 17 11
IP I0 0 2 2 0 3 4 2 4 6 3 3 3 1
IP I0 0 0 0 3 5 2 7 3 3 4 5 6 2
IP I0 0 3 0 0 1 2 7 7 3 2 4 6 2
IP I0 0 2 9 1 3 2 8 2 2 2 3 1 1
IP I0 0 0 2 5 7 9 6 3 4 4 5 1 2
IP I0 0 4 7 0 4 6 7 6 4 0 2 2 2
IP I0 0 0 1 3 1 8 4 3 2 2 2 2 1
IP I0 0 0 2 3 7 4 8 7 8 5 8 5 5
IP I0 0 3 2 8 1 5 4 4 0 2 3 6 0
IP I0 0 0 2 2 5 9 7 1 3 4 5 4 2
IP I0 0 0 1 0 8 0 0 16 5 9 11 25 16
IP100026167 2 0 4 3 2 3
IP I0 0 0 1 8 8 7 3 6 4 3 5 4 3
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N o d al m o d u la to r 1 IP I003 29352 2 1 1 4 6 2
N o n -P O U  d o m a in -co n ta in in g  o cta m e r-b in d in g  p rote in IP I0 0 3 0 4 5 9 6 11 8 5 17 8 4
N u c le a r m ig ra tio n  p rote in  nudC IP I0 0 5 5 0 7 4 6 10 3 6 6 4 6
N u c le a r p o re  c o m p le x  p rote in  N u p l0 7 IP I0 0 0 2 8 0 0 5 5 1 1 2 1 2
N u c le a r p o re  c o m p le x  p rote in  N u p l3 3 1P I0 0 2 9 1200 6 1 0 3 2 0
N u c le a r p o re  c o m p le x  p rote in  N up205 IP I0 0 7 8 3 7 8 1 11 5 2 4 6 1
N u c le a r pore  co m p le x  p rote in  N up93 IP I0 0 3 9 7 9 0 4 7 4 4 2 5 5
N u c le a r tra n sp o rt  fa c to r  2 IP I0 0 0 0 9 9 0 1 4 1 2 2 1 4
N u c le a se -se n s it iv e  e le m e n t-b in d in g  p rote in  1 IP I0 0 0 3 1 8 1 2 8 5 6 3 13 10
N u c le o b in d in -1 IP I0 0 2 9 5 5 4 2 4 3 1 3 0 1
N u c le o la r G T P -b in d in g  p rote in  1 IP I0 0 3 8 5 0 4 2 6 2 1 3 4 1
N u c le o la r p ro te in  56 1P I0 0 4 1 1937 3 1 1 6 5 1
N u c le o la r p ro te in  58 IP I0 0 0 0 6 3 7 9 4 3 2 7 5 0
N u c le o p o rin  54kD a va ria n t (Fragm en t) IP I0 0 1 7 2 5 8 0 1 2 1 0 2 1
N u c le o p ro te in  T P R IP I0 0 7 4 2 6 8 2 13 5 18 17 10 2
N u c le o sid e  d ip h o sp h a te  k in ase IP I0 0 6 0 4 5 9 0 21 14 16 16 12 8
N u c le o s id e -tr ip h o sp h a ta se  C lo r f5 7 IP I0 0 0 3 1 5 7 0 2 3 2 2 2 1
N u c le o so m e  a sse m b ly  p rote in  1-like 1 IP I0 0 0 2 3 8 6 0 12 9 10 11 12 7
N u d C  d o m a in -co n ta in in g  p rote in  2 IP I0 0 1 0 3 1 4 2 6 1 2 1 2 1
O rn ith in e  a m in o tra n sfe ra se , m ito ch o n d ria l IP I0 0 0 2 2 3 3 4 11 11 7 2 1 1
O T U  d o m a in -co n ta in in g  p rote in  6B 1P I0 0 1 8 2 180 1 1 3 4 2 2
P D Z  an d  LIM  d om a in  p rote in  1 IP I0 0 0 1 0 4 1 4 8 3 1 12 11 9
P e p tid y l-p ro ly l c is-tra n s iso m e ra se  A IP I0 0 4 1 9 5 8 5 21 16 20 18 18 14
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  B IP I0 0 6 4 6 3 0 4 11 10 11 11 11 3
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  FKB P4 IP I0 0 2 1 9 0 0 5 15 8 6 12 16 8
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  H IP I0 0 0 0 7 3 4 6 3 0 2 3 1 0
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  N IM A -in te ra ctin g  1 IP I0 0 0 1 3 7 2 3 5 1 1 4 2 1
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se -like  1 IP I0 0 0 0 7 0 1 9 2 1 4 4 1 0
P e ro x ire d o x in -1 IP I0 0 0 0 0 8 7 4 21 22 25 31 14 10
P e ro x ire d o x in -2 IP I0 0 0 2 7 3 5 0 9 13 10 9 6 3
P e ro x ire d o x in -4 IP I0 0 0 1 1 9 3 7 10 9 6 8 7 4
P e ro x ire d o x in -6 IP I0 0 2 2 0 3 0 1 20 25 26 27 17 13
P e ro x iso m a l m u ltifu n ctio n a l e n zym e  typ e  2 1P I0 0 0 1 9 9 12 8 7 4 7 5 0
P h o sd u cin -like  p rote in  3 IP I0 0 0 3 1 6 2 9 5 0 1 2 5 4
P h o sp h a tid y le th a n o la m in e -b in d in g  p rote in  1 IP I0 0 2 1 9 4 4 6 7 9 8 7 6 5
P h o sp h o g ly ce ra te  k in ase  1 IP I0 0 1 6 9 3 8 3 36 36 36 34 29 19
P h o sp h o g ly co la te  p h o sp h a ta se IP I0 0 1 7 7 0 0 8 2 2 3 3 3 2
P h o sp h o lip a se  D3 IP I0 0 3 2 8 2 4 3 2 0 1 3 0 1
P h o sp h o rib o sy lfo rm y lg ly c in a m id in e  syn th ase IP I0 0 0 0 4 5 3 4 20 10 11 20 18 14
P h o sp h o se rin e  a m in o tra n sfe ra se IP I0 0 0 0 1 7 3 4 15 15 12 14 11 6
P h o sp h o se rin e  p h o sp h a ta se IP I0 0 0 1 9 1 7 8 4 3 3 3 2 1
P la stin -3 IP I0 0 2 1 6 6 9 4 23 18 11 13 16 6
P la te le t-a ct iv a tin g  fa cto r a ce ty lh yd ro la se  IB su b u n it beta IP I0 0 0 2 6 5 4 6 3 2 3 2 2 3
P la te le t-a ct iv a tin g  fa cto r a ce ty lh yd ro la se  IB su b u n it ga m m a IP I0 0 0 1 4 8 0 8 1 1 3 1 0 2
P o d o c a ly x in -lik e  p rote in  1 p recu rso r 1P I0 0 2 9 9 116 5 3 5 3 6 3
P o ly  [A D P -rib o se ] p o lym e rase  1 IP I0 0 4 4 9 0 4 9 5 3 9 14 11 9
P o ly (rC )-b in d in g  p rote in  1 IP I0 0 0 1 6 6 1 0 10 11 11 11 10 10
P re fo ld in  su b u n it  2 IP I0 0 0 0 6 0 5 2 5 3 3 5 2 2
P re fo ld in  su b u n it  5 IP100015361 5 1 3 6 1 3
P re -m R N A -p ro ce ss in g  fa c to r  19 IP I0 0 0 0 4 9 6 8 5 2 1 7 10 0
P re -m R N A -p ro ce ss in g -sp lic in g  fa cto r 8 IP I0 0 0 0 7 9 2 8 26 19 11 9 26 15
P re -m R N A -sp lic in g  fa c to r  A T P -d e p e n d e n t R N A  h e licase  P R P16 IP I0 0 2 9 4 2 1 1 2 1 0 2 0 1
P re -m R N A -sp lic in g  fa c to r  SPF27 IP I0 0 0 2 5 1 7 8 3 3 2 3 1 2
P ro b a b le  A T P -d e p e n d e n t  R N A  h e licase  DD X5 IP I0 0 0 1 7 6 1 7 16 11 7 14 13 7
P ro b a b le  A T P -d e p e n d e n t  R N A  h e licase  D D X6 IP I0 0 0 3 0 3 2 0 6 2 5 2 1 2
P ro b a b le  fru cto se -2 ,6 -b isp h o sp h a ta se  T IG A R IP I0 0 0 0 6 9 0 7 4 2 2 2 1 0
P ro b a b le  rib o so m e  b io g e n e sis  p rote in  N EP1 IP I0 0 0 2 5 3 4 7 4 2 1 3 2 1
p ro b a b le  u b iq u itin  c a rb o xy l-te rm in a l hyd ro lase  FA F -X  iso fo rm  4 IP I0 0 0 0 3 9 6 4 12 6 12 8 14 2
1 2 0
P ro filin -1 1P I0 0 2 16691 18 13 18 18 11 9
p ro g e ste ro n e  re ce p to r m e m b ra n e  co m p o n e n t 2 IP I0 0 0 0 5 2 0 2 2 2 1 4 2 1
P ro g ra m m e d  cell death  6 -in te ra ct in g  p rote in IP I0 0 2 4 6 0 5 8 6 2 5 9 8 8
P ro g ra m m e d  cell death  p ro te in  10 IP I0 0 2 9 8 5 5 8 2 2 2 2 2 2
P ro g ra m m e d  cell death  p ro te in  6 IP I0 0 0 2 5 2 7 7 4 2 3 4 4 2
P ro h ib it in IP I0 0 0 1 7 3 3 4 5 5 5 7 3 4
P ro h ib it in -2 IP I0 0 0 2 7 2 5 2 4 3 4 10 8 5
P ro life ra t in g  cell n u c le a r a n tige n IP I0 0 0 2 1 7 0 0 10 5 8 5 4 4
P ro life ra t io n -a sso c ia te d  p rote in  2G 4 IP I0 0 2 9 9 0 0 0 14 6 8 1 3 1
P ro ly l e n d o p e p tid a se IP I0 0 0 0 8 1 6 4 3 5 2 7 5 2
P ro sta g la n d in  E syn th ase  3 IP I0 0 0 1 5 0 2 9 6 4 5 4 4 3
P ro sta g la n d in  red u ctase  1 IP I0 0 2 9 2 6 5 7 2 1 0 6 10 3
P ro té a so m e  26S n o n -A TP ase  su b u n it 11 v a ria n t (Frag m en t) IP I0 0 1 0 5 5 9 8 16 9 5 2 2 3
P ro te a so m e  a ct iv a to r c o m p le x  su b u n it 1 IP I0 0 4 7 9 7 2 2 5 4 4 6 1 2
P ro te a so m e  su b u n it a lp h a  typ e -2 IP I0 0 2 1 9 6 2 2 6 5 7 6 4 4
P ro te a so m e  su b u n it a lp h a  typ e -4 IP I0 0 2 9 9 1 5 5 6 5 6 2 5 5
P ro te a so m e  su b u n it a lp h a  typ e -5 IP I0 0 2 9 1 9 2 2 7 6 6 7 5 5
P ro te a so m e  su b u n it a lp h a  typ e -6 IP I0 0 0 2 9 6 2 3 10 10 11 8 5 6
P ro te a so m e  su b u n it beta typ e -1 IP I0 0 0 2 5 0 1 9 8 10 8 10 6 3
P ro te a so m e  su b u n it beta typ e -2 IP I0 0 0 2 8 0 0 6 7 8 6 7 3 4
P ro te a so m e  su b u n it  beta typ e -3 IP I0 0 0 2 8 0 0 4 8 9 7 9 1 3
P ro te a so m e  su b u n it beta typ e -5 IP I0 0 4 7 9 3 0 6 14 9 9 7 9 4
P ro te a so m e  su b u n it beta typ e -6 IP I0 0 0 0 0 8 1 1 4 4 4 6 4 2
p ro te a so m e -a sso c ia te d  p rote in  EC M 29 h o m o lo g IP I0 0 1 5 7 7 9 0 14 12 13 13 18 6
p ro te in  a rg in in e  N -m e th y ltra n sfe ra se  1 iso form  1 IP I0 0 0 1 8 5 2 2 12 7 11 3 10 10
P ro te in  C IO IP I0 0 0 1 6 9 2 5 3 1 3 2 0 4
P ro te in  d isu lfid e -iso m e ra se IP I0 0 0 1 0 7 9 6 21 17 10 25 16 7
P ro te in  d isu lfid e -iso m e ra se  A3 IP I0 0 0 2 5 2 5 2 27 28 18 33 32 16
P ro te in  d isu lfid e -iso m e ra se  A 4 IP I0 0 0 0 9 9 0 4 17 16 12 23 13 8
P ro te in  DJ-1 IP I0 0 2 9 8 5 4 7 11 12 10 9 7 8
P ro te in  d p y -3 0  h o m o lo g IP I0 0 0 2 8 1 0 9 0 1 2 2 0 1
P ro te in  FA M 3 C IP I0 0 3 3 4 2 8 2 4 4 3 2 1 3
P ro te in  FA M 49B IP I0 0 3 0 3 3 1 8 7 4 3 5 2 2
Pro te in  FA M 96B IP I0 0 0 0 7 0 2 4 3 0 1 2 1 0
P ro te in  k in ase , c A M P -d e p e n d e n t, regu la to ry, typ e  II, a lpha, iso form IP I0 0 0 6 3 2 3 4 2 0 1 1 2 0
C R A _ b
P ro te in  lin -28  h o m o lo g  A IP I0 0 0 0 2 9 4 8 10 13 9 11 12 9
Pro te in  lin -7  h o m o lo g  C IP I0 0 0 1 9 9 9 7 3 1 2 3 1 1
P ro te in  m ag o  nashi h o m o lo g  2 IP I0 0 0 5 9 2 9 2 5 3 7 5 2 3
P ro te in  o f  u n kn o w n  fu n ctio n  D U F858, m e th y ltra n sfe ra se -lik e  fa m ily IP I0 0 5 4 9 3 8 9 3 3 0 2 1 2
p rote in
P ro te in  p h o sp h a ta se  1G IP I0 0 0 0 6 1 6 7 2 2 4 3 4 2
P ro te in  RC C 2 IP I0 0 4 6 5 0 4 4 8 3 2 7 8 5
P ro te in  R R P 5  h o m o lo g IP I0 0 4 0 0 9 2 2 5 4 2 1 2 1
P ro te in  S 1 0 0 -A 1 1 IP I0 0 0 1 3 8 9 5 3 2 2 5 2 1
P ro te in  t ra n sp o rt  p rote in  Se c2 3 A IP I0 0 0 1 7 3 7 5 2 1 3 5 5 2
P ro te in  t ra n s p o rt  p rote in  Sec23B IP I0 0 0 1 7 3 7 6 5 4 3 3 4 0
P ro te in  t ra n s p o rt  p rote in  S ec61  su b u n it beta IP I0 0 2 2 0 8 3 5 2 2 2 1 1 3
P se u d o u rid y la te  syn th ase  7 h o m o lo g IP I0 0 0 4 4 7 6 1 2 4 3 2 1 0
P u ro m y c in -se n s it iv e  a m in o p e p tid ase IP I0 0 0 2 6 2 1 6 10 8 6 11 8 9
P u ta tiv e  p re -m R N A -sp lic in g  fa cto r A T P -d e p e n d e n t R N A  h e licase IP I0 0 3 9 6 4 3 5 8 12 6 3 1 4
D H X 1 5
P u ta tiv e  R N A -b in d in g  p ro te in  3 IP I0 0 0 2 4 3 2 0 3 2 3 2 3 3
P u ta tiv e  u n c h a ra c te r ize d  p rote in IP I0 0 0 1 0 4 0 2 3 0 2 1 1 2
P u ta tiv e  u n c h a ra c te rize d  p rote in  D K FZp 686L20222 IP I0 0 0 2 6 6 8 9 7 6 6 7 4 2
Q u in o n e  o x id o re d u c ta se IP I0 0 0 0 0 7 9 2 3 2 2 2 2 1
Rab G D P  d isso c ia t io n  in h ib ito r beta IP I0 0 9 4 0 1 4 8 29 25 25 26 20 17
R ad ix in , iso fo rm  C R A _a IP I0 0 0 1 7 3 6 7 3 2 0 6 4 2
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Ran G T P a se -a c tiv a tin g  p ro te in  1 IP I0 0 2 9 4 8 7 9 11 4 6 7 4 4
R a n -sp e c ific  G T P a se -a c tiv a tin g  p rote in IP I0 0 4 1 4 1 2 7 7 5 6 8 5 5
R as G T P a se -a ctiv a tin g  p ro te in -b in d in g  p rote in  1 IP I000 12442 9 5 5 9 9 3
R as G T P a se -a ctiv a tin g -lik e  p ro te in  IQ G A P1 IP I000 09342 15 7 8 25 24 21
R as su p p re sso r  protein  1 IP I0 0 0 1 7 2 5 6 3 3 5 4 3 4
R a s-re la te d  p rote in  Rab -10 IP I0 0 0 1 6 5 1 3 3 4 3 4 4 1
R a s-re la te d  p rote in  R a b - l lB IP I0 0 0 2 0 4 3 6 7 6 6 6 6 4
R a s-re la te d  p rote in  Rab -14 IP I0 0 2 9 1 9 2 8 5 5 4 3 1 1
R a s-re la te d  p rote in  Rab -18 IP I0 0 0 1 4 5 7 7 6 3 5 4 5 3
R a s-re la te d  p rote in  Rab-1B IP I0 0 0 0 8 9 6 4 9 6 10 13 6 3
R a s-re la te d  p rote in  Rab-21 IP I0 0 0 0 7 7 5 5 1 2 4 1 0 2
R a s-re la te d  p rote in  Rab-3B IP I0 0 3 0 0 5 6 2 4 2 3 2 2 2
R a s-re la te d  p rote in  Rab -5C IP I0 0 0 1 6 3 3 9 9 6 6 5 3 4
R a s-re la te d  p rote in  Rab-7a IP I0 0 0 1 6 3 4 2 9 5 8 2 2 1
R a s-re la te d  p ro te in  R a b -8A IP I0 0 0 2 8 4 8 1 4 1 3 2 0 1
R e p lica tio n  fa c to r  C  su b u n it 4 IP I0 0 0 1 7 3 8 1 2 2 2 0 2 1
R e ticu lo ca lb in -1 IP I0 0 0 1 5 8 4 2 5 2 2 5 1 1
R e ticu lo ca lb in -2 IP I0 0 0 2 9 6 2 8 3 3 1 2 1 2
re tin o l-b in d in g  p rote in  1 iso form  a IP I0 0 2 1 9 7 1 8 2 0 1 2 2 0
R ho G D P -d isso c ia t io n  in h ib ito r 1 IP I0 0 0 0 3 8 1 5 9 4 5 6 5 4
R ho G T P a se -a c tiv a tin g  p rote in  1 IP I0 0 0 2 0 5 6 7 5 5 2 8 7 0
R h o A  a ct iv a to r C l lo r f 5 9 IP I0 0 0 1 6 6 7 0 1 1 2 2 2 0
R h o -re la te d  G T P -b in d in g  p rote in  R hoC IP I0 0 0 2 7 4 3 4 2 1 2 2 1 3
R ib o n u c lé a se  in h ib ito r IP I0 0 5 5 0 0 6 9 4 1 4 1 3 1
R ib o n u c lé a se  U K114 IP100005038 3 0 2 2 2 1
R ib o n u c le o sid e -d ip h o sp h a te  re d u ctase  large su b u n it IP I0 0 0 1 3 8 7 1 6 5 2 1 0 2
rib o n u c le o s id e -d ip h o sp h a te  red u ctase  su b u n it M 2 iso form  1 IP I0 0 0 1 1 1 1 8 6 4 5 5 3 0
R ib o se -p h o sp h a te  p yro p h o sp h o k in a se  1 1P I0 0 2 19616 8 7 4 7 6 3
R ib o so m a l p ro te in  L14  va ria n t IP I0 0 5 5 5 7 4 4 4 5 3 4 3 2
R ib o so m e  b io g e n e sis  p ro te in  W D R 1 2 IP I0 0 3 0 4 2 3 2 3 1 1 1 5 1
R N A -b in d in g  p ro te in  w ith  m u ltip le  sp lic in g  2 IP I0 0 2 3 8 6 8 8 2 0 2 4 1 3
rR N A  2 '-0 -m e th y ltra n sfe ra s e  fib rilla rin IP I0 0 0 2 5 0 3 9 5 10 1 5 6 3
R u vB -like  2 IP I0 0 0 0 9 1 0 4 7 10 11 8 10 6
S -a d e n o sy lm e th io n in e  syn th ase  iso fo rm  typ e -2 IP I0 0 0 1 0 1 5 7 10 5 10 4 1 4
S e le n id e , w a te r d ik in a se  1 IP I0 0 0 2 9 0 5 6 8 7 7 6 6 7
S e n trin -sp e c ific  p ro tea se  8 IP I0 0 1 6 5 6 1 6 1 0 3 2 0 1
S e rin e  h y d ro xy m e th y ltra n sfe ra se , m ito ch o n d ria l IP I0 0 0 0 2 5 2 0 10 8 12 7 4 4
S e rin e /a rg in in e -r ich  sp lic in g  fa c to r  2 IP I0 0 0 0 5 9 7 8 0 4 2 1 2 4
S e rin e /a rg in in e -r ich  sp lic in g  fa c to r  3 IP I0 0 0 1 0 2 0 4 6 4 6 10 4 2
S e rin e /a rg in in e -r ich  sp lic in g  fa cto r 9 IP I0 0 0 1 2 3 4 0 5 6 4 4 2 3
S e rin e /th re o n in e -p ro te in  kin ase M ST4 IP I0 0 2 9 2 8 2 7 11 1 7 3 4 0
S e rin e /th re o n in e -p ro te in  kin ase O SR1 IP I0 0 0 1 0 0 8 0 2 3 3 2 0 1
S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  2A  55 kDa re g u la to ry  su b u n it 
B a lp h a  iso form
IP I0 0 3 3 2 5 1 1 5 2 4 0 2 1
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A 56 kDa re g u la to ry  su b u n it 
e p silo n  iso fo rm
IP I0 0 0 0 2 8 5 3 2 2 3 2 2 0
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A 65 kDa re g u la to ry  su b u n it 
A  a lp h a  iso fo rm
IP I0 0 5 5 4 7 3 7 19 14 12 25 13 9
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A cata ly tic  su b u n it  a lpha 
iso fo rm
IP I0 0 0 0 8 3 8 0 4 4 4 5 7 4
se rin e /th re o n in e -p ro te in  p h o sp h a ta se  P P l-a lp h a  ca ta ly tic  su b u n it 
iso fo rm  3
IP I0 0 0 2 7 4 2 3 12 8 9 10 10 7
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  P P l-b e ta  ca ta ly tic  su b u n it 1P I0 0 2 18236 4 2 3 1 3 3
Serp in  B6 IP I0 0 4 1 3 4 5 1 1 2 1 3 1 0
Se rp in  B9 IP I0 0 0 3 2 1 3 9 3 6 11 11 11 8
Se rp in  H I IP I0 0 0 3 2 1 4 0 20 18 17 20 19 17
S e ry l-tR N A  sy n th e ta se , cyto p la sm ic IP I0 0 2 2 0 6 3 7 3 1 2 3 2 0
SF3 A 2  p rote in  (F ra g m e n t) IP I0 0 0 1 7 3 4 1 3 1 1 1 2 1
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5 -fo rm y lg lu ta th io n e  h yd ro lase 1P I0 0 4 1 1706 2 2 1 1 2 1
S H 3  d o m a in -b in d in g  g lu ta m ic  a c id -rich -like  p rote in IP I0 0 0 2 5 3 1 8 3 2 4 6 2 4
S ia lic  a c id  syn th ase IP I0 0 1 4 7 8 7 4 3 4 3 4 3 3
S id e ro fle x in -1 IP I0 0 0 0 9 3 6 8 3 0 1 3 1 1
S ig n a l re co g n itio n  p article  72 kDa protein 1P I0 0 2 15888 3 2 0 2 1 0
S ig n a l re co g n itio n  p article  9 kDa protein IP I0 0 6 4 2 8 1 6 2 1 2 2 2 1
S in g le -s tra n d e d  D N A -b in d in g  prote in , m ito ch o n d ria l IP I0 0 0 2 9 7 4 4 6 4 7 10 5 5
S m a ll g lu ta m in e -rich  te tra tr ico p e p tid e  re p e a t-co n ta in in g  p rote in  a IP I0 0 0 1 3 9 4 9 2 5 3 7 2 3
S m a ll n u c le a r r ib o n u cle o p ro te in  E IP I0 0 0 2 9 2 6 6 3 2 2 3 1 2
S m a ll n u c le a r r ib o n u c le o p ro te in  F IP I0 0 2 2 0 5 2 8 3 2 3 2 1 1
Sm a ll n u c le a r r ib o n u c le o p ro te in  Sm  D1 IP I0 0 3 0 2 8 5 0 7 3 5 2 1 2
Sm a ll n u c le a r r ib o n u c le o p ro te in  Sm  D2 IP I0 0 0 1 7 9 6 3 6 3 4 6 4 3
Sm a ll n u c le a r r ib o n u c le o p ro te in  Sm  D3 IP I0 0 0 1 7 9 6 4 2 2 2 1 3 2
S o d iu m /p o ta ss iu m -tra n sp o rtin g  A T P a se  su b u n it beta-3 IP I0 0 0 0 8 1 6 7 4 3 2 1 2 1
S o lu te  c a rr ie r  fa m ily  2, fa c ilita te d  g lu co se  tra n sp o rte r m e m b e r 1 IP I0 0 2 2 0 1 9 4 6 4 3 4 3 1
S o lu te  c a rr ie r  fa m ily  2, fa c ilita te d  g lu cose  tra n sp o rte r m e m b e r 3 IP I0 0 0 0 3 9 0 9 2 2 2 3 3 0
So rcin IP I0 0 0 2 7 1 7 5 4 2 5 5 3 1
S p e rm -a sso c ia te d  a n tig e n  7 IP I0 0 0 0 6 8 6 3 4 0 3 2 0 2
S p e rm id in e  syn th a se IP100292020 7 5 4 7 3 3
S p lic in g  fa c to r  3A  su b u n it  1 IP100017451 7 5 5 6 8 3
S p lic in g  fa c to r  3A  su b u n it  3 IP I0 0 0 2 9 7 6 4 4 6 1 3 1 0
S p lic in g  fa c to r  3B su b u n it 1 IP I0 0 0 2 6 0 8 9 19 10 12 13 23 10
S p lic in g  fa c to r  3B su b u n it  2 IP I0 0 2 2 1 1 0 6 3 1 4 1 3 2
S p lic in g  fa c to r  U 2A F 35 kDa su b u n it IP I0 0 0 0 5 6 1 3 3 3 4 4 3 4
S q u a le n e  m o n o o xy g e n a se IP I0 0 2 9 1 5 4 4 2 1 2 1 4 0
S q u a le n e  syn th ase IP I0 0 0 2 0 9 4 4 9 9 14 7 6 3
S R A  s te m -lo o p -in te ra ct in g  R N A -b in d in g  p rote in , m ito ch o n d ria l IP I0 0 0 0 9 9 2 2 2 1 3 1 2 1
S ta p h y lo c o c c a l n u clea se  d o m a in -co n ta in in g  protein  X IP I0 0 1 4 0 4 2 0 13 8 7 14 14 14
S ta th m in IP I0 0 4 7 9 9 9 7 4 9 6 6 1 3
S te ro l-4 -a lp h a -ca rb o x y la te  3 -d e h yd ro g e n a se , d e ca rb o xy latin g IP I0 0 0 1 9 4 0 7 3 3 5 2 1 1
S tre ss -7 0  p ro te in , m ito ch o n d ria l IP I0 0 0 0 7 7 6 5 28 14 19 21 16 11
S tre ss -in d u ce d -p h o sp h o p ro te in  1 IP I0 0 0 1 3 8 9 4 16 12 4 5 5 1
S tru ctu ra l m a in te n a n ce  o f ch ro m o so m e s  p rote in  1A IP I0 0 2 9 1 9 3 9 3 1 1 3 4 3
S tru ctu ra l m a in te n a n ce  o f ch ro m o so m e s  p rote in  3 IP I0 0 2 1 9 4 2 0 5 1 3 3 6 0
S U M O -a ctiv a t in g  e n zym e  su b u n it  1 IP I0 0 0 3 3 1 3 0 5 6 6 2 1 0
S U M O -a ctiv a t in g  e n zym e  su b u n it 2 IP I0 0 0 2 3 2 3 4 6 4 3 3 6 5
S U M O -c o n ju g a tin g  e n zym e  U BC9 IP I0 0 0 3 2 9 5 7 1 2 3 2 4 2
S u p e rk ille r  v ira lic id ic  a ct iv ity  2 -like  2 IP I0 0 6 4 7 2 1 7 10 4 4 6 8 0
S u p e ro x id e  d ism u tase  [Cu-Zn] 1P I0 0 2 18733 5 3 4 4 1 1
S W I/S N F -re la te d  m a trix -a sso c ia te d  a ctin -d e p e n d e n t re g u la to r o f 
ch ro m a tin  su b fa m ily  A  m e m b e r 5
1P I0 0 2 9 7 2 11 1 0 3 1 6 3
S yn a p tic  v e sic le  m em b ra n e  p rote in  V A T-1  h o m o lo g IP I0 0 1 5 6 6 8 9 8 4 7 7 8 4
T a lin -1 IP I0 0 2 9 8 9 9 4 23 11 24 37 31 22
T -c o m p le x  p rote in  1 su b u n it a lpha IP I0 0 2 9 0 5 6 6 17 8 9 20 16 7
T -c o m p le x  p rote in  1 su b u n it beta IP I0 0 2 9 7 7 7 9 26 26 14 26 28 15
T -c o m p le x  p rote in  1 su b u n it de lta IP100302927 13 11 11 11 17 10
T -c o m p le x  p rote in  1 su b u n it ep silon IP I0 0 0 1 0 7 2 0 19 17 6 18 17 6
T -c o m p le x  p rote in  1 su b u n it eta IP I0 0 0 1 8 4 6 5 17 15 8 13 10 10
T -c o m p le x  p ro te in  1 su b u n it zeta IP I0 0 0 2 7 6 2 6 10 15 9 16 11 8
T E L 2 -in te ra c t in g  p rote in  1 h o m o lo g 1P I0 0 0 1 1702 3 2 1 2 1 1
T h im e t  o lig o p e p tid a se IP I0 0 5 4 9 1 8 9 2 2 1 2 1 0
T h io re d o x in IP I0 0 2 1 6 2 9 8 3 3 2 3 1 3
T h io re d o x in  d o m a in -co n ta in in g  p rote in  12 IP I0 0 0 2 6 3 2 8 2 3 2 2 1 0
T h io re d o x in  d o m a in -co n ta in in g  p rote in  17 IP I0 0 6 4 6 6 8 9 3 2 4 2 3 2
T h io re d o x in  d o m a in -co n ta in in g  p rote in  5 IP I0 0 1 7 1 4 3 8 4 4 4 3 5 3
T h io re d o x in -d e p e n d e n t  p e ro xid e  red u ctase , m ito ch o n d ria l IP I0 0 0 2 4 9 1 9 9 10 9 6 5 6
T h io re d o x in -lik e  p ro te in  1 IP I0 0 3 0 5 6 9 2 9 5 6 8 7 4
T H O  co m p le x  su b u n it  4 IP I0 0 3 2 8 8 4 0 8 3 5 4 6 7
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T h re o n y l-tR N A  sy n th e ta se , cyto p lasm ic  
T H U M P  d o m a in -co n ta in in g  protein  1 
T h y -1  m e m b ra n e  g lyco p ro te in  
T ra ff ic k in g  p rote in  p artic le  co m p le x su b u n it 3 
T ra n s a ld o la s e
T ra n s c rip t io n  e lo n g a tio n  fa cto r B p o lyp ep tid e  1
T ra n s fe rr in  re ce p to r protein  1
T ra n s fo rm in g  p rote in  R hoA
T ra n sg e lin
T ra n sg e lin -2
T ra n s it io n a l e n d o p la sm ic  reticu lu m  A TPa se  
T ra n s la t io n  in itiatio n  fa c to r  e lF -2 B  su b u n it a lpha 
T ra n s la t io n a l a ct iv a to r G CN 1 
T ran slin
T ra n s lin -a sso c ia te d  p ro te in  X
T ra n sm e m b ra n e  e m p 2 4  d o m a in -co n ta in in g  p rote in  10 
T ra n sm e m b ra n e  e m p 2 4  d o m a in -co n ta in in g  p rote in  2 
T ra n sm e m b ra n e  e m p 2 4  d o m a in -co n ta in in g  protein  9 
T r ifu n ctio n a l e n zym e  su b u n it  a lp h a , m ito ch o n d ria l 
tr io se p h o sp h a te  iso m e ra se  iso fo rm  2 
T r ip a rt ite  m o tif-c o n ta in in g  p ro te in  71 
T r ip e p t id y l-p e p t id a se  2 
tR N A  (cy to s in e -5 -)-m e th y ltra n sfe ra se  N SU N 2 
tR N A  (g u a n in e -N (7 )-)-m e th y ltra n sfe ra se  
tR N A  m e th y ltra n sfe ra se  112 h o m o lo g 
T ro p o m o d u lin -3
Tu tra n s la t io n  e lo n g a tio n  fa cto r, m ito ch o n d ria l p recu rso r
T U B B 6  p rote in
T u b u lin  a lp h a - lC  ch a in
T u b u lin  b e ta -2 A  ch ain
T u b u lin  b e ta -2 B  ch ain
T u b u lin  b e ta -2 C  chain
T u b u lin  b e ta-3  chain
T u b u lin  b e ta -4  ch ain
T u b u lin , beta
T u b u lin -fo ld in g  c o fa cto r B
T u b u lin -sp e c ific  ch a p e ro n e  A
T u b u lin -sp e c if ic  ch a p e ro n e  E
T u b u lin -ty ro s in e  ligase -like  p rote in  12
T u m o r p rote in , tra n s la tio n a lly -co n tro lle d  1
T w in filin -2
T y ro sy l-tR N A  syn th e ta se , cyto p la sm ic  
U1 sm all n u c le a r rib o n u cle o p ro te in  A 
U2 sm all n u c le a r rib o n u cle o p ro te in  A'
U2 sm all n u c le a r rib o n u cle o p ro te in  B"
U 6 sn R N A -a sso c ia te d  Sm -like  protein  LSm 2 
U 6 sn R N A -a sso c ia te d  Sm -like  p rote in  LSm 3 
U 6 sn R N A -a sso c ia te d  Sm -like  protein  LSm 4 
U b iq u it in  ca rb o x y l-te rm in a l h yd ro la se  10 
U b iq u it in  ca rb o x y l-te rm in a l h yd ro lase  11 
U b iq u it in  c a rb o x y l-te rm in a l h yd ro la se  14 
U b iq u itin  c a rb o x y l-te rm in a l h yd ro la se  7 
U b iq u itin  c a rb o x y l-te rm in a l h yd ro lase  iso zym e  L I  
U b iq u it in -4 0 S  r ib o so m a l p rote in  S27a 
U b iq u it in -co n ju g a tin g  e n zym e  E2 G l  
U b iq u it in -co n ju g a tin g  e n zym e  E2 L3 
U b iq u it in -co n ju g a tin g  e n zym e  E2 0  
U b iq u itin -lik e  m o d ifie r-a ct iv a t in g  e n zym e  1
IP I0 0 3 2 9 6 3 3 15 14 12 10 11 11
IP I005 50243 2 0 3 1 4 1
IP I000 22892 1 2 3 2 1 1
IP I0 0 0 0 4 3 2 4 1 0 2 2 0 1
IP I007 44692 9 8 5 12 10 6
IP I0 0 3 0 0 3 4 1 3 1 1 1 0 2
IP I0 0 0 2 2 4 6 2 10 4 4 2 3 1
l P I0 0 4 7 8 2 3 1 6 6 9 10 8 7
IP I0 0 2 1 6 1 3 8 15 16 16 19 20 10
IP I0 0 5 5 0 3 6 3 6 8 8 14 9 9
IP I0 0 0 2 2 7 7 4 34 36 20 34 32 24
1P I0 0 2 2 1300 2 0 2 3 2 0
IP I0 0 0 0 1 1 5 9 18 20 12 21 4 10
IP I0 0 0 1 8 7 6 8 6 7 5 8 4 6
IP I0 0 2 9 3 3 5 0 5 4 3 6 2 2
IP I0 0 0 2 8 0 5 5 5 7 5 8 7 2
IP I0 0 0 1 6 6 0 8 1 2 1 3 1 0
IP I0 0 0 2 3 5 4 2 2 1 3 4 2 3
IP I0 0 0 3 1 5 2 2 8 8 1 8 4 1
IP I0 0 4 6 5 0 2 8 26 30 26 31 21 16
IP I0 0 7 1 9 0 5 3 3 4 5 1 2 1
IP I0 0 0 2 0 4 1 6 8 5 4 3 7 0
IP I0 0 3 0 6 3 6 9 7 3 3 2 6 1
IP I0 0 2 9 0 1 8 4 3 1 3 2 0 1
IP100009010 2 2 2 2 2 2
IP I0 0 0 0 5 0 8 7 4 2 4 3 5 2
IP I0 0 0 2 7 1 0 7 11 6 8 11 7 1
IP I0 0 6 4 6 7 7 9 2 3 4 3 2 4
IP I0 0 2 1 8 3 4 3 3 2 1 2 3 1
IP I0 0 0 1 3 4 7 5 2 1 2 2 1 1
1P I0 0 0 3 1370 29 34 31 8 9 5
IP I0 0 0 0 7 7 5 2 4 5 3 9 8 4
IP I0 0 0 1 3 6 8 3 10 6 8 7 7 2
IP I0 0 0 2 3 5 9 8 2 2 3 3 1 1
IP I0 0 6 4 5 4 5 2 10 8 12 35 35 23
1P I0 0 2 9 3 126 4 2 5 5 3 2
1P I0 0 2 17236 7 7 7 6 6 5
IP I0 0 0 1 8 4 0 2 4 1 2 2 1 0
IP I0 0 0 2 9 0 4 8 5 7 0 9 8 4
IP I0 0 0 0 9 9 4 3 8 7 3 5 7 5
IP I0 0 5 5 0 9 1 7 1 2 1 2 2 1
IP I0 0 0 0 7 0 7 4 10 10 4 11 8 2
IP I0 0 0 1 2 3 8 2 3 0 1 3 1 0
IP I0 0 2 9 7 4 7 7 9 7 9 8 2 3
IP I0 0 0 2 9 2 6 7 2 3 2 4 1 0
IP I0 0 0 3 2 4 6 0 2 2 2 2 1 1
IP I0 0 2 1 9 2 2 9 0 1 3 2 1 0
IP I0 0 2 9 4 9 5 5 5 2 2 2 2 2
1P I0 0 2 9 1946 3 1 4 2 2 1
IP I0 0 1 8 4 5 3 3 5 5 4 1 2 1
IP I0 0 2 1 9 9 1 3 8 5 2 5 8 3
IP I0 0 0 0 3 9 6 5 9 5 8 2 1 1
IP I0 0 0 1 8 3 5 2 11 8 9 13 7 6
IP I0 0 1 7 9 3 3 0 7 3 9 10 3 5
IP I0 0 2 1 9 7 8 3 3 1 0 2 2 0
1P I0 0 0 2 1347 6 3 5 3 4 2
IP I0 0 7 8 3 3 7 8 4 2 2 3 5 1
IP I0 0 6 4 5 0 7 8 33 22 25 23 21 19
1 2 4
U D P -g lu co se  6 -d e h y d ro g e n a se
U n ch a ra cte rize d  p rote in
U n ch a ra cte rize d  p rote in  C 17 orf2 5
U P F 0 0 2 7  p ro te in  C 2 2 o rf2 8
U P F 0 1 6 0  p ro te in  M YG 1, m ito ch o n d ria l
U P F 0 3 6 4  p ro te in  C 6 o r f2 U
U P F 0 3 6 8  p ro te in  C xo rf26
U P F 0 5 6 8  p rote in  C 1 4 o r fl6 6
U P F 0 5 8 7  p rote in  C lo r f l2 3
U P F 0 7 2 7  p rote in  C 6 o r f l l5
U ro p o rp h y rin o g e n  d e ca rb o xy la se
U V e xc is io n  rep a ir p rote in  R A D 23 h o m o lo g  B
V a c u o la r  p rote in  so rtin g -a sso c ia te d  p rote in  26A
V a c u o la r p rote in  so rtin g -a sso c ia te d  p rote in  35
V a cu o la r p rote in  so rtin g -a sso c ia te d  p rote in  V TA 1  h o m o lo g
V a ly l-tR N A  syn th e ta se
V e s icu la r  in te g ra l-m e m b ra n e  p rote in  V IP 36
V im e n tin
V is in in -lik e  p rote in  1
von H ip p e l-L in d a u  b in d in g  p rote in  1, iso form  CR A _b
V -ty p e  p ro to n  A T P a se  ca ta ly tic  su b u n it A
V -ty p e  p roton  A T P a se  su b u n it C 1
V -ty p e  p ro to n  A T P a se  su b u n it E 1
V -ty p e  p roton  A T P a se  su b u n it G 1
W D  rep eat an d  H M G -b o x  D N A -b in d in g  p rote in  1
X a a -P ro  d ip e p tid a se
X -ra y  re p a ir c ro ss -c o m p le m e n tin g  p rote in  5 
X -ra y  re p a ir c ro ss -c o m p le m e n tin g  p rote in  6 
Zyx in
IP I0 0 0 3 1 4 2 0 7 2 5 2 2 0
IP I0 0 0 2 2 4 3 4 6 10 5 5 6 6
IP I000 07102 5 5 4 7 6 3
IP I0 0 5 5 0 6 8 9 6 3 2 1 1 2
IP I0 0 0 2 9 4 4 4 2 1 4 5 1 0
IP I0 0 0 0 2 2 7 0 5 2 4 4 5 1
IP I0 0 1 0 7 1 0 4 4 3 1 1 3 0
1PI00006980 7 9 7 2 0 1
IP I0 0 0 1 6 6 0 5 3 1 1 3 1 0
IP I0 0 8 5 5 8 4 6 2 2 3 3 0 1
IP I0 0 3 0 1 4 8 9 4 4 2 4 4 1
IP I0 0 0 0 8 2 2 3 2 3 1 5 4 2
IP I0 0 4 1 1 4 2 6 3 0 1 0 2 1
IP I0 0 0 1 8 9 3 1 2 4 1 10 5 4
IP I0 0 0 1 7 1 6 0 1 2 0 1 2 0
IP I0 0 0 0 0 8 7 3 12 5 6 10 5 9
IP I0 0 0 0 9 9 5 0 2 2 1 7 4 1
IP I0 0 4 1 8 4 7 1 33 10 18 47 40 27
1P I0 0 2 1 6 3 13 7 3 4 3 1 0
IP I0 0 3 3 4 1 5 9 3 2 2 1 4 1
IP I0 0 0 0 7 6 8 2 8 4 2 6 2 2
IP I0 0 0 0 7 8 1 4 1 0 2 2 1 1
IP I0 0 0 0 3 8 5 6 3 1 2 3 2 1
IP I0 0 0 2 5 2 8 5 4 0 3 3 0 1
IP I0 0 4 1 1 6 1 4 1 1 3 1 3 0
IP I0 0 2 5 7 8 8 2 4 3 2 4 4 0
IP I0 0 2 2 0 8 3 4 28 18 11 19 20 13
IP I0 0 6 4 4 7 1 2 26 23 13 38 26 9
IP I0 0 9 2 6 6 2 5 6 6 2 6 6 4
Note: "Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line.
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Appendix F All proteins identified at 72 hours in hypoxia




6 0 S  r ib o so m a l p rote in  L35a IP I000 29731 1 3 3 2 1 2
h isto n e  d e a ce ty la se  co m p le x  su b u n it SA P18 IP I0 0 0 1 1 6 9 8 2 1 0 5 1 1
Iso fo rm  1 o f Fan co n i anem ia  gro u p  1 protein IP I0 0 0 1 9 4 4 7 4 0 1 3 3 1
Iso fo rm  1 o f  Far u p stre am  e le m e n t-b in d in g  p rote in  1 IP I0 0 3 7 5 4 4 1 8 3 9 8 10 6
Iso fo rm  1 o f Iso p e n te n y l-d ip h o sp h a te  D e lta -iso m e ra se  1 IP I0 0 6 4 5 3 0 7 6 5 9 4 5 4
Iso fo rm  1 o f  Leu cin e  z ip p e r p rote in  1 IP I0 0 2 9 6 8 3 0 2 0 1 3 2 1
Iso fo rm  1 o f M ps one b in d e r k in ase  a ctiva to r-like  3 IP I0 0 3 8 6 1 2 2 2 0 1 0 3 2
Iso fo rm  1 o f T u m o r p rote in  D52 IP I0 0 6 1 9 9 5 8 3 3 3 5 5 4
Iso fo rm  2 o f  P E R Q  am in o  a cid -rich  w ith  G YF  d om a in  p rote in  2 IP I0 0 6 4 7 6 3 5 2 0 1 0 3 1
Iso fo rm  2 o f P ro co lla g e n -ly s in e ,2 -o x o g lu ta ra te  5 -d io x yg e n a se  2 IP I0 0 3 3 7 4 9 5 7 1 1 2 6 1
Isoform  2 o f P ro te in  e n ab le d  h o m o lo g IP I0 0 3 7 4 0 5 4 1 0 5 2 2 0
Iso fo rm  2 o f  R e g u latio n  o f  n u c le a r p re-m R N A  dom ain  p rote in  1A IP I0 0 0 6 2 3 3 6 2 0 6 1 2 0
Iso fo rm  4 o f A fad in IP I0 0 0 2 3 4 6 1 4 1 1 3 1 0
Iso fo rm  4 o f S o rtin g  n exin -3 IP I0 0 5 5 2 2 7 6 3 0 3 2 2 1
M a n n o sy l-o lig o sa c c h a rid e  g lu co s id a se IP I0 0 3 2 8 1 7 0 1 2 1 6 3 3
N A D H -u b iq u in o n e  o x id o re d u cta se  75 kDa su b u n it IP I0 0 6 0 4 6 6 4 4 4 2 1 1 3
P ro ly l 3 -h y d ro xy la se  2 1P I0 0 2 17055 2 1 1 2 1 0
P ro te in  FA M 1 6 2 A IP I0 0 0 2 3 0 0 1 1 3 0 3 1 1
P u ta tiv e  u n ch a ra cte rize d  p rote in  D K FZp 7 8 1 K 1 3 5 6 IP I0 0 4 1 2 5 4 5 1 0 2 1 1 2
Y rd C  d o m a in -co n ta in in g  p rote in , m ito ch o n d ria l IP I0 0 3 8 4 1 8 0 2 0 2 2 1 0
in su lin -lik e  gro w th  fa cto r-b in d in g  p rote in  2 p re cu rso r IP I0 0 2 9 7 2 8 4 4 2 7 1 2 2
S o lu te  c a rr ie r  fa m ily  2, fa c ilita te d  g lu co se  tra n sp o rte r m e m b e r 1 IP I0 0 2 2 0 1 9 4 5 5 4 7 9 5
H e x o k in a se -2 IP J001028 64 7 6 12 6 8 4
C y to p la sm ic  a co n ita te  h yd ra tase IP I0 0 0 0 8 4 8 5 11 8 6 7 9 7
Iso fo rm  1 o f M icro tu b u le -a sso c ia te d  p rote in  4 IP I0 0 3 9 6 1 7 1 6 6 4 11 9 12
Iso fo rm  1 o f  P ro ly l 4 -h y d ro xy la se  su b u n it a lp h a -1 IP I0 0 0 0 9 9 2 3 4 1 3 11 14 3
Iso fo rm  A  o f  A P -1  co m p le x  su b u n it beta-1 IP I0 0 3 2 8 2 5 7 12 4 8 5 7 4
116 kDa U 5 sm all n u c le a r r ib o n u cle o p ro te in  co m p o n e n t 1P I0 0 0 0 3 5 19 13 9 11 13 9 17
1 4 -3-3  p rote in  e p silon IP I0 0 0 0 0 8 1 6 38 21 28 31 23 19
14-3-3  p ro te in  eta IP I0 0 2 1 6 3 1 9 14 13 17 14 8 8
14-3-3  p rote in  gam m a IP I0 0 2 2 0 6 4 2 6 6 7 9 5 8
1 4-3-3  p rote in  theta IP I0 0 0 1 8 1 4 6 15 9 13 22 13 14
1 4-3-3  p rote in  ze ta/d e lta IP I0 0 0 2 1 2 6 3 22 14 23 19 12 10
15 kDa se le n o p ro te in  iso form  1 p re cu rso r IP I0 0 0 3 0 8 7 7 1 1 2 2 1 2
l-p h o s p h a tid y lin o s ito l-4 ,5 -b is p h o s p h a te  p h o sp h o d ie ste ra se  beta-3 IP I0 0 0 1 0 4 0 0 2 4 1 1 4 3
2 ,4 -d ie n o y l-C o A  red u ctase , m ito ch o n d ria l IP I0 0 0 0 3 4 8 2 2 0 1 0 2 0
22 kD a p rote in 1P I0 0 2 19910 3 2 1 1 1 2
2 4 -d e h y d ro ch o le ste ro l red u ctase IP I0 0 0 1 6 7 0 3 3 1 5 0 3 1
26 S  p ro te a se  re g u la to ry  su b u n it 10B IP I0 0 0 2 1 9 2 6 9 5 9 14 7 4
26S p ro te a se  re g u la to ry  su b u n it 4 1P I0 0 0 1 1126 6 4 6 8 6 9
2 6 S  p ro te a se  re g u la to ry  su b u n it 6A IP I0 0 0 1 8 3 9 8 12 10 12 16 10 11
26S p ro te a se  re g u la to ry  su b u n it 7 1P I0 0 0 2 1435 12 5 13 18 13 12
26S p ro te a se  re g u la to ry  su b u n it 8 1P I0 0 0 2 3 9 19 11 6 10 9 8 6
26S p ro te a so m e  n o n -A T P a se  reg u la to ry  su b u n it 10 IP I0 0 0 0 3 5 6 5 3 2 0 4 2 1
26S p ro te a so m e  n o n -A T P a se  reg u la to ry  su b u n it 12 IP I0 0 1 8 5 3 7 4 7 5 8 7 11 10
26S p ro te a so m e  n o n -A T P a se  reg u la to ry  su b u n it 14 IP I0 0 0 2 4 8 2 1 7 6 5 9 5 8
26S p ro te a so m e  n o n -A T P a se  reg u la to ry  su b u n it 2 IP I0 0 0 1 2 2 6 8 17 10 11 21 24 13
26S p ro te a so m e  n o n -A T P a se  reg u la to ry  su b u n it 3 1P I0 0 0 1 1603 7 8 6 8 12 8
26S p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 5 IP I0 0 0 0 2 1 3 4 5 3 2 7 5 6
26S p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 6 IP I0 0 0 1 4 1 5 1 12 10 9 11 13 9
26S p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 7 IP I0 0 0 1 9 9 2 7 5 5 6 6 4 4
26S p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 8 IP I0 0 9 3 7 2 7 8 3 1 2 7 5 2
28 kD a heat- a n d  a c id -sta b le  p h o sp h o p ro te in IP I0 0 0 1 3 2 9 7 2 1 2 1 1 3
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28S r ib o so m a l p rote in  S22, m ito ch o n d ria l IP I0 0 0 1 3 1 4 6 3 1 2 1 2 0
28S rib o so m a l p rote in  S29, m ito ch o n d ria l IP I0 0 0 1 8 1 2 0 2 1 0 2 2 1
29 kD a p rote in IP I0 0 4 5 3 4 7 6 28 21 28 37 23 20
2 -o x o g lu ta ra te  d e h yd ro g e n a se , m ito ch o n d ria l IP I000 98902 4 2 3 6 5 6
33 kD a p rote in IP I0 0 4 1 3 1 0 8 15 12 12 13 12 11
39S rib o so m a l p rote in  L I ,  m ito ch o n d ria l IP I005 49381 3 0 2 3 2 2
39 S  r ib o so m a l p rote in  L l l ,  m ito ch o n d ria l IP I0 0 0 0 7 0 0 1 4 2 1 3 3 2
39 S  rib o so m a l p rote in  L44, m ito ch o n d ria l IP I0 0 0 0 9 6 8 0 3 1 0 1 0 2
39S rib o so m a l p rote in  L49, m ito ch o n d ria l IP I000 13195 3 0 1 1 1 2
3 -h y d ro x y iso b u ty ra te  d e h yd ro g e n a se , m ito ch o n d ria l IP I0 0 0 1 3 8 6 0 2 1 3 5 5 0
3 -k e to a c y l-C o A  th io la se , m ito ch o n d ria l IP I0 0 0 0 1 5 3 9 5 4 6 10 9 8
3 -k e to a c y l-C o A  th io la se , p e ro xiso m al IP I0 0 0 1 2 8 2 8 1 0 2 3 1 1
3 -m e rc a p to p y ru v a te  su lfu rtra n sfe ra se IP I0 0 1 6 5 3 6 0 3 4 2 3 3 3
4 0 S  rib o so m al p rote in  S10 IP I0 0 0 0 8 4 3 8 2 3 3 6 4 5
4 0 S  rib o so m al p ro te in  S l l IP I0 0 0 2 5 0 9 1 3 3 4 4 5 5
4 0 S  rib o so m al p ro te in  S12 IP I0 0 0 1 3 9 1 7 13 7 8 12 6 4
4 0 S  rib o so m al p rote in  S13 IP I0 0 2 2 1 0 8 9 10 14 6 16 8 10
4 0 S  rib o so m al p ro te in  S14 IP I0 0 0 2 6 2 7 1 11 7 4 9 3 6
4 0 S  rib o so m al p ro te in  S15 IP I0 0 4 7 9 0 5 8 5 6 4 7 5 5
4 0 S  rib o so m al p ro te in  S15a IP I0 0 2 2 1 0 9 1 7 5 1 8 4 4
4 0 S  rib o so m al p rote in  S16 IP I0 0 2 2 1 0 9 2 8 6 3 8 5 8
4 0 S  rib o so m al p ro te in  S17 IP I0 0 2 2 1 0 9 3 11 5 7 6 9 7
4 0 S  rib o so m al p rote in  S18 IP I0 0 0 1 3 2 9 6 13 13 7 16 9 9
4 0 S  rib o so m al p ro te in  S19 IP I0 0 2 1 5 7 8 0 3 10 7 11 4 5
4 0 S  rib o so m al p rote in  S2 IP I0 0 0 1 3 4 8 5 8 7 6 9 8 9
4 0 S  rib o so m al p rote in  S20 IP I0 0 0 1 2 4 9 3 5 3 5 8 4 4
4 0 S  rib o so m al p ro te in  S21 IP I0 0 0 1 7 4 4 8 0 3 1 7 4 4
4 0 S  rib o so m al p rote in  S23 IP I0 0 2 1 8 6 0 6 2 2 1 3 1 1
4 0 S  r ib o so m a l p ro te in  S25 IP I0 0 0 1 2 7 5 0 4 5 4 5 3 3
4 0 S  rib o so m al p rote in  S26 IP I0 0 6 5 5 6 5 0 2 3 1 3 3 1
4 0 S  rib o so m al p ro te in  S28 IP I0 0 7 1 9 6 2 2 0 2 1 7 2 1
4 0 S  rib o so m al p rote in  S3 IP I0 0 0 1 1 2 5 3 17 12 20 14 14 14
4 0 S  rib o so m al p rote in  S3a IP I0 0 4 1 9 8 8 0 16 15 14 16 13 12
4 0 S  rib o so m al p rote in  S4, X iso form IP I0 0 2 1 7 0 3 0 7 8 9 13 7 9
4 0 S  rib o so m al p rote in  S5 IP I0 0 0 0 8 4 3 3 6 6 3 8 3 6
4 0 S  rib o so m al p rote in  S6 IP I0 0 0 2 1 8 4 0 9 8 8 10 2 5
4 0 S  rib o so m al p rote in  S7 IP I0 0 0 1 3 4 1 5 9 11 5 17 3 6
4 0 S  rib o so m al p rote in  S8 IP I0 0 2 1 6 5 8 7 8 9 13 20 10 8
4 0 S  rib o so m al p rote in  S9 IP I0 0 2 2 1 0 8 8 7 6 5 11 6 4
482  kDa p rote in IP I0 0 1 7 9 2 9 8 15 11 27 14 20 1
4 -trim e th y la m in o b u ty ra ld e h y d e  d e h yd ro g e n a se IP I0 0 4 7 9 8 7 7 1 1 5 1 2 0
51 kD a p rote in IP I0 0 0 3 3 0 2 5 3 2 2 6 8 3
5 '-n u c le o tid a se  d o m a in -co n ta in in g  p rote in  1 IP I0 0 1 7 7 9 6 5 4 1 5 5 5 2
60 kD a h e at sh o c k  p rote in , m ito ch o n d ria l IP I0 0 7 8 4 1 5 4 50 43 46 50 28 29
6 0 S  a cid ic  r ib o so m a l p rote in  P0 IP I0 0 0 0 8 5 3 0 17 10 11 10 14 11
6 0 S  a c id ic  r ib o so m a l p rote in  P I IP I0 0 0 0 8 5 2 7 2 2 3 4 4 3
6 0 S  a c id ic  r ib o so m a l p rote in  P2 IP100008529 11 5 4 9 7 7
6 0 S  rib o so m a l p ro te in  L10 IP I0 0 5 5 4 7 2 3 9 6 5 13 8 5
60S rib o so m a l p ro te in  L lO a IP I0 0 4 1 2 5 7 9 12 6 7 13 9 5
60S rib o so m a l p ro te in  L13 IP I0 0 4 6 5 3 6 1 3 5 4 6 4 2
60S r ib o so m a l p ro te in  L13a IP I0 0 3 0 4 6 1 2 3 2 3 3 3 2
60S r ib o so m a l p ro te in  L15 IP I0 0 4 7 0 5 2 8 4 4 3 7 3 5
60S r ib o so m a l p ro te in  L17 IP I0 0 4 1 3 3 2 4 9 5 4 14 6 5
60S r ib o so m a l p ro te in  L18 IP I0 0 2 1 5 7 1 9 9 8 4 9 8 8
60S rib o so m al p ro te in  L18a IP I0 0 0 2 6 2 0 2 5 3 1 5 4 3
60S rib o so m al p ro te in  L19 IP I0 0 0 2 5 3 2 9 4 4 4 5 3 4
6 0 S  rib o so m al p ro te in  L21 IP I0 0 2 4 7 5 8 3 5 6 6 8 7 4
60S rib o so m al p ro te in  L22 IP I0 0 2 1 9 1 5 3 7 2 3 10 3 3
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60 S  r ib o so m a l p ro te in  L23
60 S  r ib o so m a l p ro te in  L23a
60 S  r ib o so m a l p ro te in  L24
60 S  r ib o so m a l p ro te in  L26
60 S  r ib o so m a l p ro te in  L27
6 0 S  r ib o so m a l p rote in  L27a
6 0 S  r ib o so m a l p rote in  L28
6 0 S  r ib o so m a l p rote in  L3
6 0 S  rib o so m al p rote in  L30
60 S  rib o so m al p rote in  L31
60 S  rib o so m al p rote in  L32
60 S  rib o so m al p rote in  L35
60 S  rib o so m al p rote in  L36
60 S  rib o so m al p rote in  L36a -like
60 S  rib osom al p rote in  L38
60 S  rib osom al p rote in  L4
6 0 S  rib o so m al p rote in  L5
60S rib o so m al p rote in  L6
6 0 S  rib o so m al p ro te in  L7
6 0 S  rib o so m al p ro te in  L7a
6 0 S  r ib o so m a l p ro te in  L8
6 0 S  rib o so m al p ro te in  L9
6 -p h o sp h o fru c to k in a se  typ e  C
6 -p h o sp h o g lu co n a te  d e h yd ro g e n a se , d e ca rb o xy latin g
6 -p h o sp h o g lu co n o la cto n a se
A c e ty l-C o A  a ce ty ltra n sfe ra se , m ito ch o n d ria l
A c id ic  le u c in e -rich  n u c le a r p h o sp h o p ro te in  32 fa m ily  m e m b e r A
A c id ic  le u c in e -r ich  n u c le a r p h o sp h o p ro te in  32 fa m ily  m e m b e r E
A co n ita te  h yd ra tase , m ito ch o n d ria l
A ctin , a lp h a  ca rd ia c  m u scle  1
A ctin -re la te d  p rote in  2
A ctin -re la te d  p rote in  2/3  c o m p le x  su b u n it 2
A ctin -re la te d  p rote in  2/3 c o m p le x  su b u n it 3
A ctin -re la te d  p rote in  2/3 c o m p le x  su b u n it 4
A ctin -re la te d  p rote in  2/3 c o m p le x  su b u n it  5 -like  p rote in
A ctin -re la te d  p rote in  3
A ctiv a te d  R N A  p o ly m e rase  II tra n scrip tio n a l co a ctiv a to r  p l5
A ct iv a to r  o f 90  kDa h eat sh o ck  p rote in  A T P a se  h o m o lo g  1
A cy la m in o -a c id -re le a s in g  e n zym e
A cy l-p ro te in  th io e ste ra se  2
A d e n in e  p h o sp h o rib o sy ltra n sfe ra se
A d e n o sy lh o m o c y ste in a se
A d e n y la te  k in ase  iso e n zym e  1
A d e n y la te  k in ase  iso e n zym e  4, m ito ch o n d ria l
A d e n y lo su c c in a te  syn th e ta se  iso zym e  2
A D P /A T P  tra n s lo ca se  2
A D P -rib o sy la t io n  fa c to r  4
A D P -rib o sy la t io n  fa c to r  5
A D P - r ib o s y la t i o n  f a c t o r  6
A D P -rib o sy la t io n  f a c t o r - l ik e  p r o t e in  2
A D P -rib o sy la t io n  fa cto r-lik e  p rote in  3
A D P -su g a r  p yro p h o sp h a ta se
A -k in a se  a n ch o r p ro te in  12 iso fo rm  2
A la n y l-tR N A  s y n th e ta se , cyto p la sm ic
A lc o h o l d e h y d ro g e n a se  [N A D P+]
A lco h o l d e h y d ro g e n a se  c la ss-3  
A ld e h y d e  d e h y d ro g e n a se  X, m ito ch o n d ria l 
A ld e h y d e  d e h y d ro g e n a se , m ito ch o n d ria l
IP I0 0 0 1 0 1 5 3 4 2 4 4 4 4
1P I0 0 0 2 1266 8 8 9 8 5 5
IP I003 06332 3 3 2 5 3 3
IPIQ 0027270 9 8 7 9 10 4
IP I002 19155 8 6 2 6 5 5
IP I0 0 4 5 6 7 5 8 5 3 3 6 3 3
IP I001 82533 6 6 7 4 3 3
IP I0 0 5 5 0 0 2 1 9 8 9 8 7 7
1P I0 0 2 19156 4 4 3 5 4 5
IP I0 0 0 2 6 3 0 2 3 4 2 7 2 2
IP I0 0 3 9 5 9 9 8 5 3 5 6 3 3
IP I0 0 4 1 2 6 0 7 3 3 3 6 2 2
1P I0 0 2 16237 3 2 4 3 3 4
IP I0 0 0 5 6 4 9 4 2 1 2 1 2 2
IP I0 0 2 1 5 7 9 0 0 2 1 4 4 4
IP I0 0 0 0 3 9 1 8 17 9 13 26 12 13
IP I0 0 0 0 0 4 9 4 8 4 10 10 12 6
IP I0 0 3 2 9 3 8 9 6 11 9 14 7 8
IP I0 0 0 3 0 1 7 9 13 10 13 15 12 8
IP I0 0 2 9 9 5 7 3 12 12 12 9 9 9
IP I0 0 0 1 2 7 7 2 5 5 5 8 8 8
IP I0 0 0 3 1 6 9 1 6 6 1 8 4 5
IP I0 0 0 0 9 7 9 0 6 4 6 11 15 10
IP I0 0 2 1 9 5 2 5 23 13 22 18 13 15
IP I0 0 0 2 9 9 9 7 12 7 10 7 8 7
IP I0 0 0 3 0 3 6 3 4 3 2 2 0 2
IP I0 0 0 2 5 8 4 9 8 3 6 11 8 7
IP I0 0 1 6 5 3 9 3 6 5 6 7 3 3
IP I0 0 0 1 7 8 5 5 6 4 4 8 9 5
IP I0 0 0 2 3 0 0 6 9 9 7 7 10 13
IP I0 0 0 0 5 1 5 9 7 6 6 5 8 8
1P I0 0 0 0 5 161 6 5 10 10 9 8
1P I0 0 0 0 5 162 6 6 5 5 6 6
IP I0 0 5 5 4 8 1 1 4 3 5 3 4 3
IP I0 0 4 1 4 5 5 4 1 2 2 1 0 2
IP I0 0 0 2 8 0 9 1 11 5 10 14 10 14
1P I0 0 2 2 1222 3 2 3 6 2 2
IP I0 0 0 3 0 7 0 6 6 5 5 4 5 4
IP I0 0 3 3 7 7 4 1 3 4 4 6 5 6
IP I0 0 0 2 7 0 3 2 4 0 1 4 1 1
IPIÛ 0218693 14 5 9 14 6 6
IP I0 0 0 1 2 0 0 7 13 11 15 13 16 9
IP I0 0 0 1 8 3 4 2 2 4 1 6 2 3
IP I0 0 0 1 6 5 6 8 6 4 3 5 5 6
IP I0 0 0 2 6 8 3 3 12 7 9 10 8 10
IP I0 0 0 0 7 1 8 8 4 1 3 3 5 4
1P I0 0 2 15918 2 2 4 2 4 5
IP I0 0 2 1 5 9 1 9 5 1 3 3 4 3
IP IÛ 0215920 4 2
3 1
2 4 4
I P I0 0 0 0 3 3 2 6  , 5 , 4 5 4 5 5
I P I0 0 0 0 3 3 2 7 5 3 4 8 5 4
IP I0 0 2 9 6 9 1 3 2 6 6 6 4 4
1P I0 0 2 17683 6 4 14 4 6 7
IP I0 0 0 2 7 4 4 2 25 17 24 27 24 19
IP I0 0 2 2 0 2 7 1 9 6 12 9 11 10
IP I0 0 7 4 6 7 7 7 4 3 7 4 9 7
IP I0 0 1 0 3 4 6 7 8 3 5 4 8 4
1P I0 0 0 0 6 6 6 3 5 4 5 4 12 3
1 2 8
A ld o se  re d u ctase
A lk a lin e  p h o sp h a ta se , tissu e -n o n sp e c ific  isozym e
A lp h a -a ct in in -1
A lp h a -a ct in in -4
A lp h a -a m in o a d ip ic  se m ia ld e h yd e  syn th ase , m ito ch o n d ria l
A lp h a -c e n tra c t in
A lp h a -m a n n o s id a se  2
A lp h a -so lu b le  N SF a tta ch m e n t p rote in
A m id o p h o sp h o rib o sy ltra n sfe ra se
a n n e x in  A 4
A n n e x in  A5
A n n e x in  A 6
A p o lip o p ro te in  E
A rg in in o su c c in a te  syn th a se
A sp a ra g in y l-tR N A  syn th e ta se , cyto p la sm ic
A sp a rta te  a m in o tra n sfe ra se , cyto p lasm ic
A sp a rta te  a m in o tra n sfe ra se , m ito ch o n d ria l
A sp a rty l-tR N A  sy n th e ta se , cyto p la sm ic
A stro c y tic  p h o sp h o p ro te in  P EA -15
A ta x in -1 0
A T P  syn th ase  su b u n it a lp h a , m ito ch o n d ria l 
A T P  syn th a se  su b u n it  b, m ito ch o n d ria l 
A T P  syn th a se  su b u n it  beta, m ito ch o n d ria l 
A T P  syn th a se  su b u n it  O, m ito ch o n d ria l 
A T P a se  A SN A 1
A T P -b in d in g  ca sse tte  su b -fa m ily  E m e m b e r 1 
A T P -c itra te  syn th ase  
A T P -d e p e n d e n t R N A  h e licase  A 
A T P -d e p e n d e n t  R N A  h e licase  D D X1 
A T P -d e p e n d e n t R N A  h e licase  D D X 18  
A T P -d e p e n d e n t R N A  h e licase  D D X 3X  
BA G  fa m ily  m o le cu la r ch a p e ro n e  re g u la to r 2 
B an d  4 .1 -like  p rote in  2 
B asa l cell a d h esio n  m olecu le
B a sic  leu c in e  z ip p e r and W 2 d o m a in -co n ta in in g  p rote in  2 
B -ce ll re ce p to r-a sso cia te d  p rote in  31 
B e ta -h e x o sa m in id a se  su b u n it beta
B re fe ld in  A - in h ib ite d  g u a n in e  n u c le o tid e -e xch a n ge  p rote in  1 
C - l- te t ra h y d ro fo la te  syn th ase , cyto p lasm ic  
C A D  p rote in  
C a d h e rin -1
C a lc iu m -b in d in g  p ro te in  p22
C a lc iu m -re g u la te d  h e at sta b le  p rote in  1
C a lp a in  sm all su b u n it  1
C a lp a in -1  c a ta ly tic  su b u n it
C a lp o n in -2
C a lp o n in -3
IP I004 13641 4 2 7 4 5 7
IP I004 19916 3 1 3 5 3 4
IP I0 0 0 1 3 5 0 8 39 22 38 45 47 43
IP I0 0 0 1 3 8 0 8 22 15 20 30 26 21
IP I0 0 0 3 3 2 1 7 25 16 20 16 10 13
IP I0 0 0 2 9 4 6 8 3 2 3 5 6 7
IP I000 03802 2 1 2 1 1 2
IP I0 0 0 0 9 2 5 3 4 4 5 7 5 7
IP I0 0 0 2 9 5 3 4 3 3 3 8 6 5
IP I0 0 0 0 6 2 5 2 4 2 3 3 4 2
IP I0 0 0 1 1 9 1 6 4 0 2 2 3 4
1P I0 0 6 4 2 2 11 1 1 4 2 8 2
1P I0 0 2 18918 4 3 5 16 11 10
IP I0 0 0 2 4 0 9 5 11 5 12 10 10 13
1P I0 0 7 9 3 199 3 2 3 7 3 3
IP I0 0 3 2 9 8 0 1 24 17 19 28 17 13
1P I0 0 2 2 1226 17 6 5 15 17 12
1P I0 0 0 2 1842 9 2 17 3 6 7
IP I0 0 0 2 0 6 3 2 8 3 2 0 3 1
IP I0 0 3 0 6 9 6 0 4 3 4 3 7 8
IP I0 0 2 1 9 0 2 9 13 10 13 9 7 7
IP I0 0 0 1 8 2 0 6 13 12 13 10 10 9
1P I0 0 2 16951 7 6 5 8 11 12
IP I0 0 0 1 4 8 5 0 1 1 2 3 2 3
IP I0 0 0 0 1 6 3 6 7 5 4 4 10 4
IP I0 0 4 4 0 4 9 3 20 17 19 24 16 15
1P I0 0 0 2 9 133 13 7 3 8 5 6
IP I0 0 3 0 3 4 7 6 30 25 27 31 30 26
IP I0 0 0 0 7 6 1 1 5 5 7 9 4 5
IP I0 0 0 1 3 4 6 6 4 5 4 5 5 5
IP I0 0 3 0 3 2 0 7 3 0 6 2 7 5
1P I0 0 0 2 1290 28 22 63 20 14 21
IP I0 0 8 4 4 5 7 8 21 20 32 26 30 24
IP I0 0 2 9 3 6 5 5 11 7 3 12 9 6
IP I0 0 3 0 1 3 2 3 3 1 2 5 6 4
IP I0 0 2 1 5 6 3 7 10 4 7 9 5 12
IP I0 0 0 0 0 6 4 3 2 1 1 3 1 1
IP I0 0 0 1 5 9 7 3 2 1 4 4 13 3
IP I0 0 0 0 2 4 0 6 1 1 3 4 9 2
IP I0 0 0 2 2 3 0 5 1 2 1 3 1 2
IP I0 0 2 1 8 2 0 0 1 1 4 5 3 2
IP I0 0 0 1 2 5 8 5 1 1 3 4 2 3
1P I0 0 0 1 1619 2 1 1 3 6 4
IP I0 0 0 1 3 4 5 2 20 3 15 23 21 20
IP I0 0 5 5 1 0 2 4 2 1 1 4 6 0
IP I0 0 2 8 9 4 9 9 24 13 17 23 19 24
1P I0 0 2 19575 2 1 2 2 2 1
IP I0 0 3 8 2 4 1 2 9 7 5 1 1 2
1P I0 0 0 0 2 188 3 3 2 4 6 2
IP I0 0 2 1 8 3 4 2 21 16 20 21 21 25
IP I0 0 3 0 1 2 6 3 18 14 19 14 16 17
IP I0 0 0 2 5 8 6 1 3 3 7 6 6 7
1P I0 0 2 18924 2 1 1 1 2 2
IP I0 0 3 0 4 4 0 9 6 2 3 5 5 2
IP I0 0 0 2 5 0 8 4 3 1 3 4 2 5
IP I0 0 0 1 1 2 8 5 5 2 3 9 10 7
IP I0 0 0 1 5 2 6 2 5 3 9 5 4 4
IP I0 0 2 1 6 6 8 2 5 2 6 8 9 6
A m in o a c y l tR N A  syn th ase  co m p le x -in te ra ctin g  m u ltifu n ctio n a l prtn  1 
A m in o a c y l tR N A  syn th ase  co m p le x -in te ra ctin g  m u ltifu n ctio n a l prtn  2 
A m in o p e p tid a se  B 
A n n e x in  A1 
A n n e x in  A3
B ifu n ctio n a l 3 ’-p h o sp h o a d e n o sin e  5 '-p h o sp h o su lfa te  syn th a se  1 
B ifu n ctio n a l a m in o a cy l-tR N A  syn th eta se
B ifu n ctio n a l A T P -d e p e n d e n t d ih yd ro x ya ce to n e  k in a se /F A D -A M P  lyase 
B ifu n ctio n a l p u rin e  b io syn th e sis  p rote in  PURH 
B le o m y c in  h yd ro la se
B ra n ch e d -c h a in -a m in o -a c id  a m in o tra n sfe ra se
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C a lre ticu lin IP I0 0 0 2 0 5 9 9 19 9 15 11 17 13
C a rb o n ic  a n h y d ra se  2 1P I0 0 2 18414 2 1 1 3 3 2
C a rb o n y l re d u cta se  [N A D P H ] 1 IP I0 0 2 9 5 3 8 6 7 5 8 10 9 7
C a rb o x y p e p tid a se  D IP I0 0 0 2 7 0 7 8 4 0 1 1 2 0
C ase in  k in ase  II su b u n it  a lpha' IP I0 0 0 2 0 6 0 2 4 1 4 2 4 2
C a se in  k in ase  II su b u n it  beta IP I0 0 0 1 0 8 6 5 2 1 0 3 5 4
C a sp a se -3 IP I0 0 2 9 2 1 4 0 3 2 5 5 2 4
C a th e p s in  D 1P I0 0 0 1 1229 8 5 10 8 6 5
C a tio n -in d e p e n d e n t  m an n o se -6 -p h o sp h a te  rece p to r IP I0 0 2 8 9 8 1 9 3 1 6 1 5 3
C D 2 -a sso c ia te d  p rote in IP I0 0 4 1 2 7 7 1 2 1 1 5 2 2
C D G SH  iro n -su lfu r  d o m a in -co n ta in in g  protein  2 IP I0 0 1 6 6 8 6 5 2 1 1 2 2 1
cD N A  F U 2 5 6 7 8  fis, h igh ly  s im ilar to purine n u cleo sid e  p h o sp h o ry la se IP I0 0 0 1 7 6 7 2 11 12 17 15 8 11
cD N A  F U 3 1 7 7 6  fis, h igh ly  s im ila r  to  calu m en in IP I0 0 7 8 9 1 5 5 4 0 3 3 1 0
cD N A  F U 3 5 8 0 9  fis, h igh ly  s im ilar to e u ka ryo tic  tra n sla tio n  in itiation  
fa c to r  3 su b u n it  3
IP I0 0 6 4 7 6 5 0 3 4 3 5 4 6
c D N A  F U 3 6 1 9 2  fis, h igh ly  s im ilar to E u ka ryo tic  tra n sla tio n  in itiation  
fa c to r  3 su b u n it  5
IP I0 0 6 5 4 7 7 7 6 7 8 8 3 5
c D N A  F U 4 4 4 3 6  fis, h igh ly  s im ilar to  T -co m p le x  p rote in  1 su b u n it y IP I0 0 2 9 0 7 7 0 18 14 9 18 19 18
c D N A  F U 5 0 9 9 2 , h igh ly  s im ila r to  C o ro n in - lC IP I0 0 7 9 8 4 0 1 3 0 1 1 5 4
c D N A  F U 5 1 9 0 9 , h igh ly  s im ila r  to S erin e-th reo n in e  k in ase  rece p to r- 
a sso c ia te d  p rote in
IP I0 0 2 9 4 5 3 6 8 7 8 7 9 10
c D N A  F U 5 3 1 9 3 , h igh ly  s im ila r  to  H om o sap iens ca ld e sm o n  1 (C A LD 1), 
tra n scr ip t  v a ria n t 5, m R N A
IP I0 0 2 1 8 6 9 6 7 2 10 8 8 9
cD N A  F U 5 3 2 2 9 , h igh ly  s im ila r to  Im po rtin  a lp h a-7  su b u n it IP I0 0 7 4 7 7 6 4 5 0 2 5 3 2
cD N A  F U 5 3 9 7 5 , h igh ly  s im ila r  to  A ce ty l-C o A  a ce ty ltra n sfe rase 1P I0 0 2 9 1419 13 8 18 6 6 7
cD N A  F U 5 4 3 6 5 , h igh ly  s im ila r  to  D N A  rep lication  lice n sin g  facto r 
M C M 4
IP I0 0 7 9 5 3 1 8 20 8 9 21 22 17
cD N A  F U 5 4 4 9 2 , h igh ly  s im ila r  to  E u ka ry o tic  tra n sla tio n  in itiation  
fa c to r  4B
IP I0 0 0 1 2 0 7 9 3 2 2 3 2 2
cD N A  F U 5 4 5 3 6 , h igh ly  s im ila r  to  m ito ch o n d ria l 28S rib osom al protein  
S27
IP I0 0 0 2 2 0 0 2 2 2 1 2 0 1
c D N A  F U 5 4 7 1 0 , h igh ly  s im ila r  to  T a rg e t  o f  M yb p rote in  1 IP I0 0 0 2 3 1 9 1 1 0 2 1 1 2
c D N A  F U 5 5 3 8 2 , h igh ly  s im ila r  to  H sp 7 0 -b in d in g  p rote in  1 IP I0 0 1 0 0 7 4 8 4 3 6 0 5 2
c D N A  F U 5 5 4 8 2 , h igh ly  s im ila r  to  A n n e x in  A l l IP I0 0 4 1 4 3 2 0 1 1 4 4 3 2
cD N A  F U 5 5 5 4 3 , h igh ly  s im ila r  to  P h o sp h o a ce ty lg lu co sa m in e  m utase IP I0 0 0 3 0 1 1 6 2 0 1 2 2 4
cD N A  F U 5 5 5 7 4 , h igh ly  s im ila r  to  C a ln ex in IP I0 0 0 2 0 9 8 4 10 6 7 13 19 9
c D N A  F U 5 5 5 8 6 , h igh ly  s im ila r  to  M M S1 9 -like  p rote in IP I0 0 1 5 4 4 5 1 9 3 4 10 7 4
cD N A  F U 5 5 5 9 9 , h igh ly  s im ila r  to  D N A  rep licatio n  lice n sin g  fa cto r 
M C M 3
IP I0 0 0 1 3 2 1 4 15 14 14 17 14 14
cD N A  F U 5 6 2 8 5 , h igh ly  s im ila r  to  A D P -rib o sy la t io n  fa cto r-lik e  protein  
8B
cD N A  F U 5 6 3 5 7 , h igh ly  s im ila r  to  H o m o  sap ie n s a p o lip o p ro te in  A-l 
b in d in g  p rote in  (A P O A 1 B P ), m R N A
IP I0 0 0 1 8 8 7 1 3 0 1 2 2 1
IP I0 0 1 6 8 4 7 9 3 3 1 4 1 2
cD N A  F U 5 6 3 7 0 , h igh ly  s im ila r  to  H o m o  sap ie n s FK506 b in d in g  p rote in  
8, 3 8 kD a  (FK B P 8 ), m R N A
IP I0 0 3 2 8 1 6 1 2 0 2 2 2 0
cD N A  F U 5 6 4 1 4 , h igh ly  s im ila r  to  H o m o  sap ie n s p ro lin e-, g lu tam ic  
a c id -, le u c in e -r ich  p rote in  1 (PELP1), m R N A
IP I0 0 0 0 6 7 0 2 2 0 1 1 3 1
cD N A  F U 5 6 4 2 0 , h igh ly  s im ila r  to A sp arty l a m in o p e p tid a se IP I0 0 0 1 5 8 5 6 1 0 2 0 5 0
cD N A  F U 5 9 1 4 2 , h igh ly  s im ila r  to Ep id id ym al se cre to ry  p rote in  E l IP I0 0 3 0 1 5 7 9 1 0 2 1 4 0
cD N A  F U 5 9 2 1 1 , h igh ly  s im ila r  to  G lu co sid a se  2 su b u n it beta IP I0 0 0 2 6 1 5 4 6 5 8 8 9 9
cD N A  F U 5 9 3 6 7 , h igh ly  s im ila r  to  A d e n y lo su cc in a te  lyase IP I0 0 0 2 6 9 0 4 9 4 7 11 8 9
cD N A  F U 5 9 7 5 8 , h igh ly  s im ila r  to  S -m e th y l-5 -th io a d e n o sin e  
p h o sp h o ry la se
IP I0 0 0 1 1 8 7 6 10 8 8 9 7 8
cD N A  F U 6 0 0 7 6 , h ig h ly  s im ila r  to  ELA V -like  p rote in  1 IP I0 0 3 0 1 9 3 6 11 5 7 9 7 6
c D N A  F U 6 0 0 9 7 , h ig h ly  s im ila r to  Tu b u lin  a lp h a -u b iq u ito u s  chain IP I0 0 7 9 2 6 7 7 32 27 26 32 36 27
cD N A  F U 6 0 1 2 4 , h igh ly  s im ila r to  M ito ch o n d ria l d ica rb o x y la te  carrie r IP I0 0 0 0 5 5 3 7 3 1 3 2 1 0
c D N A  F U 6 0 4 2 4 , h igh ly  s im ila r  to  Ju n ctio n  p lako glob in IP I0 0 7 8 9 3 2 4 9 5 11 2 5 3
c D N A  F U 6 0 6 0 7 , h igh ly  s im ila r  to  A cy l-p ro te in  th io e ste ra se  1 IP I0 0 0 0 7 3 2 1 3 3 1 6 3 2
1 3 0
c D N A  F U 6 1 1 6 2 , h igh ly  s im ila r  to  R a s-re la te d  p rote in  R -R as2 IP I000 12512 4 3 2 8 4 3
cD N A  F U 7 5 0 8 5 , h igh ly  s im ila r  to  H o m o  sap ie n s g lu ta m in y l-tR N A  
sy n th e ta se  (O A R S), m R N A
IP100026665 9 5 6 6 12 8
c D N A  F U 7 7 1 7 7 , h igh ly  s im ila r  to  H o m o  sap ie n s a rg in in e -r ich , 
m u ta te d  in e a rly  stage  tu m o rs  (A R M E T ), m R N A
IP I0 0 3 2 8 7 4 8 3 1 3 4 3 0
cD N A  F U 7 7 4 2 2 , h igh ly  s im ila r  to  H o m o  sap ie n s R N A  b in d in g  protein , 
a u to a n tig e n ic , tra n scrip t  va ria n t 1, m R N A  (Fragm en t)
IP I0 0 0 1 1 2 6 8 2 2 3 2 1 1
cD N A , F U 9 6 5 0 8 , H o m o  sap ie n s S H 3 -d o m a in  G R B 2 -like  1 (SH 3G L1) IP I000 19169 2 2 5 4 1 3
Cell d iffe re n tia t io n  p rote in  RCD 1 h o m o lo g IP I000 23101 5 0 1 3 5 4
Cell d iv is io n  cyc le  p rote in  123 h o m o lo g IP I0 0 0 0 5 6 7 0 2 1 1 0 1 2
C e llu la r  re tin o ic  a c id -b in d in g  p rote in  1 1P I0 0 2 19930 11 10 6 12 9 8
C e llu la r  re tin o ic  a c id -b in d in g  p rote in  2 1P I0 0 2 16088 2 2 6 9 8 5
C e n tro m e re  p rote in  H IP I0 0 0 0 9 6 6 8 1 0 2 2 1 1
C e n tro m e re /k in e to c h o re  p rote in  z w lO  h om o lo g IP I000 11631 2 0 2 4 2 1
C h a rg e d  m u ltiv e sicu la r  bod y p rote in  4b 1P100025974 3 1 3 4 3 2
C h a rg e d  m u ltiv e sicu la r  b o d y p rote in  5 IP I0 0 1 0 0 7 9 6 2 1 2 2 3 1
C h lo rid e  in tra ce llu la r  ch a n n e l p rote in  1 IP I0 0 0 1 0 8 9 6 10 6 11 10 14 12
C h lo rid e  in tra ce llu la r  ch a n n e l p rote in  4 IP I0 0 0 0 1 9 6 0 11 7 12 12 11 12
C h ro m o b o x  p rote in  h o m o lo g  1 IP I0 0 0 1 0 3 2 0 5 2 1 3 2 2
C h ro m o b o x  p rote in  h o m o lo g  3 IP I0 0 2 9 7 5 7 9 6 5 5 5 6 6
C h ro m o b o x  p rote in  h o m o lo g  5 IP I0 0 0 2 4 6 6 2 1 0 2 3 5 3
C itra te  sy n th a se , m ito ch o n d ria l IP I0 0 0 2 5 3 6 6 4 4 5 5 3 4
C la u d in -6 IP I0 0 0 1 1 0 8 4 3 3 3 3 2 2
C le a v a g e  an d  p o ly a d e n y la tio n  sp e c ific ity  fa cto r su b u n it 1 IP I0 0 0 2 6 2 1 9 2 1 1 4 4 3
C le a v a g e  an d  p o ly a d e n y la tio n  sp e c ific ity  fa cto r su b u n it 2 1PI00419531 2 0 1 2 3 2
C le a v a g e  an d  p o ly a d e n y la tio n  sp e c ific ity  fa cto r su b u n it 5 IP I0 0 6 4 6 9 1 7 8 6 6 12 6 7
C le a v a g e  stim u la t io n  fa c to r  su b u n it 3 IP I0 0 0 1 5 1 9 5 3 1 4 4 5 7
C o a cto s in -like  p rote in IP I0 0 0 1 7 7 0 4 5 1 1 4 1 2
C o a to m e r su b u n it beta IP I0 0 2 9 5 8 5 1 13 2 5 15 15 11
C o a to m e r su b u n it  b e ta ’ 1P I0 0 2 2 0 2 19 4 3 6 7 10 8
C o a to m e r su b u n it de lta  va ria n t 2 IP I0 0 2 9 8 5 2 0 6 6 4 8 7 6
C o a to m e r su b u n it ep silo n 1P I0 0 4 6 5 132 9 3 3 6 4 8
C o a to m e r su b u n it  ga m m a IP I0 0 7 8 3 9 8 2 11 4 4 16 18 12
C o a to m e r su b u n it  g a m m a - 2 IP I0 0 0 0 2 5 5 7 5 1 4 9 9 6
C o a to m e r su b u n it  ze ta-1 IP I0 0 0 3 2 8 5 1 6 4 6 6 6 4
C o filin -1 IP I0 0 0 1 2 0 1 1 13 16 16 16 9 14
C o ile d -co il d o m a in -co n ta in in g  p rote in  58 IP I0 0 0 4 6 8 2 8 2 0 1 3 2 2
C o ld -in d u c ib le  R N A -b in d in g  p rote in IP I0 0 1 8 0 9 5 4 2 1 5 5 2 3
C o lla p sin  resp o n se  m e d ia to r p rote in  4  lon g va ria n t IP I0 0 0 2 9 1 1 1 13 12 20 16 19 17
C o m p le m e n t c o m p o n e n t 1 Q  su b co m p o n e n t-b in d in g  p rote in IP I0 0 0 1 4 2 3 0 15 8 8 10 8 7
C o n d e n s in  c o m p le x  su b u n it 1 IP I0 0 2 9 9 5 2 4 1 2 1 5 6 4
C o n d e n sin  c o m p le x  su b u n it 3 IP I0 0 1 0 6 4 9 5 2 1 0 2 0 2
C O P 9  s ig n a lo so m e  co m p le x su b u n it 3 IP I0 0 0 2 5 7 2 1 2 0 2 2 5 3
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 4 1P I0 0 1 7 1844 6 5 8 8 7 3
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 5 IP I0 0 0 0 9 9 5 8 3 0 2 2 2 5
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 6 IP I0 0 1 6 3 2 3 0 1 1 4 1 2 1
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 7a IP I0 0 3 0 1 4 1 9 2 2 3 6 1 1
C O P 9  s ig n a lo so m e  co m p le x  su b u n it 8 IP I0 0 0 0 9 4 8 0 5 2 3 5 2 0
C o p in e -1 IP I0 0 0 1 8 4 5 2 2 1 0 2 6 5
C o p p e r ch a p e ro n e  fo r  su p e ro x id e  d ism u tase IP I0 0 0 2 1 3 8 9 2 0 1 3 2 1
C o p ro p o rp h y rin o g e n -lll o x id a se , m ito ch o n d ria l IP I0 0 0 9 3 0 5 7 2 2 2 1 3 1
C re a tin e  k in ase  B -typ e IP I0 0 0 2 2 9 7 7 13 11 8 23 17 13
C rk-like  p rote in IP I0 0 0 0 4 8 3 9 3 3 3 5 2 2
C S N K 2 A 1  p rote in IP I0 0 0 1 6 6 1 3 9 6 5 7 7 5
C TP syn th a se  1 IP I0 0 2 9 0 1 4 2 6 2 4 3 3 8
C TP syn th a se  2 IP100645702 2 1 3 2 0 1
C u llin -1 IP I0 0 0 1 4 3 1 0 3 0 3 3 4 4
C y sta tin -B IP100021828 | 4 1 3 2 4 2
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C y ste in e  and g ly c in e -r ich  p ro te in  2 IP I0 0 0 0 2 8 2 4 2 1 5 2 3 3
cy ste in y l-tR N A  syn th e ta se , cy to p la sm ic  iso fo rm  c IP I000 27443 7 6 7 7 7 9
c y to ch ro m e  b5 typ e  B p re cu rso r IP I0 0 3 0 3 9 5 4 4 3 5 4 3 2
C y to ch ro m e  b - c l  c o m p le x  su b u n it 1, m ito ch o n d ria l IP I0 0 0 1 3 8 4 7 3 0 1 0 2 2
C y to ch ro m e  c 1P I0 0 4 6 5 3 15 7 2 4 7 5 3
C y to ch ro m e  c o x id a se  su b u n it 5A, m ito ch o n d ria l IP I0 0 0 2 5 0 8 6 2 0 1 1 1 5
C y to p la sm ic  d yn e in  1 h e av y ch ain  1 IP I004 56969 52 40 37 51 74 5
C y to p la sm ic  dyn ein  1 ligh t in te rm e d ia te  ch ain  1 IP I000 07675 2 0 1 3 2 0
C y to so lic  Fe-S c lu ste r a sse m b ly  fa c to r  N U BP2 IP I0 0 6 4 4 6 7 4 4 2 1 5 2 0
D -3 -p h o sp h o g ly ce ra te  d e h yd ro g e n a se 1P I0 0 0 1 1200 16 13 23 14 13 14
D C N l- lik e  p rote in  5 IP I0 0 1 6 5 3 6 1 4 1 0 2 3 1
d C TP  p yro p h o sp h a ta se  1 1P I0 0 0 1 2 197 1 2 3 2 1 1
D -d o p a ch ro m e  d e ca rb o xy la se IP I0 0 2 9 3 8 6 7 3 3 4 7 3 4
D e lta (3 ,5 )-D e lta (2 ,4 )-d ie n o y l-C o A  iso m e ra se , m ito ch o n d ria l IP I0 0 0 1 1 4 1 6 4 5 9 7 4 1
D e lta -l-p y rro lin e -5 -c a rb o x y la te  d e h yd ro g e n a se , m ito ch o n d ria l IP I0 0 2 1 7 8 7 1 3 1 1 4 3 2
D e n sity -re g u la te d  p rote in IP I0 0 3 0 6 2 8 0 1 1 2 2 3 1
D e sm o g le in -2 IP I0 0 0 2 8 9 3 1 2 0 5 2 6 3
D estrin IP I0 0 4 7 3 0 1 4 3 1 1 3 5 4
D e ve lo p m e n ta l p lu rip o te n cy -a sso c ia te d  protein  4 IP I0 0 0 1 8 8 7 8 1 1 2 0 2 2
D e v e lo p m e n ta lly -re g u la te d  G T P -b in d in g  protein  1 IP I0 0 0 3 1 8 3 6 6 6 2 6 4 6
D e v e lo p m e n ta lly -re g u la te d  G T P -b in d in g  protein  2 IP I0 0 0 2 2 6 9 7 1 1 3 3 4 1
D ia b lo  h o m o lo g , m ito ch o n d ria l p recu rso r IP I0 0 0 0 8 4 1 8 4 2 4 4 4 2
D ih y d ro fo la te  re d u ctase IP I0 0 0 3 0 3 5 7 1 2 0 1 3 4
D ih y d ro lip o y l d e h yd ro g e n a se , m ito ch o n d ria l IP I0 0 0 1 5 9 1 1 3 1 2 2 4 5
D ih y d ro lip o y lly s in e -re s id u e  a ce ty ltra n sfe ra se  co m p o n e n t o f pyru vate IP I0 0 0 2 1 3 3 8 4 1 4 3 5 3
d e h y d ro g e n a se  co m p le x , m ito ch o n d ria l 
D ih y d ro lip o y lly s in e -re s id u e  su cc in y ltra n sfe ra se  co m p o n e n t o f 2- IP I0 0 4 2 0 1 0 8 2 3 3 2 3 2
o x o g lu ta ra te  d e h y d ro g e n a se  co m p le x , m ito ch o n d ria l 
D ih y d ro p te rid in e  red u ctase IP I0 0 0 1 4 4 3 9 2 1 3 2 5 3
D ih y d ro p y rim id in a se -re la te d  p rote in  1 IP I0 0 4 1 4 1 2 3 4 2 3 1 3 3
D ih y d ro p y rim id in a se -re la te d  p rote in  2 IP I0 0 2 5 7 5 0 8 14 12 15 10 16 17
D ip h o sp h o in o sito l p o ly p h o sp h a te  p h o sp h o h yd ro la se  1 IP I0 0 0 0 9 1 4 8 1 2 0 2 1 1
D N A  d a m a g e -b in d in g  p rote in  1 IP I0 0 2 9 3 4 6 4 3 3 12 6 4 12
D N A  ligase  1 1P I0 0 2 19841 6 1 1 4 2 2
D N A  m ism a tch  re p a ir p rote in  M sh2 IP I0 0 0 1 7 3 0 3 10 5 5 11 14 8
D N A  p o ly m e ra se  delta ca ta ly tic  su b u n it IP I0 0 0 0 2 8 9 4 6 0 2 4 9 8
D N A  re p lica tio n  co m p le x  G IN S  p rote in  PSF1 IP I0 0 0 3 2 3 8 7 3 0 1 3 2 2
D N A  re p lica tio n  lice n sin g  fa c to r  M CM 2 IP I0 0 1 8 4 3 3 0 15 12 15 16 20 22
D N A  re p lica tio n  lice n sin g  fa cto r M CM 5 IP I0 0 0 1 8 3 5 0 13 8 7 7 12 11
D N A  re p lica tio n  lice n sin g  fa cto r M CM 6 IP I0 0 0 3 1 5 1 7 14 10 13 14 14 14
D N A -(a p u rin ic  o r a p yrim id in ic  site ) lyase 1P I0 0 2 15911 6 3 6 7 13 12
D N A -d ire cte d  R N A  p o lym e rase  II su b u n it RPB1 IP I0 0 0 3 1 6 2 7 2 0 4 4 3 2
D N A -d ire cte d  R N A  p o lym e rase  II su b u n it RPB2 IP I0 0 0 2 7 8 0 8 2 1 1 2 6 6
D N A -d ire cte d  R N A  p o lym e rase  II su b u n it RPB3 IP I0 0 0 1 8 2 8 8 3 4 5 2 4 3
D N A -d ire cte d  R N A  p o ly m e rase s 1, II, and III su b u n it R P A B C 1 IP I0 0 2 9 1 0 9 3 2 2 1 1 2 3
D N A -d ire cte d  R N A  p o ly m e rase s 1, II, and III su b u n it R P A B C 3 IP I0 0 0 0 3 3 0 9 4 4 5 7 3 3
D n aJ h o m o lo g  su b fa m ily  A  m e m b e r 1 IP I0 0 0 1 2 5 3 5 6 5 7 6 4 4
D n aJ h o m o lo g  su b fa m ily  A  m e m b e r 2 IP I0 0 0 3 2 4 0 6 7 3 5 3 5 7
D n aJ h o m o lo g  su b fa m ily  B m em b e r 1 IP I0 0 0 1 5 9 4 7 2 1 0 1 3 0
D n aJ h o m o lo g  su b fa m ily  B m e m b e r 11 IP I0 0 0 0 8 4 5 4 3 0 2 2 3 0
D n aJ h o m o lo g  su b fa m ily  C m e m b e r 7 IP I0 0 3 2 9 6 2 9 2 1 1 2 5 4
D n aJ h o m o lo g  su b fa m ily  C m e m b e r 8 IP I0 0 0 0 3 4 3 8 3 2 5 4 5 3
D o lic h o l-p h o sp h a te  m a n n o sy ltra n sfe ra se IP I0 0 0 2 2 0 1 8 3 1 1 4 1 2
D o lic h y l-d ip h o s p h o o lig o s a c c h a r id e -p ro te in  g ly co sy ltra n sfe ra se  48 IP I0 0 2 9 7 0 8 4 5 3 1 1 5 5
kDa su b u n it
D o lic h y l-d ip h o s p h o o lig o s a c c h a r id e -p ro te in  g ly co sy ltra n sfe ra se IP I0 0 0 2 5 8 7 4 3 1 3 7 11 7
su b u n it 1 p re cu rso r 
D -ty ro sy l-tR N A (T y r) d e a cy la se  1 IP I0 0 1 5 2 6 9 2 1 1 2 1 2 1
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D u al s p e c ific ity  m ito g e n -a ctiv a te d  p rote in  k in ase  k in ase  1 IP I0 0 2 1 9 6 0 4 3 1 1 2 6 2
D u al s p e c ific ity  p ro te in  p h o sp h a ta se  3 IP I000 18671 1 1 3 3 3 1
d yn a ctin  su b u n it  2 IP I0 0 2 2 0 5 0 3 2 4 4 3 4 1
D y n e in  lig h t ch a in  T cte x -ty p e  1 IP I0 0 0 1 9 4 9 5 2 1 2 3 2 3
E3 S U M O -p ro te in  ligase  R an B P2 IP I002 21325 6 1 2 2 6 2
E a rly  e n d o so m e  a n tige n  1 IP I0 0 3 2 9 5 3 6 2 0 1 1 6 0
E F -h a n d  d o m a in -co n ta in in g  p rote in  D2 IP I0 0 0 6 0 1 8 1 0 1 3 6 1 0
E le ctro n  tra n sfe r  f la vo p ro te in  su b u n it a lp h a, m ito ch o n d ria l IP I0 0 0 1 0 8 1 0 8 6 2 7 6 9
E lo n g a tio n  fa c to r  1-alpha 1 IP I0 0 3 9 6 4 8 5 21 17 24 24 21 14
E lo n g a tio n  fa c to r  1-beta IP I0 0 1 7 8 4 4 0 4 3 5 5 3 4
E lo n g a tio n  fa c to r  1-gam m a IP I0 0 9 3 7 6 1 5 21 8 10 10 18 17
E lo n g a tio n  fa c to r  2 IP I0 0 1 8 6 2 9 0 60 41 42 51 52 42
E lo n g a to r co m p le x  p rote in  1 IP I0 0 2 9 3 7 3 5 2 1 0 3 10 1
Em erin IP I0 0 0 3 2 0 0 3 3 0 3 3 4 2
E n d o p la sm ic  reticu lu m  re sid e n t p rote in  29 IP I0 0 0 2 4 9 1 1 8 9 10 16 6 7
E n d o p la sm ic  re ticu lu m  re s id e n t p ro te in  44 IP I0 0 4 0 1 2 6 4 3 0 3 6 2 3
E n d o p la sm in IP I0 0 0 2 7 2 3 0 43 25 41 34 39 28
E n o y l-C o A  h yd ra tase , m ito ch o n d ria l IP I0 0 0 2 4 9 9 3 12 6 9 13 10 7
Ep ip lak in IP I0 0 0 1 0 9 5 1 6 4 4 6 5 0
E p ith e lia l ce ll a d h e s io n  m o le cu le IP I0 0 29 6 2 1 5 2 2 3 5 4 2
E p o xid e  h yd ro la se  1 IP I0 0 0 0 9 8 9 6 5 3 3 2 5 1
E R O l- lik e  p ro te in  a lpha IP I0 0 3 8 6 7 5 5 2 0 4 3 5 3
E stra d io l 1 7 -b e ta -d e h y d ro g e n a se  12 IP I0 0 0 0 7 6 7 6 13 10 13 10 5 6
E u k a ry o tic  in itia tio n  fa c to r  4A -I IP I0 0 0 2 5 4 9 1 24 23 22 18 24 19
E u k a ry o tic  in itia tio n  fa c to r  4A -III IP I0 0 0 0 9 3 2 8 9 3 4 4 9 6
e u ka ry o tic  p e p tid e  ch ain  re le ase  fa cto r G T P -b in d in g  su b u n it ER F3A  
iso fo rm  2
IP I0 0 9 0 9 0 8 3 3 1 1 6 6 6
E u k a ry o tic  p e p tid e  ch ain  re le ase  fa c to r  su b u n it 1 IP I0 0 4 2 9 1 9 1 6 2 5 3 6 5
E u k a ry o tic  tra n s la t io n  e lo n g a tio n  fa c to r  1 e p silon -1 IP100003588 5 4 6 6 4 6
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  2 su b u n it 1 1P I0 0 2 19678 4 5 3 5 6 7
E u k a ry o tic  tra n s la t io n  in itia tio n  fa c to r  2 su b u n it 3 IP I0 0 2 9 7 9 8 2 ' 9 8 6 2 9 8
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it A IP I0 0 0 2 9 0 1 2 25 15 17 22 22 19
E u k a ry o tic  tra n s la t io n  in itia tio n  fa c to r  3 su b u n it C IP I0 0 0 1 6 9 1 0 9 6 7 7 7 12
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it D IP I0 0 0 0 6 1 8 1 3 1 1 3 4 5
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it E IP I0 0 0 1 3 0 6 8 12 3 8 13 10 7
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it G IP100290460 4 3 5 6 4 2
E u k a ry o tic  tra n s la tio n  in itia tio n  fa c to r  3 su b u n it 1 IP I0 0 0 1 2 7 9 5 7 3 4 3 6 6
E u k a ry o tic  tra n sla tio n  in itia tio n  fa c to r  3 su b u n it K IP I0 0 0 3 3 1 4 3 4 3 2 5 5 3
E u k a ry o tic  tra n sla tio n  in itia tio n  fa c to r  3 su b u n it M IP I0 0 1 0 2 0 6 9 5 9 7 11 6 8
E u k a ry o tic  tra n sla tio n  in itiation  fa c to r  3, su b u n it E in te ra ct in g  protein IP I0 0 4 6 5 2 3 3 5 3 7 4 10 11
E u k a ry o tic  tra n s la tio n  in itiation  fa c to r  5 IP I0 0 0 2 2 6 4 8 2 2 5 5 7 5
E u k a ry o tic  tra n s la tio n  in itiation  fa c to r  5B IP100299254 4 2 0 6 4 2
E u k a ry o tic  tra n s la tio n  in itiation  fa c to r  6 IP I0 0 0 1 0 1 0 5 6 4 6 7 7 7
E xo so m e  c o m p le x  e xo n u cle a se  M TR3 IP I0 0 0 7 3 6 0 2 3 2 2 2 2 1
E xo so m e  c o m p le x  e xo n u c le a se  RRP4 IP I0 0 0 1 5 9 0 5 3 3 1 2 6 3
E xo so m e  c o m p le x  e xo n u cle a se  R R P40 IP I0 0 0 1 5 9 5 6 3 1 1 1 2 0
E xo so m e  c o m p le x  e xo n u c le a se  R RP41 IP I0 0 7 4 5 6 1 3 3 3 2 6 3 1
E xo so m e  c o m p le x  e xo n u c le a se  R RP43 IP I0 0 5 5 2 9 2 0 2 0 1 0 1 2
E x p o r t in - l IP I0 0 2 9 8 9 6 1 22 17 21 27 23 21
E xp o rtin -4 IP I0 0 0 2 8 3 5 7 2 1 1 1 0 5
Exp o rtin -5 IP I0 0 6 4 0 7 0 3 13 7 5 13 13 12
E xp o rtin -7 IP I0 0 3 0 2 4 5 8 9 3 11 10 11 9
E xp o rtin -T IP I0 0 3 0 6 2 9 0 7 3 4 6 9 6
Ezrin IP I0 0 8 4 3 9 7 5 12 6 10 26 22 17
F A C T  c o m p le x  su b u n it  S P T 1 6 IP I0 0 0 2 6 9 7 0 2 2 9 11 9 10
F A C T  co m p le x  su b u n it  SSR P 1 IP I0 0 0 0 5 1 5 4 4 0 1 9 7 5
F -a ctin -ca p p in g  p rote in  su b u n it  a lp h a-1 IP I0 0 0 0 5 9 6 9 9 4 8 4 10 8
F -a c tin -c a p p in g  p rote in  su b u n it  a lp h a-2 IP I0 0 0 2 6 1 8 2 3 3 4 4 6 7
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F a rn e sy ltra n sfe ra se , C A A X  box, a lpha, iso fo rm  CR A _a 
Fascin
F atty  a cid  sy n th a se
F atty  a c id -b in d in g  p rote in , e p id e rm al 
F a tty  a c id -b in d in g  protein , heart 
F -b o x  o n ly  p ro te in  2 
Fe rrit in  h e a v y  chain  
F la p  e n d o n u c le a se  1 
F ru cto se -b isp h o sp h a te  a ld o lase  
F ru cto se -b isp h o sp h a te  a ld o lase  A 
G a m m a -e n o la se  
G D P -L-fu co se  syn th ase  
G D P -m a n n o se  4 ,6  d e h yd ra ta se
G lu ta th io n e  S -tra n sfe ra se  o m e g a -1
G lu ta th io n e  S -tra n sfe ra se  P
G ly c e ra ld e h y d e -3 -p h o sp h a te  d e h yd ro g e n a se
G lyc in e  d e h y d ro g e n a se  [d e ca rb o x y la tin g ], m ito ch o n d ria l
G ly co g e n  p h o sp h o ry la se , brain  fo rm
G ly co g e n  p h o sp h o ry la se , liver fo rm
G ly o x y la te  re d u cta se /h y d ro x y p y ru v a te  red u ctase
G ly p ica n -4
G M P  syn th a se  [g lu ta m in e -h yd ro lyz in g ]
G o lg i p h o sp h o p ro te in  3 
G o lg i p h o sp h o p ro te in  3-like  
G rp E  p rote in  h o m o lo g  1, m ito ch o n d ria l 
G T P :A M P  p h o sp h o tra n sfe ra se , m ito ch o n d ria l 
G T P a se  N Ras
G T P -b in d in g  n u c le a r p rote in  Ran 
G T P -b in d in g  p ro te in  Rheb 
G T P -b in d in g  p rote in  S A R la
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (I)/G (S)/G (T ) su b u n it beta-1
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (I)/G (S)/G (T ) su b u n it beta-2
G u a n in e  n u c le o tid e -b in d in g  p rote in  G (q ) su b u n it a lpha
G u a n in e  n u c le o tid e -b in d in g  p rote in  su b u n it b e ta -2 -like  1
H E A T  re p e a t-c o n ta in in g  p rote in  1
H e a t sh o ck  70 kDa p rote in  1A /1B
H e a t sh o ck  70 kD a p rote in  4
H e a t sh o ck  p ro te in  75  kDa, m ito ch o n d ria l
H e a t sh o ck  p ro te in  beta-1
H e a t sh o ck  p ro te in  H SP  90-b e ta
H e a t sh o c k-re la te d  70  kDa p rote in  2
H e m e -b in d in g  p ro te in  1
H e p a to m a -d e riv e d  g ro w th  fa cto r
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  AO
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  F
IP I0 0 0 2 6 8 1 3 2 1 0 0 2 1
1P I0 0 1 6 3 187 16 14 16 17 17 11
IP I000 26781 85 76 11
n
61 60 55
IP I0 0 0 0 7 7 9 7 11 6
u
12 11 9 8
1P I0 0 2 19684 3 3 7 2 2 2
IP I0 0 0 0 7 0 8 7 2 0 1 1 4 1
IP I0 0 5 5 4 5 2 1 3 1 1 4 1 0
IP I0 0 0 2 6 2 1 5 3 2 0 3 3 3
IP I0 0 4 1 8 2 6 2 12 7 17 11 13 7
IP I0 0 4 6 5 4 3 9 33 29 26 31 28 19
1P I0 0 2 16171 9 6 8 9 7 7
IP I0 0 0 1 4 3 6 1 2 1 0 2 1 0
IP I0 0 0 3 0 2 0 7 3 1 1 1 2 1
1P I0 0 2 9 1783 0 1 2 3 4 1
IP I0 0 0 1 6 7 2 5 2 0 1 2 2 0
IP I0 0 4 1 2 9 8 7 3 4 4 7 3 2
IP I0 0 0 6 1 5 2 5 4 2 2 3 4 4
IP I0 0 0 0 9 3 0 5 4 2 4 3 8 4
1P I0 0 2 16159 4 1 2 2 2 3
IP I0 0 0 2 7 4 9 7 27 18 22 21 20 19
IP I0 0 0 1 6 8 0 1 2 2 2 5 5 0
IP I0 0 0 1 0 0 9 0 2 0 2 1 3 0
IP I0 0 0 0 8 5 5 2 15 16 7 10 9 7
IP I0 0 9 2 7 6 0 6 3 2 0 4 3 3
1P I0 0 2 19067 1 2 2 3 1 2
IP I0 0 0 1 9 7 5 5 3 2 4 7 3 2
1P I0 0 2 19757 18 19 9 20 18 14
1P I0 0 2 19018 58 47 42 54 29 29
IP I0 0 8 4 3 7 8 9 5 3 5 5 6 5
IP I0 0 0 0 4 3 5 8 6 2 5 13 9 5
IP I0 0 7 8 3 3 1 3 1 1 2 2 4 1
IP I0 0 0 3 7 4 4 8 3 4 5 2 4 2
IP I0 0 2 3 2 5 7 1 7 6 14 4 3 8
IP I0 0 0 2 9 0 7 9 16 11 7 12 15 15
IP I0 0 0 0 5 4 9 0 4 2 2 4 1 2
IP I0 0 0 1 2 3 1 3 2 1 1 2 1 0
IP I0 0 0 2 9 5 5 7 1 4 2 5 4 2
IP I0 0 4 6 5 2 5 6 3 2 4 5 4 5
IP I0 0 0 0 0 0 0 5 2 1 5 7 2 3
IP I0 0 6 4 3 0 4 1 9 9 10 14 7 8
IP I0 0 0 1 6 6 6 9 1 2 2 3 2 1
IP I0 0 0 1 5 9 5 4 4 4 2 8 4 2
IP I0 0 0 2 6 2 6 8 8 6 7 7 10 7
IP I0 0 0 0 3 3 4 8 3 1 3 2 3 6
IP I0 0 2 8 8 9 4 7 4 3 3 5 6 2
IP I0 0 8 4 8 2 2 6 16 9 17 15 18 14
IP I0 0 0 2 4 2 7 9 1 1 4 4 9 4
IP I0 0 3 0 4 9 2 5 10 10 11 6 11 12
IP I0 0 0 0 2 9 6 6 30 26 30 26 28 23
IP I0 0 0 3 0 2 7 5 12 9 4 5 8 9
IP I0 0 0 2 5 5 1 2 4 3 4 5 3 4
IP I0 0 4 1 4 6 7 6 78 71 60 72 61 40
IP I0 0 0 0 7 7 0 2 2 1 2 2 3 6
IP I0 0 1 4 8 0 6 3 8 3 2 2 4 3
IP I0 0 0 2 0 9 5 6 5 2 4 6 6 3
IP I0 0 0 1 1 9 1 3 8 2 4 9 5 7
IP I0 0 0 0 3 8 8 1 6 5 6 5 5 5
G e m -a sso c ia te d  p rote in  5
G e n e ra l tra n scrip tio n  fa c to r  3C  p o ly p e p tid e  4
G lia  m atu ra tio n  fa cto r, beta
G lu co sa m in e  6 -p h o sp h a te  N -a ce ty ltra n sfe ra se
G lu co sa m in e -6 -p h o sp h a te  iso m e ra se  1
G lu c o s a m in e -fru c to s e -6 -p h o s p h a te  a m in o tra n sfe ra se  [iso m eriz in g] 2
G lu co se -6 -p h o sp h a te  iso m e ra se
G lu ta m a te  d e h y d ro g e n a se  1, m ito ch o n d ria l
G lu ta m a te -c y s te in e  ligase  re g u la to ry  su b u n it
G lu ta re d o x in -3
G lu ta th io n e  p e ro xid a se  1
G lu ta th io n e  S -tra n sfe ra se  M u 2
1 3 4
H e te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  G IP I003 04692 11 4 8 9 8 5
H e te ro g e n e o u s n u c le a r rib o n u cle o p ro te in  H IP I000 13881 6 6 5 7 13 9
H e te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  H2 IP I0 0 0 2 6 2 3 0 2 0 1 1 4 0
H e te ro g e n e o u s  n u c le a r rib o n u cle o p ro te in  K IP I005 14561 25 15 21 16 19 17
H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  L IP I0 0 0 2 7 8 3 4 9 9 7 11 9 12
H e te ro g e n e o u s  n u c le a r rib o n u cle o p ro te in  U -like  p ro te in  2 IP I0 0 4 5 6 8 8 7 2 1 3 6 5 5
H igh  m o b ility  gro u p  p rote in  B1 IP I0 0 4 1 9 2 5 8 5 5 6 10 8 8
H igh  m o b ility  gro u p  p rote in  B3 IP I0 0 2 1 7 4 7 7 2 0 1 4 1 4
H istid in e  tria d  n u c le o tid e -b in d in g  p rote in  1 IP I0 0 2 3 9 0 7 7 1 0 2 4 1 4
H istid in e  tria d  n u c le o tid e -b in d in g  p rote in  2, m ito ch o n d ria l IP I0 0 0 0 0 3 3 5 2 1 1 2 2 2
H istid y l-tR N A  syn th e ta se , c yto p la sm ic IP I0 0 0 2 1 8 0 8 6 2 5 3 4 4
H isto n e  a ce ty ltra n sfe ra se  typ e  B ca ta ly tic  su bunit IP I0 0 0 2 4 7 1 9 3 2 3 2 3 3
H iston e  d e a ce ty la se  2 IP I0 0 2 8 9 6 0 1 5 3 3 3 7 6
H isto n e  H I . 2 1P I0 0 2 17465 1 3 13 7 4 3
H isto n e  H I . 5 1P I0 0 2 17468 2 5 10 6 3 4
H isto n e  H 2A .V IP I0 0 0 1 8 2 7 8 1 1 2 4 1 3
H isto n e  H4 IP I0 0 4 5 3 4 7 3 7 7 15 22 10 10
H isto n e -b in d in g  p ro te in  R B B P 7 IP I0 0 3 9 5 8 6 5 6 3 3 0 2 2
H sc 7 0 -in te ra ct in g  p rote in IP100032826 4 3 5 11 5 6
H sp 9 0  co -c h a p e ro n e  C d c3 7 IP I0 0 0 1 3 1 2 2 9 4 9 8 6 5
H SP A 5  p rote in IP I0 0 0 0 3 3 6 2 31 27 21 40 30 28
H 5P C 0 2 7 IP I0 0 5 4 9 6 7 2 7 8 12 16 8 6
h u n tin g tin IP I0 0 0 0 2 3 3 5 1 1 3 2 1 0
H y d ro x y m e th y lg lu ta ry l-C o A  syn th ase , cyto p lasm ic IP I0 0 0 0 8 4 7 5 23 16 31 10 12 11
H y p o x a n th in e -g u a n in e  p h o sp h o rib o sy ltra n sfe ra se IP I0 0 2 1 8 4 9 3 6 6 4 8 8 7
H yp o xia  u p -re g u la te d  p rote in  1 IP I0 0 0 0 0 8 7 7 24 19 19 28 29 24
Im p o rtin  su b u n it  a lp h a -2 IP I0 0 0 0 2 2 1 4 17 9 13 11 14 17
Im p o rtin  su b u n it a lp h a -3 IP I0 0 2 9 9 0 3 3 6 0 4 4 2 1
Im p o rtin  su b u n it  a lp h a -4 IP I0 0 0 1 2 5 7 8 3 1 3 4 4 2
Im p o rtin  su b u n it beta-1 IP I0 0 0 0 1 6 3 9 25 15 17 26 24 16
lm p o rtin -1 1 1P I0 0 3 0 1 107 5 1 4 6 1 2
lm p o rtin -7 IP I0 0 0 0 7 4 0 2 15 11 14 16 7 11
lm p o rtin -9 IP I0 0 1 8 5 1 4 6 8 8 12 12 9 12
In o rg a n ic  p yro p h o sp h a ta se IP I0 0 0 1 5 0 1 8 5 2 9 7 8 11
In o sin e  trip h o sp h a te  p yro p h o sp h ata se IP I0 0 0 1 8 7 8 3 2 2 0 3 1 0
ln o s in e -5 ’-m o n o p h o sp h a te  d e h yd ro g e n a se  2 IP I0 0 2 9 1 5 1 0 14 10 13 8 11 13
In o sito l m o n o p h o sp h a ta se  1 IP I0 0 0 2 0 9 0 6 1 1 3 2 3 2
in o s ito l-3 -p h o sp h a te  syn th ase  1 iso fo rm  2 IP I0 0 4 7 8 8 6 1 5 5 4 5 5 7
In su lin -d e g ra d in g  en zym e IP I0 0 2 2 0 3 7 3 9 4 5 3 4 1
In su lin -lik e  gro w th  fa cto r 2 m R N A -b in d in g  p rote in  1 IP I0 0 0 0 8 5 5 7 7 5 7 13 13 10
In te rle u k in  e n h a n ce r-b in d in g  fa c to r  2 IP I0 0 0 0 5 1 9 8 14 9 12 12 11 9
Iso ch o rism a ta se  d o m a in -co n ta in in g  p rote in  1 IP I0 0 3 0 4 0 8 2 3 5 4 2 2 3
Iso c itra te  d e h yd ro g e n a se  [N A D P] cyto p lasm ic IP I0 0 0 2 7 2 2 3 20 20 24 25 17 14
Iso c itra te  d e h yd ro g e n a se  [N A D P], m ito ch o n d ria l 1P I0 0 0 1 1107 3 1 2 5 8 0
Iso fo rm  1 o f 182 kDa ta n k y ra se -l-b in d in g  protein IP I0 0 3 0 4 5 8 9 4 1 3 4 3 0
Iso fo rm  1 o f l-p h o sp h a tid y lin o s ito l-4 ,5 -b isp h o sp h a te  
p h o sp h o d ie ste ra se  ga m m a -1
IP I0 0 0 1 6 7 3 6 8 1 3 2 5 7
Iso fo rm  1 o f 26S p ro tea se  re g u la to ry  su b u n it 6B IP I0 0 0 2 0 0 4 2 11 6 6 15 7 5
Iso fo rm  1 o f  2 6 S  p ro te a so m e  n on -A TP ase  re g u la to ry  su b u n it  1 IP I0 0 2 9 9 6 0 8 11 10 12 14 13 11
Iso fo rm  1 o f  3 ,2 -tra n s-e n o y l-C o A  iso m erase , m ito ch o n d ria l IP I0 0 3 0 0 5 6 7 3 2 3 3 3 3
Iso fo rm  1 o f  3 -h y d ro x y a c y l-C o A  d e h yd ro g en a se  typ e -2 IP I0 0 0 1 7 7 2 6 10 5 5 10 8 10
Iso fo rm  1 o f 3 -h y d ro x y b u ty ra te  d e h yd ro g e n a se  typ e  2 IP I0 0 6 0 7 7 9 9 3 0 4 5 1 2
Iso fo rm  1 o f  3 -h y d ro x y iso b u ty ry l-C o A  h yd ro lase, m ito ch o n d ria l IP I0 0 4 1 9 8 0 2 1 1 3 4 6 2
Iso fo rm  1 o f S 'p 'J -d e o x y r ib o n u c le o t id a s e , cyto so lic  typ e IP I0 0 0 0 5 5 7 3 2 4 1 3 4 2
Iso fo rm  1 o f  5 '-3 ' e x o rib o n u c le a se  2 IP I0 0 1 0 0 1 5 1 11 5 8 9 9 2
Iso fo rm  1 o f 5 '-n u c le o tid a se  d o m a in -co n ta in in g  p rote in  2 IP I0 0 0 0 9 6 6 2 2 1 3 2 2 2
Iso fo rm  1 o f 60S r ib o so m a l p rote in  L l l IP I0 0 3 7 6 7 9 8 4 6 3 3 3 2
Iso fo rm  1 o f 60 S  r ib o so m a l p rote in  L12 IP I0 0 0 2 4 9 3 3 5 6 6 4 5 5
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Iso fo rm  1 o f 6 -p h o sp h o fru cto k in a se , liver typ e IP I0 0 3 3 2 3 7 1 3 2 3 5 10 8
Iso fo rm  1 o f A ce ty l-C o A  ca rb o xy la se  1 IP I0 0 0 1 1 5 6 9 6 8 19 3 11 6
Iso fo rm  1 o f A cid  sp h in g o m y e lin a se -lik e  p h o sp h o d ie ste ra se  3b IP I0 0 5 5 0 1 1 5 2 1 4 1 4 1
Iso fo rm  1 o f A cid ic  leu cin e-rich  n u c le a r p h o sp h o p ro te in  32 fam ily  
m e m b e r B
IP I000 07423 3 1 3 4 2 2
Iso fo rm  1 o f A ctin -like  p rote in  6A IP I0 0 0 0 3 6 2 7 1 1 3 5 4 1
Iso fo rm  1 o f  A ctin -re la te d  p rote in  2/3  co m p le x  su b u n it  5 IP I0 0 5 5 0 2 3 4 2 1 4 5 1 3
Iso fo rm  1 o f A d e n y la te  k in ase  2, m ito ch o n d ria l IP I0 0 2 1 5 9 0 1 5 5 8 11 5 5
Iso fo rm  1 o f  A d ip o cy te  p lasm a m e m b ra n e -a sso cia te d  protein IP I0 0 0 3 1 1 3 1 2 4 3 3 3 4
Iso fo rm  1 o f  A lp h a -a d d u cin IP I0 0 0 1 9 9 0 1 5 0 2 4 6 2
Iso fo rm  1 o f  A lp h a -a m in o a d ip ic  se m ia ld e h yd e  d e h yd ro g e n a se IP I0 0 2 2 1 2 3 4 8 5 13 11 14 12
Isoform  1 o f  A lp h a -k e to g lu ta ra te -d e p e n d e n t d io xy ge n a se  FTO IP I0 0 0 2 8 2 7 7 3 1 1 2 1 1
Iso fo rm  1 o f A P -1  c o m p le x  su b u n it  m u-2 IP I0 0 0 0 2 5 5 2 3 1 1 0 5 2
Isoform  1 o f  A P -2  co m p le x  su b u n it  beta IP I0 0 7 8 4 1 5 6 6 1 2 10 16 10
Iso fo rm  1 o f A P -3  c o m p le x  su b u n it beta-1 IP I0 0 0 2 1 1 2 9 2 1 1 2 5 1
Iso fo rm  1 o f A p o p to s is -a sso c ia te d  sp eck-like  p rote in  co n ta in in g  a 
C A R D
IP I0 0 0 0 1 6 9 9 4 5 3 3 1 0
Iso fo rm  1 o f A rm a d illo  re p e a t-co n ta in in g  p rote in  6 IP I0 0 0 2 0 1 9 6 3 0 1 2 2 2
Iso fo rm  1 o f A TP  syn th a se  su b u n it  d, m ito ch o n d ria l IP I0 0 2 2 0 4 8 7 4 4 5 8 1 3
Iso fo rm  1 o f A T P -d e p e n d e n t R N A  he licase  D D X42 IP I0 0 4 0 9 6 7 1 4 3 2 7 8 3
Iso fo rm  1 o f A xin  in te ra cto r, d o rsa liza tio n -a sso cia te d  p rote in IP I0 0 3 0 3 6 0 2 1 0 2 3 1 4
Iso fo rm  1 o f  B asic  leu cin e  z ip p e r and W 2 d o m a in -co n ta in in g  p rote in  1 IP I0 0 7 8 5 0 9 6 8 5 4 7 6 4
Iso fo rm  1 o f  B e ta -e n o lase IP I0 0 2 1 8 4 7 4 2 2 3 3 1 2
Iso fo rm  1 o f  B e ta -g a la cto sid a se IP I0 0 4 4 1 3 4 4 3 1 1 3 1 1
Iso fo rm  1 o f B H 3 -in te ra ctin g  d o m a in  death  agon ist IP I0 0 4 1 3 5 8 7 2 0 1 3 1 0
Iso fo rm  1 o f  B R C A 1 -A  c o m p le x  su b u n it BRE IP100149276 2 1 2 2 2 1
Iso fo rm  1 o f  BR C A 2 and C D K N IA -in te ra c t in g  protein IP I0 0 0 0 2 2 0 3 3 2 1 3 3 3
Iso fo rm  1 o f  C a lcy c lin -b in d in g  p rote in IP I0 0 3 9 5 6 2 7 10 10 15 18 11 9
Iso fo rm  1 o f C a p rin -1 IP100783872 s 3 7 7 5 5
Iso fo rm  1 o f C a ten in  a lp h a -1 IP I0 0 2 1 5 9 4 8 22 14 17 23 19 23
Iso fo rm  1 o f C a ten in  b e ta-1 IP I0 0 0 1 7 2 9 2 8 6 5 7 10 6
Iso fo rm  1 o f  C C R 4 -N O T  tra n scrip tio n  co m p le x  su b u n it 1 IP I0 0 1 6 6 0 1 0 6 2 6 2 8 3
Iso fo rm  1 o f C e llu la r n u c le ic  a c id -b in d in g  p rote in IP I0 0 4 3 0 8 1 2 1 2 2 0 2 1
Iso fo rm  1 o f C lath rin  h e av y ch ain  1 IP100024067 37 36 48 54 52 40
Iso fo rm  1 o f  C le a v a g e  and p o ly a d e n y la tio n  sp e c ific ity  fa c to r  su b u n it 6 IP I0 0 0 1 2 9 9 8 3 3 4 4 4 4
Iso fo rm  1 o f  C le a v a g e  an d  p o ly a d e n y la tio n  sp e c ific ity  fa c to r  su b u n it 7 IP I0 0 5 5 0 8 2 1 1 1 2 2 2 0
Iso fo rm  1 o f C o a to m e r su b u n it a lp h a IP I0 0 2 9 5 8 5 7 9 5 6 12 10 14
Iso fo rm  1 o f C o ile d -co il d o m a in -co n ta in in g  p rote in  47 IP I0 0 0 2 4 6 4 2 2 0 1 0 4 1
Iso fo rm  1 o f C O P 9  s ig n a lo so m e  co m p le x  su b u n it  1 IP I0 0 1 5 6 2 8 2 1 1 2 2 4 5
Iso fo rm  1 o f  C O P 9 s ig n a lo so m e  c o m p le x  su b u n it 7b IP I0 0 0 0 9 3 0 1 3 3 5 3 1 1
Iso fo rm  1 o f C -te rm in a l-b in d in g  p rote in  2 IP I0 0 0 1 0 1 2 0 3 3 3 1 3 4
Iso fo rm  1 o f Cu llin -3 IP I0 0 0 1 4 3 1 2 7 4 6 9 6 5
Iso fo rm  1 o f  C u llin -4 A IP I0 0 4 1 9 2 7 3 6 1 3 3 2 3
Iso fo rm  1 o f C u llin -a sso cia te d  N E D D 8 -d isso cia te d  p ro te in  1 IP I0 0 1 0 0 1 6 0 24 18 26 30 20 21
Iso fo rm  1 o f C y sta th io n in e  b e ta -sy n th ase IP I0 0 2 1 9 3 5 2 12 6 6 6 8 5
Iso fo rm  1 o f C ysta th io n in e  g a m m a-lya se IP I0 0 0 3 1 5 5 7 6 5 4 0 5 3
Iso fo rm  1 o f  C y ste in e  and h istid in e-rich  d o m a in -co n ta in in g  p rote in  1 IP I0 0 0 1 5 8 9 7 4 0 6 1 4 3
Iso fo rm  1 o f  C y to sk e le to n -a sso c ia te d  p rote in  4 IP I0 0 1 4 1 3 1 8 0 1 2 10 5 3
Iso fo rm  1 o f C yto so l a m in o p e p tid ase IP I0 0 4 1 9 2 3 7 5 1 4 6 10 8
Iso fo rm  1 o f  C y to so lic  acyl co e n zym e  A  th io e ste r h yd ro la se IP I0 0 0 1 0 4 1 5 5 6 9 6 8 7
Iso fo rm  1 o f  C y to so lic  n o n -sp e cific  d ip ep tid a se IP I0 0 1 7 7 7 2 8 18 14 14 11 16 12
Iso fo rm  1 o f  D A Z -a sso c ia te d  p rote in  1 IP I0 0 1 6 5 2 3 0 4 2 5 1 1 2
Iso fo rm  1 o f  D e o x y cy tid y la te  d e am in ase IP I0 0 2 9 6 8 6 3 0 1 2 3 3 1
Iso fo rm  1 o f D ip e p tid y l p e p tid a se  3 IP I0 0 0 2 0 6 7 2 15 7 8 14 7 10
Iso fo rm  1 o f  D N A  p rim a se  large su b u n it IP I0 0 0 2 7 7 0 5 2 2 2 3 2 1
Iso fo rm  1 o f D N A  re p lica tio n  co m p le x G IN S  p rote in  PSF3 IP I0 0 7 4 8 7 0 0 1 0 4 2 1 2
Iso fo rm  1 o f  D N A  re p lica tio n  lice n sin g  fa cto r M CM 7 IP I0 0 2 9 9 9 0 4 13 9 10 18 16 16
Iso fo rm  1 o f D N A -b in d in g  p rote in  A IP I0 0 0 3 1 8 0 1 1 o 2 1 4 2
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Iso fo rm  1 o f D N A -d e p e n d e n t p rote in  k in ase  ca ta ly tic  su b u n it IP100296337 36 20 39 40 47 36
Iso fo rm  1 o f  D N A -d ire cte d  R N A  p o ly m e rase s 1 and III su b u n it R PA C 1 IP I000 05179 3 0 2 1 0 2
Iso fo rm  1 o f  E le ctro n  tra n sfe r f la vo p ro te in  su b u n it beta IP I0 0 0 0 4 9 0 2 2 2 2 6 2 3
Iso fo rm  1 o f E lo n g a tio n  fa cto r G, m ito ch o n d ria l IP I001 54473 3 1 1 1 3 6
Iso fo rm  1 o f E lo n g atio n  fa cto r Ts, m ito ch o n d ria l 1P I0 0 0 2 1016 2 1 1 2 2 3
Iso fo rm  1 o f E lo n g atio n  fa cto r Tu G T P -b in d in g  d o m a in -co n ta in in g IP I0 0 2 9 3 0 2 6 4 1 1 1 3 2
p ro te in  1
Iso fo rm  1 o f En o la se -p h o sp h a ta se  E l IP I0 0 0 3 8 3 7 8 5 2 2 7 2 4
Iso fo rm  1 o f En o yl-C o A  h yd ratase  d o m a in -co n ta in in g  p ro te in  1 IP I0 0 3 0 2 6 8 8 4 2 1 0 2 2
Iso fo rm  1 o f  Erlin-2 IP I0 0 0 2 6 9 4 2 4 3 2 5 4 0
Iso fo rm  1 o f Eu ka ry o tic  in itia tio n  fa c to r  4A-II IP I0 0 3 2 8 3 2 8 8 2 5 2 5 2
Iso fo rm  1 o f Eu ka ry o tic  tra n s la tio n  in itia tio n  fa cto r 3 su b u n it  B IP I0 0 3 9 6 3 7 0 17 11 13 13 22 15
Isoform  1 o f E xp o rtin -2 IP I0 0 0 2 2 7 4 4 31 14 30 32 28 23
Isoform  1 o f Exte n d ed  syn a p to ta g m in -1 IP I0 0 0 2 2 1 4 3 10 3 5 7 14 14
Isoform  1 o f FAD syn th ase IP I0 0 2 2 0 2 9 9 2 1 2 3 1 2
Iso fo rm  1 o f Far u p stre am  e le m e n t-b in d in g  p rote in  2 IP I0 0 4 7 9 7 8 6 17 8 8 20 13 14
Iso fo rm  1 o f  Ferm itin  fa m ily  h o m o lo g  2 IP I0 0 0 0 0 8 5 6 2 3 5 4 6 5
Iso fo rm  1 o f F ila m in -B IP I0 0 2 8 9 3 3 4 43 27 44 65 72 59
Iso fo rm  1 o f  F ila m in -C IP I0 0 1 7 8 3 5 2 1 4 4 38 42 25
Iso fo rm  1 o f Frag ile  X m en ta l reta rd a tio n  syn d ro m e -re la te d  p rote in  1 IP I0 0 0 1 6 2 4 9 2 1 2 2 7 5
Iso fo rm  1 o f G a m m a -g lu ta m y lcy c lo tra n sfe ra se IP I0 0 0 3 1 5 6 4 4 3 8 9 3 1
Iso fo rm  1 o f G e lso lin IP I0 0 0 2 6 3 1 4 4 1 1 9 13 4
Iso fo rm  1 o f G e n era l tra n scrip tio n  fa cto r ll-l IP I0 0 0 5 4 0 4 2 7 4 2 7 4 3
Iso fo rm  1 o f G e n e ra l ve sicu la r  tra n sp o rt  fa cto r p l l 5 IP I0 0 9 4 1 1 6 1 13 7 15 17 16 16
Iso fo rm  1 o f G lu c o sa m in e -fru c to s e -6 -p h o s p h a te  a m in o tra n sfe ra se IP I0 0 2 1 7 9 5 2 10 8 5 12 14 16
[iso m e riz in g] 1
Iso fo rm  1 o f G ly ce ro l-3 -p h o sp h a te  d e h yd ro g en a se , m ito ch o n d ria l IP100017895 3 1 0 1 3 2
Iso fo rm  1 o f  G ro w th  fa c to r  re ce p to r-b o u n d  protein  2 IP I0 0 0 2 1 3 2 7 4 5 2 4 4 3
Iso fo rm  1 o f G u a n in e  n u c le o tid e -b in d in g  protein  G(i) su b u n it a lp h a -2 IP I0 0 7 4 8 1 4 5 5 3 3 4 8 6
Iso fo rm  1 o f  H e a t sh o c k  co g n a te  71 kDa protein IP I0 0 0 0 3 8 6 5 46 37 39 38 39 31
Iso fo rm  1 o f H e m a to lo g ica l an d  n e u ro lo g ica l e xp ressed  1-like protein IP I0 0 0 2 7 3 9 7 2 2 3 1 3 0
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r rib o n u cle o p ro te in  A3 IP I0 0 4 1 9 3 7 3 10 6 8 15 17 10
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r rib o n u cle o p ro te in  DO IP I0 0 0 2 8 8 8 8 16 10 15 13 13 6
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  H3 IP I0 0 0 1 3 8 7 7 4 4 3 4 4 5
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  M IP I0 0 1 7 1 9 0 3 13 11 14 13 22 19
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r r ib o n u cle o p ro te in  Q IP I0 0 0 1 8 1 4 0 9 6 4 11 12 14
Iso fo rm  1 o f H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  R IP I0 0 0 1 2 0 7 4 9 7 8 8 7 6
Iso fo rm  1 o f H e te ro ge n e o u s n u c le a r r ib o n u c le o p ro te in  U -like  protein IP I0 0 0 1 3 0 7 0 2 0 2 3 4 1
i
Iso fo rm  1 o f H exo kin a se-1 IP I0 0 0 1 8 2 4 6 2 2 10 9 7 5
Iso fo rm  1 o f  H is to n e -b in d in g  p ro te in  R B B P 4 IP I0 0 3 2 8 3 1 9 2 1 4 2 6 7
Iso fo rm  1 o f H y d ro x ya cy l-co e n zy m e  A  d e h yd ro g e n a se , m ito ch o n d ria l IP I0 0 2 9 4 3 9 8 5 5 3 4 0 5
Iso fo rm  1 o f lm p o rtin -4 IP I0 0 1 5 6 3 7 4 11 8 13 11 8 10
Iso fo rm  1 o f lm p ortin -5 IP I0 0 7 9 3 4 4 3 36 24 35 34 25 28
Iso fo rm  1 o f In o rgan ic  p yro p h o sp h ata se  2, m ito ch o n d ria l 1P I0 0 3 0 1 109 2 1 2 1 2 0
Iso fo rm  1 o f In su lin -like  gro w th  fa cto r 2 m R N A -b in d in g  p rote in  2 IP I0 0 1 7 9 7 1 3 7 1 3 4 6 0
Iso fo rm  1 o f  In su lin -like  g ro w th  fa cto r 2 m R N A -b in d in g  p rote in  3 IP I0 0 6 5 8 0 0 0 7 6 11 7 10 7
Iso fo rm  1 o f In te grin  a lp h a -V IP I0 0 0 2 7 5 0 5 1 0 2 2 8 5
Iso fo rm  1 o f In tra fla g e lla r  tra n sp o rt  p rote in  27 h o m o lo g IP I0 0 8 7 2 2 9 2 2 0 2 3 1 0
Iso fo rm  1 o f  Iso c itra te  d e h yd ro g e n a se  [N A D] su b u n it a lp h a IP I0 0 0 3 0 7 0 2 3 3 1 3 3 3
Iso fo rm  1 o f  IST1  h o m o lo g IP I0 0 0 2 4 6 6 0 2 1 2 2 1 1
Iso fo rm  1 o f  KH d o m a in -co n ta in in g , R N A -b in d in g , s ig n a l tra n sd u ctio n - IP I0 0 0 0 8 5 7 5 5 4 3 8 7 3
a sso c ia te d  p ro te in  1 
Iso fo rm  1 o f K in e ctin IP I0 0 3 2 8 7 5 3 3 1 4 7 12 2
Iso fo rm  1 o f K in e sin  h e av y ch ain  iso form  5C IP I0 0 0 2 8 5 6 1 5 3 2 3 3 2
Iso fo rm  1 o f K in e sin -lik e  p rote in  K IF1A IP I0 0 6 0 4 7 1 1 3 2 6 1 4 4
Iso fo rm  1 o f K y n u re n in e -o x o g lu ta ra te  tra n sam in a se  3 IP I0 0 4 6 5 3 7 3 3 1 2 2 2 0
Iso fo rm  1 o f Large  p ro lin e -r ich  p rote in  BAT3 IP I0 0 4 6 5 1 2 8 4 4 2 7 5 3
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Iso fo rm  1 o f  LE T M 1  and EF-h an d  d o m a in -co n ta in in g  p rote in  1, 
m ito ch o n d ria l
Iso fo rm  1 o f Le u ko trie n e  A -4  hyd ro lase
Iso fo rm  1 o f LIM  and SH 3 d om a in  p rote in  1
Iso fo rm  1 o f L-la cta te  d e h yd ro g e n a se  A  ch ain
Iso fo rm  1 o f Lo w  m o le cu la r w e igh t p h o sp h o ty ro sin e  p rote in
p h o sp h a ta se
Iso fo rm  1 o f M ag n e s iu m -d e p e n d e n t p h o sp h a ta se  1 
Iso fo rm  1 o f M align a n t T  ce ll-a m p lifie d  seq u e n ce  1 
Iso fo rm  1 o f M ed iu m -ch a in  sp e c ific  a cy l-C o A  d e h yd ro g e n a se , 
m ito ch o n d ria l
Iso fo rm  1 o f  M e la n o m a -a sso c ia te d  an tige n  D2
Isoform  1 o f M e ta sta s is-a sso c ia te d  p rote in  M TA3
Iso fo rm  1 o f M e th io n in e  a d e n o sy ltra n sfe ra se  2 su b u n it beta
Iso fo rm  1 o f M e th y l-C p G -b in d in g  d om a in  p rote in  3
Iso fo rm  1 o f  M ito tic  ch e c k p o in t p rote in  BU B3
Iso fo rm  1 o f M ps on e  b in d e r k in ase  a ctiva to r-like  IB
Iso fo rm  1 o f M yb -b in d in g  p rote in  1A
Iso fo rm  1 o f M yo sin -1 0
Iso fo rm  1 o f M yo sin -9
Iso fo rm  1 o f M yo sin -lb
Iso fo rm  1 o f N A C H T, LRR and PYD d o m a in s-co n ta in in g  p rote in  2
Iso fo rm  1 o f N A D H -cy to ch ro m e  b5 red u ctase  2
Iso fo rm  1 o f N A D H -cy to ch ro m e  b5 red u ctase  3
Iso fo rm  1 o f N -a lp h a -a ce ty ltra n sfe ra se  50, N atE ca ta ly tic  su b u n it
Iso fo rm  1 o f N e u ro ch o n d rin
Iso fo rm  1 o f N icastrin
Iso fo rm  1 o f N ico tin a te  p h o sp h o rib o sy ltra n sfe ra se
Iso fo rm  1 o f  N IF3 -like  p rote in  1
Iso fo rm  1 o f N SFL1  c o fa cto r  p47
iso fo rm  1 o f N u c le a r a u to a n tig e n ic  sp erm  p rote in
Iso fo rm  1 o f N u c le a r pore c o m p le x  p rote in  N u p l5 5
Iso fo rm  1 o f N u c le a r pore c o m p le x  p rote in  N u p l6 0
Iso fo rm  1 o f N u c le a r pore c o m p le x  p rote in  N u p 9 8 -N u p 9 6
Iso fo rm  1 o f N u c le o la r p rote in  6
Iso fo rm  1 o f N u c le o la r R N A  h e licase  2
Iso fo rm  1 o f N u cleo re d o xin
Iso fo rm  1 o f N u cleo sid e  d ip h o sp h a te  k in ase  A
Iso fo rm  1 o f O b g-like  A T P a se  1
Iso fo rm  1 o f O lig o rib o n u cle a se , m ito ch o n d ria l (Frag m e n t)
Iso fo rm  1 o f P ara sp e ckle  co m p o n e n t 1
Iso fo rm  1 o f P C 4 and S F R S l- in te ra c t in g  protein
Iso fo rm  1 o f P ero x id asin  h o m o lo g
Iso fo rm  1 o f P ero x iso m a l a cy l-co e n zy m e  A  o x id a se  1
Iso fo rm  1 o f  P h o sp h a tid y lin o sito l tra n sfe r p rote in  beta iso form
Iso fo rm  1 o f P h o sp h o e n o lp yru v a te  ca rb o xyk in a se  [G TP]
Iso fo rm  1 o f P h o sp h o g lu co m u ta se -1
Iso fo rm  1 o f  P h o sp h o rib o sy l p yro p h o sp h ate  syn th a se -a sso c ia te d  
p ro te in  1
Iso fo rm  1 o f  P la te le t-a ct iv a tin g  fa cto r a ce ty lh yd ro la se  IB su b u n it a
Iso fo rm  1 o f  P o ly a d e n y la te -b in d in g  protein  1
Iso fo rm  1 o f  P o ly a d e n y la te -b in d in g  protein  2
Iso fo rm  1 o f  P o ly a d e n y la te -b in d in g  p rote in  4
Iso fo rm  1 o f P o ly p y rim id in e  tra ct-b in d in g  protein  1
Iso fo rm  1 o f P o ly p y rim id in e  tra ct-b in d in g  protein  2
Iso fo rm  1 o f P o rp h o b ilin o g e n  d e am in ase
Iso fo rm  1 o f  P re -m R N A -p ro ce ss in g  fa cto r 40 h o m o lo g A
Iso fo rm  1 o f P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  D H X 36
IP I000 17592 3 0 2 4 2 3
IP I0 0 2 1 9 0 7 7 14 7 8 4 10 7
IP I000 00861 3 1 4 4 6 4
IP I0 0 2 1 7 9 6 6 50 37 42 32 26 30
IP I002 19861 4 2 3 4 5 5
IP I0 0 3 3 7 5 5 6 0 1 2 2 1 0
IP I0 0 1 7 9 0 2 6 2 1 1 5 3 3
IP I0 0 0 0 5 0 4 0 3 1 0 2 1 1
IP I0 0 0 0 9 5 4 2 3 0 1 0 4 5
IP I0 0 1 6 5 3 5 7 5 2 1 1 4 0
IP I0 0 0 0 2 3 2 4 2 3 3 4 3 2
IP I0 0 4 3 9 1 9 4 1 1 2 4 1 1
IP I0 0 0 1 3 4 6 8 3 4 6 5 2 2
IP I0 0 3 0 1 5 1 8 3 3 1 3 0 1
IP I0 0 0 0 5 0 2 4 6 2 5 8 6 5
IP I0 0 3 9 7 5 2 6 33 26 58 48 39 37
IP I0 0 0 1 9 5 0 2 67 54 88 77 66 61
IP I0 0 3 7 6 3 4 4 5 2 1 3 5 2
IP I0 0 0 1 6 4 8 0 7 2 8 9 5 12
IP I0 0 0 0 8 2 3 4 1 1 4 3 0 1
IP I0 0 3 2 8 4 1 5 5 2 4 6 5 5
IP I0 0 0 1 8 6 2 7 6 0 6 12 5 7
IP I0 0 5 4 9 5 4 3 2 2 2 2 4 4
IP I0 0 0 2 1 9 8 3 1 1 2 1 1 2
IP I0 0 4 6 5 0 8 5 3 0 1 2 2 2
IP I0 0 6 0 4 6 2 4 3 1 1 2 5 2
IP I0 0 1 0 0 1 9 7 4 0 4 4 4 2
IP I0 0 1 7 9 9 5 3 27 19 21 23 27 26
IP I0 0 0 2 6 6 2 5 9 4 5 5 8 7
IP I0 0 7 4 8 8 0 7 1 2 5 7 6 4
IP I0 0 0 0 6 0 3 8 2 1 1 1 2 1
IP I0 0 1 5 2 8 9 0 2 0 3 2 1 0
IP I0 0 0 1 5 9 5 3 11 9 9 9 12 11
IP I0 0 3 0 4 2 6 7 3 1 3 2 6 6
IP I0 0 0 1 2 0 4 8 2 2 2 2 2 1
IP I0 0 2 9 0 4 1 6 5 6 11 7 7 7
IP I0 0 0 3 2 8 3 0 2 2 2 4 2 2
IP I0 0 1 0 3 5 2 5 5 2 2 3 4 2
IP I0 0 0 2 8 1 2 2 2 0 3 3 2 2
1P I0 0 0 1 6 1 12 3 1 1 1 3 1
IP I0 0 2 9 6 9 0 7 3 0 1 2 0 1
IP I0 0 3 3 4 9 0 7 6 2 4 2 5 2
IP I0 0 7 9 7 0 3 8 5 3 5 5 6 6
1P I0 0 2 19526 14 13 14 13 12 7
IP I0 0 2 9 1 5 7 8 3 1 1 2 4 1
1P I0 0 2 18728 1 0 4 3 4 5
IP I0 0 0 0 8 5 2 4 17 7 10 16 16 13
IP I0 0 0 0 5 7 9 2 1 3 3 3 1 2
IP I0 0 0 1 2 7 2 6 3 1 3 5 3 4
IP I0 0 1 7 9 9 6 4 15 11 13 17 15 13
IP I0 0 5 1 4 0 6 4 1 1 3 5 3 3
IP I0 0 0 2 8 1 6 0 2 1 2 3 0 2
IP I0 0 3 3 7 3 8 5 4 1 1 2 5 3
IP I0 0 0 2 7 4 1 5 1 1 3 2 2 1
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Iso fo rm  1 o f P ro te a so m e  a ctiva to r co m p le x  su b u n it  3 IP I000 30243 8 6 9 8 10 6
Iso fo rm  1 o f P ro te a so m e  a ctiva to r co m p le x  su b u n it 4 IP I0 0 0 0 5 2 6 0 5 4 3 2 7 3
Iso fo rm  1 o f  P ro te a so m e  a sse m b ly  ch a p e ro n e  1 IP I0 0 0 3 0 7 7 0 1 1 2 1 3 2
Iso fo rm  1 o f P ro te a so m e  su b u n it a lpha typ e -7 IP I0 0 0 2 4 1 7 5 16 8 12 16 11 12
Iso fo rm  1 o f  P ro te in  ca n o p y  h o m o lo g  2 IP I0 0 4 4 3 9 0 9 5 4 3 6 5 6
Iso fo rm  1 o f Pro te in  d iap h an o u s h o m o lo g  1 IP I0 0 8 5 2 6 8 5 2 2 7 7 6 2
Iso fo rm  1 o f Pro te in  K IA A 1967 IP I0 0 1 8 2 7 5 7 7 5 9 7 13 11
Iso fo rm  1 o f Prote in  LSM 12 h o m o lo g IP I0 0 4 1 0 3 2 4 2 2 2 1 0 2
Iso fo rm  1 o f Pro te in  p h o sp h a ta se  1 re g u la to ry  su b u n it 12A IP I0 0 1 8 3 0 0 2 4 1 3 3 3 0
Iso fo rm  1 o f  Pro te in  p h o sp h a ta se  1 re g u la to ry  su b u n it 7 IP I0 0 0 3 3 6 0 0 3 1 4 1 4 1
Iso fo rm  1 o f Pro te in  p h o sp h a ta se  m eth y le ste ra se  1 IP I0 0 0 0 7 6 9 4 2 3 4 4 2 2
Isoform  1 o f Pro te in  SET IP I0 0 0 7 2 3 7 7 14 9 10 15 5 10
Iso fo rm  1 o f Pro te in  syn d e sm o s IP I0 0 0 3 1 6 5 0 2 2 0 3 4 2
Isoform  1 o f Pro te in  tra n sp o rt  p ro te in  S ec24A IP I0 0 8 7 3 4 7 2 4 1 0 3 3 1
Iso fo rm  1 o f Pro te in  u n c-4 5  h o m o lo g  A IP I0 0 0 7 2 5 3 4 2 2 4 5 1 0
Iso fo rm  1 o f Pro te in  v ir ilize r  h o m o lo g IP I0 0 0 3 6 7 4 2 1 1 2 3 1 1
Iso fo rm  1 o f  P u ta tive  A T P -d e p e n d e n t R N A  he licase  D H X 30 IP I0 0 4 1 1 7 3 3 2 2 0 0 5 1
Iso fo rm  1 o f  P u ta tiv e  d e o xy rib o n u cle a se  TA TD N 1 IP I0 0 0 1 2 4 6 3 2 1 1 3 6 1
Iso fo rm  1 o f P u ta tiv e  h e licase  M O V -IO IP I0 0 4 4 4 4 5 2 2 1 2 2 2 0
Iso fo rm  1 o f P u ta tiv e  R N A -b in d in g  protein  Lu c7-like  1 1P I0 0 0 7 1 3 18 1 0 2 1 3 0
Iso fo rm  1 o f P yrid o xa l k in ase IP I0 0 0 1 3 0 0 4 4 1 3 6 2 3
Iso fo rm  1 o f P yru va te  d e h yd ro g e n a se  E l  co m p o n e n t su b u n it beta IP I0 0 0 0 3 9 2 5 8 6 8 8 8 6
Iso fo rm  1 o f Q u in o n e  o x id o re d u cta se  PIG3 IP I0 0 3 8 4 6 4 3 3 0 3 1 0 2
Iso fo rm  1 o f  R a s-re la te d  p rote in  R ab -1A IP I0 0 0 0 5 7 1 9 3 2 3 4 2 1
Iso fo rm  1 o f  R a s-re la te d  p rote in  Rab -34 IP I0 0 3 2 8 1 8 0 3 1 1 1 5 5
Iso fo rm  1 o f R e g u la to r o f  n o n se n se  tra n scrip ts  1 IP I0 0 0 3 4 0 4 9 6 5 3 8 7 6
iso fo rm  1 o f R ep licatio n  fa c to r  C su b u n it 2 IP I0 0 0 1 7 4 1 2 4 1 1 3 3 1
Iso fo rm  1 o f R e p lica tio n  p ro te in  A  32 kDa su b u n it IP I0 0 0 1 3 9 3 9 4 2 5 3 2 3
Iso fo rm  1 o f R e ticu lo n -4 1P I0 0 0 2 1766 3 3 4 2 5 4
Iso fo rm  1 o f R etin o l d e h y d ro g e n a se  11 IP I0 0 3 3 9 3 8 4 3 1 3 2 4 2
Iso fo rm  1 o f R ho g u a n in e  n u c le o tid e  e xch a n g e  fa cto r 2 IP I0 0 2 9 1 3 1 6 2 0 2 4 2 0
Iso fo rm  1 o f R ib o n u c le o s id e -d ip h o sp h a te  re d u ctase  su b u n it M 2 B IP100100213 4 2 4 4 4 2
Iso fo rm  1 o f R N A  p o ly m e ra se  II su b u n it  A  C -te rm in a l dom ain  
p h o sp h a ta se  SSU 72
IP I0 0 0 2 3 5 5 6 2 0 2 2 3 3
Iso fo rm  1 o f R N A -b in d in g  p ro te in  8A IP I0 0 0 0 1 7 5 7 3 2 0 2 5 2
Iso fo rm  1 o f  R R P 1 2-like  p rote in 1P I0 0 1 0 1 186 4 3 4 2 3 2
Iso fo rm  1 o f R u vB -like  1 IP I0 0 0 2 1 1 8 7 9 8 6 14 17 11
Iso fo rm  1 o f Sep tin -2 IP I0 0 0 1 4 1 7 7 8 5 7 6 7 5
Iso fo rm  1 o f S e rin e /a rg in in e -r ich  sp lic in g  fa c to r  7 IP100003377 3 2 4 6 1 3
Iso fo rm  1 o f S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  4  re g u la to ry  
su b u n it  3A
IP I0 0 2 1 7 0 1 3 3 1 1 1 3 0
Iso fo rm  1 o f S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  6 ca ta ly tic  
su b u n it
IP I0 0 0 1 2 9 7 0 6 2 3 4 3 2
Iso fo rm  1 o f S o d iu m /p o ta ss iu m -tra n sp o rtin g  A TP a se  su b u n it beta-1 IP I0 0 7 4 7 8 4 9 1 0 2 1 4 0
Iso fo rm  1 o f S p ectrin  a lpha chain , brain IP I0 0 8 4 4 2 1 5 38 24 38 53 52 44
Iso fo rm  1 o f  S p erm in e  syn th ase IP I0 0 0 0 5 1 0 2 9 7 8 5 6 6
Iso fo rm  1 o f  S -p h ase  k in ase -a sso cia te d  p rote in  1 IP I0 0 3 0 1 3 6 4 5 6 6 8 5 5
Iso fo rm  1 o f S p lic in g  fa cto r 3B su b u n it 3 IP I0 0 3 0 0 3 7 1 11 5 8 17 19 14
Iso fo rm  1 o f  S p lic in g  fa cto r U 2A F 65 kDa su b u n it IP I0 0 0 3 1 5 5 6 3 2 2 2 6 6
Iso fo rm  1 o f S q u a m o u s cell carc in o m a  a ntigen  reco g n ized  by T -ce lls  3 IP I0 0 0 0 6 0 2 5 2 1 2 2 7 4
Iso fo rm  1 o f  S tru ctu ra l m ain te n an ce  o f ch ro m o so m e s p rote in  2 IP I0 0 0 0 7 9 2 7 7 2 1 3 4 2
Iso fo rm  1 o f S u rfe it  locus p rote in  4 IP I0 0 0 0 5 7 3 7 2 2 1 2 3 2
Iso fo rm  1 o f S y n ta x in -7 IP I0 0 2 8 9 8 7 6 2 0 3 0 3 3
Iso fo rm  1 o f  T h y ro id  re ce p to r-in te ra ctin g  protein  13 IP I0 0 0 0 3 5 0 5 5 2 0 2 2 0
Iso fo rm  1 o f  T IP 4 1 -lik e  p rote in IP I0 0 7 4 5 5 6 8 2 0 5 3 2 2
Iso fo rm  1 o f T ra n sc rip t io n  e lo n g a tio n  fa cto r A  p rote in  1 1P I0 0 3 3 3 2 15 4 3 10 3 5 4
Iso fo rm  1 o f T ra n sc rip t io n  in te rm e d ia ry  fa cto r 1-beta IP I0 0 4 3 8 2 2 9 12 13 15 20 16 16
Iso fo rm  1 o f T ra n sfo rm e r-2  p rote in  h o m o lo g  beta IP I0 0 3 0 1 5 0 3 4 1 2 3 5 2
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Iso fo rm  1 o f T ra n s la t io n  in itia tio n  fa cto r e lF -2 B  su b u n it delta IP100005979 1 3 1 1 2 0
Iso fo rm  1 o f T ra n sp o rt in -1 IP I0 0 0 2 4 3 6 4 9 4 11 13 12 8
Iso fo rm  1 o f  tR N A -n u c le o tid y ltra n sfe ra se  1, m ito ch o n d ria l IP I0 0 2 8 9 8 0 7 2 0 1 2 1 1
Iso fo rm  1 o f T ro p o m y o sin  a lp h a -4  chain IP I000 10779 6 7 17 15 6 9
Iso fo rm  1 o f  T ry p to p h a n y l-tR N A  syn th eta se , c yto p la sm ic IP I0 0 2 9 5 4 0 0 16 10 13 8 11 6
Iso fo rm  1 o f T yro sin e -p ro te in  k in ase-like  7 IP I0 0 2 9 8 2 9 2 4 1 2 2 3 0
Iso fo rm  1 o f U5 sm all n u clea r rib o n u cle o p ro te in  200 kDa he licase IP I0 0 4 2 0 0 1 4 15 15 17 23 27 22
Iso fo rm  1 o f U biq u itin  ca rb o xy l-te rm in a l h yd ro lase  28 IP I0 0 0 4 S 4 9 6 2 1 0 3 5 1
Iso fo rm  1 o f U biq u itin  co n ju g a tio n  fa cto r E4 B IP I0 0 0 0 5 7 1 5 1 1 4 2 4 1
Iso fo rm  1 o f U b iq u itin -co n ju g a tin g  e n zym e  E2 D3 IP I0 0 0 2 6 9 6 5 2 1 1 3 2 2
Iso fo rm  1 o f U b iq u itin -co n ju g a tin g  e n zym e  E2 K IP100021370 8 5 3 10 5 6
Isoform  1 o f  U b iq u it in -lik e -co n ju g a tin g  e n zym e  A TG 3 IP I0 0 0 2 2 2 5 4 3 1 0 1 4 1
Iso fo rm  1 o f U BX d o m a in -co n ta in in g  p rote in  1 IP I0 0 0 2 7 3 7 8 1 3 2 0 3 4
Iso fo rm  1 o f  U D P -g lu co se ;g ly co p ro te in  g lu co sy ltra n sfe ra se  1 IP I0 0 0 2 4 4 6 6 11 3 9 12 14 8
Iso fo rm  1 o f U rid in e  5 ’-m o n o p h o sp h a te  syn th ase IP I0 0 0 0 3 9 2 3 2 2 1 6 4 5
Iso fo rm  1 o f U rid in e -cy tid in e  k in ase  2 IP I0 0 0 6 5 6 7 1 2 3 0 4 3 3
Iso fo rm  1 o f U T P -g lu c o s e - l-p h o s p h a te  u rid y ly ltra n sfe ra se IP I0 0 3 2 9 3 3 1 28 18 25 20 24 14
Iso fo rm  1 o f V a c u o la r  p rote in  so rtin g -a sso cia te d  p rote in  29 IP I0 0 1 7 0 7 9 6 2 1 3 5 2 1
Iso fo rm  1 o f V e s ic le -a sso c ia te d  m em b ran e  p ro te in -a sso c ia te d  prtn A IP I0 0 1 7 0 6 9 2 1 0 2 3 5 3
Iso fo rm  1 o f V e s ic le -a sso c ia te d  m em b ra n e  p ro te in -a sso c iate d  p rote in  
B/C
Iso fo rm  1 o f V in cu lin
IP I0 0 0 0 6 2 1 1 1 1 3 2 2 1
1P I0 0 2 9 1175 58 48 65 51 40 48
Iso fo rm  1 o f  W D  re p e a t-co n ta in in g  p rote in  1 IP I0 0 7 4 6 1 6 5 7 3 4 8 12 11
Iso fo rm  1 o f Z in c  f in g e r p rote in  326 IP I0 0 3 7 3 8 7 7 0 1 2 2 3 2
Iso fo rm  1 o f Z in c  p h o sp h o d ie ste ra se  ELA C p rote in  2 IP I0 0 3 9 6 6 2 7 6 2 2 1 5 1
Iso fo rm  1AB o f C aten in  d e lta -1 IP I0 0 1 8 2 4 6 9 3 2 1 4 7 5
Iso fo rm  2 o f 6 -p h o sp h o fru cto k in a se , m u scle  type IP I0 0 2 1 9 5 8 5 1 3 1 2 11 7
Iso fo rm  2 o f  A n n e x in  A2 IP I0 0 4 1 8 1 6 9 20 17 11 4 0 23 20
Iso fo rm  2 o f A P -1  c o m p le x  su b u n it ga m m a-1 IP I0 0 2 9 3 3 9 6 4 2 0 4 5 2
Iso fo rm  2 o f  A P -2  c o m p le x  su b u n it  a lp h a -2 IP I0 0 0 1 6 6 2 1 2 0 1 4 5 1
Iso fo rm  2 o f A p o p to s is  in h ib ito r 5 IP I0 0 5 5 4 7 4 2 6 5 4 8 6 3
Iso fo rm  2 o f A T P -b in d in g  ca sse tte  su b -fa m ily  F m e m b e r 1 IP I0 0 0 1 3 4 9 5 4 1 1 4 3 6
Iso fo rm  2 o f A T P -d e p e n d e n t R N A  h e licase  D D X54 IP I0 0 1 5 2 5 1 0 2 1 2 1 2 1
Iso fo rm  2 o f Basig in IP100019906 8 7 9 7 7 6
Iso fo rm  2 o f C at eye  syn d ro m e  crit ica l reg ion  p rote in  5 1P I0 0 0 1 1511 4 2 2 4 5 5
Iso fo rm  2 o f Cell d iv ision  co n tro l p rote in  42  h o m o lo g IP I0 0 0 1 6 7 8 6 4 2 5 7 5 3
Iso fo rm  2 o f C u llin -4B IP I0 0 1 7 9 0 5 7 2 0 2 5 3 3
Iso fo rm  2 o f C yto ch ro m e  P450 2S1 IP I0 0 1 6 4 0 1 8 7 3 4 3 6 3
Iso fo rm  2 o f  D e o xyu rid in e  5 '-tr ip h o sp h a te  n u c le o tid o h y d ro la se IP I0 0 3 7 5 0 1 5 5 3 6 4 8 7
Iso fo rm  2 o f E u ka ry o tic  tra n sla tio n  in itia tio n  fa c to r  5A -1 IP I0 0 3 7 6 0 0 5 16 9 9 12 9 8
Iso fo rm  2 o f F -a ctin -ca p p in g  p ro te in  su b u n it beta IP I0 0 6 4 2 2 5 6 13 8 13 12 11 7
Iso fo rm  2 o f F ilam in -A IP I0 0 3 0 2 5 9 2 101 75 79 94 101 89
Iso fo rm  2 o f G o lgi a p p a ra tu s  p rote in  1 IP I0 0 4 1 4 7 1 7 4 0 6 5 10 6
Iso fo rm  2 o f HD d o m a in -co n ta in in g  p rote in  2 IP I0 0 3 8 6 7 5 1 1 2 1 5 2 0
Iso fo rm  2 o f  H eat sh o ck  p rote in  H SP 9 0 -a lp h a IP I0 0 3 8 2 4 7 0 35 27 25 40 32 20
Iso fo rm  2 o f  H e te ro g e n e o u s n u clea r rib o n u cle o p ro te in  A /B IP I0 0 3 3 4 5 8 7 5 7 7 7 7 7
Iso fo rm  2 o f Iso ch o rism a ta se  d o m a in -co n ta in in g  p ro te in  2 IP I0 0 0 0 3 0 3 1 2 2 0 3 1 1
Iso fo rm  2 o f  Ly s in e -sp e c ific  h iston e  d e m e th y la se  1A IP I0 0 2 1 7 5 4 0 1 0 2 3 5 0
Iso fo rm  2 o f M icro tu b u le -a ctin  cro ss-lin k in g  fa c to r  1 IP I0 0 2 5 6 8 6 1 19 11 11 13 26 0
Iso fo rm  2 o f m R N A  cap  guanine~N 7 m eth y ltran sfera se IP I0 0 4 1 0 6 5 7 1 0 3 1 2 2
Iso fo rm  2 o f N itrilase  h o m o lo g  1 IP I0 0 0 2 3 7 7 9 1 1 2 2 2 0
Iso fo rm  2 o f N u c le a r m ito tic  a p p ara tu s p rote in  1 IP I0 0 0 0 6 1 9 6 6 2 13 9 14 3
Iso fo rm  2 o f N u c le o p o rin  N U P 188  h om o lo g IP I0 0 3 8 5 0 0 1 0 1 3 2 2 0
Iso fo rm  2 o f  P h o sp h a tid y lin o s ito l-b in d in g  c la th rin  a sse m b ly  p rote in 1P I0 0 2 16184 1 1 2 3 3 2
Iso fo rm  2 o f  P ro te a so m e  su b u n it  a lpha type-3 IP I0 0 1 7 1 1 9 9 10 9 6 8 5 5
Iso fo rm  2 o f Pro te in  d isu lfid e -iso m e ra se  A6 IP I0 0 2 9 9 5 7 1 19 13 19 26 12 15
Iso fo rm  2 o f  R a s-re la te d  p ro te in  R a b -6A IP I0 0 2 1 7 9 4 3 4 3 5 7 4 1
Iso fo rm  2 o f S a rco p la sm ic/e n d o p la sm ic  reticu lu m  ca lc iu m  A TP a se  2 IP I0 0 1 7 7 8 1 7 5 6 2 9 11 8
1 4 0
Iso fo rm  2 o f  S e rra te  R N A  e ffe cto r m ole cu le  h o m o lo g IP I0 0 2 2 0 0 3 8 1 3 7 4 5 5
Iso fo rm  2 o f  S p lic e o so m e  R N A  h e licase  B A U IP I0 0 6 4 1 8 2 9 13 7 10 18 13 14
Iso fo rm  2 o f S tru ctu ra l m a in te n a n ce  o f ch ro m o so m e s p rote in  4 IP I0 0 3 2 8 2 9 8 3 0 3 5 3 2
Iso fo rm  2 o f S u p p re sso r o f G 2 a lle le  o f  SKP1 h om o lo g IP I0 0 7 9 1573 6 6 7 4 8 5
Iso fo rm  2 o f T A R  D N A -b in d in g  p rote in  43 IP I000 25815 4 2 7 6 7 4
Iso fo rm  2 o f  T ra n sp o rt in -3 IP I0 0 3 9 5 6 9 4 8 2 5 10 7 6
Iso fo rm  2 o f tR N A  p se u d o u rid in e  syn th ase  A, m ito ch o n d ria l IP I0 0 0 0 1 7 1 6 2 1 4 1 3 0
Iso fo rm  2 o f T ro p o m y o s in  a lp h a -3  chain IP I0 0 2 1 8 3 1 9 22 26 29 32 17 12
Iso fo rm  2 o f T u m o r p rote in  D54 1P I0 0 2 2 1178 4 2 8 5 7 3
Iso fo rm  2 o f U1 sm all n u c le a r rib o n u cle o p ro te in  70 kDa IP I002 19483 3 4 2 5 5 4
Iso fo rm  2 o f U b iq u ilin -1 IP I0 0 0 7 1 1 8 0 3 0 1 1 1 2
Iso fo rm  2 o f U P F 0 5 5 7  p ro te in  C 1 0 o r f l l9 IP I0 0 5 5 2 5 4 6 2 1 2 3 3 1
Iso fo rm  2 o f V a la cy c lo v ir  h yd ro la se IP I0 0 0 0 3 9 9 0 2 1 1 2 1 0
Iso fo rm  2 o f V o lta g e -d e p e n d e n t a n io n -se le ctiv e  ch a n n e l p rote in  2 IP I0 0 0 2 4 1 4 5 1 0 3 2 4 3
Iso fo rm  2C o f C y to p la sm ic  d yn e in  1 in te rm e d ia te  ch ain  2 IP I0 0 2 1 6 3 4 8 2 1 1 2 4 3
Iso fo rm  3 o f A n a m o rsin IP I0 0 0 2 5 3 3 3 2 3 3 3 3 3
Iso fo rm  3 o f  D N A  to p o iso m e ra se  2-a lp h a IP I0 0 2 1 8 7 5 3 1 0 6 3 9 7
Iso fo rm  3 o f  Ep ith e lia l sp lic in g  re g u la to ry  p rote in  1 IP I0 0 1 8 4 2 6 2 4 0 2 2 2 4
Iso fo rm  3 o f  P ro ly l 3 -h y d ro xy la se  1 IP I0 0 0 4 5 8 3 9 2 0 1 2 2 2
Iso fo rm  3 o f Pro te in  D D I1  h o m o lo g  2 IP I0 0 0 3 1 6 1 8 5 0 2 1 2 0
Iso fo rm  3 o f P ro te in  t ra n sp o rt  p rote in  Se c3 1 A IP I0 0 3 0 5 1 5 2 4 1 3 5 4 3
Iso fo rm  3 o f R e ticu lo n -3 IP I0 0 0 2 8 9 4 6 1 3 2 1 4 0
Iso fo rm  3 o f R ib o so m e -b in d in g  p rote in  1 IP100215743 1 0 9 7 10 1
Iso fo rm  3 o f S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A a ct iv a to r IP I0 0 2 1 7 2 9 6 4 4 2 1 3 2
Iso fo rm  3 o f U b iq u it in -co n ju g a tin g  e n zym e  E2 v a r ia n t 1 1P100472498 6 4 3 2 1 1
Iso fo rm  4 o f E3 u b iq u itin -p ro te in  ligase  U BR4 IP I0 0 6 4 0 9 8 1 8 9 14 7 13 1
Iso fo rm  4  o f P ro b a b le  A T P -d e p e n d e n t R N A  he licase  D D X17 IP I0 0 8 8 9 5 4 1 9 2 4 15 11 11
Iso fo rm  4 o f T ro p o m y o sin  a lp h a -1  chain IP I0 0 2 9 6 0 3 9 5 3 17 13 4 6
Iso fo rm  4  o f  T u b u lin -sp e c ific  c h a p e ro n e  D IP I0 0 0 3 0 7 7 4 6 0 4 6 8 7
Iso fo rm  5 o f  In te rle u k in  e n h a n c e r-b in d in g  fa c to r  3 IP I0 0 2 1 9 3 3 0 8 9 13 14 18 16
Iso fo rm  5 o f  T h io re d o x in  re d u cta se  1, cyto p la sm ic IP I0 0 5 5 4 7 8 6 8 3 8 5 10 6
Iso fo rm  6 o f  Pro te in  q u a k in g IP I0 0 3 8 5 5 6 2 2 0 2 2 4 0
Iso fo rm  A  o f Pro te in  Cu tA IP I0 0 0 3 4 3 1 9 4 1 1 2 2 2
Iso fo rm  A  o f Ras G T P a se -a ctiv a tin g  p ro te in -b in d in g  p rote in  2 IP I0 0 0 0 9 0 5 7 2 1 2 1 3 2
Iso fo rm  A  o f  R a s-re la te d  C3 b o tu lin u m  to xin  su b stra te  1 IP I0 0 0 1 0 2 7 1 3 2 2 5 4 4
Iso fo rm  A  o f R N A -b in d in g  p rote in  w ith  m u ltip le  sp lic in g IP I0 0 0 0 4 0 4 5 1 0 3 7 3 3
Iso fo rm  A  o f T ryp s in -3 IP I0 0 0 1 5 6 1 4 1 1 2 1 2 1
Iso fo rm  A l- B  o f H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  A1 IP I0 0 2 1 5 9 6 5 34 28 23 34 28 22
Iso fo rm  A lp h a  o f A p o p to s is  re g u la to r BAX IP I0 0 4 4 3 7 7 3 7 6 5 5 6 3
Iso fo rm  A lp h a  o f  S ig n a l tra n sd u ce r  and a ct iv a to r o f tra n scrip tio n  la / ß IP I0 0 0 3 0 7 8 1 7 0 1 3 8 1
Iso fo rm  A lp h a -6 X 1 X 2 B  o f  Integrin  a lp h a -6 IP I0 0 0 1 0 6 9 7 2 2 4 7 10 6
Iso fo rm  a lp h a -e n o la se  o f A lp h a -e n o la se IP I0 0 4 6 5 2 4 8 50 45 63 72 30 25
Iso fo rm  A P P 7 7 0  o f A m y lo id  beta A 4 p rote in  (Fragm en t) IP I0 0 0 0 6 6 0 8 2 2 3 2 3 0
Iso fo rm  A SF -1  o f S e rin e /a rg in in e -r ich  sp lic in g  fa cto r 1 IP I0 0 2 1 5 8 8 4 7 8 10 14 9 10
Iso fo rm  B o f A P -2  co m p le x  su b u n it a lp h a-1 IP I0 0 2 5 6 6 8 4 8 1 4 7 12 8
Iso fo rm  B o f A rfa p tin -1 IP I0 0 0 2 1 2 5 8 2 1 1 2 3 0
Iso fo rm  B o f P e rilip in -3 IP I0 0 3 0 3 8 8 2 9 6 7 14 12 6
Iso fo rm  B1 o f H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in s  A 2/B 1 IP I0 0 3 9 6 3 7 8 23 14 18 23 20 18
Iso fo rm  Beta  o f H eat sh o ck  protein  105 kDa IP I0 0 2 1 8 9 9 3 22 10 22 19 20 14
Iso fo rm  B e ta -1  o f P ro te in  p h o sp h a ta se  I B IP I0 0 0 2 6 6 1 2 2 1 2 2 7 3
Iso fo rm  C l  o f H e te ro g e n e o u s n u clear r ib o n u c le o p ro te in s  C 1/C 2 1P I0 0 2 16592 11 11 13 20 14 10
Iso fo rm  C o m p le xe d  o f A rg in y l-tR N A  syn th e ta se , c yto p la sm ic IP I0 0 0 0 4 8 6 0 8 4 7 9 10 10
Iso fo rm  C rk -ll o f A d a p te r  m ole cu le  crk IP I0 0 0 0 4 8 3 8 5 1 2 3 3 2
Iso fo rm  C y to p la sm ic  o f  Ly sy l-tR N A  syn th eta se IP I0 0 0 1 4 2 3 8 8 5 6 9 9 8
Iso fo rm  D e l-701  o f  S ig n a l tra n sd u ce r  and a ct iv a to r o f tra n scrip tio n  3 IP I0 0 3 0 6 4 3 6 4 1 3 3 6 3
Iso fo rm  D e lta -1  o f  S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A  56 kDa IP I0 0 0 0 0 0 3 0 2 0 1 3 3 3
re g u la to ry  su b u n it  d e lta  iso form
Iso fo rm  D FF4 5  o f D N A  fra g m e n ta tio n  fa cto r su b u n it a lp h a  (Frag m en t) IP100010882 3 0 1 2 1 1
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Iso fo rm  G a m m a -1  o f S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  PP1- 
g a m m a  ca ta ly tic  su b u n it
IP1000Q57Q5 2 1 2 2 2
Iso fo rm  G T B P -N  o f D N A  m ism a tch  rep a ir p rote in  M sh 6 IP I0 0 3 8 4 4 5 6 9 7 3 6 10
Iso fo rm  H e a rt o f  A T P  syn th ase  su b u n it ga m m a, m ito cho ndria! IP I0 0 3 9 5 7 6 9 5 2 3 5 3
Iso fo rm  II o f U b iq u it in -p ro te in  ligase  E3A IP I0 0 0 1 1 6 0 9 3 1 3 3 3
Iso fo rm  Lo n g  o f  14-3-3  p rote in  b eta/alp h a IP I002 16318 13 9 14 18 11
Iso fo rm  Lo n g  o f 60  kDa S S-A /R o  rib o n u cle o p ro te in IP I0 0 0 1 9 4 5 0 4 2 2 4 3
Iso fo rm  Lo n g  o f Co ld  sh o ck  d o m a in -co n ta in in g  p rote in  E l IP I004 70891 3 1 2 5 5
Iso fo rm  Lo n g  o f D e lta -l-p y rro lin e -5 -c a rb o x y la te  syn th ase IP I0 0 0 0 8 9 8 2 11 6 4 8 6
Iso fo rm  Lo n g o f D o u b le -stra n d e d  R N A -b in d in g  p rote in  Staufen  
h o m o lo g  1
IP I0 0 0 0 0 0 0 1 3 1 2 2 4
Iso fo rm  Lo n g o f  E S I  p rote in  h o m o lo g , m ito ch o n d ria l 1P I0 0 0 2 4 9 13 2 2 1 4 5
Iso fo rm  Lo n g o f E u k a ry o tic  tra n sla tio n  in itiatio n  fa cto r 4H IP I0 0 0 1 4 2 6 3 6 2 6 5 3
Iso fo rm  Lo n g o f G lu co se -6 -p h o sp h a te  1 -d e h yd ro g e n a se IP I0 0 2 1 6 0 0 8 2 2 7 9 10
Iso fo rm  Lo n g o f  G ly cy lp e p tid e  N -te tra d e ca n o y ltra n sfe ra se  1 IP I0 0 3 2 9 6 9 2 2 0 3 2 4
Iso fo rm  Lo n g o f  H e te ro g e n e o u s n u c le a r r ib o n u c le o p ro te in  U IP I0 0 8 8 3 8 5 7 20 12 25 23 11
Iso fo rm  Lo n g o f  S o d iu m /p o ta ss iu m -tra n sp o rtin g  A T P a se  su b u n it a -1 IP I0 0 0 0 6 4 8 2 17 15 12 14 20
Iso fo rm  Lo n g o f S p e ctrin  beta ch ain , brain  1 IP I0 0 0 0 5 6 1 4 30 24 38 58 49
Iso fo rm  Lo n g  o f S p lic in g  fa cto r, p ro lin e - an d  g lu ta m in e -rich IP I0 0 0 1 0 7 4 0 14 6 8 17 18
Iso fo rm  Lo n g  o f  T ig h t  ju n ctio n  p ro te in  ZO -1 IP I0 0 2 1 6 2 1 9 4 1 3 1 6
Iso fo rm  Lo n g o f T r ifu n ctio n a l purine  b io syn th e tic  p ro te in  a d e n o sin e -3 IP I0 0 0 2 5 2 7 3 14 8 9 14 12
Iso fo rm  Lo n g o f  U b iq u itin  ca rb o xy l-te rm in a l h yd ro la se  5 IP I0 0 0 2 4 6 6 4 11 5 9 7 11
Iso fo rm  M 2 o f  P yru va te  k in ase  iso zym e s M 1/M 2 IP I0 0 4 7 9 1 8 6 44 36 38 51 35
Iso fo rm  M ito ch o n d ria l o f Fu m a rate  h yd ra tase , m ito ch o n d ria l IP I0 0 2 9 6 0 5 3 9 4 7 5 5
Iso fo rm  M ito ch o n d ria l o f  G lu ta th io n e  red u ctase , m ito ch o n d ria l IP I0 0 0 1 6 8 6 2 7 5 2 3 4
Iso fo rm  M ito ch o n d ria l o f P h o sp h o lip id  h yd ro p ero xid e  g lu tath io n e  
p e ro xid a se , m ito ch o n d ria l
IP I0 0 3 0 4 8 1 4 5 3 4 4 5
Iso fo rm  N o n -b ra in  o f  C la th rin  ligh t ch ain  A IP I0 0 2 1 6 3 9 3 3 1 4 1 2
Iso fo rm  N o n -m u sc le  o f  M yo sin  ligh t p o lyp ep tid e  6 1P I0 0 3 3 5 168 12 5 6 9 11
Iso fo rm  p26 o f 7 ,8 -d ih y d ro -8 -o x o g u a n in e  trip h o sp h a ta se IP I0 0 0 0 4 3 9 2 3 1 4 6 3
Iso fo rm  p 2 7 -L  o f 26S p ro te a so m e  n o n -A TP ase  re g u la to ry  su b u n it 9 IP I0 0 0 1 0 8 6 0 0 1 2 5 2
Iso fo rm  R p n lO A  o f  2 6 S  p ro te a so m e  n o n -A T P a se  re g u la to ry  su b u n it 4 IP I0 0 0 2 2 6 9 4 6 6 3 5 9
Iso fo rm  S h o rt o f P ro te a so m e  su b u n it a lp h a  typ e -1 IP I0 0 0 1 6 8 3 2 10 2 12 10 8
Iso fo rm  S h o rt o f R N A -b in d in g  p rote in  FU S IP I0 0 2 2 1 3 5 4 3 2 5 6 6
Iso fo rm  S M -B ’ o f Sm all n u c le a r r ib o n u c le o p ro te in -a sso c ia te d  p rote in s IP I0 0 0 2 7 2 8 5 2 2 4 4 2
Iso fo rm  SN A P -2 3 a  o f S y n a p to so m a l-a sso c ia te d  p rote in  23 IP I0 0 0 1 0 4 3 8 3 1 2 3 2
Iso fo rm  S R P 5 5 -1  o f S e rin e /a rg in in e -r ich  sp lic in g  fa c to r  6 IP I0 0 0 1 2 3 4 5 1 2 3 3 2
Iso le u cy l-tR N A  syn th eta se , c yto p la sm ic IP I0 0 6 4 4 1 2 7 25 14 10 18 25
Ju n c tio n  p lako g lo b in IP I0 0 5 5 4 7 1 1 2 0 1 6 6
Ju n c tio n a l a d h e sio n  m o le cu le  A IP I0 0 0 0 1 7 5 4 2 0 3 3 6
K e ratin , typ e  1 cyto ske le ta l 10 IP I0 0 0 0 9 8 6 5 10 5 8 10 24
Ke ratin , typ e  II cyto ske le ta l 8 IP I0 0 5 5 4 6 4 8 16 13 21 51 31
K in e sin -1  h e av y chain IP I0 0 0 1 2 8 3 7 15 4 14 18 12
K in e sin -lik e  p rote in  KIF11 IP I0 0 3 0 5 2 8 9 4 4 1 8 6
K in e to ch o re -a sso c ia te d  p rote in  1 IP I0 0 0 0 1 4 5 8 1 2 1 2 5
La cto y lg lu ta th io n e  lyase IP I0 0 2 2 0 7 6 6 5 4 3 9 3
L a m in -B l IP I0 0 2 1 7 9 7 5 3 0 6 5 7
La m in -B 2 IP I0 0 0 0 9 7 7 1 1 0 3 2 1
La m in in  su b u n it  a lp h a -1 IP I0 0 3 7 5 2 9 4 2 3 4 2 2
La m in in  su b u n it  b e ta-1 IP I0 0 0 1 3 9 7 6 3 0 2 7 8
La m in in  su b u n it  g a m m a -1 IP I0 0 2 9 8 2 8 1 6 3 5 2 10
L -a m in o a d ip a te -se m ia ld e h y d e  d e h y d ro g e n a se -p h o sp h o p a n te th e in y l 
tra n sfe ra se
IP I0 0 2 5 0 2 9 7 3 0 2 1 0
la n o ste ro l 14 -a lp h a  d e m e th y la se  iso fo rm  1 IP I0 0 2 9 S 7 7 2 11 6 11 4 8
La n o ste ro l syn th a se IP I0 0 0 0 9 7 4 7 5 3 12 4 7
Large  n e u tra l a m in o  a c id s  tra n sp o rte r  sm all su b u n it 1 IP I0 0 0 0 8 9 8 6 5 0 4 0 5
LD LR  c h a p e ro n e  M ESD IP I0 0 3 9 9 0 8 9 2 1 0 1 2
























































Le u c in e -rich  re p e a t-c o n ta in in g  p rote in  40
Le u c in e -rich  re p e a t-co n ta in in g  p rote in  47
Le u c in e -r ich  re p e a t-c o n ta in in g  p rote in  59
Le u cy l-tR N A  syn th e ta se , cyto p la sm ic
LIN E -1  typ e  tra n sp o sa se  d o m a in -co n ta in in g  p rote in  1
L-la cta te  d e h yd ro g e n a se  B chain
Lon p ro tea se  h o m o lo g , m ito ch o n d ria l
L o n g -c h a in -fa tty -a c id -C o A  ligase  3
Lu p u s La p rote in
L-xy lu lo se  red u ctase
Ly so p h o sp h a tid y lch o lin e  a cy ltra n sfe ra se  1
Ly so so m e -a sso c ia te d  m e m b ra n e  glyco p ro te in  1
M a c ro p h a g e -c a p p in g  p rote in
M A G U K  p55 s u b fa m ily  m e m b e r 6
M ala te  d e h y d ro g e n a se
M ala te  d e h y d ro g e n a se , m ito ch o n d ria l
M ale ctin
m a le y la ce to a c e ta te  iso m e ra se  iso form  1
M A R C K S -re la te d  p ro te in
M a trin -3
M e m b ra n e -a sso c ia te d  p ro g e ste ro n e  recep to r co m p o n e n t 1 
M e th io n y l-tR N A  sy n th e ta se , cyto p lasm ic
M e th y le n e te tra h y d ro fo la te  d e h yd ro g e n a se  (N A D P+  d e p e n d e n t) 1- 
like
M e th y lo so m e  p rote in  50 
M e th y lo so m e  su b u n it  p lC ln  
M icro so m a l g lu ta th io n e  S -tra n sfe ra se  1 
M icro tu b u le -a sso c ia te d  p ro te in  I B  
M icro tu b u le -a sso c ia te d  p ro te in  R P /EB  fa m ily  m em b e r 1 
M id asin
M ito ch o n d ria l fiss io n  1 p rote in
M ito ch o n d ria l im p o rt in n e r m e m b ra n e  tra n s lo ca se  su b u n it T IM 4 4  
M ito c h o n d ria l-p ro ce ss in g  p e p tid a se  su b u n it a lpha 
M ito c h o n d ria l-p ro ce ss in g  p e p tid a se  su b u n it beta 
M ito g e n -a ctiv a te d  p rote in  k in ase  1 
M ito g e n -a ctiv a te d  p rote in  k in ase  sca ffo ld  p rote in  1 
M LL1 /M LL  co m p le x su b u n it C 1 7 o rf4 9  iso fo rm  1 
M o e sin
M o n o ca rb o xy la te  tra n sp o rte r 1 
m R N A  tu rn o v e r p rote in  4  h o m o lo g  
M u ltifu n ctio n a l p rote in  A D E2  
M yo sin -le  
M y o tro p h in
M y risto y la te d  a la n in e -rich  C -k in ase  su b strate  
N (G ),N (G )-d im e th y la rg in in e  d im e th y la m in o h yd ro la se  1 
N (G ),N (G )-d im e th y la rg in in e  d im e th y la m in o h yd ro la se  2 
N a (+ )/H (+ ) e xch a n g e  re g u la to ry  co fa cto r N H E-R F1 
N -a c e ty l-D -g lu c o sa m in e  k inase 
N -a c e ty ltra n sfe ra se  10
N A D -d e p e n d e n t  m alic  e n zym e , m ito ch o n d ria l 
N A D H  d e h y d ro g e n a se  [u b iq u in o n e ] iro n -su lfu r p rote in  3 
N A D P H -c y to c h ro m e  P 450  redu ctase  
N -a lp h a -a c e ty ltra n sfe ra se  10, N atA  cata lytic  su b u n it 
N -a lp h a -a c e ty ltra n sfe ra se  38, N atC  a u xilia ry  su b u n it 
n a rd ilys in  iso fo rm  a
N a sce n t p o ly p e p tid e -a sso c ia te d  co m p le x  su b u n it a lpha 
N E D D 8 -a ctiv a tin g  e n zy m e  E l  cata ly tic  su b u n it 
N E D D 8 -a c tiv a tin g  e n zy m e  E l  reg u la to ry  su b u n it
IP I0 0 1 5 2 9 9 8 2 1 2 1 3 3
IP I0 0 1 7 0 9 3 5 5 4 2 7 5 4
IP I0 0 3 9 6 3 2 1 3 4 3 5 6 5
IP I0 0 1 0 3 9 9 4 20 11 13 17 19 21
IP I0 0 2 5 3 0 5 0 16 10 12 15 18 14
1P I0 0 2 19217 27 19 23 22 18 14
IP I0 0 0 0 5 1 5 8 9 5 5 10 7 9
IP I0 0 0 3 1 3 9 7 2 0 2 1 10 2
IP I0 0 0 0 9 0 3 2 22 13 18 19 14 13
IP I0 0 4 4 8 0 9 5 2 1 3 2 1 0
IP I0 0 1 7 1 6 2 6 4 2 3 2 5 1
IP I0 0 8 8 4 1 0 5 3 3 4 3 1 1
IP I0 0 0 2 7 3 4 1 2 1 2 6 7 4
IP I0 0 3 0 3 2 8 0 2 0 2 3 2 1
IP I0 0 9 1 6 1 1 1 12 10 11 10 10 9
IP I0 0 2 9 1 0 0 6 20 15 20 16 14 12
IP I0 0 0 2 9 0 4 6 2 1 2 2 4 2
IP I0 0 5 5 6 5 7 9 1 1 2 2 1 1
IP I0 0 6 4 1 1 8 1 1 2 2 0 1 2
IP I0 0 0 1 7 2 9 7 14 14 13 18 15 15
IP I0 0 2 2 0 7 3 9 8 3 3 8 3 3
IP I0 0 0 0 8 2 4 0 17 12 12 15 18 17
IP I0 0 2 9 1 6 4 6 5 3 3 3 4 3
IP I0 0 0 1 2 2 0 2 3 0 2 2 4 2
IP I0 0 0 0 4 7 9 5 2 2 2 3 0 1
IP I0 0 0 2 1 8 0 5 3 1 1 0 2 2
IP I0 0 0 0 8 8 6 8 6 3 17 5 5 6
IP I0 0 0 1 7 5 9 6 10 4 10 15 13 9
IP I0 0 1 6 7 9 4 1 15 5 3 5 11 0
IP I0 0 0 0 7 0 5 2 3 3 1 2 3 0
IP I0 0 3 0 6 5 1 6 6 3 5 5 3 4
IP I0 0 1 6 6 7 4 9 2 0 1 2 3 1
IP I0 0 9 2 7 8 9 2 4 2 4 4 4 3
IP I0 0 0 0 3 4 7 9 3 2 4 4 4 1
IP I0 0 0 3 0 9 1 9 1 0 2 1 1 2
IP I0 0 3 7 3 8 6 9 2 0 2 3 1 2
1P I0 0 2 19365 15 12 11 22 18 14
IP I0 0 0 2 4 6 5 0 2 1 1 2 1 1
IP I0 0 1 0 6 4 9 1 7 2 3 5 4 4
IP I0 0 2 1 7 2 2 3 23 17 26 24 14 15
IP I0 0 3 2 9 6 7 2 2 1 1 1 3 2
IP I0 0 9 2 4 8 1 6 1 0 2 5 1 3
IP I0 0 2 1 9 3 0 1 0 1 5 0 4 1
IP I0 0 2 2 0 3 4 2 4 6 5 4 2 2
IP I0 0 0 0 0 7 6 0 3 0 3 4 6 3
IP I0 0 0 0 3 5 2 7 4 4 9 7 3 3
IP I0 0 2 9 6 5 2 6 3 0 5 1 3 2
IP I0 0 3 0 0 1 2 7 3 5 4 6 7 5
IP I000 11201 2 0 3 1 3 0
IP I0 0 0 2 5 7 9 6 4 3 6 5 5 2
IP I0 0 4 7 0 4 6 7 7 6 6 6 6 10
1P I0 0 0 1 3 184 1 1 2 0 4 1
IP I0 0 2 1 9 8 7 1 1 1 2 6 0 4
IP I0 0 2 4 3 2 2 1 4 0 3 0 4 6
IP I0 0 0 2 3 7 4 8 6 7 8 8 5 6
IP I0 0 3 2 8 1 5 4 4 0 4 3 5 2
IP I0 0 0 1 8 9 6 8 5 1 2 4 2 4
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N E D D 8 -c o n ju g a tin g  e n zym e  U b c l2 IP I0 0 0 2 2 5 9 7 3 1 6 4 3 2
N estin IP I0 0 0 1 0 8 0 0 18 5 22 13 22 27
N e u ro ly s in , m ito ch o n d ria l IP I0 0 0 1 0 3 4 6 7 7 5 8 10 9
N e u tra l a m in o  acid  tra n sp o rte r B(0) IP I0 0 0 1 9 4 7 2 7 5 6 3 4 7
N H P 2 -lik e  p ro te in  1 IP I0 0 0 2 6 1 6 7 2 1 3 5 3 3
N ib a n -lik e  p rote in  1 IP I0 0 4 5 6 7 5 0 2 1 1 5 5 4
N ico tin a m id e  p h o sp h o rib o sy ltra n sfe ra se IP I0 0 0 1 8 8 7 3 8 4 5 7 7 8
N ico tin a te -n u c le o tid e  p yro p h o sp h o ry la se  [carb o xyla tin g] IP I0 0 3 0 0 0 8 6 2 0 2 1 3 2
N o n -P O U  d o m a in -co n ta in in g  o cta m e r-b in d in g  p rote in IP I0 0 3 0 4 5 9 6 9 5 9 15 12 8
N u cle a r ca p -b in d in g  p rote in  su b u n it 1 IP I0 0 0 1 9 3 8 0 7 2 5 10 5 5
N u cle a r m igratio n  p ro te in  n u d C IP I0 0 5 5 0 7 4 6 7 5 6 8 10 7
N u cle a r pore c o m p le x  p ro te in  N u p l0 7 IP I0 0 0 2 8 0 0 5 7 3 2 2 4 3
N u cle a r pore  co m p le x  p rote in  N u p l3 3 IP I0 0 2 9 1 2 0 0 2 2 3 5 8 2
N u clea r pore  co m p le x  p rote in  N up205 IP I0 0 7 8 3 7 8 1 2 8 4 10 14 10
N u cle a r pore  co m p le x  p rote in  N up50 IP I0 0 0 2 6 9 4 0 0 1 4 1 3 0
N u cle a r pore  co m p le x  p rote in  N up93 IP I0 0 3 9 7 9 0 4 8 8 3 8 9 7
N u c le a r re ce p to r-b in d in g  p rote in IP I0 0 6 0 4 7 5 6 2 1 1 2 1 1
N u c le a r  tra n sp o rt  fa cto r 2 IP I0 0 0 0 9 9 0 1 2 0 3 4 3 5
N u c le a se -se n s it iv e  e le m e n t-b in d in g  p rote in  1 1P I0 0 0 3 1812 6 1 13 0 11 14
N u c le o b in d in -1 IP I0 0 2 9 5 5 4 2 5 1 4 6 2 1
N u c le o la r  G T P -b in d in g  p rote in  1 IP I0 0 3 8 5 0 4 2 3 1 1 3 7 3
N u c le o la r p ro te in  56 IP I0 0 4 1 1 9 3 7 3 1 2 5 7 6
N u c le o la r p rote in  58 IP I0 0 0 0 6 3 7 9 5 2 2 7 8 6
N u c le o p o rin  54kD a  v a r ia n t (Frag m e n t) IP I0 0 1 7 2 5 8 0 3 0 2 3 6 2
N u c le o p o rin  N up37 IP I0 0 1 7 1 6 6 5 1 0 2 1 2 1
N u c le o p ro te in  T P R IP I0 0 7 4 2 6 8 2 15 12 25 21 23 14
N u c le o sid e  d ip h o sp h a te  k in ase IP I0 0 6 0 4 5 9 0 18 17 10 19 17 11
N u c le o s id e -tr ip h o sp h a ta se  C lo r f5 7 IP I0 0 0 3 1 5 7 0 3 2 1 6 4 2
N u c le o so m e  a sse m b ly  p ro te in  1-like  1 IP I0 0 0 2 3 8 6 0 14 10 14 10 9 12
N u d C  d o m a in -co n ta in in g  p ro te in  2 1P I0 0 1 0 3 142 4 0 1 4 3 3
O rn ith in e  a m in o tra n sfe ra se , m ito ch o n d ria l IP I0 0 0 2 2 3 3 4 12 9 10 7 5 7
O s te o c la st-s tim u la t in g  fa c to r  1 IP I0 0 4 1 4 8 3 6 2 1 0 3 2 2
O TU  d o m a in -co n ta in in g  p ro te in  6B IP I0 0 9 3 5 7 2 2 3 4 2 3 0 3
P alad in IP I0 0 2 9 7 2 1 2 2 0 1 3 0 1
P a lm ito y l-p ro te in  th io e ste ra se  1 IP I0 0 0 0 2 4 1 2 4 1 4 1 2 2
P D Z an d  LIM  d o m a in  p ro te in  1 IP I0 0 0 1 0 4 1 4 11 4 6 16 10 12
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  A IP I0 0 4 1 9 5 8 5 23 16 14 21 14 15
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  B IP I0 0 6 4 6 3 0 4 12 6 13 10 9 8
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  D IP I0 0 0 0 3 9 2 7 1 0 2 6 2 3
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  FKB P3 IP I0 0 0 2 4 1 5 7 4 3 6 9 5 4
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  FKB P4 IP I0 0 2 1 9 0 0 5 13 11 16 17 19 15
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  H IP I0 0 0 0 7 3 4 6 3 0 4 4 3 1
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se  N IM A -in te ra ct in g  1 IP I0 0 0 1 3 7 2 3 3 2 0 5 0 2
P e p tid y l-p ro ly l c is -tra n s  iso m e ra se -like  1 IP I0 0 0 0 7 0 1 9 2 1 3 4 3 3
P e ro x ire d o x in -1 IP100000874 16 19 16 30 12 11
P e ro x ire d o x in -2 IP I0 0 0 2 7 3 5 0 8 15 8 12 4 3
P e ro x ire d o x in -4 IP I0 0 0 1 1 9 3 7 10 7 9 10 3 5
P e ro x ire d o x in -6 IP I0 0 2 2 0 3 0 1 22 16 20 32 21 18
P e ro x iso m a l m u ltifu n ctio n a l e n zym e  typ e  2 IP I0 0 0 1 9 9 1 2 15 9 16 7 9 9
P h e n y la la n y l-tR N A  syn th e ta se  a lpha chain IP I0 0 0 3 1820 3 1 3 3 4 3
P h e n y la la n y l-tR N A  syn th e ta se  beta chain IP I0030Q 074 2 0 5 3 6 2
P h o sd u cin -like  p ro te in  3 IP I0 0 0 3 1 6 2 9 5 0 3 0 4 2
P h o s p h a tid y le th a n o la m in e -b in d in g  p rote in  1 IP I0 0 2 1 9 4 4 6 8 9 9 10 7 8
P h o sp h o g ly ce ra te  k in a se  1 IP I0 0 1 6 9 3 8 3 41 40 41 45 35 27
P h o sp h o g ly co la te  p h o sp h a ta se IP I0 0 1 7 7 0 0 8 4 3 4 2 4 2
P h o sp h o m a n n o m u ta se  2 IP I0 0 0 0 6 0 9 2 2 0 1 4 5 1
P h o sp h o m e v a lo n a te  k in ase IPIÛ 0220648 4 2 1 3 2 1
P h o sp h o rib o sy l p y ro p h o sp h a te  syn th a se -a sso cia te d  p rote in  2 IP I0 0 0 0 3 1 6 8 6 3 5 8 6 3
1 4 4
P h o sp h o rib o sy lfo rm y lg ly c in a m id in e  syn th ase
P h o sp h o se rin e  a m in o tra n sfe ra se
P h o sp h o se r in e  p h o sp h a ta se
P la stin -1
P la stin -3
P la te le t-a ct iv a tin g  fa cto r a ce ty lh yd ro la se  IB su b u n it beta
P la te le t-a ct iv a tin g  fa c to r  a ce ty lh y d ro la se  IB su b u n it ga m m a
P o d o ca ly x in -lik e  p rote in  1 p re cu rso r
P o ly  [A D P -rib o se ] p o ly m e ra se  1
P o ly (rC )-b in d in g  p rote in  1
P o lym e ra se  d e lta -in te ra ctin g  p rote in  2
P re fo ld in  su b u n it 2
P re fo ld in  su b u n it  5
P re -m R N A  b ran ch  site  p rote in  p l4
P re -m R N A -p ro ce ssin g  fa c to r  19
P re -m R N A -p ro ce ss in g -sp lic in g  fa c to r  8
P re -m R N A -sp lic in g  fa cto r SPF27
P re n y lcy ste in e  o x id a se  1
P re -rR N A -p ro ce ss in g  p rote in  TSR 1  h o m o lo g
P R K C  a p o p to s is  W T1  re g u la to r protein
P R M T 3  p rote in  (Frag m en t)
P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  D D X27 
P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  D D X47 
P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  DD X5 
P ro b a b le  A T P -d e p e n d e n t R N A  h e licase  DD X6 
P ro b a b le  fru cto se -2 ,6 -b isp h o sp h a ta se  T IG A R  
P ro b a b le  rib o so m e  b io g e n e sis  p rote in  N EP1 
P ro b a b le  R N A -b in d in g  p rote in  EIF1A D
p ro b a b le  u b iq u itin  ca rb o x y l-te rm in a l h yd ro lase  FA F-X  iso fo rm  4
P ro filin
P ro filin -1
p ro g e ste ro n e  re ce p to r m e m b ra n e  co m p o n e n t 2
P ro g ra m m e d  cell d e ath  6 -in te ra c t in g  p rote in
P ro g ra m m e d  cell death  p ro te in  10
P ro g ra m m e d  cell death  p ro te in  5
P ro g ra m m e d  cell death  p rote in  6
P ro h ib it in
P ro h ib it in -2
P ro life ra t in g  cell n u clea r an tigen  
P ro life ra t io n -a sso c ia te d  p rote in  2G 4
P ro lin e  syn th e ta se  co -tra n scrib e d  h o m o lo g  (B acte ria l), iso form  (
P ro lo w -d e n s ity  lip o p ro te in  re ce p to r-re la te d  p rote in  1
P ro ly l e n d o p e p tid a se
P ro sta g la n d in  E syn th ase  3
P ro te a so m a l u b iq u itin  re ce p to r A D R M 1
P ro té a so m e  26S n o n -A TP ase  su b u n it 11 v a ria n t (Frag m e n t)
P ro te a so m e  a ct iv a to r co m p le x  su b u n it 1
P ro te a so m e  a sse m b ly  ch a p e ro n e  3
P ro te a so m e  in h ib ito r P I31 su b u n it
P ro te a so m e  su b u n it a lp h a  typ e -2
P ro te a so m e  su b u n it  a lpha typ e -4
P ro te a so m e  su b u n it  a lp h a  typ e -5
P ro te a so m e  su b u n it  a lp h a  typ e -6
P ro te a so m e  su b u n it  beta typ e -1
P ro te a so m e  su b u n it  beta typ e -2
P ro te a so m e  su b u n it  beta typ e -3
P ro te a so m e  su b u n it  beta typ e -4
P ro te a so m e  su b u n it  beta typ e -5
IP I0 0 0 0 4 5 3 4 16 15 20 18 16 15
IP I0 0 0 0 1 7 3 4 17 13 18 12 12 12
1P I0 0 0 1 9 178 4 1 5 2 2 3
IP I0 0 0 3 2 3 0 4 2 3 2 1 1 3
IP I0 0 2 1 6 6 9 4 22 18 16 20 18 19
IP I0 0 0 2 6 5 4 6 1 1 2 4 2 1
IP I0 0 0 1 4 8 0 8 1 0 4 5 4 1
1P I0 0 2 9 9 116 4 4 5 5 6 3
IP I0 0 4 4 9 0 4 9 6 3 11 28 25 19
IP I0 0 0 1 6 6 1 0 13 7 10 9 13 12
IP I0 0 1 6 5 5 0 6 4 2 2 1 1 3
IP I0 0 0 0 6 0 5 2 3 2 3 5 5 3
IP I0 0 0 1 5 3 6 1 4 4 4 7 3 3
IP I0 0 0 3 2 8 2 7 3 2 2 3 3 3
IP I0 0 0 0 4 9 6 8 7 2 4 5 5 5
IP I0 0 0 0 7 9 2 8 17 15 13 24 30 24
IP I0 0 0 2 5 1 7 8 2 0 2 4 3 2
IP I0 0 3 8 4 2 8 0 1 0 2 1 5 1
IP I0 0 2 9 2 8 9 4 6 4 3 3 3 2
IP I0 0 0 0 1 8 7 1 2 1 2 2 2 1
IP I0 0 1 0 3 0 2 6 1 0 2 3 1 1
IP I0 0 2 9 3 0 7 8 2 1 0 2 1 2
IP I0 0 0 2 3 9 7 2 2 1 2 2 4 1
IP I0 0 0 1 7 6 1 7 15 7 10 9 12 10
IP100030320 5 2 5 3 8 3
IP I0 0 0 0 6 9 0 7 3 0 4 5 4 2
IP I0 0 0 2 5 3 4 7 2 2 4 1 0 5
IP I0 0 2 9 8 6 1 8 2 1 2 1 1 2
IP I0 0 0 0 3 9 6 4 11 6 10 21 24 16
IP I0 0 1 0 7 5 5 5 2 1 2 5 3 3
IP I0 0 2 1 6 6 9 1 21 17 19 18 11 12
IP I0 0 0 0 5 2 0 2 2 1 2 2 3 2
IP I0 0 2 4 6 0 5 8 12 5 10 13 13 9
IP I0 0 2 9 8 5 5 8 2 0 1 3 4 3
IP I0 0 0 2 3 6 4 0 3 3 4 4 1 3
IP I0 0 0 2 5 2 7 7 6 2 2 4 3 0
IP I0 0 0 1 7 3 3 4 5 2 5 7 5 6
IP I0 0 0 2 7 2 5 2 5 2 6 7 5 8
IP I0 0 0 2 1 7 0 0 8 7 8 7 8 7
IP I0 0 2 9 9 0 0 0 9 6 13 8 9 9
IP I0 0 0 1 6 3 4 6 2 2 4 3 2 1
IP I0 0 0 2 0 5 5 7 2 1 3 4 2 0
IP I0 0 0 0 8 1 6 4 9 5 3 10 11 15
IP I0 0 0 1 5 0 2 9 4 3 5 4 4 5
IP I0 0 0 3 3 0 3 0 2 0 2 1 3 1
IP I0 0 1 0 5 5 9 8 14 7 10 7 15 9
IP I0 0 4 7 9 7 2 2 3 3 6 7 8 5
1P I0 0 0 3 1106 3 1 2 2 2 0
IP I0 0 0 0 9 9 4 9 1 0 3 3 1 1
1P I0 0 2 19622 9 8 6 11 6 4
1P I0 0 2 9 9 155 6 5 9 8 5 7
IP I0 0 2 9 1 9 2 2 8 4 7 9 8 6
IP I0 0 0 2 9 6 2 3 5 7 11 10 9 9
IP I0 0 0 2 5 0 1 9 8 5 4 15 5 5
IP I0 0 0 2 8 0 0 6 6 3 6 9 5 6
IP I0 0 0 2 8 0 0 4 8 6 1 9 4 4
IP I0 0 5 5 5 9 5 6 7 4 6 6 5 4
IP100479306 15 7 4 11 10 6
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P ro te a so m e  su b u n it  beta typ e -6 IP I0 0 0 0 0 8 1 1 3 1 2 5 2 3
P ro te a so m e  su b u n it  beta typ e -7 IP I0 0 0 0 3 2 1 7 2 2 2 4 2 2
p ro te a so m e -a sso c ia te d  p rote in  EC M 29 h o m o lo g IP I0 0 1 5 7 7 9 0 15 4 10 14 16 9
p ro te in  a rg in in e  N -m e th y ltra n sfe ra se  1 iso form  1 IP I0 0 0 1 8 5 2 2 5 5 14 4 13 12
P ro te in  a rg in in e  N -m e th y ltra n sfe ra se  5 IP I0 0 4 4 1 4 7 3 5 0 3 1 5 5
P ro te in  C IO IP I0 0 0 1 6 9 2 5 3 1 3 2 1 2
P ro te in  d isu lfid e -iso m e ra se IP I0 0 0 1 0 7 9 6 24 21 22 32 22 19
P ro te in  d isu lfid e -iso m e ra se  A3 IP I0 0 0 2 5 2 5 2 39 25 29 37 35 27
P ro te in  d isu lfid e -iso m e ra se  A 4 IP10Q009904 21 14 16 21 29 22
Pro te in  DJ-1 IP I0 0 2 9 8 5 4 7 8 11 3 11 8 6
P ro te in  FA M 3 C IP I0 0 3 3 4 2 8 2 5 4 1 4 3 1
Pro te in  FA M 49B IP I0 0 3 0 3 3 1 8 7 6 8 6 6 4
P ro te in  FA M 96B IP I0 0 0 0 7 0 2 4 2 1 1 2 1 0
P ro te in  f lig h tle ss-1  h o m o lo g IP I0 0 0 3 1 0 2 3 2 0 1 2 5 2
P ro te in  K IA A 0 6 6 4 IP I0 0 9 3 9 7 0 7 5 5 3 1 5 3
P ro te in  k in ase , cA M P -d e p e n d e n t, regu la to ry, typ e  II, a lpha IP I0 0 0 6 3 2 3 4 3 1 2 3 3 1
P ro te in  lin -2 8  h o m o lo g  A IP I0 0 0 0 2 9 4 8 12 9 7 13 15 11
P ro te in  lin -7  h o m o lo g  C IP100019997 3 1 0 2 2 1
P ro te in  m ag o  nashi h o m o lo g 2 IP I0 0 0 5 9 2 9 2 4 6 1 6 4 4
P ro te in  N ip S n a p  h o m o lo g  1 1PI00304435 3 3 2 5 3 3
P ro te in  o f u n kn o w n  fu n ctio n  D U F 4 1 0  fa m ily  protein IP I0 0 4 1 9 5 7 5 2 1 2 2 6 2
P ro te in  o f u n kn o w n  fu n ctio n  D U F858, m e th y itra n sfe ra se -like  fa m ily IP I0 0 5 4 9 3 8 9 3 1 0 3 1 4
P ro te in  p h o sp h a ta se  1G IP I0 0 0 0 6 1 6 7 7 2 4 6 5 11
P ro te in  R C C 2 IP I0 0 4 6 5 0 4 4 6 0 7 0 10 7
P ro te in  R R P5  h o m o lo g IP I0 0 4 0 0 9 2 2 2 2 1 2 7 7
P ro te in  S EC 1 3  h o m o lo g IP I0 0 3 7 5 3 7 0 3 0 1 0 5 2
P ro te in  tra n sp o rt  p ro te in  S e c2 3 A IP I0 0 0 1 7 3 7 5 2 0 1 6 10 8
P ro te in  tra n sp o rt  p ro te in  S e c23B IP I0 0 0 1 7 3 7 6 3 3 4 6 5 3
P ro te in  tra n sp o rt  p ro te in  S e c2 4 C IP I0 0 0 2 4 6 6 1 3 3 4 5 2 2
P ro te in  tra n sp o rt  p ro te in  S e c6 1  su b u n it beta IP I0 0 2 2 0 8 3 5 2 1 3 2 3 2
P se u d o u rid y la te  sy n th a se  7 h o m o lo g IP I0 0 0 4 4 7 6 1 6 3 3 5 7 5
P u m ilio  d o m a in -co n ta in in g  p ro te in  K IA A 0020 IP I0 0 7 9 1 3 2 5 3 4 1 3 3 4
P u ro m y c in -se n sit iv e  a m in o p e p tid a se IP I0 0 0 2 6 2 1 6 14 6 15 15 15 18
P u ta tiv e  A T P -d e p e n d e n t C lp  p ro te a se  p ro te o lytic  su b u n it IP100003870 2 0 1 1 2 1
P u ta tiv e  d e o x y rib o se -p h o sp h a te  a ld o lase IP I0 0 2 1 9 6 7 7 1 1 2 0 3 1
P u ta tiv e  p h o sp h o lip a se  B -like  2 IP I0 0 1 6 9 2 8 5 1 0 2 2 2 0
P u ta tiv e  p re -m R N A -sp lic in g  fa c to r  A T P -d p e n d e n t RN A  h e licase  D H X15 IP I0 0 3 9 6 4 3 5 9 6 9 16 15 15
P u ta tiv e  R N A -b in d in g  p rote in  3 IP I0 0 0 2 4 3 2 0 4 2 1 4 1 3
P u ta tiv e  u n ch a ra cte rize d  p rote in IP I0 0 0 1 0 4 0 2 0 1 2 2 3 4
P u ta tiv e  u n ch a ra cte rize d  p rote in  G A RS IP I0 0 9 1 5 8 0 8 15 14 9 20 15 12
P yrid o xa l p h o sp h a te  p h o sp h a ta se IP I0 0 0 2 5 3 4 0 1 3 2 2 4 1
P y rro lin e -5 -ca rb o xy la te  re d u ctase  2 IP I0 0 4 7 0 6 1 0 2 3 0 0 2 2
p yru v ate  d e h y d ro g e n a se  E l  a lpha 1 iso fo rm  2 p re cu rso r IP I0 0 3 0 6 3 0 1 2 1 3 2 3 0
Q u in o n e  o x id o re d u cta se IP I0 0 0 0 0 7 9 2 3 4 3 5 4 2
Rab G D P  d isso c ia tio n  in h ib ito r a lpha IP I0 0 0 1 0 1 5 4 1 0 3 4 8 4
R a d ix in , iso fo rm  C RA _a IP I0 0 0 1 7 3 6 7 8 4 2 7 5 5
Ran G T P a se -a c tiv a tin g  p rote in  1 IP I0 0 2 9 4 8 7 9 12 5 6 10 8 5
R a n -sp e c ific  G T P a se -a c tiv a tin g  protein IP I0 0 4 1 4 1 2 7 7 9 8 12 5 8
Ras G T P a se -a c tiv a tin g  p ro te in -b in d in g  p rote in  1 IP I0 0 0 1 2 4 4 2 6 5 7 4 9 7
Ras G T P a se -a c tiv a tin g -lik e  p rote in  IQ G A P1 IP100009342 17 9 22 33 37 28
Ras s u p p re s so r  p rote in  1 IP I0 0 0 1 7 2 5 6 4 2 4 3 3 4
R a s-re la te d  p ro te in  R a b -1 0 IP I0 0 0 1 6 5 1 3 4 3 1 4 7 2
R a s-re la te d  p ro te in  R a b - l lB IP I0 0 0 2 0 4 3 6 7 7 6 9 7 7
R a s-re la te d  p ro te in  R a b -1 4 IP I0 0 2 9 1 9 2 8 4 7 6 6 3 5
R a s-re la te d  p ro te in  R ab -18 IP I0 0 0 1 4 5 7 7 4 0 2 2 5 5
R a s-re la te d  p ro te in  R a b -1 B IP I0 0 0 0 8 9 6 4 11 10 6 10 7 7
R a s-re la te d  p ro te in  R ab -21 IP I0 0 0 0 7 7 5 5 1 1 2 4 3 1
R a s-re la te d  p ro te in  R a b -2A IP I0 0 0 3 1 1 6 9 5 3 4 9 6 5
1 4 6
R a s-re la te d  p ro te in  R ab -3B IP I0 0 3 0 0 5 6 2 1 1 3 1 4 1
R a s-re la te d  p ro te in  R a b -5A IP I0 0 0 2 3 5 1 0 4 3 3 6 3 5
R a s-re la te d  p ro te in  R ab -5B IP I0 0 0 1 7 3 4 4 2 2 2 1 2 1
R a s-re la te d  p ro te in  R ab -5C IP I0 0 0 1 6 3 3 9 7 6 8 6 6 7
R a s-re la te d  p rote in  Rab-7a IP I0 0 0 1 6 3 4 2 9 6 7 12 7 8
R a s-re la te d  p rote in  R ab -8A IP I0 0 0 2 8 4 8 1 4 1 1 1 1 2
R a s-re la te d  p ro te in  R a l-A IP I0 0 2 1 7 5 1 9 1 2 2 1 2 2
R a s-re la te d  p rote in  R a p - lb IP I0 0 0 1 5 1 4 8 2 4 3 6 6 3
R e g u la tio n  o f  n u c le a r p re -m R N A  d o m a in -co n ta in in g  p rote in  IB IP I0 0 0 0 9 6 5 9 1 0 5 4 4 1
R e p lica tio n  fa c to r  C su b u n it 4 IP I0 0 0 1 7 3 8 1 4 3 1 4 3 5
R e p lica tio n  fa c to r  C su b u n it  5 1P I0 0 0 3 1514 1 0 2 1 3 2
R e p lica tio n  p ro te in  A  14 kDa su bunit IP I0 0 0 1 7 3 7 3 3 0 4 4 1 5
R e p lica tio n  p ro te in  A  70 kDa D N A -b in d in g su bunit IP100020127 5 2 6 5 6 4
R e ticu lo ca lb in -1 IP I0 0 0 1 5 8 4 2 4 1 4 4 3 2
R e tin a l rod rh o d o p sin -se n s it iv e  cG M P  3 ',5 ,-cyclic  p h o sp h o d ie ste ra se s IP I0 0 0 1 5 1 6 1 3 1 1 2 0 2
R e tin o l-b in d in g  p ro te in  1 IP I0 0 9 4 0 5 1 3 3 1 2 4 4 1
R h o  G D P -d isso c ia t io n  in h ib ito r 1 IP I0 0 0 0 3 8 1 5 6 6 8 7 6 6
R h o  G T P a se -a c tiv a tin g  p rote in  1 IP I0 0 0 2 0 5 6 7 7 2 7 7 11 4
R h o A  a ct iv a to r  C l lo r f 5 9 IP I0 0 0 1 6 6 7 0 1 2 1 4 1 1
R ib o n u c lé a se  in h ib ito r IP I0 0 5 5 0 0 6 9 3 1 5 1 6 3
R ib o n u c lé a se  U K114 IP I0 0 0 0 5 0 3 8 3 1 5 5 1 2
R ib o n u c le o s id e -d ip h o sp h a te  red u ctase  large su b u n it IP I0 0 0 1 3 8 7 1 4 4 2 11 9 3
R ib o se -p h o sp h a te  p yro p h o sp h o k in a se  1 IP I0 0 2 1 9 6 1 6 7 6 7 8 3 3
R ib o so m a l L I  d o m a in -co n ta in in g  protein  1 IP I0 0 0 0 8 7 0 8 5 4 2 5 8 4
R ib o so m a l p ro te in  L14 va ria n t IP I0 0 5 5 5 7 4 4 5 2 3 3 2 4
R ib o so m e  b io ge n e sis  p rote in  W D R 1 2 IP I0 0 3 0 4 2 3 2 2 2 1 1 4 2
R ib o so m e  m atu ra tio n  p ro te in  SB D S IP I0 0 4 2 7 3 3 0 0 2 1 2 2 1
R N A -b in d in g  p ro te in  EW S  iso fo rm  1 IP I0 0 0 0 9 8 4 1 1 1 2 2 3 1
rR N A  2 '-0 -m e th y ltra n sfe ra s e  fib rilla rin IP I0 0 0 2 5 0 3 9 5 4 2 10 5 5
R u vB -like  2 IP I0 0 0 0 9 1 0 4 8 7 8 12 10 7
S -a d e n o sy lm e th io n in e  syn th a se  iso fo rm  type-2 IP I0 0 0 1 0 1 5 7 8 6 5 7 3 5
SA P  d o m a in -co n ta in in g  rib o n u c le o p ro te in IP I0 0 0 1 4 9 3 8 2 0 4 3 3 1
S D H A  p rote in IP I0 0 2 1 7 1 4 3 2 0 1 2 2 2
S e e l  fa m ily  d o m a in -co n ta in in g  p ro te in  1 IP I0 0 1 6 5 2 6 1 1 0 3 4 3 1
S e ce rn in -1 IP I0 0 2 8 9 8 6 2 1 2 2 2 3 3
S e c re te d  fr iz z le d -re la te d  p ro te in  1 IP100749245 2 1 2 1 3 1
S e le n id e , w a te r d ik in a se  1 IP I0 0 0 2 9 0 5 6 8 7 7 10 10 8
S e p ia p te rin  red u ctase IP I0 0 0 1 7 4 6 9 2 2 1 3 0 1
se p tin -9  iso form  e IP I0 0 4 5 5 0 3 3 3 3 4 2 3 1
S e rin e  h yd ro xy m e th y ltra n sfe ra se , m ito ch o n d ria l IP I0 0 0 0 2 5 2 0 11 7 13 6 6 9
S e rin e  p a lm ito y ltra n sfe ra se  1 IP I0 0 0 0 5 7 4 5 3 0 1 2 3 0
S e rin e /a rg in in e -r ic h  sp lic in g  fa cto r 2 IP I0 0 0 0 5 9 7 8 2 1 4 1 2 4
S e rin e /a rg in in e -r ic h  sp lic in g  fa cto r 3 IP I0 0 0 1 0 2 0 4 9 2 5 9 5 3
S e rin e /a rg in in e -r ic h  sp lic in g  fa c to r  9 IP I0 0 0 1 2 3 4 0 4 3 3 8 6 4
S e rin e /th re o n in e -p ro te in  kin ase M ST4 IP I0 0 2 9 2 8 2 7 9 4 7 3 4 5
S e rin e /th re o n in e -p ro te in  k in ase  O SR 1 IP I0 0 0 1 0 0 8 0 4 2 3 4 5 4
S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  2A 55 kDa re g u la to ry  su b u n it 1P I0 0 3 3 2 5 11 2 2 5 5 4 5
B a lp h a  iso form
S e rin e /th re o n in e -p ro te in  p h o sp h a ta se  2A 65 kDa re g u la to ry  su b u n it IP I0 0 5 5 4 7 3 7 16 14 17 16 18 17
A  a lp h a  iso fo rm
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  2A cata ly tic  su b u n it a  iso form IP I0 0 0 0 8 3 8 0 6 2 7 6 5 5
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  4 cata ly tic  su b u n it IP I0 0 0 1 2 8 3 3 2 1 1 0 4 2
S e r in e /th re o n in e -p ro te in  p h o sp h a ta se  P P l-b e ta  ca ta ly tic  su b u n it IP I0 0 2 1 8 2 3 6 3 4 1 5 2 3
Se rp in  B6 IP I0 0 4 1 3 4 5 1 2 2 2 4 7 3
Serp in  B9 IP I0 0 0 3 2 1 3 9 7 3 14 13 8 12
Se rp in  H I IP I0 0 0 3 2 1 4 0 21 12 18 22 21 18
S e ry l-tR N A  syn th e ta se , cyto p la sm ic IP I0 0 2 2 0 6 3 7 2 1 5 7 12 5
SF3 A 2  p rote in  (Fra g m e n t) IP I0 0 0 1 7 3 4 1 6 1 0 2 2 2
1 4 7
S -fo rm y lg lu ta th io n e  h yd ro la se IP I0 0 4 1 1 7 0 6 2 2 2 3 2
SH 3  d o m a in -b in d in g  g lu ta m ic  a c id -rich -like  protein 1P I0 0 0 2 5 3 18 3 2 5 7 3
S ia lic  a cid  syn th a se IP I0 0 1 4 7 8 7 4 5 4 5 5 5
S id e ro fle x in -1 IP I0 0 0 0 9 3 6 8 2 1 0 3 2
S ig n a l re co g n itio n  particle  14 kDa protein IP I0 0 2 9 3 4 3 4 4 4 4 7 5
S ig n a l reco g n itio n  particle  19 kDa protein IP I0 0 2 9 5 8 8 9 3 1 1 2 0
S ig n a l reco g n itio n  p artic le  72 kDa protein IP I0 0 2 1 5 8 8 8 4 2 3 5 6
S im ila r  to  Pro te in  SA A L1 . Iso fo rm  2 IP I0 0 3 0 4 9 3 5 2 1 1 2 1
S in g le -stra n d e d  D N A -b in d in g  p rote in , m ito ch o n d ria l IP I0 0 0 2 9 7 4 4 6 4 7 8 5
Sm a ll g lu ta m in e -rich  te tra tr ico p e p tid e  re p e a t-co n ta in in g  p rote in  a IP I0 0 0 1 3 9 4 9 1 1 5 4 5
Sm a ll n u c le a r r ib o n u c le o p ro te in  E IP100029266 0 2 1 3 1
Sm all n u c le a r r ib o n u c le o p ro te in  Sm  D1 IP I0 0 3 0 2 8 5 0 5 2 2 2 2
Sm a ll n u c le a r r ib o n u c le o p ro te in  Sm  D2 IP I0 0 0 1 7 9 6 3 6 4 7 5 5
Sm a ll n u c le a r r ib o n u c le o p ro te in  Sm  D3 IP I0 0 0 1 7 9 6 4 1 2 2 1 3
S o d iu m /p o ta ss iu m -tra n sp o rtin g  A T P a se  su b u n it beta-3 IP I0 0 0 0 8 1 6 7 3 4 5 5 3
S o lu te  c a rr ie r  fa m ily  2, fa c ilita te d  g lu cose  tra n sp o rte r m e m b e r 3 IP I0 0 0 0 3 9 0 9 5 4 3 4 2
S o rb ito l d e h y d ro g e n a se 1P I0 0 2 16057 5 5 5 4 4
S orcin IP I0 0 0 2 7 1 7 5 6 2 4 5 7
S o rtin g  n exin -2 IP I0 0 2 9 9 0 9 5 2 1 2 4 6
S o rtin g  n exin -5 IP I0 0 2 9 5 2 0 9 1 0 2 2 2
S p a rtin IP I0 0 4 3 0 6 2 2 2 0 2 2 3
S p e rm -a sso c ia te d  a n tig e n  7 IP I0 0 0 0 6 8 6 3 3 2 5 3 3
S p e rm id in e  syn th a se IP I0 0 2 9 2 0 2 0 6 4 5 5 6
S p lic in g  fa c to r  3A  su b u n it  1 IP100017451 4 3 6 7 7
S p lic in g  fa c to r  3A  su b u n it 3 IP I0 0 0 2 9 7 6 4 8 3 5 7 5
S p lic in g  fa c to r  3B su b u n it 1 1PI00026089 19 12 20 29 27
S p lic in g  fa c to r  3B su b u n it 2 IP I0 0 2 2 1 1 0 6 7 1 4 6 9
S p lic in g  fa c to r  3B su b u n it  4 IP I0 0 0 1 7 3 3 9 3 1 0 1 1
S p lic in g  fa c to r  U 2A F 35  kD a su b u n it IP I0 0 0 0 5 6 1 3 2 3 3 2 4
S q u a le n e  syn th ase IP I0 0 0 2 0 9 4 4 9 8 14 5 8
S R A  s te m -lo o p -in te ra ct in g  R N A -b in d in g  p rote in , m ito ch o n d ria l IP I0 0 0 0 9 9 2 2 3 2 3 2 3
Src su b stra te  co rta ctin IP I0 0 0 2 9 6 0 1 3 1 3 3 5
S ta p h y lo c o c c a l n u clea se  d o m a in -co n ta in in g  p rote in  1 IP I0 0 1 4 0 4 2 0 18 12 17 14 17
S ta th m in IP I0 0 4 7 9 9 9 7 5 3 6 8 2
S te ro l-4 -a lp h a -ca rb o x y la te  3 -d e h y d ro g e n a se , d e ca rb o xy la tin g IP I0 0 0 1 9 4 0 7 3 2 5 4 1
S to m a tin -like  p rote in  2 IP I0 0 3 3 4 1 9 0 2 1 3 2 8
S tre ss -7 0  p ro te in , m ito ch o n d ria l IP100007765 32 23 22 19 20
S tre ss -in d u ce d -p h o sp h o p ro te in  1 IP I0 0 0 1 3 8 9 4 20 10 11 18 16
S tru ctu ra l m a in te n a n ce  o f ch ro m o so m e s p rote in  1A 1P I0 0 2 9 1939 2 0 2 0 4
S u cc in y l-C o A :3 -k e to a c id -c o e n zy m e  A  tra n sfe ra se  1, m ito ch o n d ria l IP I0 0 0 2 6 5 1 6 3 1 2 2 1
S U M O -a ctiv a t in g  e n zym e  su b u n it 1 IP I0 0 0 3 3 1 3 0 6 4 8 5 7
S U M O -a ctiv a t in g  e n zy m e  su b u n it 2 IP I0 0 0 2 3 2 3 4 7 3 6 7 11
S U M O -c o n ju g a tin g  e n zym e  U BC9 IP I0 0 0 3 2 9 5 7 2 3 3 6 3
S u p e rk ille r  v ira lic id ic  a ct iv ity  2 -like  2 1P I0 0 6 4 7 2 17 6 3 7 10 8
S u p e ro x id e  d ism u ta se  [C u-Zn] IP100218733 3 5 6 9 2
S u p e ro x id e  d ism u ta se  [M n], m ito ch o n d ria l IP I0 0 0 2 2 3 1 4 2 2 3 3 2
S y n a p tic  v e s ic le  m e m b ra n e  p rote in  V A T -1  h o m o lo g IP I0 0 1 5 6 6 8 9 6 3 6 6 7
S y n a p tic  ve sic le  m em b ra n e  p rote in  V A T-1  h o m o lo g-like IP I0 0 0 3 0 5 7 8 4 0 3 1 2
T a lin -1 IP I0 0 2 9 8 9 9 4 25 23 40 48 49
T -c o m p le x  p ro te in  1 su b u n it a lpha IP100290566 14 9 8 11 21
T -c o m p le x  p ro te in  1 su b u n it beta IP I0 0 2 9 7 7 7 9 29 23 27 23 19
T -c o m p le x  p ro te in  1 su b u n it delta IP I0 0 3 0 2 9 2 7 18 9 12 20 19
T -c o m p le x  p ro te in  1 su b u n it  e p silon IP I0 0 0 1 0 7 2 0 21 11 15 24 17
T -c o m p le x  p ro te in  1 su b u n it  eta IP I0 0 0 1 8 4 6 5 19 9 17 16 17
T -c o m p le x  p ro te in  1 su b u n it  zeta IP I0 0 0 2 7 6 2 6 17 12 13 21 10
T e lo m e re  len gth  re g u la t io n  p rote in  T E L2  h om o lo g IP I0 0 0 1 6 8 6 8 2 1 2 2 1
T e stis -e x p re sse d  se q u e n ce  10 p rote in IP I0 0 5 4 9 6 6 4 5 3 1 3 5




























































T h im e t o lig o p e p tid a se IP I0 0 5 4 9 1 8 9 6 1 1 3 6
T h io re d o x in IP I0 0 2 1 6 2 9 8 2 4 4 4 2
T h io re d o x in  d o m a in -co n ta in in g  protein  12 IP100026328 2 2 3 3 3
T h io re d o x in  d o m a in -co n ta in in g  p rote in  17 IP I0 0 6 4 6 6 8 9 4 1 3 2 2
T h io re d o x in  d o m a in -co n ta in in g  p rote in  5 IP I0 0 1 7 1 4 3 8 5 3 8 9 5
T h io re d o x in -d e p e n d e n t  p e ro xid e  red u ctase , m ito ch o n d ria l IP I0 0 0 2 4 9 1 9 10 10 4 12 6
T h io re d o x in -lik e  p rote in  1 IP I0 0 3 0 5 6 9 2 6 4 9 6 9
T h io re d o x in -re la te d  tra n sm e m b ra n e  p rote in  1 IP I0 0 3 9 5 8 8 7 1 2 5 4 1
T H O  co m p le x  su b u n it 2 IP I0 0 1 5 8 6 1 5 2 1 1 1 2
T H O  c o m p le x  su b u n it 4 IP I0 0 3 2 8 8 4 0 7 2 5 6 7
T h re o n y l-tR N A  syn th eta se , cyto p lasm ic IP I0 0 3 2 9 6 3 3 17 11 10 11 16
T H U M P  d o m a in -co n ta in in g  p rote in  1 IP I0 0 5 5 0 2 4 3 2 0 4 2 4
T h y -1  m e m b ra n e  g lyco p ro te in IP I0 0 0 2 2 8 9 2 2 2 3 3 3
T h y m id y la te  k in ase IP100Û13862 1 2 0 3 3
T ra ff ic k in g  p rote in  p artic le  co m p le x su b u n it 3 IP I0 0 0 0 4 3 2 4 2 1 0 3 3
T ra ff ick in g  protein  p artic le  co m p lex su b u n it 4 IP I0 0 0 0 7 6 9 1 2 1 2 2 2
T ra n sa ld o la se IP I0 0 7 4 4 6 9 2 10 7 11 16 15
T ra n sc rip t io n  e lo n g a tio n  fa cto r B p o ly p ep tid e  2 IP I0 0 0 2 6 6 7 0 2 1 0 3 1
T ra n sfe rr in  rece p to r p rote in  1 IP I0 0 0 2 2 4 6 2 12 6 5 7 13
T ra n s fo rm in g  p rote in  R hoA IP I0 0 4 7 8 2 3 1 5 6 11 12 10
T ra n sg e lin IP I0 0 2 1 6 1 3 8 13 9 11 19 12
T ra n sg e lin -2 IP I0 0 5 5 0 3 6 3 7 6 7 14 8
T ra n s it io n a l e n d o p la sm ic  reticu lu m  A TPase IP I0 0 0 2 2 7 7 4 41 28 39 41 32
T ra n s la t io n  in itia tio n  fa c to r  e lF -2 B  su b u n it a lpha IP I0 0 2 2 1 3 0 0 4 1 5 5 6
T ra n s la t io n a l a ct iv a to r G CN 1 IP I0 0 0 0 1 1 5 9 14 11 15 21 20
T ra n s la t io n a l a ct iv a to r o f cyto ch ro m e  c ox id ase  1 IP I0 0 0 1 9 9 0 3 2 0 1 2 1
T ra n s lin IP I0 0 0 1 8 7 6 8 10 7 5 14 7
T ra n s lin -a s so c ia te d  p ro te in  X IP I0 0 2 9 3 3 5 0 7 3 5 5 6
T ra n s lo c o n -a sso c ia te d  p ro te in  su b u n it de lta  p recu rsor IP I0 0 0 1 9 3 8 5 3 3 3 4 3
T ra n sm e m b ra n e  e m p 2 4  d o m a in -co n ta in in g  p rote in  10 IP I0 0 0 2 8 0 5 5 6 8 4 7 7
T ra n sm e m b ra n e  e m p 2 4  d o m a in -co n ta in in g  p rote in  9 IP I0 0 0 2 3 5 4 2 2 2 2 3 3
T r ifu n c tio n a l e n zym e  su b u n it  a lp h a , m ito ch o n d ria l IP I0 0 0 3 1 5 2 2 8 6 4 7 6
T rip a rt ite  m o tif-co n ta in in g  p ro te in  71 IP I0 0 7 1 9 0 5 3 5 5 3 5 5
T r ip e p tid y l-p e p tid a se  2 IP I0 0 0 2 0 4 1 6 8 6 10 5 15
tR N A  (cy to s in e -5 -)-m e th y ltra n sfe ra se  N SU N 2 IP I0 0 3 0 6 3 6 9 7 2 4 6 11
tR N A  (gu a n in e -N (7 )-)-m e th y ltra n sfe ra se IP I0 0 2 9 0 1 8 4 2 2 3 2 1
tR N A  m e th y ltra n sfe ra se  112 h o m o lo g IP I0 0 0 0 9 0 1 0 2 2 4 4 2
T ro p o m o d u lin -3 IP I0 0 0 0 5 0 8 7 4 3 2 4 2
Tu  tra n s la t io n  e lo n ga tio n  facto r, m ito ch o n d ria l p re cu rso r IP I0 0 0 2 7 1 0 7 11 6 11 13 10
T U B B 6  p rote in IP I0 0 6 4 6 7 7 9 3 2 6 4 6
T u b u lin  a lp h a - lC  chain IP I0 0 2 1 8 3 4 3 3 1 3 1 2
T u b u lin  b e ta -2 A  chain IP I0 0 0 1 3 4 7 5 2 1 2 4 1
T u b u lin  b e ta -2 B  chain IP I0 0 0 3 1 3 7 0 32 26 32 42 33
T u b u lin  b e ta -2 C  chain IP I0 0 0 0 7 7 5 2 4 4 4 6 6
T u b u lin  b e ta -3  chain IP I0 0 0 1 3 6 8 3 7 7 8 11 5
T u b u lin  b e ta -4  ch a in IP I0 0 0 2 3 5 9 8 3 3 1 2 4
T u b u lin , beta IP I0 0 6 4 5 4 5 2 11 10 14 15 11
T u b u lin -fo ld in g  c o fa cto r B IP I0 0 2 9 3 1 2 6 5 4 8 7 6
T u b u lin -sp e c if ic  ch a p e ro n e  A IP I0 0 2 1 7 2 3 6 8 5 6 5 8
T u b u lin -sp e c if ic  ch a p e ro n e  E IP I0 0 0 1 8 4 0 2 3 0 5 2 3
T u b u lin - ty ro s in e  lig a se -like  p rote in  12 IP I0 0 0 2 9 0 4 8 11 8 4 9 5
T u m o r p ro te in , tra n s la t io n a lly -co n tro lle d  1 IP I0 0 0 0 9 9 4 3 8 4 1 7 8
T w in filin -2 IP I0 0 5 5 0 9 1 7 3 0 3 3 4
T y ro sy l-tR N A  sy n th e ta se , cyto p la sm ic IP I0 0 0 0 7 0 7 4 8 14 10 8 12
U1 sm a ll n u c le a r r ib o n u c le o p ro te in  A IP I0 0 0 1 2 3 8 2 2 0 1 4 2
U2 sm a ll n u c le a r r ib o n u c le o p ro te in  A' IP I0 0 2 9 7 4 7 7 8 7 8 9 5
U2 sm a ll n u c le a r r ib o n u c le o p ro te in  B" IP I0 0 0 2 9 2 6 7 1 2 2 5 2




























































U 8 sn o R N A -d e c a p p in g  e n zym e  
U b iq u ilin -2
U b iq u itin  ca rb o xy l-te rm in a l h yd ro lase  10
U b iq u it in  ca rb o xy l-te rm in a l h yd ro la se  11
U b iq u it in  ca rb o xy l-te rm in a l h yd ro la se  14
U b iq u itin  ca rb o xy l-te rm in a l h yd ro la se  7
U b iq u itin  ca rb o xy l-te rm in a l h yd ro la se  iso zym e  L I
U b iq u itin  ca rb o xy l-te rm in a l h yd ro la se  iso zym e  L3
U b iq u itin -4 0 S  rib o so m al p rote in  S27a
U b iq u it in -co n ju g a tin g  e n zym e  E2 C
U b iq u itin -co n ju g a tin g  e n zym e  E2 L3
U b iq u it in -co n ju g a tin g  e n zym e  E2 O
U b iq u it in -co n ju g a tin g  e n zym e  E2 va ria n t 2
U b iq u itin -like  m o d ifie r-a ct iv a t in g  e n zym e  1
U b iq u it in -lik e  p rote in  4A
U D P -g lu co se  6 -d e h yd ro g e n a se
U M P -C M P  kinase iso form  a
U n ch a ra cte rize d  protein
U n ch a ra cte rize d  p rote in  C l lo r f 7 3
U n ch a ra cte rize d  p rote in  C 17 o rf2 5
U n ch a ra cte rize d  p rote in  C 2o rf79
U P F 0 0 2 7  p rote in  C 2 2 o rf2 8
U P F 0 1 6 0  p rote in  M YG 1, m ito ch o n d ria l
U P F 0 3 6 4  p rote in  C 6 o rf2 1 1
U P F 0 3 6 8  p ro te in  C xo rf26
U P F 0 4 6 8  p rote in  C 1 6 o rf8 0
U P F 0 5 5 6  p ro te in  C 1 9 o r f l0
U P F 0 5 6 8  p rote in  C 1 4 o r f l6 6
U P F 0 5 8 7  p ro te in  C lo r f l2 3
U P F 0 6 0 9  p ro te in  C 4 o rf2 7
U P F 0 7 2 7  p ro te in  C 6 o r f l l5
U P F 0 7 6 5  p ro te in  C 1 0 o rf5 8
U ro p o rp h y rin o g e n  d e ca rb o xy la se
U V  e xc is io n  rep a ir p rote in  R A D 23  h o m o lo g  B
V a c u o la r  p rote in  so rtin g -a sso c ia te d  p rote in  35
V a ly l-tR N A  syn th eta se
V a so d ila to r-stim u la te d  p h o sp h o p ro te in
V e s ic le -tra ffic k in g  p rote in  S E C 2 2 b
V e s icu la r  in te g ra l-m e m b ra n e  p rote in  V IP 3 6
V ig ilin
V im e n tin
V is in in -lik e  p rote in  1
v o n  H ip p e l-L in d a u  b in d in g p rote in  1, iso form  CR A _b
V -ty p e  p roton  A T P a se  cata ly tic  su b u n it A
V -ty p e  p ro to n  A T P a se  su b u n it B, brain iso form
V -ty p e  p ro to n  A T P a se  su b u n it D
V -ty p e  p roton  A T P a se  su b u n it E 1
V -ty p e  p roton  A T P a se  su b u n it G 1
W A SH  c o m p le x  su b u n it stru m p e llin
W D  rep e a t an d  H M G -b o x D N A -b in d in g  p rote in  1
W D  re p e a t-co n ta in in g  p rote in  61
X a a -P ro  d ip e p tid a se
X -ra y  re p a ir  c ro ss -c o m p le m e n tin g  protein  5 
X -ra y  re p a ir c ro ss -c o m p le m e n tin g  protein  6 
Zyx in
IP I0 0 7 8 3 4 9 7 2 1 1 3 1 2
IP I0 0 4 0 9 6 5 9 1 0 2 0 4 2
IP I0 0 2 9 1 9 4 6 2 3 2 2 2 5
IP I0 0 1 8 4 5 3 3 3 1 6 5 0 2
1P I0 0 2 19913 6 4 5 9 7 9
IP I0 0 0 0 3 9 6 5 7 5 5 16 10 8
IP I0 0 0 1 8 3 5 2 17 8 10 13 11 11
IP I0 0 0 1 1 2 5 0 4 1 2 3 5 4
IP I0 0 1 7 9 3 3 0 5 3 4 10 6 7
ÏP I0 0 0 1 3 0 0 2 3 2 3 0 2 2
IP I0 0 0 2 1 3 4 7 7 4 5 3 4 4
IP I0 0 7 8 3 3 7 8 5 1 5 3 4 4
IP I0 0 0 1 9 6 0 0 2 0 2 3 6 2
IP I0 0 6 4 5 0 7 8 41 30 42 30 31 28
IP I0 0 0 0 5 6 5 8 1 1 2 1 2 1
IP I0 0 0 3 1 4 2 0 9 4 8 11 10 10
IP I0 0 2 1 9 9 5 3 3 1 1 8 0 2
IP I0 0 0 2 2 4 3 4 5 7 5 6 14 5
IP I0 0 4 1 0 0 9 1 1 1 2 1 2 0
IP I0 0 0 0 7 1 0 2 7 3 7 4 3 3
IP I0 0 4 3 0 8 0 3 2 2 2 3 2 1
IP I0 0 5 5 0 6 8 9 5 6 6 8 6 8
IP I0 0 0 2 9 4 4 4 2 1 2 2 3 1
IP I0 0 0 0 2 2 7 0 7 3 4 3 2 2
IP I0 0 1 0 7 1 0 4 6 2 3 4 6 2
IP I0 0 0 0 1 6 5 5 2 2 1 1 2 1
IP I0 0 0 5 6 3 5 7 3 1 1 2 4 1
IP I0 0 0 0 6 9 8 0 6 5 7 9 7 6
IP I0 0 0 1 6 6 0 5 2 2 0 2 1 0
IP I0 0 0 1 6 5 3 2 1 0 2 2 2 0
IP I0 0 8 5 5 8 4 6 0 2 3 5 0 2
IP I0 0 2 9 6 1 9 0 2 3 2 5 2 2
IP I0 0 3 0 1 4 8 9 5 3 2 4 2 4
IP I0 0 0 0 8 2 2 3 3 1 2 7 3 5
IP I0 0 0 1 8 9 3 1 6 1 1 11 9 5
IP I0 0 0 0 0 8 7 3 16 11 15 10 20 14
IP I0 0 3 0 1 0 5 8 1 1 6 5 3 4
IP I0 0 0 0 6 8 6 5 2 1 0 4 2 1
IP I0 0 0 0 9 9 5 0 4 2 1 2 2 1
IP I0 0 0 2 2 2 2 8 4 4 4 10 14 6
IP I0 0 4 1 8 4 7 1 33 17 25 65 33 26
1P I0 0 2 16313 8 7 6 2 4 2
IP I0 0 3 3 4 1 5 9 5 4 0 5 4 2
IP I0 0 0 0 7 6 8 2 4 3 3 5 6 4
IP I0 0 0 0 7 8 1 2 3 2 6 5 4 3
IP I0 0 0 0 1 5 6 8 3 1 0 3 2 0
IP I0 0 0 0 3 8 5 6 4 3 3 4 2 1
IP I0 0 0 2 5 2 8 5 1 1 3 2 2 3
IP I0 0 0 2 9 1 7 5 1 1 2 1 1 2
1P I0 0 4 1 1614 2 1 0 4 5 2
IP I0 0 0 1 9 2 6 9 2 2 2 1 2 2
IP I0 0 2 5 7 8 8 2 6 3 3 3 4 3
IP I0 0 2 2 0 8 3 4 29 18 12 29 28 24
IP I0 0 6 4 4 7 1 2 27 23 15 28 34 22
IP I0 0 9 2 6 6 2 5 5 1 5 5 3 10
Note: "Peptide IDs" means the number of unique peptides that were identified from the corresponding 
protein during one replicate of the experiment. Three replicates are shown for each cell line.
